

0000950170-24-102458S-1 Aptevo Therapeutics Inc. 2024083020240830172658172659172659 0 0000950170-24-102458 S-1 14  
20240830 20240830 Aptevo Therapeutics Inc. 0001671584 2834 811567056 DE 1231 S-1 33 333-281892 241271218 2401 4TH AVE.  
SUITE 1050 SEATTLE WA 98121 206-838-0500 2401 4TH AVE. SUITE 1050 SEATTLE WA 98121 S-1 1 apvo-2024-s1 - sept\_offe.htm S-1  
S-1 A As filed with the Securities and Exchange Commission on August 30, 2024. Registration No. 333- A UNITED STATES SECURITIES  
AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 A A FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES  
ACT OF 1933 A A APTEVO THERAPEUTICS INC. (Exact Name of Registrant as Specified in Its Charter) A A Delaware A 2834 A 81-  
1567056 (State or Other Jurisdiction of Incorporation or Organization) A (Primary Standard Industrial Classification Code Number) A  
(I.R.S. Employer Identification Number) A 2401 4th Avenue, Suite 1050 Seattle, Washington, 98121 (206) 838-0500 (Address, Including  
Zip Code, and Telephone Number, Including Area Code, of Registrant's Principal Executive Offices) A A Marvin L. White President  
and Chief Executive Officer Aptevo Therapeutics Inc. 2401 4th Avenue, Suite 1050 Seattle, Washington, 98121 (206) 838-0500 (Name,  
Address, Including Zip Code, and Telephone Number, Including Area Code, of Agent For Service) Copies to: A A Sean M. Donahue Paul  
Hastings LLP 2050 M Street, NW Washington, DC 20036 (202) 551-1704 A A SoYoung Kwon Senior Vice President and General  
Counsel Aptevo Therapeutics Inc. 2401 4th Avenue, Suite 1050 Seattle, Washington, 98121 (206) 838-0500 A Charles E. Phillips Ellenoff  
Grossman & Schole LLP 1345 Avenue of the Americas New York, NY 10105 (212) 370-1300 A Approximate date of commencement of  
proposed sale to the public: As soon as practicable after the effective date of this registration statement. If any of the securities being  
registered on this Form are to be offered on a delayed or continuous basis pursuant to Rule 415 under the Securities Act of 1933, check  
the following box. A If this Form is filed to register additional securities for an offering pursuant to Rule 462(b) under the Securities Act,  
please check the following box and list the Securities Act registration statement number of the earlier effective registration statement for  
the same offering. A If this Form is a post-effective amendment filed pursuant to Rule 462(c) under the Securities Act, check the following  
box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. A If this  
Form is a post-effective amendment filed pursuant to Rule 462(d) under the Securities Act, check the following box and list the Securities  
Act registration statement number of the earlier effective registration statement for the same offering. A Indicate by check mark whether  
the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth  
company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company" and "emerging  
growth company" in Rule 12b-2 of the Exchange Act. A Large Accelerated filer A A Accelerated filer A A A A Non-accelerated  
filer A A Smaller reporting company A A A A A A A A Emerging growth company A A If an emerging growth company, indicate  
by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial  
accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. A The registrant hereby amends this registration  
statement on such date or dates as may be necessary to delay its effective date until the registrant files a further amendment which  
specifically states that this registration statement shall thereafter become effective in accordance with Section 8(a) of the Securities Act of  
1933, as amended, or until the registration statement shall become effective on such date as the Securities and Exchange Commission,  
acting pursuant to said Section 8(a), may determine. A A The information in this prospectus is not complete and may be changed. These  
securities may not be sold until the registration statement filed with the Securities and Exchange Commission is effective. This prospectus  
is not an offer to sell these securities and it is not soliciting an offer to buy these securities in any state where the offer or sale is not  
permitted. A A A SUBJECT TO COMPLETION DATED August 30, 2024 A A PRELIMINARY PROSPECTUS A Up to 13,513,513 Shares of  
Common Stock Up to 13,513,513 Pre-Funded Warrants to Purchase up to 13,513,513 Shares of Common Stock Up to 27,027,026 Common  
Warrants to Purchase up to 27,027,026 Shares of Common Stock Up to 40,540,539 Shares of Common Stock underlying the Pre-Funded  
Warrants and Common Warrants A A A This is a reasonable best efforts public offering of up to 13,513,513 shares (the "shares")  
of our common stock, par value \$0.001 per share ("common stock") together with up to 27,027,026 common warrants to purchase up to  
27,027,026 shares of common stock at an assumed combined public offering price of \$0.37 per share and common warrant (the last  
reported sale price per share of our common stock on the Nasdaq Capital Market, on August 27, 2024). Each share of common stock is  
being offered together with two common warrants, each to purchase one share of common stock. The common warrants will be  
exercisable beginning on the effective date of such stockholder approval as may be required by the applicable rules and regulations of the  
Nasdaq Capital Market (or any successor entity) to permit the exercise of the common warrants ("Stockholder Approval") at an  
exercise price of \$ per share and will expire five years from the date of Stockholder Approval. In the event that we are unable to obtain  
any required Stockholder Approval, the common warrants will not be exercisable and therefore have no value. In addition, the common  
warrants will include a provision that resets their exercise price in the event of a share split, share dividend, share combination or other  
such event (the "Share Combination Event"), of our common stock, to a price equal to the lower of (i) the then current exercise price and  
(ii) lowest volume weighted average price ("VWAP") during the period commencing five consecutive trading days immediately preceding  
and ending immediately after the five consecutive trading days beginning on the date we effect a Share Combination Event. The shares of  
common stock and common warrants will be separately issued. This prospectus also covers the shares of common stock issuable from time  
to time upon the exercise of the common warrants. We are also offering pre-funded warrants to those purchasers, whose purchase of  
shares of common stock in this offering would result in the purchaser, together with its affiliates and certain related parties, beneficially  
owning more than 4.99% (or, at the election of the purchaser, 9.99%) of our outstanding common stock following the consummation of this  
offering in lieu of the shares of our common stock that would result in ownership in excess of 4.99% (or, at the election of the purchaser,  
9.99%). Each pre-funded warrant will be exercisable for one share of common stock at an exercise price of \$0.0001 per share. Each pre-  
funded warrant is being offered together with the same two common warrants, each to purchase one share of common stock described  
above being offered with each share of common stock. The purchase price of each pre-funded warrant will equal the combined public  
offering price per share of common stock and common warrants being sold in this offering, less the \$0.0001 per share exercise price of  
each such pre-funded warrant. Each pre-funded warrant will be exercisable upon issuance and will expire when exercised in full. The pre-  
funded warrants and common warrants will be separately issued. For each pre-funded warrant that we sell, the number of shares of  
common stock that we are selling will be decreased on a one-for-one basis. This prospectus also covers the shares of common stock  
issuable from time to time upon the exercise of the pre-funded warrants. A A There is no established public trading market for the pre-  
funded warrants or common warrants, and we do not expect a market to develop. We do not intend to apply for listing of the pre-funded  
warrants or common warrants on any securities exchange or other nationally recognized trading system. Without an active trading  
market, the liquidity of the pre-funded warrants and common warrants will be limited. We have engaged Roth Capital Partners, LLC, or  
the placement agent, to act as our exclusive placement agent in connection with this offering. Dawson James Securities, Inc. will act as co-  
agent. The placement agent has agreed to use its reasonable best efforts to arrange for the sale of the securities offered by this  
prospectus. The placement agent is not purchasing or selling any of the securities we are offering and the placement agent is not required  
to arrange the purchase or sale of any specific number or dollar amount of securities. We have agreed to pay to the placement agent the  
placement agent fees set forth in the table below, which assumes that we sell all of the securities offered by this prospectus. There is no  
arrangement for funds to be received in escrow, trust or similar arrangement. There is no minimum number of shares of securities or  
minimum aggregate amount of proceeds that is a condition for this offering to close. We may sell fewer than all of the securities offered  
hereby, which may significantly reduce the amount of proceeds received by us, and investors in this offering will not receive a refund if we  
do not sell all of the securities offered hereby. Because there is no escrow account and no minimum number of securities or amount of  
proceeds, investors could be in a position where they have invested in us, but we have not raised sufficient proceeds in this offering to  
adequately fund the intended uses of the proceeds as described in this prospectus. We will bear all costs associated with the offering. See  
"Plan of Distribution" on page 25 of this prospectus for more information regarding these arrangements. This offering will terminate  
no later than October 15, 2024, unless we decide to terminate the offering (which we may do at any time in our discretion) prior to that  
date. Our common stock is listed on the Nasdaq Capital Market under the symbol "APVO." On August 27, 2024, the last reported sale  
price of our common stock on the Nasdaq Capital Market was \$0.37 per share. All share, common warrant and pre-funded warrant  
numbers are based on an assumed combined public offering price of \$0.37 per share or pre-funded warrant, as applicable, and common  
warrants. The actual combined public offering price per share and common warrants and the actual combined public offering price per  
pre-funded warrant and common warrants will be determined between us and investors based on market conditions at the time of pricing,  
and may be at a discount to the current market price of our common stock. Therefore, the assumed public offering price used throughout  
this prospectus may not be indicative of the final public offering price. You should read this prospectus, together with additional

information described under the headings “Incorporation of Certain Information By Reference” and “Where You Can Find More Information,” carefully before you invest in any of our securities. Investing in our securities involves a high degree of risk. See the section entitled “Risk Factors” beginning on page 7 of this prospectus and in the documents incorporated by reference into this prospectus for a discussion of risks that should be considered in connection with an investment in our securities. Per Share and Common Warrant Per Pre-Funded Warrant and Common Warrant Total Public offering price \$ \$ \$ Placement Agent fees(1) \$ \$ \$ Proceeds to us, before expenses(2) \$ \$ \$ (1)We have agreed to pay the placement agent a cash placement commission equal to 7% of the aggregate proceeds from this offering subject to a partial adjustment in the event certain investors participate. We have also agreed to reimburse the Placement Agent for certain expenses incurred in connection with this offering. See “Plan of Distribution” for additional information about the compensation payable to the placement agent. (2)Because there is no minimum number of securities or amount of proceeds required as a condition to closing in this offering, the actual public offering amount, placement agent fees, and proceeds to us, if any, are not presently determinable and may be substantially less than the total maximum offering amounts set forth above. We estimate the total expenses of this offering payable by us, excluding the placement agent fee, will be approximately \$265,000. The delivery of the shares of common stock and any pre-funded warrants and common warrants to purchasers is expected to be made no later than October 15, 2024. Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or passed upon the adequacy or accuracy of this prospectus. Any representation to the contrary is a criminal offense. Roth Capital Partners Dawson James Securities, Inc. The date of this prospectus is, 2024. TABLE OF CONTENTS Page ABOUT THIS PROSPECTUS i CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS ii PROSPECTUS SUMMARY 1 THE OFFERING 5 RISK FACTORS 7 USE OF PROCEEDS 11 CAPITALIZATION 12 DILUTION 14 DESCRIPTION OF CAPITAL STOCK 15 description of securities we are offering 21 PLAN OF DISTRIBUTION 25 Incorporation of certain information by reference 28 WHERE YOU CAN FIND MORE INFORMATION 28 LEGAL MATTERS 29 EXPERTS 29 ABOUT THIS PROSPECTUS We incorporate by reference important information into this prospectus. You may obtain the information incorporated by reference without charge by following the instructions under “Where You Can Find More Information.” You should carefully read this prospectus as well as additional information described under “Incorporation of Certain Information by Reference,” before deciding to invest in our securities. We have not, and the placement agent has not, authorized anyone to provide any information or to make any representations other than those contained in this prospectus or in any free writing prospectuses prepared by or on behalf of us or to which we have referred you. We take no responsibility for, and can provide no assurance as to the reliability of, any other information that others may give you. This prospectus is an offer to sell only the securities offered hereby, and only under circumstances and in jurisdictions where it is lawful to do so. The information contained in this prospectus or in any applicable free writing prospectus is current only as of its date, regardless of its time of delivery or any sale of our securities. Our business, financial condition, results of operations and prospects may have changed since that date. The information incorporated by reference or provided in this prospectus contains statistical data and estimates, including those relating to market size and competitive position of the markets in which we participate, that we obtained from our own internal estimates and research, as well as from industry and general publications and research, surveys and studies conducted by third parties. Industry publications, studies and surveys generally state that they have been obtained from sources believed to be reliable. While we believe our internal company research is reliable and the definitions of our market and industry are appropriate, neither this research nor these definitions have been verified by any independent source. For investors outside the United States: We have not, and the placement agent has not, done anything that would permit this offering or possession or distribution of this prospectus in any jurisdiction where action for that purpose is required, other than in the United States. Persons outside the United States who come into possession of this prospectus must inform themselves about, and observe any restrictions relating to, the offering of the securities and the distribution of this prospectus outside the United States. This prospectus and the information incorporated by reference into this prospectus contain references to our trademarks and to trademarks belonging to other entities. Solely for convenience, trademarks and trade names referred to in this prospectus and the information incorporated by reference into this prospectus, including logos, artwork, and other visual displays, may appear without the ® or TM symbols, but such references are not intended to indicate, in any way, that we will not assert, to the fullest extent under applicable law, our rights or the rights of the applicable licensor to these trademarks and trade names. We do not intend our use or display of other companies’ trade names or trademarks to imply a relationship with, or endorsement or sponsorship of us by, any other company. i CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS This prospectus, and any documents we incorporate by reference, contain certain forward-looking statements that involve substantial risks and uncertainties. All statements contained in this prospectus and any documents we incorporate by reference, other than statements of historical facts, are forward-looking statements including statements regarding our strategy, future operations, future financial position, future revenue, projected costs, prospects, plans, objectives of management and expected market growth. These statements involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. The words “anticipate,” “believe,” “estimate,” “expect,” “intend,” “may,” “plan,” “predict,” “project,” “target,” “potential,” “will,” “would,” “could,” “should,” “continue” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. These forward-looking statements include, among other things, statements about: our ability to continue as a going concern; our failure to maintain compliance with the Nasdaq Capital Market’s (“Nasdaq”) continued listing requirements could result in the delisting of our common stock; our plans to develop and commercialize our drug candidates; our ability to become profitable; our estimates regarding expenses, future revenue, capital requirements and needs for additional financing; our ability to maintain and establish collaborations or obtain additional funding; our ability to obtain regulatory approval of current and future drug candidates; our expectations regarding our ability to fund operating expenses and capital expenditure requirements with our existing cash and cash equivalents, and future expenses and expenditures; our ability to secure sufficient funding and alternative source of funding to support when needed and on terms favorable to us to support our business objective, product development, other operations or commercialization efforts; the success of our clinical development activities, clinical trials and research and development programs; our ability to retain key employees, consultants and advisors; our ability to obtain, maintain, protect and enforce sufficient intellectual property rights for our candidates and technology; our anticipated strategies and our ability to manage our business operations effectively; the impact of legislative, regulatory or policy changes; the possibility that we may be adversely impacted by other economic, business, and/or competitive factors; and other risks and uncertainties, including those listed in the “Risk Factors” section of this prospectus and the documents incorporated by reference herein. These forward-looking statements are only predictions and we may not actually achieve the plans, intentions or expectations disclosed in our forward-looking statements, so you should not place undue reliance on our forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in the forward-looking statements we make. We have based these forward-looking statements largely on our current expectations and projections about future events and trends that we believe may affect our business, financial condition and operating results. We have included important factors in the cautionary statements included in this prospectus that could cause actual future results or events to differ materially from the forward-looking statements that we make. Our forward-looking statements do not reflect the potential impact of any future acquisitions, mergers, dispositions, joint ventures or investments we may make. You should read this prospectus with the understanding that our actual future results may be materially different from what we expect. We do not assume any obligation to update any forward-looking statements whether as a result of new information, future events or otherwise, except as required by applicable law. iii PROSPECTUS SUMMARY This summary highlights information contained elsewhere in this prospectus. This summary does not contain all of the information that you should consider before deciding to invest in our securities. You should read this entire prospectus carefully, including the “Risk Factors” section in this prospectus and under similar captions in the documents incorporated by reference into this prospectus. In this prospectus, unless otherwise stated or the context otherwise requires, references to the terms “APVO,” “the Company,” “we,” “us” and “our” refer to Aptevo Therapeutics Inc., together with its subsidiaries, unless the context otherwise requires. This prospectus and the information incorporated herein by reference include trademarks, service marks and trade names owned by us or other companies. All trademarks, service marks and trade names included or incorporated by reference into this prospectus and the information incorporated herein by reference are the property of their respective owners. Business Overview We are a

clinical-stage, research and development biotechnology company focused on developing novel immunotherapy candidates for the treatment of different forms of cancer. We have developed two versatile and enabling platform technologies for rational design of precision immune modulatory drugs and have two clinical candidates and three preclinical candidates currently in development. Clinical candidate mipektamig (formerly APVO436) is a CD3xCD123 T-cell engager currently being clinically evaluated in the RAINIER trial, part one of a Phase 1b/2 program initiated in August 2024 for the treatment of acute myelogenous leukemia (AML). Clinical candidate ALG.APV-527 targets 4-1BB (co-stimulatory receptor) and 5T4 (tumor antigen). The compound is designed to reactivate antigen-primed T-cells to specifically kill tumor cells and is currently being evaluated for the treatment of multiple solid tumor types. Preclinical candidates, APVO603 and APVO711, were also developed using our ADAPTIR, a modular protein technology platform. Our preclinical candidate APVO442 was developed using our ADAPTIR-FLEX, a modular protein technology platform. Our ADAPTIR and ADAPTIR-FLEX platforms are designed to generate monospecific, bispecific, and multi-specific antibody candidates capable of enhancing the human immune system against cancer cells. ADAPTIR and ADAPTIR-FLEX are both modular platforms, which gives us the flexibility to potentially generate immunotherapeutic candidates with a variety of mechanisms of action. This flexibility in design allows us to generate novel therapeutic candidates that may provide effective strategies against difficult to treat, as well as advanced forms of cancer. We have successfully designed and constructed numerous investigational-stage product candidates based on our ADAPTIR platform. The ADAPTIR platform technology is designed to generate monospecific and bispecific immunotherapeutic proteins that specifically bind to one or more targets, for example, bispecific therapeutic molecules, which may have structural and functional advantages over monoclonal antibodies. The structural differences of ADAPTIR molecules over monoclonal antibodies allow for the development of ADAPTIR immunotherapies that are designed to engage immune effector cells and disease targets to produce signaling responses that modulate the immune system to kill tumor cells. We believe we are skilled at candidate generation, validation, and subsequent preclinical and clinical development using the ADAPTIR platform and the ADAPTIR-FLEX platform to generate bispecific and multi-specific candidates or other candidates to our platform capabilities. We have developed a preclinical candidate based on the ADAPTIR-FLEX platform which is advancing in our pipeline. We are developing our ADAPTIR and ADAPTIR-FLEX molecules using our protein engineering, preclinical development, process development, and clinical development capabilities. Our Strategy We seek to grow our business by, among other things: Advancing our lead clinical blood cancer candidate, mipektamig, through clinical development to evaluate its therapeutic potential alone and in combination with other therapies. Based on the positive results from our Phase 1 dose escalation and Phase 1b dose expansion studies, we initiated RAINIER in August 2024 as part of our ongoing program to evaluate mipektamig in combination with venetoclax + azacitidine for frontline patients with acute myeloid leukemia (AML). RAINIER will be conducted in two parts, first with a Phase 1b frontline AML study followed by a Phase 2 study. 1. Advancing our lead solid tumor candidate, ALG.APV-527, developed in partnership with Alligator Bioscience AB (Alligator), further in the clinic. Aptevo and Alligator continue to investigate ALG.APV-527 for the treatment of multiple solid tumor types with 5T4-tumor expressing antigens. This drug candidate is in an ongoing first-in-human Phase I clinical trial that started in the first quarter of 2023. ALG.APV-527 targets the 4-1BB co-stimulatory receptor (on T lymphocytes and NK cells) and 5T4 (solid tumor antigen) and is designed to promote anti-tumor immunity. Aptevo believes this compound has the potential to be clinically important because 4-1BB can stimulate the immune cells (tumor-specific T-cells and NK cells) involved in tumor control, making 4-1BB a particularly compelling target for cancer immunotherapy. Continued development and advancement of our preclinical candidates, APVO603 (targeting 4-1BB (CD137) and OX40 (CD134), both members of the TNF-receptor family), APVO442 (targeting Prostate Specific Membrane Antigen (PSMA), a tumor antigen that is highly expressed on prostate cancer cells and CD3), and APVO711 (an anti-PD-L1 x anti-CD40 compound). We continue to advance APVO711, APVO603 and APVO442 through preclinical and IND-enabling studies. In January 2023, we filed a provisional patent with the U.S. Patent and Trademark Office (USPTO) pertaining to APVO711. In January 2024, the provisional patent was amended to include new preclinical data and a patent application under the Patent Cooperation Treaty ("PCT") was filed pertaining to APVO711, which has the potential to treat a range of solid malignancies such as head and neck cancer. APVO711 is a dual mechanism bispecific antibody candidate that is designed to provide synergistic stimulation of CD40 on antigen presenting cells while simultaneously blocking the PD-1/PD-L1 inhibitory pathway to potentially promote a robust anti-tumor response. Preclinical studies are planned to further evaluate the mechanism of action and efficacy of APVO711. Development of novel bispecific and multi-specific proteins for the treatment of cancer using our ADAPTIR and ADAPTIR-FLEX platforms. We have expertise in molecular and cellular biology, immunology, oncology, pharmacology, translational sciences, antibody engineering and the development of protein therapeutics. This includes target validation, preclinical proof of concept, cell line development, protein purification, bioassay and process development and analytical characterization. We focus on product development using our ADAPTIR and ADAPTIR-FLEX platforms. We plan to generate additional monospecific, bispecific, and multi-specific protein immunotherapies for development, potentially with other collaborative partners, to exploit the potential of the ADAPTIR and ADAPTIR-FLEX platforms. We will select novel candidates that have the potential to demonstrate proof of concept early in development. We expect to continue to expand the ADAPTIR and ADAPTIR-FLEX product pipelines to address areas of unmet medical need. Bispecific therapeutics are increasingly recognized as potent anti-cancer agents. Eleven new bispecific agents have been approved for use by the FDA in the last three years and there is a total of 125 bispecific drug candidates currently in development. We believe our candidates in development and our future molecules derived from our ADAPTIR and ADAPTIR-FLEX platforms will be highly competitive in the market as they are rationally designed for safety and tolerability as well as efficacy. Establishing collaborative partnerships to broaden our pipeline and provide funding for research and development. We intend to pursue collaborations with other biotechnology and pharmaceutical companies, academia, and non-governmental organizations to advance our product portfolio. 2. Product Candidates and Platform Technology Product Portfolio Our current product candidate pipeline is summarized in the table below: Platform Technologies 3. Smaller Reporting Company Additionally, we are a "smaller reporting company" as defined in Rule 10(f)(1) of Regulation S-K. To the extent we qualify as a smaller reporting company, we may continue to take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not smaller reporting companies, including, among other things, providing only two years of audited financial statements and we are also permitted to elect to incorporate by reference information filed after the effective date of the S-1 registration statement of which this prospectus forms a part. We will remain a smaller reporting company until the last day of the fiscal year in which (1) the market value of our shares of Common Stock held by non-affiliates exceeds \$250 million as of the prior June 30, or (2) our annual revenues exceeded \$100 million during such completed fiscal year and the market value of our shares of Common Stock held by non-affiliates exceeds \$700 million as of the prior June 30. Corporate Information On August 6, 2015, Emergent BioSolutions Inc. ("Emergent"), announced a plan to separate into two independent publicly traded companies. To accomplish this separation, Emergent created Aptevo Therapeutics Inc. ("Aptevo"), to be the parent company for the development-based biotechnology business focused on novel oncology and hematology therapeutics. Aptevo was incorporated in Delaware in February 2016 as a wholly owned subsidiary of Emergent. To effect the separation, Emergent made a pro rata distribution of Aptevo's Common Stock to Emergent's stockholders on August 1, 2016. Our Common Stock currently trades on the Nasdaq under the symbol "APVO." Our primary executive offices are located at 2401 4th Avenue, Suite 1050, Seattle, Washington and our telephone number is (206) 838-0500. Our website address is www.aptevotherapeutics.com. The information contained in, or that can be accessed through, our website is not a part of or incorporated by reference in this prospectus, and you should not consider it part of this prospectus or of any prospectus supplement. We have included our website address in this prospectus solely as an inactive textual reference. 4. THE OFFERING Common Stock to be Offered Up to 13,513,513 shares. Pre-funded Warrants to be Offered We are also offering to certain purchasers whose purchase of shares of common stock in this offering would otherwise result in the purchaser, together with its affiliates and certain related parties, beneficially owning more than 4.99% (or, at the election of the purchaser, 9.99%) of our outstanding common stock immediately following the consummation of this offering, the opportunity to purchase, if such purchasers so choose, pre-funded warrants to purchase shares of common stock, in lieu of shares of common stock that would otherwise result in any such purchaser's beneficial ownership exceeding 4.99% (or, at the election of the purchaser, 9.99%) of our outstanding common stock. Each pre-funded warrant will be exercisable for one share of our common stock. The purchase price of each pre-funded warrant and accompanying common warrants will equal the price at which the share of common stock and accompanying common warrants are being sold to the public in this offering, minus \$0.0001, and the exercise price of each pre-funded warrant will be \$0.0001 per share. The pre-funded warrants will be exercisable immediately and may be exercised at any time until all of the pre-funded warrants are exercised in full. This offering also relates to the shares of common stock issuable upon exercise of any pre-funded warrants sold in this offering. For each pre-funded warrant we sell, the number of shares of common stock we are offering will be decreased on a

one-for-one basis. Because we will issue two common warrants, each to purchase one share of common stock for each share of our common stock and for each pre-funded warrant to purchase one share of our common stock sold in this offering, the number of common warrants sold in this offering will not change as a result of a change in the mix of the shares of our common stock and pre-funded warrants sold. **Common Warrants to be Offered** Common warrants to purchase up to 27,027,026 shares of our common stock. Each common warrant has an exercise price of \$ per share of common stock. Common warrants will become exercisable beginning on the date of the Stockholder Approval and will expire five years from the date of Stockholder Approval. The shares of common stock and pre-funded warrants, and the accompanying common warrant, as the case may be, can only be purchased together in this offering but will be issued separately and will be immediately separable upon issuance. This prospectus also relates to the offering of the shares of common stock issuable upon exercise of the common warrants. **Common Stock to be Outstanding Before this Offering** 9,421,174 shares. **Common Stock to be Outstanding Immediately After this Offering** 22,934,687 shares, (assuming full exercise of the pre-funded warrants and assuming no exercise of the common warrants). **Use of Proceeds** We estimate that the net proceeds from this offering will be approximately \$4.4 million, excluding the proceeds, if any, from the cash exercise of the common warrants in this offering. We currently intend to use the net proceeds from this offering for working capital and general corporate purposes, including the further development of our product candidates. See "Use of Proceeds" for additional information. **Risk Factors** An investment in our securities involves a high degree of risk. See "Risk Factors" beginning on page 7A of this prospectus and the other information included and incorporated by reference in 5 A this prospectus for a discussion of the risk factors you should carefully consider before deciding to invest in our securities. **Nasdaq Symbol** Our common stock is listed on the Nasdaq Capital Market under the symbol "APVO." There is no established public trading market for the pre-funded warrants or common warrants, and we do not expect a market to develop. In addition, we do not intend to apply to list the pre-funded warrants or common warrants on any national securities exchange or other nationally recognized trading system. Without an active trading market, the liquidity of the pre-funded warrants and common warrants will be limited. The above discussion is based on 9,421,174 shares of our common stock outstanding as of August 27, 2024, assumes no sale of pre-funded warrants and excludes, as of that date, the following: 9,648 shares of Common Stock issuable upon the exercise of stock options outstanding at a weighted average exercise price of \$559.22 per share; 69,458 shares of Common Stock issuable upon the vesting of outstanding restricted stock units at a weighted average fair value per unit of \$6.68 per share; 101,766 shares of Common Stock reserved for future grants of equity-based awards under our equity incentive plans; 1,316 and 1,316 shares of Common Stock issuable upon the exercise of Series A and Series B common warrants, respectively, at an exercise price of \$27.28 per share; 8,762 and 8,762 shares of Common Stock issuable upon the exercise of Series A-1 and Series A-2 common warrants, respectively, at an exercise price of \$10.25; 8,762 and 8,762 shares of Common Stock issuable upon the exercise of Series B-1 and Series B-2 common warrants, respectively, at an exercise price of \$10.25; 133,332 shares of Common Stock issuable upon the exercise of common warrants at an exercise price of \$1.35; and 17,997,853 shares of Common Stock issuable upon the exercise of common warrants at an exercise price of \$0.515. **6 RISK FACTORS** An investment in our securities involves a high degree of risk. Before deciding whether to purchase our securities, including the shares of common stock offered by this prospectus, you should carefully consider the risks and uncertainties described under "Risk Factors" in our Annual Report on Form 10-K for the fiscal year ended December 31, 2023, any subsequent Quarterly Report on Form 10-Q and our other filings with the SEC, all of which are incorporated by reference herein. If any of these risks actually occur, our business, financial condition and results of operations could be materially affected and we may not be able to achieve our goals, the value of our securities could decline and you could lose some or all of your investment. Additional risks not presently known to us or that we currently believe are immaterial may also significantly impair our business operations. If any of these risks occur, our business, results of operations or financial condition and prospects could be harmed. In that event, the market price of our common stock and the value of the warrants could decline, and you could lose all or part of your investment. **Risks Related to This Offering** We have broad discretion in the use of the net proceeds from this offering and may not use them effectively. Our management will have broad discretion in the application of the net proceeds, including for any of the purposes described in the section of this prospectus entitled "Use of Proceeds." You will be relying on the judgment of our management with regard to the use of these net proceeds, and you will not have the opportunity, as part of your investment decision, to assess whether the net proceeds are being used appropriately. The failure by our management to apply these funds effectively could result in financial losses that could have a material adverse effect on our business, cause the price of our securities to decline and delay the development of our product candidates. Pending the application of these funds, we may invest the net proceeds from this offering in a manner that does not produce income or that loses value. You will experience immediate and substantial dilution in the net tangible book value per share of the common stock you purchase. You may also experience future dilution as a result of future equity offerings. The price per share, together with the number of shares of our common stock we propose to issue and ultimately will issue if this offering is completed, may result in an immediate decrease in the market price of our common stock. Our historical net tangible book value as of July 31, 2024 was \$2.5 million, or approximately \$0.26 per share of our common stock. After giving effect to the 13,513,513 shares of our common stock or the exercise of the pre-funded warrants to be sold in this offering at an assumed public offering price of \$0.37 per share, our as adjusted net tangible book value as of July 31, 2024 would have been \$6.9 million, or approximately \$0.30 per share of our common stock. This represents an immediate increase in the net tangible book value of \$0.04 per share of our common stock to our existing stockholders and an immediate dilution in net tangible book value of approximately \$0.07 per share of our common stock to new investors, representing the difference between the assumed public offering price and our as adjusted net tangible book value as of July 31, 2024, after giving effect to this offering, and the assumed public offering price per share. In addition, in order to raise additional capital, we may in the future offer additional shares of our common stock or other securities convertible into or exchangeable for our common stock at prices that may not be the same as the price per share in this offering. In the event that the outstanding options or warrants are exercised or settled, or that we make additional issuances of common stock or other convertible or exchangeable securities, you could experience additional dilution. We cannot assure you that we will be able to sell shares or other securities in any other offering at a price per share that is equal to or greater than the price per share paid by investors in this offering, and investors purchasing shares or other securities in the future could have rights superior to existing stockholders, including investors who purchase shares of common stock in this offering. The price per share at which we sell additional shares of our common stock or securities convertible into common stock in future transactions, may be higher or lower than the price per share in this offering. As a result, purchasers of the shares we sell, as well as our existing stockholders, will experience significant dilution if we sell at prices significantly below the price at which they invested. **7** There is no public market for the common warrants or pre-funded warrants being offered by us in this offering. There is no established public trading market for the common warrants or the pre-funded warrants, and we do not expect a market to develop. In addition, we do not intend to apply to list the common warrants or pre-funded warrants on any national securities exchange or other nationally recognized trading system. Without an active market, the liquidity of the common warrants and pre-funded warrants will be limited. The common warrants are not exercisable until Stockholder Approval and may not have any value. Under Nasdaq listing rules, the common warrants are not exercisable without Stockholder Approval for the issuance of shares issuable upon exercise of the common warrants. While we intend to use reasonable best efforts to seek Stockholder Approval for issuances of shares of common stock issuable upon exercise of the common warrants, there is no guarantee that the Stockholder Approval will ever be obtained. The common warrants will be exercisable commencing on the date Stockholder Approval is obtained, if at all, at an initial exercise price per share of \$ . In the event that the price of a share of our common stock does not exceed the exercise price of the common warrants during the period when the common warrants are exercisable, the common warrants may not have any value. If we are unable to obtain the Stockholder Approval, the common warrants will not be exercisable and therefore would have no value. In addition, we may incur substantial cost, and management may devote substantial time and attention, in attempting to obtain Stockholder Approval of the issuance of shares of common stock upon exercise of the common warrants issued in this offering. The common warrants and pre-funded warrants are speculative in nature. The common warrants and pre-funded warrants offered hereby do not confer any rights of share of common stock ownership on their holders, such as voting rights or the right to receive dividends, but rather merely represent the right to acquire shares of common stock at a fixed price. Specifically, only following receipt of the Stockholder Approval, holders of the common warrants may acquire the shares of common stock issuable upon exercise of such warrants at an exercise price of \$ per share of common stock, and holders of the pre-funded warrants may acquire the shares of common stock issuable upon exercise of such warrants at an exercise price of \$0.0001 per share of common stock. Moreover, following this offering, the market value of the common warrants and pre-funded warrants is uncertain and there can be no assurance that

the market value of the common warrants or pre-funded warrants will equal or exceed their respective public offering prices. There can be no assurance that the market price of the shares of common stock will ever equal or exceed the exercise price of the common warrants or pre-funded warrants, and consequently, whether it will ever be profitable for holders of common warrants to exercise the common warrants or for holders of the pre-funded warrants to exercise the pre-funded warrants. Holders of the warrants offered hereby will have no rights as common stockholders with respect to the shares of our common stock underlying the warrants until such holders exercise their warrants and acquire our common stock, except as otherwise provided in the warrants. Until holders of the common warrants and the pre-funded warrants acquire shares of our common stock upon exercise thereof, such holders will have no rights with respect to the shares of our common stock underlying such warrants, except to the extent that holders of such warrants will have certain rights to participate in distributions or dividends paid on our common stock as set forth in the warrants. Upon exercise of the common warrants and the pre-funded warrants, the holders will be entitled to exercise the rights of a common stockholder only as to matters for which the record date occurs after the exercise date. This is a reasonable best efforts offering, no minimum amount of securities is required to be sold, and we may not raise the amount of capital we believe is required for our business plans, including our near-term business plans. The placement agent has agreed to use its reasonable best efforts to solicit offers to purchase the securities in this offering. The placement agent has no obligation to buy any of the securities from us or to arrange for the purchase or sale of any specific number or dollar amount of the securities. There is no required minimum number of securities that must be sold as a condition to completion of this offering.

Because there is no minimum offering amount required as a condition to the closing of this offering, the actual offering amount, placement agent fees and proceeds to us are not presently determinable and may be substantially less than the maximum amounts set forth above. We may sell fewer than all of the securities offered hereby, which may significantly reduce the amount of proceeds received by us, 8 Â and investors in this offering will not receive a refund in the event that we do not sell an amount of securities sufficient to support our continued operations, including our near-term continued operations. Thus, we may not raise the amount of capital we believe is required for our operations in the short-term and may need to raise additional funds, which may not be available or available on terms acceptable to us. Purchasers who purchase our securities in this offering pursuant to a securities purchase agreement may have rights not available to purchasers that purchase without the benefit of a securities purchase agreement. In addition to rights and remedies available to all purchasers in this offering under federal securities and state law, the purchasers that enter into a securities purchase agreement will also be able to bring claims of breach of contract against us. The ability to pursue a claim for breach of contract provides those investors with the means to enforce the covenants uniquely available to them under the securities purchase agreement including, but not limited to: (i) timely delivery of securities; (ii) agreement to not enter into any financings for 60 days from closing; and (iii) indemnification for breach of contract. Resales of our common stock in the public market during this offering by our stockholders may cause the market price of our common stock to fall. Â Sales of a substantial number of shares of our common stock could occur at any time. The issuance of new shares of our common stock could result in resales of our common stock by our current stockholders concerned about the potential ownership dilution of their holdings. In turn, these resales could have the effect of depressing the market price for our common stock. Â Our common stock may be at risk for delisting from the Nasdaq Capital Market in the future if we do not maintain compliance with Nasdaqâ€™s continued listing requirements. Delisting could adversely affect the liquidity of our common stock and the market price of our common stock could decrease. Our common stock is currently listed on Nasdaq. Nasdaq has minimum requirements that a company must meet in order to remain listed on Nasdaq, including corporate governance standards and a requirement that we maintain a minimum closing bid price of \$1.00 per share. On June 25, 2024, the Company received a letter from Nasdaq notifying the Company that, for the last 30 consecutive business days, the bid price of the Companyâ€™s common stock had closed below \$1.00 per share, the minimum closing bid price required by the continued listing requirements of Nasdaq Listing Rule 5550(a)(2) (the "Bid Price Requirement"). Nasdaqâ€™s letter has no immediate impact on the listing of the Companyâ€™s common stock, which will continue to be listed and traded on Nasdaq, subject to the Companyâ€™s compliance with the other continued listing requirements. Nasdaqâ€™s letter provides the Company 180 calendar days, or until December 23, 2024 (the "Compliance Date"), to regain compliance with the Bid Price Requirement. To regain compliance with the Bid Price Requirement, the closing bid price of the Companyâ€™s common stock must be at least \$1.00 per share for a minimum of ten consecutive business days before the Compliance Date. The Company may be eligible for an additional 180-day period to regain compliance if the Company meets all other listing standards of Nasdaq, with the exception of the bid price requirement, and provides written notice to Nasdaq of its intention to cure the deficiency during the second compliance period, by effecting a reverse stock split, if necessary. However, Nasdaq Listing Rule 5810(c)(3)(A)(iv) states that any listed company that fails to meet the Bid-Price Requirement after effecting one or more reverse stock splits over the prior two-year period with a cumulative ratio of 250 shares or more to one, then the company is not eligible for a compliance period to regain compliance and would be subject to delisting by Nasdaq. If during any compliance period, a company's security has a closing bid price of \$0.10 or less for ten consecutive trading days, the Company's security would be subject to delisting immediately. In addition, under proposed Nasdaq rules, if the price of the Company's common stock fails to satisfy the Bid Price Requirement within one year of the Company's previous 1-for-44 reverse stock split effectuated on March 5, 2024, then the Company's common stock would be subject to delisting by Nasdaq without any opportunity for a cure period. In the event the Company fails to regain compliance, the Company would have the right to a hearing before the Nasdaq Listing Qualifications Panel (the "Panel"). There can be no assurance that, if the Company receives a delisting notice and appeals the delisting determination by the Panel, such appeal would be successful. 9 Â The Company intends to take all reasonable measures available to regain compliance under the Nasdaq Listing Rules and remain listed on Nasdaq, including by effecting a reverse stock split. In the future, if we fail to maintain such minimum requirements and a final determination is made by Nasdaq that our common stock must be delisted, the liquidity of our common stock would be adversely affected and the market price of our common stock could decrease. In addition, if delisted, we would no longer be subject to Nasdaq rules, including rules requiring us to have a certain number of independent directors and to meet other corporate governance standards. Our failure to be listed on Nasdaq or another established securities market would have a material adverse effect on the value of your investment in us. If our common stock is not listed on Nasdaq or another national exchange, the trading price of our common stock is below \$5.00 per share and we have net tangible assets of \$6,000,000 or less, the open-market trading of our common stock will be subject to the "penny stock" rules promulgated under the Securities Exchange Act of 1934, as amended. If our shares become subject to the "penny stock" rules, broker-dealers may find it difficult to effectuate customer transactions and trading activity in our securities may be adversely affected. Â This offering may cause the trading price of our common stock to decrease. Â The price per share, together with the number of shares of common stock we propose to issue and ultimately will issue if this offering is completed, may result in an immediate decrease in the market price of our common stock. This decrease may continue after the completion of this offering. Â 10 Â USE OF PROCEEDS We estimate that the net proceeds from the offering will be approximately \$4.4 million, after deducting the placement agent fees and estimated offering expenses payable by us, assuming no sale of any fixed combinations of pre-funded warrants and warrants offered hereunder. We may only receive additional proceeds from the exercise of the common warrants issuable in connection with this offering if the Stockholder Approval is obtained and, if such common warrants are exercised in full for cash, the estimated net proceeds will increase to \$9.2 million. However, because this is a reasonable best-efforts offering and there is no minimum offering amount required as a condition to the closing of this offering, the actual offering amount, the placement agentâ€™s fees and net proceeds to us are not presently determinable and may be substantially less than the maximum amounts set forth on the cover page of this prospectus. We currently intend to use the net proceeds from this offering for working capital to fund our clinical programs and general corporate purposes, including the further development of our product candidates. This expected use of proceeds from this offering represents our intentions based upon our current plans and prevailing business conditions, which could change in the future as our plans and prevailing business conditions evolve. The amounts and timing of our use of proceeds will vary depending on a number of factors, including the amount of cash generated or used by our operations. As a result, we will retain broad discretion in the allocation of the net proceeds of this offering. Â 11 Â CAPITALIZATION The following table presents a summary of our cash and cash equivalents and capitalization as of July 31, 2024: â€¢on an actual basis; and â€¢on an as adjusted basis to reflect the issuance and sale of common stock and accompanying common warrants in this offering, after deducting placement agent fees and estimated offering expenses payable by us. The as adjusted basis assumes no Pre-Funded warrants are sold in this offering and excludes the proceeds, if any, from the exercise of any Common Warrants issued in this offering. The unaudited as adjusted information below is prepared for illustrative purposes only and our capitalization following the completion of this offering will be adjusted based on the actual public offering price and other terms of this offering determined at pricing. You should read the following

table in conjunction with Management's Discussion and Analysis of Financial Condition and Results of Operations and the historical financial statements and related notes in the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2023 and our Quarterly Report on Form 10-Q for the period ended June 30, 2024, incorporated herein by reference. As of July 31, 2024 (in thousands) Actual As adjusted Cash and cash equivalents \$ 7,554 \$ 11,953 Common stock: \$0.001 par value; 500,000,000 shares authorized; 9,420,489 shares issued and outstanding, actual; 22,934,002 shares issued and outstanding, pro forma as adjusted 74 88 Additional paid-in capital 242,905 247,290 Accumulated deficit (237,971 ) (237,971 ) Total stockholders' equity \$ 5,008 \$ 9,407 Each \$0.25 increase (decrease) in the assumed public offering price of \$0.37 per share would increase (decrease) each of cash and cash equivalents, additional paid-in capital and total shareholders' equity by approximately \$3.6 million, assuming the number of shares of common stock and common warrants offered, as set forth on the cover page of this prospectus, remains the same, and after deducting estimated placement agent fees and estimated offering expenses. Similarly, each increase (decrease) of 100,000 shares in the number of shares of common stock and common warrants offered would increase (decrease) cash and cash equivalents, additional paid-in capital and total shareholders' equity by approximately \$0.03 million, assuming the assumed public offering price remains the same, and after deducting estimated placement agent fees and estimated offering expenses payable by us. The pro forma as adjusted information discussed above is illustrative only and will be adjusted based on the actual public offering price and other terms of this offering determined at pricing. The above discussion is based on 9,420,489 shares of our common stock outstanding as of July 31, 2024, assumes no sale of pre-funded warrants and excludes, as of that date, the following: 9,656 shares of Common Stock issuable upon the exercise of stock options outstanding at a weighted average exercise price of \$559.05 per share; 70,205 shares of Common Stock issuable upon the vesting of outstanding restricted stock units at a weighted average fair value per unit of \$8.51 per share; 101,686 shares of Common Stock reserved for future grants of equity-based awards under our equity incentive plans; 1,316 and 1,316 shares of Common Stock issuable upon the exercise of Series A and Series B common warrants, respectively, at an exercise price of \$27.28 per share; 8,762 and 8,762 shares of Common Stock issuable upon the exercise of Series A-1 and Series A-2 common warrants, respectively, at an exercise price of \$10.25; 8,762 and 8,762 shares of Common Stock issuable upon the exercise of Series B-1 and Series B-2 common warrants, respectively, at an exercise price of \$10.25; 133,332 shares of Common Stock issuable upon the exercise of common warrants at an exercise price of \$1.35; and 17,997,853 shares of Common Stock issuable upon the exercise of common warrants at an exercise price of \$0.515.

**13 DILUTION** If you purchase shares of our common stock, your interest will be diluted immediately to the extent of the difference between the offering price per share you will pay in this offering and the as adjusted net tangible book value per share of our common stock after this offering. Net tangible book value per share represents our total tangible assets less total liabilities, divided by the number of shares of our common stock outstanding. As of July 31, 2024, our net tangible book value was \$2.5 million, or \$0.26 per share of Common Stock. After giving effect to the foregoing pro forma adjustments and the sale by us of 13,513,513 shares of common stock and accompanying common warrants at an assumed public offering price of \$0.37 per share and \$0.0001 per pre-funded warrant and accompanying common warrant, and after deducting the placement agent fees and estimated offering expenses payable by us, our as adjusted net tangible book value as of July 31, 2024, would have been \$6.9 million, or \$0.30 per share. This represents an immediate increase in as adjusted net tangible book value of approximately \$0.04 per share to our existing stockholders, and an immediate dilution of \$0.07 per share to purchasers of shares in this offering, as illustrated in the following table: Assumed public offering price per Share \$ 0.37 Net tangible book value per share as of July 31, 2024 \$ 0.26 Net increase in net tangible book value per share attributable to existing shareholders \$ 0.04 As adjusted net tangible book value per share after this offering \$ 0.30 Dilution in net tangible book value per share to new investors in the offering \$ (0.07 ) The above discussion is based on 9,420,489 shares of our common stock outstanding as of July 31, 2024, assumes no sale of pre-funded warrants and excludes, as of that date, the following: 9,656 shares of Common Stock issuable upon the exercise of stock options outstanding at a weighted average exercise price of \$559.05 per share; 70,205 shares of Common Stock issuable upon the vesting of outstanding restricted stock units at a weighted average fair value per unit of \$8.51 per share; 101,686 shares of Common Stock reserved for future grants of equity-based awards under our equity incentive plans; 1,316 and 1,316 shares of Common Stock issuable upon the exercise of Series A and Series B common warrants, respectively, at an exercise price of \$27.28 per share; 8,762 and 8,762 shares of Common Stock issuable upon the exercise of Series A-1 and Series A-2 common warrants, respectively, at an exercise price of \$10.25; 8,762 and 8,762 shares of Common Stock issuable upon the exercise of Series B-1 and Series B-2 common warrants, respectively, at an exercise price of \$10.25; 133,332 shares of Common Stock issuable upon the exercise of common warrants at an exercise price of \$1.35; and 17,997,853 shares of Common Stock issuable upon the exercise of common warrants at an exercise price of \$0.515.

**14 DESCRIPTION OF CAPITAL STOCK** The following summary of the rights of our capital stock is not complete and is subject to and qualified in its entirety by reference to our Charter and Bylaws, copies of which are filed as exhibits to our Annual Report on Form 10-K for the year ended December 31, 2023, filed with the SEC on March 5, 2024, and the Certificate of Designations and forms of securities, copies of which are filed as exhibits to the registration statement of which this prospectus forms a part, which are incorporated by reference herein. As of the date of this prospectus, our certificate of incorporation, authorizes us to issue up to 500,000,000 shares of Common Stock, \$0.001 par value per share, and 15,000,000 shares of preferred stock, \$0.001 par value per share. Our Common Stock is registered under Section 12(b) of the Exchange Act and is listed on the Nasdaq under the trading symbol "APVO." As of August 27, 2024, 9,421,174 shares of Common Stock were outstanding and no shares of preferred stock were outstanding. The following summary describes the material terms of our capital stock. The summary is qualified in its entirety by reference to our certificate of incorporation and our bylaws.

**Authorized Shares** Our authorized Shares consists of 500,000,000 shares of Common Stock and 15,000,000 shares of preferred stock, \$0.001 par value per share (the "Preferred Stock"). Our Common Stock is registered under Section 12(b) of the Exchange Act and is listed on the Nasdaq under the trading symbol "APVO." Common Stock Voting Rights Each holder of our Common Stock is entitled to one vote for each share on all matters submitted to a vote of the stockholders, including the election of directors. Under our amended and restated certificate of incorporation and amended and restated bylaws, our stockholders do not have cumulative voting rights. Because of this, the holders of a majority of the shares of Common Stock entitled to vote in any election of directors can elect all of the directors standing for election, if they should so choose. Dividends Subject to preferences that may be applicable to any then-outstanding shares of preferred stock, holders of Common Stock are entitled to receive ratably those dividends, if any, as may be declared from time to time by our board of directors out of legally available funds.

**Liquidation** In the event of our liquidation, dissolution or winding up, holders of Common Stock will be entitled to share ratably in the net assets legally available for distribution to stockholders after the payment of all of our debts and other liabilities and the satisfaction of any liquidation preference granted to the holders of any then-outstanding shares of preferred stock. Rights and Preferences Each share of Common Stock includes an associated right pursuant to and as set forth in the Rights Agreement that we entered into with Broadridge Corporate Issuer Solutions, Inc. on November 8, 2020 (the "rights agreement"). Each right initially represents the right to purchase from us one one-thousandth of a share of our Series A Junior Participating Preferred Stock, par value \$0.001 per share. This right is not exercisable until the occurrence of certain events specified in such rights agreement. The value attributable to these rights, if any, is reflected in the value of our Common Stock. The rights agreement and the rights granted thereunder will expire upon the earliest to occur of (i) the date on which all of such rights are redeemed, (ii) the date on which such rights are exchanged, and (iii) the close of business on November 4, 2024.

**Fully Paid and Nonassessable.** All of our outstanding shares of Common Stock are fully paid and nonassessable.

**15 Preferred Stock** Pursuant to our amended and restated certificate of incorporation, our board of directors has the authority, without further action by our stockholders, to designate up to 15,000,000 shares of preferred stock in one or more series and to fix the rights, preferences, privileges and restrictions thereof. These rights, preferences and privileges could include dividend rights, conversion rights, voting rights, terms of redemption, liquidation preferences, sinking fund terms and the number of shares constituting, or the designation of, such series, any or all of which may be greater than the rights of common stock. The Delaware General Corporation Law ("DGCL") provides that the holders of preferred stock will have the right to vote separately as a class on any proposal involving fundamental changes in the rights of holders of that preferred stock. This right is in addition to any voting rights that may be provided for in the applicable certificate of designation.

**Warrants** Series A and Series B Common Warrants 2023 - As of August 27, 2024, we have issued and outstanding 1,316 Series A and 1,316 Series B common warrants to purchase shares of our Common Stock at an exercise price of \$27.28 per share and 41,239 Series A common warrants outstanding with an amended exercise price of \$0.515 per share. The Series A common warrants and Series B common warrants are immediately exercisable and expire in August 2028 and February 2025, respectively. The exercise price

and the number of shares of Common Stock purchasable upon the exercise of the warrants are subject to adjustment upon the occurrence of specific events, including sales of additional shares of Common Stock, stock dividends, stock splits, reclassifications and combinations of our Common Stock. If, at any time warrants are outstanding, any fundamental transaction occurs, as described in the warrants, the successor entity must assume the obligations to the warrant holders. Additionally, in the event of a fundamental transaction, the holders of the warrants will be entitled to receive upon exercise of the warrants the kind and amount of securities, cash or other property that the holders would have received had they exercised the warrants immediately prior to such fundamental transaction. Holders of the warrants do not have the rights or privileges of holders of our common shares, including any voting rights, until they exercise their warrants, with exceptions for participation in rights offerings or extraordinary distributions.

**New Series A and Series B Common Warrants - November 2023** - On November 9, 2023, we entered into a warrant Inducement Agreement (the "Inducement Agreement") with certain holders of our existing Series A common warrants and Series B common warrants (together, the "Existing Warrants") to purchase shares of common stock. Pursuant to the terms of the Inducement Agreement, the holders agreed to exercise for cash their Existing Warrants to purchase up to an aggregate of 363,930 shares of common stock at an exercise price of \$10.25 during the period from the date of the Inducement Agreement until December 8, 2023. In consideration of the holder's agreement to exercise the Existing Warrants, we agreed to issue new Series A and new Series B common warrants (together, the "New Warrants"), to purchase a number of shares of common stock equal to 200% of the number of shares of common stock issued upon exercise of the Existing Warrants. Holders exercised 140,726 Existing Series A and 181,965 Existing Series B Warrants and the Company received \$3.3 million in gross proceeds. As of August 27, 2024, we have 17,524 New Series A and 17,524 New Series B Common Warrants outstanding from our November 2023 warrant inducement with an exercise price of \$10.25 per share and 263,928 New Series A and 346,406 New Series B common warrants with an amended exercise price of \$0.515 per share. If the New Warrants are exercised, we may receive up to an additional \$0.7 million in gross proceeds.

**Common Warrants April 2024** - As of August 27, 2024, we have issued and outstanding common warrants to purchase 133,332 shares of our Common Stock at an exercise price of \$1.35 per share issued as part of our April 2024 public offering (the "April 2024 Warrants") and 6,666,668 common warrants outstanding with an amended exercise price of \$0.515 per share. The April 2024 Warrants are immediately exercisable and expire on April 10, 2029. The exercise price and the number of shares of Common Stock purchasable upon the exercise of the April 2024 Warrants are subject to adjustment upon the occurrence of specific events, including stock dividends, stock splits, reclassifications and combinations of our Common Stock. If, at any time the April 2024 Warrants are outstanding and a fundamental transaction, as described in the April 2024 Warrant, and generally including any reorganization, recapitalization or reclassification of our common stock, the sale, transfer or other disposition of all or substantially all of our properties or assets, our consolidation or merger with or into another person, the acquisition of more than 50% of our outstanding common stock, or any person or group becoming the beneficial owner of 50% of the voting power represented by our outstanding common stock, occurs the holders of the April 2024 Warrants will be entitled to receive upon exercise of the April 2024 Warrants the kind and amount of securities, cash or other property that the holders would have received had they exercised the April 2024 Warrants immediately prior to such fundamental transaction, other than one in which a successor entity that is a publicly traded corporation (whose stock is quoted or listed for trading on a national securities exchange, including, but not limited to, the New York Stock Exchange, the NYSE American, the Nasdaq Global Select Market, the Nasdaq Global Market or the Nasdaq Capital Market) assumes the common warrant such that the warrant shall be exercisable for the publicly traded common stock of such successor entity. Additionally, as more fully described in the common warrants, at the option of the holders of the common warrants the holder can receive consideration in the same type and form of an amount equal to the Black Scholes value (as defined in the common warrant) of such unexercised common warrants on the date of consummation of such transaction. Except as otherwise provided in the April 2024 Warrants or by virtue of the holder's ownership of shares of our common stock, such holder of April 2024 Warrants does not have the rights or privileges of a holder of our common stock, including any voting rights, until such holder exercises such holder's April 2024 Warrants. The April 2024 Warrants provide that the holders of the April 2024 Warrants have the right to participate in distributions or dividends paid on our shares of common stock.

**Common Warrants - July 2024** - As of August 27, 2024, we have issued and outstanding common warrants to purchase up to 10,679,612 shares of our Common Stock at an exercise price of \$0.515 per share issued as part of our July 2024 registered direct offering (the "July 2024 Warrants"). The July 2024 Warrants became exercisable upon approval by stockholders on August 6, 2024, and expire on August 6, 2029. The exercise price of the July 2024 Warrants is subject to adjustment for stock splits and similar capital transactions and is subject to repricing in the event of a share split, share dividend, share combination or other such event as described in the July 2024 Warrants. If, at any time the July 2024 Warrants are outstanding and a fundamental transaction, as described in the July 2024 Warrant, and generally including any reorganization, recapitalization or reclassification of our common stock, the sale, transfer or other disposition of all or substantially all of our properties or assets, our consolidation or merger with or into another person, the acquisition of more than 50% of our outstanding common stock, or any person or group becoming the beneficial owner of 50% of the voting power represented by our outstanding common stock occurs, the holders of the July 2024 Warrants will be entitled to receive upon exercise of the July 2024 Warrants the kind and amount of securities, cash or other property that the holders would have received had they exercised the July 2024 Warrants immediately prior to such fundamental transaction, other than one in which a successor entity that is a publicly traded corporation (whose stock is quoted or listed for trading on a national securities exchange, including, but not limited to, the New York Stock Exchange, the NYSE American, the Nasdaq Global Select Market, the Nasdaq Global Market or the Nasdaq Capital Market) assumes the common warrant such that the warrant shall be exercisable for the publicly traded common stock of such successor entity. Additionally, as more fully described in the common warrants, at the option of the holders of the common warrants, the holder can receive consideration in the same type and form of an amount equal to the Black Scholes value (as defined in the common warrant) of such unexercised common warrants on the date of consummation of such transaction. Except as otherwise provided in the July 2024 Warrants or by virtue of the holder's ownership of shares of our common stock, such holder of July 2024 Warrants does not have the rights or privileges of a holder of our common stock, including any voting rights, until such holder exercises such holder's July 2024 Warrants. The July 2024 Warrants provide that the holders of the July 2024 Warrants have the right to participate in distributions or dividends paid on our shares of common stock.

**Stockholder Registration Rights** Certain holders of shares of our Common Stock are entitled to certain rights with respect to registration of such shares under the Securities Act. These shares are referred to as registrable securities. The holders of these registrable securities possess registration rights described in additional detail below pursuant to the terms of a registration rights agreement. The registration of shares of our Common Stock pursuant to the exercise of registration rights described below would enable the holders to trade these shares without restriction under the Securities Act when the applicable registration statement is declared effective. We will pay the registration expenses, other than underwriting discounts, selling commissions and stock transfer taxes, of the shares registered pursuant to the demand and piggyback registration rights described below. Generally, in an underwritten offering, the managing underwriter, if any, has the right, subject to specified conditions, to limit the number of shares the holders may include.

**17 Demand Registration Rights** The holders of the registrable securities are entitled to certain demand registration rights. At any time, the holders of at least 20% of the registrable securities, on not more than two occasions, may request that we register all or a portion of their shares, subject to certain specified exceptions. Such request for registration must cover securities the aggregate offering price of which, before payment of underwriting discounts and commissions, exceeds \$10,000,000.

**Piggyback Registration Rights** In connection with the filing of the registration statement of which this prospectus forms a part, the holders of the registrable securities were entitled to, and the necessary percentage of holders waived, their rights to notice of such filing and to include their shares of registrable securities in the registration statement of which this prospectus forms a part. If we propose to register for offer and sale any of our securities under the Securities Act in a future offering, either for our own account or for the account of other security holders, the holders of these shares will be entitled to certain "piggyback" registration rights allowing them to include their shares in such registration, subject to certain marketing and other limitations. As a result, whenever we propose to file a registration statement under the Securities Act, including a registration statement on Form S-3 as discussed below, other than with respect to a demand registration or a registration statement on Forms S-4 or S-8 or related to stock issued upon conversion of debt securities, the holders of these shares are entitled to notice of the registration and have the right, subject to limitations that the underwriters may impose on the number of shares included in the registration, to include their shares in the registration.

**Lincoln Park Registration Rights** On February 16, 2022, we entered into a Purchase Agreement ("2022 Purchase Agreement") and a Registration Rights Agreement with Lincoln Park (the "Registration Rights Agreement"). The 2022 Purchase Agreement and Registration Rights Agreement replaced the Purchase Agreement and Registration Rights Agreement with Lincoln Park

that we entered into on December 20, 2018. Under the 2022 Purchase Agreement, Lincoln Park committed to purchase up to \$35.0 million of our common stock over a 36-month period commencing after the satisfaction of certain conditions, which are within our control, as set forth in the 2022 Purchase Agreement. The purchase price per share will be based on prevailing market prices; provided, however, that the prevailing market price is not below \$1.00. We agreed to and issued 2,256 shares of our common stock to Lincoln Park for no cash consideration as an initial fee for its commitment to purchase shares of our common stock under the 2022 Purchase Agreement. Certain Anti-Takeover Provisions of Our Certificate of Incorporation, Our Bylaws, the DGCL and our Rights Plan Delaware Law We are subject to Section 203 of the DGCL, which prohibits a Delaware corporation from engaging in any business combination with any interested stockholder for a period of three years after the date that such stockholder became an interested stockholder, with the following exceptions: “before such date, the board of directors of the corporation approved either the business combination or the transaction that resulted in the stockholder becoming an interested stockholder;” “completion of the transaction that resulted in the stockholder becoming an interested stockholder, the interested stockholder owned at least 85% of the voting stock of the corporation outstanding at the time the transaction began, excluding for purposes of determining the voting stock outstanding (but not the outstanding voting stock owned by the interested stockholder) those shares owned (1) by persons who are directors and also officers and (2) employee stock plans in which employee participants do not have the right to determine confidentially whether shares held subject to the plan will be tendered in a tender or exchange offer; or” “on or after such date, the business combination is approved by the board of directors and authorized at an annual or special meeting of the stockholders, and not by written consent, by the affirmative vote of at least 66 2/3% of the outstanding voting stock that is not owned by the interested stockholder. In general, Section 203 defines a “business combination” to include the following: 18 “any merger or consolidation involving the corporation and the interested stockholder;” “any sale, transfer, pledge or other disposition of 10% or more of the assets of the corporation involving the interested stockholder;” “subject to certain exceptions, any transaction that results in the issuance or transfer by the corporation of any stock of the corporation to the interested stockholder;” “any transaction involving the corporation that has the effect of increasing the proportionate share of the stock or any class or series of the corporation beneficially owned by the interested stockholder; or” “the receipt by the interested stockholder of the benefit of any loans, advances, guarantees, pledges or other financial benefits by or through the corporation. In general, Section 203 defines an “interested stockholder” as an entity or person who, together with the person’s affiliates and associates, beneficially owns, or within three years prior to the time of determination of interested stockholder status did own, 15% or more of the outstanding voting stock of the corporation. Staggered Board; Removal of Directors. Our amended and restated certificate of incorporation provides for our board of directors to be divided into three classes with staggered three-year terms. Only one class of directors is elected at each annual meeting of our stockholders, with the other classes continuing for the remainder of their respective three-year terms. Because our stockholders do not have cumulative voting rights, stockholders holding a majority of the shares of Common Stock outstanding are able to elect all of our directors. Our certificate of incorporation and our bylaws also provide that directors may be removed by the stockholders only for cause upon the vote of 75% of our outstanding Common Stock. Furthermore, the authorized number of directors may be changed only by resolution of the board of directors, and vacancies and newly created directorships on the board of directors may, except as otherwise required by law or determined by the board, only be filled by a majority vote of the directors then serving on the board, even though less than a quorum. Stockholder Action by Written Consent. Our amended and restated certificate of incorporation and amended and restated bylaws also provide that all stockholder actions must be effected at a duly called meeting of stockholders and eliminates the right of stockholders to act by written consent without a meeting. Our amended and restated bylaws also provide that only our chairman of the board, chief executive officer or the board of directors pursuant to a resolution adopted by a majority of the total number of authorized directors may call a special meeting of stockholders. Requirements for Advance Notification of Stockholder Nominations, Proposals and Amendments. Our amended and restated bylaws also provide that stockholders seeking to present proposals before a meeting of stockholders to nominate candidates for election as directors at a meeting of stockholders must provide timely advance notice in writing, and specify requirements as to the form and content of a stockholder’s notice. Our certificate of incorporation and bylaws provide that the stockholders cannot amend many of the provisions described above except by a vote of 75% or more of our outstanding Common Stock. Shareholder Rights Plan. On November 8, 2020, our board of directors adopted a rights plan pursuant to our rights agreement. The rights plan works by causing substantial dilution to any person or group that acquires beneficial ownership of ten percent (10%) or more of our Common Stock without the approval of our board of directors. As a result, the overall effect of the rights plan and the issuance of the rights pursuant to the rights plan may be to render more difficult or discourage a merger, tender or exchange offer or other business combination involving the Company that is not approved by our board of directors. The rights plan is not intended to interfere with any merger, tender or exchange offer or other business combination approved by our board of directors. The rights plan also does not prevent our board of directors from considering any offer that it considers to be in the best interest of our stockholders. These provisions are intended to enhance the likelihood of continued stability in the composition of our board of directors and its policies and to discourage coercive takeover practices and inadequate takeover bids. These provisions are also designed to reduce our vulnerability to hostile takeovers and to discourage certain tactics that may be used in proxy fights. However, such provisions could have the effect of discouraging others from making tender offers for our shares and may have the effect of delaying changes in our control or management. As a consequence, these provisions may also inhibit fluctuations in the market price of our stock that could result from actual or rumored takeover attempts. We believe that the benefits of these provisions, including increased protection of our potential ability to negotiate with the proponent of an unfriendly or unsolicited proposal to acquire or restructure our company, outweigh the disadvantages of discouraging takeover proposals, because negotiation of takeover proposals could result in an improvement of their terms. 19 “ On November 2, 2023, Aptevo Therapeutics Inc. entered into Amendment No. 3 to the Rights Agreement, dated as of November 8, 2020, between the Company and Broadridge Corporate Issuer Solutions, Inc., as Rights Agent, as amended. The Amendment extends the definition of “Final Expiration Date” (as defined in the Rights Agreement) and certain related language in the Rights Agreement to November 4, 2024. The Amendment also changes the definition of “Purchase Price” (as defined in the Rights Agreement) and certain related language in the Rights Agreement to \$2.02 per one one-thousandth of a Preferred Share. Transfer Agent and Registrar The transfer agent and registrar for our Common Stock is Broadridge, which can be contacted at 51 Mercedes Way, Edgewood, NY 11717, shareholder@broadridge.com, or +1 (720) 378-5591. The transfer agent for any series of preferred stock that we may offer under this prospectus will be named and described in the prospectus supplement for that series. Listing on the Nasdaq Capital Market Our Common Stock is listed on the Nasdaq Capital Market under the symbol “APVO.” 20 “ DESCRIPTION OF SECURITIES WE ARE OFFERING We are offering up to 13,513,513 shares of our common stock (or pre-funded warrants in lieu of) and up to 27,027,026 common warrants to purchase up to 27,027,026 shares of common stock. Each share of common stock is being offered together with two common warrants, each to purchase one share of common stock. We are also offering pre-funded warrants to those purchasers whose purchase of shares of common stock in this offering would result in the purchaser, together with its affiliates and certain related parties, beneficially owning more than 4.99% (or, at the election of the purchaser, 9.99%) of our outstanding shares of common stock following the consummation of this offering in lieu of the shares of common stocks that would result in such excess ownership. Each pre-funded warrant will be exercisable for one share of common stock. Each pre-funded warrant is being offered together with two common warrants, each to purchase one share of common stock. No warrant for fractional shares of common stock will be issued, rather warrants will be issued only for whole shares of common stock. We are also registering the shares of common stock issuable from time to time upon exercise of the pre-funded warrants and common warrants offered hereby. Common Stock The material terms and provisions of our common stock are described under the caption “Description of Capital Stock” in this prospectus and are incorporated herein by reference. Common Warrants General The following is a summary of certain terms and provisions of the common warrants that are being offered hereby is not complete and is subject to, and qualified in its entirety by, the provisions of the common warrant, the form of which will be filed as an exhibit to the registration statement of which this prospectus forms a part. Prospective investors should carefully review the terms and provisions of the form of common warrant for a complete description of the terms and conditions of the common warrants. Stockholder Approval Under Nasdaq listing rules, the common warrants are not exercisable without Stockholder Approval. We have agreed to hold a special meeting of the stockholders, within ninety (90) days following the closing of this offering, in order to seek such Stockholder Approval as may be required by the applicable rules and regulations of the Nasdaq Capital Market (or any successor entity) from our stockholders in order to permit the exercise of the common warrants. We cannot assure you that we will be able to obtain Stockholder Approval. In the event that we are unable to obtain the Stockholder Approval, the common warrants

will not be exercisable and therefore have no value. We have agreed to use reasonable best efforts to hold a special meeting of stockholders (which may also be at the annual meeting of stockholders) at the earliest practicable date after the date hereof, but in no event later than ninety days after the closing of the offering, in order to obtain Stockholder Approval. If the Company does not obtain Stockholder Approval with respect to the terms of the common warrants at the first special meeting of the stockholders, the Company shall call a meeting every sixty (60) days thereafter to seek such Stockholder Approval until the date on which Stockholder Approval is obtained or the Warrants are no longer outstanding. Duration, Exercise Price and Form The Company is offering common warrants to purchase up to an aggregate of 27,027,026 shares of our common stock. Each common warrant may be exercised, in cash or by a cashless exercise at the election of the holder at any time following the date of Stockholder Approval and from time to time thereafter through and including the five year anniversary of the initial exercise date. The exercise price and number of shares of common stock issuable upon exercise is subject to appropriate adjustment in the event of stock dividends, stock splits, reorganizations or similar events affecting our common stock and the exercise price. Subject to the rules and regulations of the applicable trading market, the Company may at any time during the term of the common warrant reduce the then current exercise price to any amount and for any period of time deemed appropriate by the board of directors of the Company. The common warrants will be issued separately from the common stock and will be held separately immediately thereafter. Two common warrants, each to purchase one share of our common stock will be issued for every share of common 21  stock or pre-funded warrant to purchase one share purchased in this offering. The common warrants will be issued in certificated form only. Exercisability The common warrants are not exercisable without first obtaining the Stockholder Approval. Assuming the Stockholder Approval is obtained, the common warrants will be exercisable, at the option of each holder, in whole or in part, by delivering to us a duly executed exercise notice accompanied by payment in full for the number of shares of our common stock purchased upon such exercise (except in the case of a cashless exercise as discussed below). A holder (together with its affiliates) may not exercise any portion of such holder common warrants to the extent that the holder would own more than 4.99% of the outstanding common stock immediately after exercise, except that upon at least 61 days prior notice from the holder to us, the holder may increase the amount of ownership of outstanding stock after exercising the holder common warrants up to 9.99% of the number of shares of our common stock outstanding immediately after giving effect to the exercise, as such percentage ownership is determined in accordance with the terms of the common warrants. Cashless Exercise If, at the time a holder exercises its common warrants, a registration statement registering the issuance of the shares of common stock underlying the common warrants under the Securities Act is not then effective or available for the issuance of such shares, then in lieu of making the cash payment otherwise contemplated to be made to us upon such exercise in payment of the aggregate exercise price, the holder may elect instead to receive upon such exercise (either in whole or in part) the net number of shares of common stock determined according to a formula set forth in the common warrant. Fundamental Transactions In the event of a fundamental transaction, as described in the form of common warrant, and generally including any reorganization, recapitalization or reclassification of our common stock, the sale, transfer or other disposition of all or substantially all of our properties or assets, our consolidation or merger with or into another person, the acquisition of more than 50% of our outstanding common stock, or any person or group becoming the beneficial owner of 50% of the voting power represented by our outstanding common stock, the holders of the common warrants will be entitled to receive upon exercise of the common warrants the kind and amount of securities, cash or other property that the holders would have received had they exercised the common warrants immediately prior to such fundamental transaction, other than one in which a successor entity that is a publicly traded corporation (whose stock is quoted or listed for trading on a national securities exchange, including, but not limited to, the New York Stock Exchange, the NYSE American, the Nasdaq Global Select Market, the Nasdaq Global Market or the Nasdaq Capital Market) assumes the common warrant such that the warrant shall be exercisable for the publicly traded common stock of such successor entity. Additionally, as more fully described in the common warrants, at the option of the holders of the common warrants the holder can receive consideration in the same type and form of an amount equal to the Black Scholes value (as defined in the common warrant) of such unexercised common warrants on the date of consummation of such transaction. Exercise Price Adjustments If at any time on or after the date of issuance there occurs any share split, share dividend, share combination recapitalization or other similar transaction involving our common stock and the lowest daily volume weighted average price during the period commencing five consecutive trading days immediately preceding and ending immediately after the five consecutive trading days beginning on the date of such Share Combination Event, is less than the exercise price of the common warrants then in effect, then the exercise price of the common warrants will be reduced to the lowest daily volume weighted average price during such period. Notwithstanding the foregoing, if one or more Share Combination Events occur prior to the Stockholder Approval being obtained and a reduction of the exercise price did not occur, once the Shareholder Approval is obtained, the exercise price will automatically be reduced to equal the lowest price with respect to any Share Combination Event that occurred prior to the Stockholder Approval being obtained. 22  Transferability Subject to applicable laws, a common warrant may be transferred at the option of the holder upon surrender of the common warrant to us together with the appropriate instruments of transfer. Fractional Shares No fractional shares of common stock will be issued upon the exercise of the common warrants. Rather, the number of shares of common stock to be issued will, at the Company's election, either be rounded up to the next whole share or we will pay a cash adjustment in respect of such final fraction in an amount equal to such fraction multiplied by the exercise price. Trading Market There is no established trading market for the common warrants, and we do not expect an active trading market to develop. We do not intend to apply to list the common warrants on any securities exchange or other trading market. Without a trading market, the liquidity of the common warrants will be extremely limited. Right as a Stockholder Except as otherwise provided in the common warrants or by virtue of the holder ownership of shares of our common stock, such holder of common warrants does not have the rights or privileges of a holder of our common stock, including any voting rights until such holder exercises such holder common warrants. The common warrants will provide that the holders of the common warrants have the right to participate in distributions or dividends paid on our shares of common stock. Waivers and Amendments The common warrant may be modified or amended or the provisions of the common warrant waived with our and the holder written consent. Pre-funded Warrants General The following summary of certain terms and provisions of the pre-funded warrants that are being offered hereby is not complete and is subject to, and qualified in its entirety by, the provisions of the pre-funded warrant, the form of which will be filed as an exhibit to the registration statement of which this prospectus forms a part. Prospective investors should carefully review the terms and provisions of the form of pre-funded warrant for a complete description of the terms and conditions of the pre-funded warrants. Duration, Exercise Price and Form Each pre-funded warrant offered hereby will have an initial exercise price per share of common stock equal to \$0.0001. The pre-funded warrants will be immediately exercisable and will expire when exercised in full. The exercise price and number of shares of common stock issuable upon exercise is subject to appropriate adjustment in the event of share dividends, share splits, reorganizations or similar events affecting our shares of common stock and the exercise price. Subject to the rules and regulations of the applicable trading market, we may at any time during the term of the pre-funded warrant, subject to the prior written consent of the holders, reduce the then current exercise price to any amount and for any period of time deemed appropriate by our board of directors. The pre-funded warrants will be issued in certificated form only. Exercisability The pre-funded warrants will be exercisable, at the option of each holder, in whole or in part, by delivering to us a duly executed exercise notice accompanied by payment in full for the number of shares of common stock purchased upon such exercise (except in the case of a cashless exercise as discussed below). A holder (together with its affiliates) may not exercise any portion of the pre-funded warrant to the extent that the holder would own more than 4.99% of the outstanding shares of common stock immediately after exercise, except that upon at least 61 days prior notice from the holder to us, the holder may increase the amount of beneficial ownership of outstanding shares after exercising the holder pre-funded warrants up to 9.99% of the number of our shares of common stock outstanding immediately after giving effect to the exercise, as such percentage ownership is determined in accordance with the terms of the pre-funded warrants. Purchasers of pre-funded warrants in this offering may also elect prior to 23  the issuance of the pre-funded warrants to have the initial exercise limitation set at 9.99% of our outstanding shares of common stock. Cashless Exercise If, at the time a holder exercises its pre-funded warrants, a registration statement registering the issuance of the shares of common stock underlying the pre-funded warrants under the Securities Act is not then effective or available, then in lieu of making the cash payment otherwise contemplated to be made to us upon such exercise in payment of the aggregate exercise price, the holder may elect instead to receive upon such exercise (either in whole or in part) the net number of shares of common stock determined according to a formula set forth in the pre-funded warrants. Fractional Shares No fractional shares of common stock will be issued upon the exercise of the pre-funded warrants. Rather, the number of shares of common stock to be issued will be, at the Company's election, either rounded up to the next whole share or we will pay a cash

adjustment in respect of such final fraction in an amount equal to such fraction multiplied by the exercise price. Transferability Subject to applicable laws, a pre-funded warrant may be transferred at the option of the holder upon surrender of the pre-funded warrants to us together with the appropriate instruments of transfer. Trading Market There is no trading market available for the pre-funded warrants on any securities exchange or nationally recognized trading system, and we do not expect a trading market to develop. We do not intend to list the pre-funded warrants on any securities exchange or nationally recognized trading market. Without a trading market, the liquidity of the pre-funded warrants will be extremely limited. The shares of common stock issuable upon exercise of the pre-funded warrants are currently traded on the Nasdaq Capital Market. Right as a Shareholder Except as otherwise provided in the pre-funded warrants or by virtue of such holder's ownership of shares of common stock, the holders of the pre-funded warrants do not have the rights or privileges of holders of our shares of common stock, including any voting rights, until they exercise their pre-funded warrants. The pre-funded warrants will provide that the holders of the pre-funded warrants have the right to participate in distributions or dividends paid on our shares of common stock. Fundamental Transaction In the event of a fundamental transaction, as described in the pre-funded warrants and generally including any reorganization, recapitalization or reclassification of our common stock, the sale, transfer or other disposition of all or substantially all of our properties or assets, our consolidation or merger with or into another person, the acquisition of more than 50% of our outstanding common stock, or any person or group becoming the beneficial owner of 50% of the voting power represented by our outstanding common stock, the holders of the pre-funded warrants will be entitled to receive upon exercise of the pre-funded warrants the kind and amount of securities, cash or other property that the holders would have received had they exercised the pre-funded warrants immediately prior to such fundamental transaction, other than one in which a successor entity that is a publicly traded corporation (whose stock is quoted or listed for trading on a national securities exchange, including, but not limited to, the New York Stock Exchange, the NYSE American, the Nasdaq Global Select Market, the Nasdaq Global Market or the Nasdaq Capital Market) assumes the common warrant such that the warrant shall be exercisable for the publicly traded common stock of such successor entity. Waivers and Amendments The pre-funded warrant may be modified or amended or the provisions of the pre-funded warrant waived with our and the holder's written consent. 24 PLAN OF DISTRIBUTION We engaged Roth Capital Partners, LLC (the "placement agent"), to act as our exclusive placement agent, and Dawson James Securities, Inc. as co-agent to solicit offers to purchase the securities offered by this prospectus on a reasonable best efforts basis. Roth is not purchasing or selling any securities, nor are they required to arrange for the purchase and sale of any specific number or dollar amount of securities, other than to use their reasonable best efforts to arrange for the sale of the securities by us. Therefore, we may not sell the entire amount of securities being offered. There is no minimum amount of proceeds that is a condition to closing of this offering. The placement agent does not guarantee that it will be able to raise new capital in this offering. The terms of this offering were subject to market conditions and negotiations between us and prospective investors in consultation with the placement agent. The placement agent will have no authority to bind us. This offering will terminate no later than October 15, 2024, unless we decide to terminate the offering (which we may do at any time in our discretion) prior to that date. We will have one closing for all the securities purchased in this offering. The combined public offering price per share (or pre-funded warrant) and accompanying common warrant will be fixed for the duration of this offering. Roth may engage one or more sub-placement agents or selected dealers to assist with the offering. We will enter into a securities purchase agreement directly with the institutional investors, at the investor's option, who purchase our securities in this offering. Investors who do not enter into a securities purchase agreement shall rely solely on this prospectus in connection with the purchase of our securities in this offering. Placement Agent Fees and Expenses The following table shows the per share and accompanying common warrants, and per pre-funded and accompanying common warrants, and total placement agent fees we will pay in connection with the sale of the securities in this offering.

	Per Share and Common Warrant	Per Pre-Funded Warrant and Common Warrant	Total Public offering price
	\$ 1.00	\$ 1.00	\$ 1.00
Placement Agent fees(1)	\$ 0.50	\$ 0.50	\$ 0.50
Proceeds to us, before expenses(2)	\$ 0.50	\$ 0.50	\$ 0.50

We have agreed to pay to the placement agent a cash fee equal to 7% of the aggregate gross proceeds raised in this offering subject to a partial adjustment in the event certain investors participate. Because there is no minimum offering amount required as a condition to closing in this offering, the actual aggregate cash placement fee, if any, is not presently determinable and may be substantially less than the maximum amount set forth above. 2. We have also agreed to reimburse the Placement Agent at closing for legal and other expenses incurred by the placement agent in connection with this offering in an amount equal to \$100,000. We estimate that the total expenses of the offering, including registration, filing and listing fees, printing fees and legal and accounting expenses, but excluding placement agent fees, will be approximately \$265,000, all of which are payable by us. This figure includes the placement agent's accountable expenses, including, but not limited to, legal fees for placement agent's legal counsel, that we have agreed to pay at the closing of the offering up to an aggregate expense reimbursement of \$100,000. Tail In the event this offering does not close we have also agreed to pay the Placement Agent a tail fee equal to the cash compensation in this offering, subject to certain exceptions, if any investor, who the Placement Agent conducted discussions with on behalf of the Company during the 90 days following its engagement, or if any of the separately agreed upon investors, provides us with capital in any offering of the Company's securities during the six month period following expiration or termination of our engagement of the Placement Agent. 25 Other Relationships The placement agent may, from time to time, engage in transactions with or perform services for us in the ordinary course of its business and may continue to receive compensation from us for such services. Determination of Offering Price The combined public offering price per share and common warrants and the combined public offering price per pre-funded warrant and common warrants we are offering and the exercise prices and other terms of the warrants were negotiated between us and the investors, in consultation with the placement agent based on the trading of our common stock prior to this offering, among other things. Other factors considered in determining the public offering prices of the securities we are offering and the exercise prices and other terms of the warrants include the history and prospects of our company, the stage of development of our business, our business plans for the future and the extent to which they have been implemented, an assessment of our management, general conditions of the securities markets at the time of the offering and such other factors as were deemed relevant. Lock-Up Agreements Each of our officers and directors have agreed to be subject to a lock-up period of 90 days following the date of this prospectus. This means that, during the applicable lock-up period, they may not offer for sale, contract to sell, or sell any shares of our common stock or any securities convertible into, or exercisable or exchangeable for, shares of our common stock subject to certain customary exceptions. In addition, we have agreed to not issue any shares of common stock or securities exercisable or convertible into shares of common stock for a period of 60 days following the closing date of this offering, subject to certain exceptions, or enter into an agreement to issue securities at a future determined price, for a period of 90 days following the closing date of this offering. Transfer Agent and Registrar Broadridge Financial Solutions, Inc. is the transfer agent and registrar for our common stock, which can be contacted at 51 Mercedes Way, Edgewood, NY 11717, shareholder@broadridge.com, or +1 (720) 378-5591. The Nasdaq Capital Market Listing Our common stock is currently listed on the Nasdaq Stock Market LLC under the symbol "APVO." On August 27, 2024, the reported closing price per share of our common stock was \$0.37. The final public offering price will be determined between us, the placement agent and the investors in the offering, and may be at a discount to the current market price of our common stock. Therefore, the assumed public offering price used throughout this prospectus may not be indicative of the final public offering price. There is no established public trading market for the common warrants or pre-funded warrants, and we do not expect such markets to develop. In addition, we do not intend to apply for a listing of the common warrants or pre-funded warrants on any national securities exchange or other nationally recognized trading system. Indemnification We have agreed to indemnify the placement agent against certain liabilities, including certain liabilities arising under the Securities Act, or to contribute to payments that the placement agent may be required to make for these liabilities. 26 Regulation M The placement agent may be deemed to be an underwriter within the meaning of Section 2(a)(11) of the Securities Act and any fees received by it and any profit realized on the sale of the securities by it while acting as principal might be deemed to be underwriting discounts or commissions under the Securities Act. The placement agent will be required to comply with the requirements of the Securities Act and the Exchange Act of 1934, as amended (the "Exchange Act"), including, without limitation, Rule 10b-5 and Regulation M under the Exchange Act. These rules and regulations may limit the timing of purchases and sales of our securities by the placement agent. Under these rules and regulations, the placement agent may not (i) engage in any stabilization activity in connection with our securities; and (ii) bid for or purchase any of our securities or attempt to induce any person to purchase any of our securities, other than as permitted under the Exchange Act, until they have completed their participation in the distribution. Electronic Distribution A prospectus in electronic format may be made available on a website maintained by the placement agent and the placement agent may distribute prospectuses electronically. Other than the prospectus in electronic format, the information on these

websites is not part of this prospectus or the registration statement of which this prospectus forms a part, has not been approved and/or endorsed by us or the placement agent and should not be relied upon by investors.

**27 Â INCORPORATION OF CERTAIN INFORMATION BY REFERENCE** The SEC allows us to incorporate by reference the information we file with it, which means that we can disclose important information to you by referring you to those documents instead of having to repeat the information in this prospectus. The information incorporated by reference is considered to be part of this prospectus, and because we are a smaller reporting company, later information that we file with the SEC will automatically update and supersede this information. We incorporate by reference the documents listed below and any future filings (including those made after the initial filing of the registration statement of which this prospectus is a part and prior to the effectiveness of such registration statement) we will make with the SEC under Sections 13(a), 13(c), 14, or 15(d) of the Exchange Act until the termination of the offering of the shares covered by this prospectus (other than information furnished under Item 2.02 or Item 7.01 of Form 8-K): our Annual Report on Form 10-K for the year ended December 31, 2023 filed with the SEC on March 5, 2024; our Quarterly Report on Form 10-Q for the quarter ended March 31 and June 30, 2024, filed with the SEC on May 8, 2024, and August 8, 2024, respectively; our definitive proxy statement on Schedule 14A, filed with the SEC on April 23, 2024, and July 15, 2024; our Current Report on Form 8-K filed with the SEC on February 6, 2024, March 5, 2024, March 7, 2024, April 15, 2024, May 8, 2024, June 10, 2024; July 1, 2024, July 1, 2024 and August 7, 2024; and the description of our Common Stock contained in Exhibit 4.8 to our Annual Report on Form 10-K for the year ended December 31, 2023 filed with the SEC on March 5, 2024, including any amendment or report filed for the purpose of updating such description. As a smaller reporting company, we also are incorporating by reference any future information filed (rather than furnished) by us with the SEC under Section 13(a), 13(c), 14 or 15(d) of the Securities Exchange Act of 1934, as amended, after the date of the initial filing of the registration statement of which this prospectus is a part and before the effective date of the registration statement and after the date of this prospectus until the termination of the offering. Any statements contained in a previously filed document incorporated by reference into this prospectus is deemed to be modified or superseded for purposes of this prospectus to the extent that a statement contained in this prospectus, or in a subsequently filed document also incorporated by reference herein, modifies or supersedes that statement. We will provide to each person, including any beneficial owner, to whom a prospectus is delivered, at no cost, upon written or oral request, a copy of any or all of the reports or documents that have been incorporated by reference in the prospectus contained in the registration statement but not delivered with the prospectus. You should direct requests for documents to: Aptevo Therapeutics Inc. 2401 4th Avenue, Suite 1050 Seattle, WA 98121 Attn: General Counsel (206) 838-0500 This prospectus is part of a registration statement we filed with the SEC. That registration statement and the exhibits filed along with the registration statement contain more information about us and the shares in this offering. Because information about documents referred to in this prospectus is not always complete, you should read the full documents which are filed as exhibits to the registration statement. You may read and copy the full registration statement and its exhibits at the SEC's website.

**WHERE YOU CAN FIND MORE INFORMATION** This prospectus is part of a registration statement we filed with the SEC. This prospectus does not contain all of the information set forth in the registration statement and the exhibits to the registration statement. For further information with respect to us and the securities we are offering under this prospectus, we refer you to the registration statement and the exhibits and schedules filed as a part of the registration statement. You should rely only on the information contained in this prospectus or incorporated by reference into this prospectus. We have not authorized anyone else to provide you with different information. We are not making an offer of these securities in any jurisdiction where the offer is not permitted. You should assume that the information contained in this prospectus, or any document incorporated by reference in this prospectus, is accurate only as of the date of those respective documents, regardless of the time of delivery of this prospectus or any sale of our securities. We are subject to the informational requirements of the Exchange Act and in accordance therewith we file annual, quarterly, and other reports, proxy statements and other information with the Commission under the Exchange Act. Such reports, proxy statements and other information, including the Registration Statement, and exhibits and schedules thereto, are available to the public through the Commission's website at [www.sec.gov](http://www.sec.gov). We make available free of charge on or through our website our Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q, Current Reports on Form 8-K and amendments to those reports filed or furnished pursuant to Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended, as soon as reasonably practicable after we electronically file such material with or otherwise furnish it to the Commission. The registration statement and the documents referred to under Incorporation of Certain Information by Reference are also available on our website, <https://aptevotherapeutics.gcs-web.com/financial-reports/sec-filings>. We have not incorporated by reference into this prospectus the information on our website, and you should not consider it to be a part of this prospectus.

**LEGAL MATTERS** The validity of the securities offered hereby will be passed upon for us by Paul Hastings LLP, Washington, DC. The placement agent is being represented by Ellenoff Grossman & Schole LLP, New York, NY.

**EXPERTS** Our consolidated financial statements as of December 31, 2023 and 2022, and for the years then ended, incorporated in this prospectus by reference and included in our Annual Report on Form 10-K for the year ended December 31, 2023, have been audited by Moss Adams LLP, an independent registered public accounting firm, as stated in their report (which report expresses an unqualified opinion and includes an explanatory paragraph related to a going concern uncertainty), which is incorporated herein by reference. Such consolidated financial statements are incorporated by reference in reliance upon the report of such firm given their authority as experts in accounting and auditing.

**29 Â Up to 13,513,513 Shares of Common Stock Up to 13,513,513 Pre-Funded Warrants to Purchase up to 13,513,513 Shares of Common Stock Up to 27,027,026 Common Warrants to Purchase up to 27,027,026 Shares of Common Stock Up to 40,540,539 Shares of Common Stock underlying the Pre-Funded Warrants and Common Warrants** Â Â Â Â **PRELIMINARY PROSPECTUS** Â Â Roth Capital Partners Dawson James Securities, Inc. Â Â Â Â Â Â Â Â The date of this prospectus is , 2024.

**30 Â PART II INFORMATION NOT REQUIRED IN PROSPECTUS**

**Item 13. Other Expenses of Issuance and Distributions** The following table indicates the expenses to be incurred in connection with the offering described in this registration statement, other than underwriting discounts and commissions, all of which will be paid by us. All amounts are estimated except the Securities and Exchange Commission registration fee. SEC registration fee Â \$ 2,214 Â FINRA filing fee Â \$ 4,100 Â Accounting fees and expenses Â \$ 55,000 Â Legal fees and expenses Â \$ 100,000 Â Miscellaneous Â \$ 4,000 Â Total Â \$ 165,314 Â

**Item 14. Indemnification of Directors and Officers** Section 145 of the Delaware General Corporation Law (the "DGCL"), authorizes a court to award, or a corporation's board of directors to grant, indemnity to directors and officers in terms sufficiently broad to permit such indemnification under certain circumstances for liabilities, including reimbursement for expenses incurred, arising under the Securities Act of 1933, as amended (the "Securities Act"). The registrant's certificate of incorporation and bylaws each provide for indemnification of the registrant's directors, officers, employees and other agents to the maximum extent permitted by the DGCL. The registrant has entered into indemnification agreements with its directors and officers whereby it has agreed to indemnify its directors and officers to the fullest extent permitted by law, including indemnification against expenses and liabilities incurred in legal proceedings to which the director or officer was, or is threatened to be made, a party by reason of the fact that such director or officer is or was a director, officer, employee or agent of the registrant, provided that such director or officer acted in good faith and in a manner that the director or officer reasonably believed to be in, or not opposed to, the best interest of the registrant. At present, there is no pending litigation or proceeding involving a director or officer of the registrant regarding which indemnification is sought, nor is the registrant aware of any threatened litigation that may result in claims for indemnification. The registrant maintains insurance policies that indemnify its directors and officers against various liabilities arising under the Securities Act and the Exchange Act of 1934, as amended, that might be incurred by any director or officer in his or her capacity as such.

**Item 15. Recent Sales of Unregistered Securities** We did not sell any unregistered securities during the quarter ended June 30, 2024.

**Item 16. Exhibits and Financial Statement Schedules**

(a) Exhibits	31 Â Exhibit Index	Â ExhibitNumber	Â Description	Form	Exhibit	Filing	Date	File No.																											
Filed Herewith	2.1 Â Contribution Agreement, dated July 29, 2016, by and among Emergent BioSolutions Inc., Aptevo Therapeutics Inc., Aptevo Research and Development LLC and Aptevo BioTherapeutics LLC	8-K 2.1	August 2, 2016	001-37746	Â Â Â Â Â Â Â Â	Â Â Â Â Â Â Â Â	Â 2.2 Â Separation and Distribution Agreement, dated July 29, 2016, by and between Emergent BioSolutions Inc. and Aptevo Therapeutics Inc.	8-K 2.2	August 2, 2016	001-37746	Â Â Â Â Â Â Â Â	Â Â Â Â Â Â Â Â	Â +2.2 Â LLC Purchase Agreement, dated as of August 31, 2017, by and among Aptevo BioTherapeutics LLC, Aptevo Therapeutics Inc., Venus Bio Therapeutics Sub LLC, and Saol International Limited.	10-Q 2.1	November 13, 2017	001-37746	Â Â Â Â Â Â Â Â	Â +2.4 Â LLC Purchase Agreement by and among Aptevo Therapeutics Inc. and Medexus Pharma, Inc.	dated February 28, 2020.	8-K 2.1	March 2, 2020	001-37746	Â Â Â Â Â Â Â Â	Â Â Â Â Â Â Â Â	Â 3.1 Â Amended and Restated Certificate of Incorporation of Aptevo Therapeutics Inc.	8-K 3.1	August 2, 2016	001-37746	Â Â Â Â Â Â Â Â	Â Â Â Â Â Â Â Â	Â 3.2 Â Amended and Restated By-laws of the Company, as amended and restated on November 8, 2022.	10-Q 3.1	November 10, 2022	001-37746	Â Â Â Â Â Â Â Â

A 3.3 Certificate of Amendment of Amended and Restated Certificate of Incorporation of Aptevo Therapeutics Inc. 8-K 3.1 March 27, 2020 001-37746 A A A A A A A A 3.4 Certificate of Designation of Series A Junior Participating Preferred Stock of Aptevo Therapeutics Inc. 8-K 3.1 November 9, 2020 001-37746 A A A A A A A A 3.5 Amended and Restated Bylaws of Aptevo Therapeutics Inc. 10-Q 3.1 November 10, 2022 001-37746 A A A A A A A A 4.1 Form of Common Stock Certificate 10 4.1 June 29, 2016 001-37746 A A A A A A A A 4.2 Registration Rights Agreement, dated as of August 1, 2016, by and among Aptevo Therapeutics Inc. and certain of its stockholders 8-K 4 August 2, 2016 001-37746 A A A A A A A A 4.3 Registration Rights Agreement, dated December 20, 2018, by and between Aptevo Therapeutics Inc. and Lincoln Park Capital Fund, LLC. 8-K 10.2 December 24, 2018 001-37746 A A A A A A A A 4.4 Rights Agreement, dated as of November 8, 2020, by and between Aptevo Therapeutics Inc. and Broadridge Corporate Issuer Solutions, Inc., as rights agent 8-K 4.1 November 9, 2020 001-37746 A A A A A A A A 4.5 Amendment No. 1 to Rights Agreement, dated as of November 5, 2021, between the Company and Broadridge Corporate Issuer Solutions, Inc., as Rights Agent 8-K 4.1 November 5, 2021 001-37746 A A A A A A A A 4.6 Amendment No. 2 to Rights Agreement, dated as of November 4, 2022, between the Company and Broadridge Corporate Issuer Solutions, Inc., as Rights Agent. 8-K 4.1 November 4, 2022 001-37746 A A A A A A A A 4.7 Amendment No. 3 to Rights Agreement, dated as of November 5, 2023, between the Company and Broadridge Corporate Issuer Solutions, Inc., as Rights Agent 8-K 4.1 November 3, 2023 001-37746 A A A A A A A A 4.8 Description of Capital Stock of Aptevo Therapeutics A 4.5 March 31, 2021 001-37746 A A A A A A A A 4.9 Agreement to Terminate Registration Rights Agreement between the Company and Intervac L.L.C. and BioVac L.L.C. 10-K 4.7 March 24, 2022 001-37746 A A A A A A A A 4.10 Form of Pre-Funded Warrant, dated August 4, 2023 10-Q 10.3 August 10, 2023 001-37746 A A A A A A A A 4.11 Series B Common Warrant, dated August 4, 2023 10-Q 10.2 August 10, 2023 001-37746 A A A A A A A A 4.12 Series A Common Warrant, dated August 4, 2023 10-Q 10.1 August 10, 2023 001-37746 A A A A A A A A 32 4.13 Common Warrant, dated April 15, 2024 8-K 4.1 April 15, 2024 001-37746 A A A A A A A A 4.14 Pre-funded Warrant, dated April 15, 2024 8-K 4.2 April 15, 2024 001-37746 A A A A A A A A 4.15 Pre-funded Warrant, dated July 1, 2024 8-K 4.2 July 1, 2024 001-37746 A A A A A A A A 4.16 Common Warrant, dated July 1, 2024 8-K 4.1 July 1, 2024 001-37746 A A A A A A A A 4.17 Form of Pre-Funded Warrant A A A X A A A A A A 4.18 Form of Common Warrant A A A X A A A A A A 5.1 Opinion of Paul Hastings, LLP A A A X A A A A A A 10.1 Transition Services Agreement, dated July 29, 2016, by and between Emergent BioSolutions Inc. and Aptevo Therapeutics Inc. 8-K 10.2 August 2, 2016 001-37746 A A A A A A A A 10.2 Tax Matters Agreement, dated July 29, 2016, by and between Emergent BioSolutions Inc. and Aptevo Therapeutics Inc. 8-K 10.3 August 2, 2016 001-37746 A A A A A A A A 10.3 Product License Agreement, dated July 29, 2016, by and between Emergent BioSolutions Inc. and Aptevo Therapeutics Inc. 8-K 10.8 August 2, 2016 001-37746 A A A A A A A A 10.4 Aptevo Therapeutics Inc. Amended and Restated 2016 Stock Incentive Plan. 10-Q 4.1 August 10, 2017 001-37746 A A A A A A A A 10.5 Aptevo Therapeutics Inc. Converted Equity Awards Incentive Plan 8-K 10.10 August 2, 2016 001-37746 A A A A A A A A 10.6 Aptevo Therapeutics Inc. Amended and Restated Senior Management Severance Plan 10-K 10.6 March 24, 2022 001-37746 A A A A A A A A 10.7 Form of Indemnity Agreement for directors and senior officers 10 10.9 April 15, 2016 001-37746 A A A A A A A A 10.8 Fourth and Battery Office Lease, dated as of April 28, 2003, by and between Emergent Product Development Seattle, LLC (as successor-in-interest to Trubion Pharmaceuticals, Inc. and Genecraft, Inc.) and Selig Real Estate Holdings Eight L.L.C. , or the Seattle Office Lease 10 10.12 April 15, 2016 001-37746 A A A A A A A A 10.9 Seattle Office Lease Amendment, dated December 8, 2004 10 10.13 April 15, 2016 001-37746 A A A A A A A A 10.10 Seattle Office Lease Amendment, dated February 1, 2006 10 10.14 April 15, 2016 001-37746 A A A A A A A A 10.11 Seattle Office Lease Amendment, dated February 2, 2007 10 10.15 April 15, 2016 001-37746 A A A A A A A A 10.12 Seattle Office Lease Amendment, dated June 7, 2010 10 10.16 April 15, 2016 001-37746 A A A A A A A A 10.13 Seattle Office Lease Amendment, dated December 21, 2010 10 10.17 April 15, 2016 001-37746 A A A A A A A A 10.14 Seattle Office Lease Amendment, dated July 17, 2012 10 10.18 April 15, 2016 001-37746 A A A A A A A A 10.15 Seventh Amendment to Seattle Office Lease, dated December 5, 2014 10 10.19 April 15, 2016 001-37746 A A A A A A A A æ 10.16 License and Co-Development Agreement, dated as of August 19, 2014, by and between Emergent Product Development Seattle, LLC and MorphoSys AG, or the MorphoSys Collaboration Agreement 10 10.20 June 29, 2016 001-37746 A A A A A A A A æ 10.17 First Amendment to MorphoSys Collaboration Agreement, dated June 19, 2015 10 10.21 April 15, 2016 001-37746 A A A A A A A A æ 10.18 Second Amendment to MorphoSys Collaboration Agreement, dated December 7, 2015 10 10.22 April 15, 2016 001-37746 A A A A A A A A 10.19 Third Amendment to MorphoSys Collaboration Agreement, dated December 12, 2016 8-K 10.1 December 15, 2016 001-37746 A A A A A A A A 10.20 Fourth Amendment MorphoSys Collaboration Agreement, dated June 19, 2017. 10 10.3 August 10, 2017 001-37746 A A A A A A A A 33 10.21 Equity Distribution Agreement, dated November 9, 2017, between Aptevo Therapeutics, Inc. and Piper Jaffray and Company LLC. 8-K 1.1 November 9, 2017 001-37746 A A A A A A A A 10.22 Collaboration and Option Agreement, dated as of July 20, 2017, by and between Aptevo Research and Development LLC, and Alligator Bioscience AB. 10-Q 10.2 November 13, 2017 001-37746 A A A A A A A A 10.23 Amendment No. 3 to Credit and Security Agreement, dated as of February 23, 2018, by and among Aptevo Therapeutics Inc. and certain of its subsidiaries and Midcap Financial Trust. 10-K 10.38 March 13, 2018 001-37746 A A A A A A A A 10.24 Third Amendment to Credit and Security Agreement dated August 30, 2022. 10-Q 3.1 November 10, 2022 001-37746 A A A A A A A A 10.25 Aptevo Therapeutics Inc. 2018 Stock Incentive Plan. 10-Q 10.1 August 9, 2018 001-37746 A A A A A A A A 10.26 Aptevo Therapeutics Inc. Non-Statutory Stock Option Agreement. 10-Q 10.2 August 9, 2018 001-37746 A A A A A A A A 10.27 Eighth Amendment to Office Lease, dated as of March 19, 2019, by and between Aptevo Therapeutics Inc. and Selig Real Estate Holdings Eight L.L.C. 8-K 10.1 March 22, 2019 001-37746 A A A A A A A A 10.28 Ninth Amendment to Office Lease, dated May 26, 2022, by and between Aptevo Therapeutics Inc. and Selig Real Estate Holdings Eight L.L.C. 10-K 10.3 August 11, 2022 001-37746 A A A A A A A A 10.29 Amendment to LLC Purchase Agreement, dated as of August 31, 2017, by and among Aptevo BioTherapeutics LLC, Aptevo Therapeutics Inc., Venus Bio Therapeutics Sub LLC, and Saol International Limited. 10-Q 10.1 August 9, 2019 001-37746 A A A A A A A A 10.30 Collaboration and License Agreement, dated as of December 19, 2005, by and among Wyeth Pharmaceuticals and Trubion Pharmaceuticals, Inc. 10-Q 10.1 August 14, 2020 001-37746 A A A A A A A A 10.31 Amendment No. 1 to the Collaboration and License Agreement dated as of December 19, 2005 (the "Agreement") by and between Trubion Pharmaceuticals, Inc. ("Trubion") and Wyeth, acting through its Wyeth Pharmaceuticals Division ("Wyeth"). 10-Q 10.2 August 14, 2020 001-37746 A A A A A A A A 10.32 Amendment No. 2 to the Collaboration and License Agreement dated as of December 19, 2005 (as previously amended, the "Agreement") by and between Trubion Pharmaceuticals, Inc. ("Trubion") and Wyeth LLC (formerly known as Wyeth), acting through its Wyeth Pharmaceuticals Division ("Wyeth"). 10-Q 10.3 August 14, 2020 001-37746 A A A A A A A A 10.33 Amendment No. 3 to the Collaboration and License Agreement dated as of December 19, 2005 (as previously amended, the "Agreement") by and between Emergent Product Development Seattle, LLC (successor to Trubion Pharmaceuticals, Inc. ("Trubion")) ("EPDS") and Wyeth LLC (formerly known as Wyeth), acting through its Wyeth Pharmaceuticals Division ("Wyeth"). 8-K 10.4 August 14, 2020 001-37746 A A A A A A A A 10.34 Amendment No. 4 to the Collaboration and License Agreement dated as of December 19, 2005 (as previously amended, the "Agreement") by and between Emergent Product Development Seattle, LLC (successor to Trubion Pharmaceuticals, Inc. ("Trubion")) and Wyeth LLC (formerly known as Wyeth), acting through its Wyeth Pharmaceuticals Division ("Wyeth"). 10-Q 10.5 August 14, 2020 001-37746 A A A A A A A A 10.35 Credit and Security Agreement, dated as of August 5, 2020, by and among Aptevo Therapeutics Inc., and MidCap Financial Trust. 10-Q 10.1 November 10, 2019 001-37746 A 34 A A A A A A 10.36 Equity Distribution Agreement, dated December 14, 2020, between Aptevo Therapeutics Inc. and Piper Sandler & Co. 8-K 1.1 December 14, 2020 001-37746 A A A A A A A A 10.37 Royalty Purchase Agreement by and among Aptevo Therapeutics Inc. and Healthcare Royalty Partners IV, LP. dated as of March 30, 2021. 10-Q 10.1 May 11, 2021 001-37746 A A A A A A A A 10.38 Amendment to Royalty Purchase Agreement dated June 7, 2022. 10-Q 10.1 August 11, 2022 001-37746 A A A A A A A A 10.39 First Amendment to Credit and Security Agreement dated March 30, 2021. 10

10.45 Purchase Agreement, dated February 16, 2022, by and between the Company and Lincoln Park. 8-K 10.1 February 17, 2022 001-37746 10.46 Registration Rights Agreement, dated February 16, 2022, by and between the Company and Lincoln Park. 8-K 10.2 February 17, 2022 001-37746 10.47 Payment Interest Purchase Agreement by and between Aptevo Therapeutics Inc. and XOMA (US) LLC, dated March 29, 2023. 10-Q 10.1 May 11, 2023 001-37746 10.48 Form of Securities Purchase Agreement X 10.49 Form of Placement Agency Agreement X 21.1 Subsidiaries of Aptevo Therapeutics Inc. 10-K 21.1 March 5, 2023 001-37746 23.1 Consent of Independent Registered Public Accounting Firm X X 23.2 Consent of Paul Hastings LLP (included in Exhibit 5.1) X X 24.1 Power of Attorney X 107 Filing Fee Table X Confidential treatment granted from the Securities and Exchange Commission as to certain portions, which portions have been omitted and filed separately with the Securities and Exchange Commission. + Schedules have been omitted pursuant to Item 601(b)(2) of Regulation S-K. Aptevo will furnish copies of any such schedules to the Securities and Exchange Commission upon request. Item 17. Undertakings (1)The undersigned registrant hereby undertakes: a.To file, during any period in which offers or sales are being made, a post-effective amendment to this registration statement: i.To include any prospectus required by Section 10(a)(3) of the Securities Act; ii.To reflect in the prospectus any facts or events arising after the effective date of the registration statement (or the most recent post-effective amendment thereof) which, individually or in the aggregate, represent a fundamental change in the information set forth in the registration statement. Notwithstanding the foregoing, any increase or decrease in volume of securities offered (if the total dollar value of securities offered would not exceed 35 % that which was registered) and any deviation from the low or high end of the estimated maximum offering range may be reflected in the form of prospectus filed with the SEC pursuant to Rule 424(b) if, in the aggregate, the changes in volume and price represent no more than 20 percent change in the maximum aggregate offering price set forth in the "Calculation of Registration Fee" table in the effective registration statement; and iii.To include any material information with respect to the plan of distribution not previously disclosed in the registration statement or any material change to such information in the registration statement; provided, however, that paragraphs (1)(i), (1)(ii) and (1)(iii) above do not apply if the information required to be included in a post-effective amendment by those paragraphs is contained in reports filed with or furnished to the Securities and Exchange Commission by the registrant pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 that are incorporated by reference in the registration statement. b.That, for the purpose of determining any liability under the Securities Act, each such post-effective amendment shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof. c.To remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold at the termination of the offering. d.That, for the purpose of determining liability under the Securities Act of 1933 to any purchaser, each prospectus filed pursuant to Rule 424(b) as part of a registration statement relating to an offering, other than registration statements relying on Rule 430B or other than prospectuses filed in reliance on Rule 430A, shall be deemed to be part of and included in the registration statement as of the date it is first used after effectiveness. Provided, however, that no statement made in a registration statement or prospectus that is part of the registration statement or made in a document incorporated or deemed incorporated by reference into the registration statement or prospectus that is part of the registration statement will, as to a purchaser with a time of contract of sale prior to such first use, supersede or modify any statement that was made in the registration statement or prospectus that was part of the registration statement or made in any such document immediately prior to such date of first use. e.That, for the purpose of determining liability of the registrant under the Securities Act to any purchaser in the initial distribution of the securities, the undersigned registrant hereby undertakes that in a primary offering of securities of the undersigned registrant pursuant to this registration statement, regardless of the underwriting method used to sell the securities to the purchaser, if the securities are offered or sold to such purchaser by means of any of the following communications, the undersigned registrant will be a seller to the purchaser and will be considered to offer or sell such securities to such purchaser: i.Any preliminary prospectus or prospectus of the undersigned registrant relating to the offering required to be filed pursuant to Rule 424 (§ 230.424 of this chapter);A ii.Any free writing prospectus relating to the offering prepared by or on behalf of the undersigned registrant or used or referred to by the undersigned registrant; iii.The portion of any other free writing prospectus relating to the offering containing material information about the undersigned registrant or its securities provided by or on behalf of the undersigned registrant; and iv.Any other communication that is an offer in the offering made by the undersigned registrant to the purchaser. (2)The undersigned registrant hereby undertakes that, for purposes of determining any liability under the Securities Act, each filing of the registrant's annual report pursuant to Section 13(a) or Section 15(d) of the Exchange Act (and, where applicable, each filing of an employee benefit plan's annual report pursuant to Section 15(d) of the Exchange Act) that is incorporated by reference in the registration statement shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof. (3)The undersigned registrant hereby undertakes that: a.For purposes of determining any liability under the Securities Act, the information omitted from the form of prospectus filed as part of this registration statement in reliance on Rule 430A and contained in a form of prospectus filed by the undersigned registrant pursuant to Rule 424(b)(1) or (4) or 497(h) under the Securities Act shall be deemed to be part of this registration statement as of the time it was declared effective; and b.For the purpose of determining any liability under the Securities Act, each post-effective amendment that contains a form of prospectus shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof. (4)Insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers and controlling persons of the registrant pursuant to the foregoing provisions, or otherwise, the registrant has been advised that in the opinion of the SEC such indemnification is against public policy as expressed in the Securities Act and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the registrant of expenses incurred or paid by a director, officer or controlling person of the registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, the registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Securities Act and will be governed by the final adjudication of such issue. 37 SIGNATURES Pursuant to the requirements of the Securities Act of 1933, the registrant has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized in the City of Seattle, State of Washington, on August 30, 2024. Aptevo Therapeutics, Inc. Date: August 30, 2024 By: /s/ Marvin L. White Marvin L. White President and Chief Executive Officer Aptevo Therapeutics, Inc. I, \_\_\_\_\_, do hereby certify that each person whose signature appears below constitutes and appoints Marvin L. White, Daphne Taylor, and SoYoung Kwon and each of them, each with full power to act without the other, his or her true and lawful attorneys-in-fact and agents, each with full power of substitution and resubstitution, for such person and in his or her name, place and stead, in any and all capacities, to sign any amendments to this registration statement, and to sign any registration statement for the same offering covered by this registration statement, including post-effective amendments or registration statements filed pursuant to Rule 462(b) under the Securities Act of 1933, and to file the same, with all exhibits thereto and other documents in connection therewith, with the Securities and Exchange Commission, hereby ratifying and confirming that each of said such attorneys-in-fact and agents or his or her substitute or substitutes, may do or cause to be done by virtue hereof. Pursuant to the requirements of the Securities Act of 1933, as amended this registration statement has been signed by the following persons in the capacities indicated on the 30th day of August, 2024. Signatures Title /s/Marvin L. White President, Chief Executive Officer and Director Marvin L. White (Principal Executive Officer) /s/ Daphne Taylor Senior Vice President and Chief Financial Officer Daphne Taylor (Principal Financial and Accounting Officer) /s/John E. Niederhuber, M.D. Chairman of the Board of Directors John E. Niederhuber, M.D. /s/Daniel J. Abdun-Nabi Director Daniel J. Abdun-Nabi /s/Grady Grant, III Director Grady Grant, III /s/Zsolt Harsanyi, Ph. D. Director Zsolt Harsanyi, Ph. D. /s/Barbara Lopez Kunz Director Barbara Lopez Kunz EX-4.17 2 apvo-ex4\_17.htm EX-4.17 EX-4.17 EXHIBIT 4.17 PRE-FUNDED COMMON STOCK PURCHASE WARRANT Aptevo therapeutics inc. Warrant Shares: \_\_\_\_\_ Initial Exercise Date: \_\_\_\_\_, 2024 A THIS PRE-FUNDED COMMON STOCK PURCHASE WARRANT (the "Warrant") certifies that, for value received, \_\_\_\_\_ or its assigns (the "Holder") is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date hereof (the "Initial Exercise Date") until this Warrant is exercised in full (the "Termination Date") but not thereafter, to subscribe for and purchase from Aptevo Therapeutics Inc., a Delaware corporation (the "Company"), up to \_\_\_\_\_ shares (as subject to adjustment hereunder, the

“Warrant Shares”) of Common Stock. The purchase price of one share of Common Stock under this Warrant shall be equal to the Exercise Price, as defined in Section 2(b). Section 1. Definitions. In addition to the terms defined elsewhere in this Section 1. Definitions. In addition to the terms defined elsewhere in this Warrant, the following terms have the meanings indicated in this Section 1:

“Affiliate” means any Person that, directly or indirectly through one or more intermediaries, controls or is controlled by or is under common control with a Person, as such terms are used in and construed under Rule 405 under the Securities Act. “Bid Price” means, for any date, the price determined by the first of the following clauses that applies: (a) if the Common Stock is then listed or quoted on a Trading Market, the bid price of the Common Stock for the time in question (or the nearest preceding date) on the Trading Market on which the Common Stock is then listed or quoted as reported by Bloomberg L.P. (based on a Trading Day from 9:30 a.m. (New York City time) to 4:02 p.m. (New York City time)), (b) if OTCQB or OTCQX is not a Trading Market, the volume weighted average price of the Common Stock for such date (or the nearest preceding date) on OTCQB or OTCQX as applicable, (c) if the Common Stock is not then listed or quoted for trading on OTCQB or OTCQX and if prices for the Common Stock are then reported on the Pink Open Market (or a similar organization or agency succeeding to its functions of reporting prices), the most recent bid price per share of the Common Stock so reported, or (d) in all other cases, the fair market value of a share of Common Stock as determined by an independent appraiser selected in good faith by the Holders of a majority in interest of the Warrants then outstanding and reasonably acceptable to the Company, the fees and expenses of which shall be paid by the Company. “Board of Directors” means the board of directors of the Company.

“Business Day” means any day other than Saturday, Sunday or other day on which commercial banks in The City of New York are authorized or required by law to remain closed; provided, however, for clarification, commercial banks shall not be deemed to be authorized or 1. required by law to remain closed due to “stay at home”, “shelter-in-place”, “non-essential employee” or any other similar orders or restrictions or the closure of any physical branch locations at the direction of any governmental authority so long as the electronic funds transfer systems (including for wire transfers) of commercial banks in The City of New York generally are open for use by customers on such day. “Commission” means the United States Securities and Exchange Commission. “Common Stock” means the common stock of the Company, par value \$0.001 per share, and any other class of securities into which such securities may hereafter be reclassified or changed. “Common Stock Equivalents” means any securities of the Company or the Subsidiaries which would entitle the holder thereof to acquire at any time Common Stock, including, without limitation, any debt, preferred stock, right, option, warrant or other instrument that is at any time convertible into or exercisable or exchangeable for, or otherwise entitles the holder thereof to receive, Common Stock. “Exchange Act” means the Securities Exchange Act of 1934, as amended, and the rules and regulations promulgated thereunder. “Person” means an individual or corporation, partnership, trust, incorporated or unincorporated association, joint venture, limited liability company, joint stock company, government (or an agency or subdivision thereof) or other entity of any kind. “Purchase Agreement” means the securities purchase agreement, dated as of \_\_\_\_\_, 2024, by and between the Company and each of the purchasers signatory thereto. “Registration Statement” means the Company’s registration statement on Form S-1 (File No. 333-\_\_\_\_\_). “Securities Act” means the Securities Act of 1933, as amended, and the rules and regulations promulgated thereunder. “Subsidiary” means any subsidiary of the Company and shall, where applicable, also include any direct or indirect subsidiary of the Company formed or acquired after the date hereof. “Trading Day” means a day on which the Common Stock is traded on a Trading Market. “Trading Market” means any of the following markets or exchanges on which the Common Stock is listed or quoted for trading on the date in question: the NYSE American, the Nasdaq Capital Market, the Nasdaq Global Market, the Nasdaq Global Select Market, and the New York Stock Exchange (or any successors to any of the foregoing). 2. “Transfer Agent” means Broadridge the current transfer agent of the Company, with a mailing address of 51 Mercedes Way, Edgewood, NY 11717 and an email address of BCISERM@Broadridge.com, and any successor transfer agent of the Company. “VWAP” means, for any date, the price determined by the first of the following clauses that applies: (a) if the Common Stock is then listed or quoted on a Trading Market, the daily volume weighted average price of the Common Stock for such date (or the nearest preceding date) on the Trading Market on which the Common Stock is then listed or quoted as reported by Bloomberg L.P. (based on a Trading Day from 9:30 a.m. (New York City time) to 4:02 p.m. (New York City time)), (b) if OTCQB or OTCQX is not a Trading Market, the volume weighted average price of the Common Stock for such date (or the nearest preceding date) on OTCQB or OTCQX as applicable, (c) if the Common Stock is not then listed or quoted for trading on OTCQB or OTCQX and if prices for the Common Stock are then reported on the Pink Open Market (or a similar organization or agency succeeding to its functions of reporting prices), the most recent bid price per share of the Common Stock so reported, or (d) in all other cases, the fair market value of a share of Common Stock as determined by an independent appraiser selected in good faith by the holders of a majority in interest of the Warrants then outstanding and reasonably acceptable to the Company, the fees and expenses of which shall be paid by the Company. “Warrants” means this Warrant and other Common Stock purchase warrants issued by the Company pursuant to the Registration Statement. Section 2. Exercise. a) Exercise of Warrant. Exercise of the purchase rights represented by this Warrant may be made, in whole or in part, at any time or times on or after the Initial Exercise Date and on or before the Termination Date by delivery to the Company of a duly executed PDF copy submitted by e-mail (or e-mail attachment) of the Notice of Exercise in the form annexed hereto (the “Notice of Exercise”). Within the earlier of (i) one (1) Trading Day and (ii) the number of Trading Days comprising the Standard Settlement Period (as defined in Section 2(d)(i) herein) following the date of exercise as aforesaid, the Holder shall deliver the aggregate Exercise Price for the shares specified in the applicable Notice of Exercise by wire transfer or cashier’s check drawn on a United States bank unless the cashless exercise procedure specified in Section 2(c) below is specified in the applicable Notice of Exercise. No ink-original Notice of Exercise shall be required, nor shall any medallion guarantee (or other type of guarantee or notarization) of any Notice of Exercise be required. Notwithstanding anything herein to the contrary, the Holder shall not be required to physically surrender this Warrant to the Company until the Holder has purchased all of the Warrant Shares available hereunder and the Warrant has been exercised in full, in which case, the Holder shall surrender this Warrant to the Company for cancellation as soon as reasonably practicable of the date on which the final Notice of Exercise is delivered to the Company. Partial exercises of this Warrant resulting in purchases of a portion of the total number of Warrant Shares available hereunder shall have the effect of lowering the outstanding number of Warrant Shares purchasable hereunder in an amount equal to the applicable number of Warrant Shares purchased. The Holder and the Company shall maintain records showing the number of Warrant Shares purchased and the date of such purchases. The Company shall deliver any objection to any Notice of 3. Exercise within one (1) Business Day of receipt of such notice. The Holder and any assignee, by acceptance of this Warrant, acknowledge and agree that, by reason of the provisions of this paragraph, following the purchase of a portion of the Warrant Shares hereunder, the number of Warrant Shares available for purchase hereunder at any given time may be less than the amount stated on the face hereof. b) Exercise Price. The aggregate exercise price of this Warrant, except for a nominal exercise price of \$0.0001 per Warrant Share, was pre-funded to the Company on or prior to the Initial Exercise Date and, consequently, no additional consideration (other than the nominal exercise price of \$0.0001 per Warrant Share) shall be required to be paid by the Holder to any Person to effect any exercise of this Warrant. The Holder shall not be entitled to the return or refund of all, or any portion, of such pre-paid aggregate exercise price under any circumstance or for any reason whatsoever. The remaining unpaid exercise price per share of Common Stock under this Warrant shall be \$0.0001, subject to adjustment hereunder (the “Exercise Price”). c) Cashless Exercise. If at the time of exercise hereof there is no effective registration statement registering, or the prospectus contained therein is not available for the issuance of the Warrant Shares to the Holder, then this Warrant may also be exercised, in whole or in part, at such time by means of a “cashless exercise” in which the Holder shall be entitled to receive a number of Warrant Shares equal to the quotient obtained by dividing [(A-B) (X)] by (A), where: (A) = as applicable: (i) the VWAP on the Trading Day immediately preceding the date of the applicable Notice of Exercise if such Notice of Exercise is (1) both executed and delivered pursuant to Section 2(a) hereof on a day that is not a Trading Day or (2) both executed and delivered pursuant to Section 2(a) hereof on a Trading Day prior to the opening of “regular trading hours” (as defined in Rule 600(b) of Regulation NMS promulgated under the federal securities laws) on such Trading Day, (ii) at the option of the Holder, either (y) the VWAP on the Trading Day immediately preceding the date of the applicable Notice of Exercise or (z) the Bid Price of the Common Stock on the principal Trading Market as reported by Bloomberg L.P. (“Bloomberg”) as of the time of the Holder’s execution of the applicable Notice of Exercise if such Notice of Exercise is executed during “regular trading hours” on a Trading Day and is delivered within two (2) hours thereafter (including until two (2) hours after the close of “regular trading hours” on a Trading Day) pursuant to Section 2(a) hereof or (iii) the VWAP on the date of the applicable Notice of Exercise if the date of such Notice of Exercise is a Trading Day and such Notice of Exercise is both executed and delivered pursuant to Section 2(a) hereof after the close of “regular trading hours” on such Trading

Day;  $\hat{A}$  (B) = the Exercise Price of this Warrant, as adjusted hereunder; and  $\hat{A}$  (X) = the number of Warrant Shares that would be issuable upon exercise of this Warrant in accordance with the terms of this Warrant if such exercise were by means of a cash exercise rather than a cashless exercise. 4  $\hat{A}$   $\hat{A}$  If Warrant Shares are issued in such a cashless exercise, the parties acknowledge and agree that in accordance with Section 3(a)(9) of the Securities Act, the Warrant Shares shall take on the registered characteristics of the Warrants being exercised. The Company agrees not to take any position contrary to this Section 2(c).  $\hat{A}$  Notwithstanding anything herein to the contrary, on the Termination Date, this Warrant shall be automatically exercised via cashless exercise pursuant to this Section 2(c).  $\hat{A}$  d)Mechanics of Exercise. i.Delivery of Warrant Shares Upon Exercise. The Company shall cause the Warrant Shares purchased hereunder to be transmitted by the Transfer Agent to the Holder by crediting the account of the Holder $\hat{A}$ ™s or its designee $\hat{A}$ ™s balance account with The Depository Trust Company through its Deposit or Withdrawal at Custodian system ( $\hat{A}$ œDWAC $\hat{A}$ œ) if the Company is then a participant in such system and either (A) there is an effective registration statement permitting the issuance of the Warrant Shares to or resale of the Warrant Shares by the Holder or (B) this Warrant is being exercised via cashless exercise, and otherwise by physical delivery of a certificate, registered in the Company $\hat{A}$ ™s share register in the name of the Holder or its designee, for the number of Warrant Shares to which the Holder is entitled pursuant to such exercise to the address specified by the Holder in the Notice of Exercise by the date that is the earlier of (i) one (1) Trading Day after the delivery to the Company of the Notice of Exercise, and (ii) the number of Trading Days comprising the Standard Settlement Period after the delivery to the Company of the Notice of Exercise (such date, the  $\hat{A}$ œWarrant Share Delivery Date $\hat{A}$ œ). Upon delivery of the Notice of Exercise, the Holder shall be deemed for all corporate purposes to have become the holder of record of the Warrant Shares with respect to which this Warrant has been exercised, irrespective of the date of delivery of the Warrant Shares, provided that payment of the aggregate Exercise Price (other than in the case of a cashless exercise) is received within the earlier of (i) two (2) Trading Days and (ii) the number of Trading Days comprising the Standard Settlement Period following delivery of the Notice of Exercise. If the Company fails for any reason to deliver to the Holder the Warrant Shares subject to a Notice of Exercise by the Warrant Share Delivery Date, the Company shall pay to the Holder, in cash, as liquidated damages and not as a penalty, for each \$1,000 of Warrant Shares subject to such exercise (based on the VWAP of the Common Stock on the date of the applicable Notice of Exercise), \$10 per Trading Day (increasing to \$20 per Trading Day on the third Trading Day after the Warrant Share Delivery Date) for each Trading Day after such Warrant Share Delivery Date until such Warrant Shares are delivered or Holder rescinds such exercise. The Company agrees to maintain a transfer agent that is a participant in the FAST program so long as this Warrant remains outstanding and exercisable. As used herein, 5  $\hat{A}$   $\hat{A}$ œStandard Settlement Period $\hat{A}$ œ means the standard settlement period, expressed in a number of Trading Days (including no Trading Days if the settlement date is the trade date), on the Company $\hat{A}$ ™s primary Trading Market with respect to the Common Stock as in effect on the date of delivery of the Notice of Exercise. Notwithstanding the foregoing, with respect to any Notice(s) of Exercise delivered on or prior to 12:00 p.m. (New York City time) on the Initial Exercise Date, which may be delivered at any time after the time of execution of the Purchase Agreement, the Company agrees to deliver the Warrant Shares subject to such notice(s) by 4:00 p.m. (New York City time) on the Initial Exercise Date and the Initial Exercise Date shall be the Warrant Share Delivery Date for purposes hereunder, provided that payment of the aggregate Exercise Price (other than in the case of a cashless exercise) is received by such Warrant Share Delivery Date. ii.Delivery of New Warrants Upon Exercise. If this Warrant shall have been exercised in part, the Company shall, at the request of a Holder and upon surrender of this Warrant certificate, at the time of delivery of the Warrant Shares, deliver to the Holder a new Warrant evidencing the rights of the Holder to purchase the unpurchased Warrant Shares called for by this Warrant, which new Warrant shall in all other respects be identical with this Warrant. iii.Rescission Rights. If the Company fails to cause the Transfer Agent to transmit to the Holder the Warrant Shares pursuant to Section 2(d)(i) by the Warrant Share Delivery Date, then the Holder will have the right to rescind such exercise. iv.Compensation for Buy-In on Failure to Timely Deliver Warrant Shares Upon Exercise. In addition to any other rights available to the Holder, if the Company fails to cause the Transfer Agent to transmit to the Holder the Warrant Shares in accordance with the provisions of Section 2(d)(i) above pursuant to an exercise on or before the Warrant Share Delivery Date, and if after such date the Holder is required by its broker to purchase (in an open market transaction or otherwise) or the Holder $\hat{A}$ ™s brokerage firm otherwise purchases, shares of Common Stock to deliver in satisfaction of a sale by the Holder of the Warrant Shares which the Holder anticipated receiving upon such exercise (a  $\hat{A}$ œBuy-In $\hat{A}$ œ), then the Company shall (A) pay in cash to the Holder the amount, if any, by which (x) the Holder $\hat{A}$ ™s total purchase price (including brokerage commissions, if any) for the shares of Common Stock so purchased exceeds (y) the amount obtained by multiplying (1) the number of Warrant Shares that the Company was required to deliver to the Holder in connection with the exercise at issue times (2) the price at which the sell order giving rise to such purchase obligation was executed, and (B) at the option of the Holder, either reinstate the portion of the Warrant and equivalent number of Warrant Shares for which such exercise was not 6  $\hat{A}$  honored (in which case such exercise shall be deemed rescinded) or deliver to the Holder the number of shares of Common Stock that would have been issued had the Company timely complied with its exercise and delivery obligations hereunder. For example, if the Holder purchases Common Stock having a total purchase price of \$11,000 to cover a Buy-In with respect to an attempted exercise of shares of Common Stock with an aggregate sale price giving rise to such purchase obligation of \$10,000, under clause (A) of the immediately preceding sentence the Company shall be required to pay the Holder \$1,000. The Holder shall provide the Company written notice indicating the amounts payable to the Holder in respect of the Buy-In and, upon request of the Company, evidence of the amount of such loss. Nothing herein shall limit a Holder $\hat{A}$ ™s right to pursue any other remedies available to it hereunder, at law or in equity including, without limitation, a decree of specific performance and/or injunctive relief with respect to the Company $\hat{A}$ ™s failure to timely deliver shares of Common Stock upon exercise of the Warrant as required pursuant to the terms hereof. v.No Fractional Shares or Scrip. No fractional shares or scrip representing fractional shares shall be issued upon the exercise of this Warrant. As to any fraction of a share which the Holder would otherwise be entitled to purchase upon such exercise, the Company shall, at its election, either pay a cash adjustment in respect of such final fraction in an amount equal to such fraction multiplied by the Exercise Price or round up to the next whole share. vi.Charges, Taxes and Expenses. Issuance of Warrant Shares shall be made without charge to the Holder for any issue or transfer tax or other incidental expense in respect of the issuance of such Warrant Shares, all of which taxes and expenses shall be paid by the Company, and such Warrant Shares shall be issued in the name of the Holder or in such name or names as may be directed by the Holder; provided, however, that, in the event that Warrant Shares are to be issued in a name other than the name of the Holder, this Warrant when surrendered for exercise shall be accompanied by the Assignment Form attached hereto duly executed by the Holder and the Company may require, as a condition thereto, the payment of a sum sufficient to reimburse it for any transfer tax incidental thereto. The Company shall pay all Transfer Agent fees required for same-day processing of any Notice of Exercise and all fees to the Depository Trust Company (or another established clearing corporation performing similar functions) required for same-day electronic delivery of the Warrant Shares. vii.Closing of Books. The Company will not close its stockholder books or records in any manner which prevents the timely exercise of this Warrant, pursuant to the terms hereof. 7  $\hat{A}$  e) Holder $\hat{A}$ ™s Exercise Limitations. The Company shall not effect any exercise of this Warrant, and a Holder shall not have the right to exercise any portion of this Warrant, pursuant to Section 2 or otherwise, to the extent that after giving effect to such issuance after exercise as set forth on the applicable Notice of Exercise, the Holder (together with the Holder $\hat{A}$ ™s Affiliates, and any other Persons acting as a group together with the Holder or any of the Holder $\hat{A}$ ™s Affiliates (such Persons,  $\hat{A}$ œAttribution Parties $\hat{A}$ œ)), would beneficially own in excess of the Beneficial Ownership Limitation (as defined below). For purposes of the foregoing sentence, the number of shares of Common Stock beneficially owned by the Holder and its Affiliates and Attribution Parties shall include the number of shares of Common Stock issuable upon exercise of this Warrant with respect to which such determination is being made, but shall exclude the number of shares of Common Stock which would be issuable upon (i) exercise of the remaining, nonexercised portion of this Warrant beneficially owned by the Holder or any of its Affiliates or Attribution Parties and (ii) exercise or conversion of the unexercised or nonconverted portion of any other securities of the Company (including, without limitation, any other Common Stock Equivalents) subject to a limitation on conversion or exercise analogous to the limitation contained herein beneficially owned by the Holder or any of its Affiliates or Attribution Parties. Except as set forth in the preceding sentence, for purposes of this Section 2(e), beneficial ownership shall be calculated in accordance with Section 13(d) of the Exchange Act and the rules and regulations promulgated thereunder, it being acknowledged by the Holder that the Company is not representing to the Holder that such calculation is in compliance with Section 13(d) of the Exchange Act and the Holder is solely responsible for any schedules required to be filed in accordance therewith. To the extent that the limitation contained in this Section 2(e) applies, the determination of whether this Warrant is exercisable (in relation to other securities owned by the Holder together with any Affiliates and Attribution Parties) and of which portion of this Warrant is exercisable shall be in the sole discretion of the Holder, and the

submission of a Notice of Exercise shall be deemed to be the Holder's determination of whether this Warrant is exercisable (in relation to other securities owned by the Holder together with any Affiliates and Attribution Parties) and of which portion of this Warrant is exercisable, in each case subject to the Beneficial Ownership Limitation, and the Company shall have no obligation to verify or confirm the accuracy of such determination. In addition, a determination as to any group status as contemplated above shall be determined in accordance with Section 13(d) of the Exchange Act and the rules and regulations promulgated thereunder. For purposes of this Section 2(e), in determining the number of outstanding shares of Common Stock, a Holder may rely on the number of outstanding shares of Common Stock as reflected in (A) the Company's most recent periodic or annual report filed with the Commission, as the case may be, (B) a more recent public announcement by the Company or (C) a more recent written notice by the Company or the Transfer Agent setting forth the number of shares of Common Stock outstanding. Upon the written or oral request of a Holder, the Company shall within one Trading Day confirm orally and in writing to the Holder the number of shares of Common Stock then outstanding. In any case, the number of outstanding shares of Common Stock shall be determined after giving effect to the conversion or exercise of securities of the Company, including this Warrant, by the Holder or its Affiliates or Attribution Parties since the date as of which such number of outstanding shares of Common Stock was reported. The Beneficial Ownership Limitation shall be 9.99/4.99% of the number of shares of the Common Stock outstanding immediately after giving effect to the issuance of shares of Common Stock issuable upon exercise of this Warrant. The Holder, upon notice to the Company, may increase or decrease the Beneficial Ownership Limitation provisions of this Section 2(e), provided that the Beneficial Ownership Limitation in no event exceeds 9.99% of the number of shares of the Common Stock outstanding immediately after giving effect to the issuance of shares of Common Stock upon exercise of this Warrant held by the Holder and the provisions of this Section 2(e) shall continue to apply. Any increase in the Beneficial Ownership Limitation will not be effective until the 61st day after such notice is delivered to the Company. The provisions of this paragraph shall be construed and implemented in a manner otherwise than in strict conformity with the terms of this Section 2(e) to correct this paragraph (or any portion hereof) which may be defective or inconsistent with the intended Beneficial Ownership Limitation herein contained or to make changes or supplements necessary or desirable to properly give effect to such limitation. The limitations contained in this paragraph shall apply to a successor holder of this Warrant.

**Section 3. Certain Adjustments.**

**a) Stock Dividends and Splits.** If the Company, at any time while this Warrant is outstanding: (i) pays a stock dividend or otherwise makes a distribution or distributions on shares of its Common Stock or any other equity or equity equivalent securities payable in shares of Common Stock (which, for avoidance of doubt, shall not include any shares of Common Stock issued by the Company upon exercise of this Warrant), (ii) subdivides outstanding shares of Common Stock into a larger number of shares, (iii) combines (including by way of reverse stock split) outstanding shares of Common Stock into a smaller number of shares, or (iv) issues by reclassification of shares of the Common Stock any shares of capital stock of the Company, then in each case the Exercise Price shall be multiplied by a fraction of which the numerator shall be the number of shares of Common Stock (excluding treasury shares, if any) outstanding immediately before such event and of which the denominator shall be the number of shares of Common Stock outstanding immediately after such event, and the number of shares issuable upon exercise of this Warrant shall be proportionately adjusted such that the aggregate Exercise Price of this Warrant shall remain unchanged. Any adjustment made pursuant to this Section 3(a) shall become effective immediately after the record date for the determination of stockholders entitled to receive such dividend or distribution and shall become effective immediately after the effective date in the case of a subdivision, combination or reclassification.

**b) Subsequent Rights Offerings.** In addition to any adjustments pursuant to Section 3(a) above, if at any time the Company grants, issues or sells any Common Stock Equivalents or rights to purchase stock, warrants, securities or other property pro rata to the record holders of any class of shares of Common Stock (the Purchase Rights), then the Holder will be entitled to acquire, upon the terms applicable to such Purchase Rights, the aggregate Purchase Rights which the Holder could have acquired if the Holder had held the number of shares of Common Stock acquirable upon complete exercise of this Warrant (without regard to any limitations on exercise hereof, including without limitation, the Beneficial Ownership Limitation) immediately before the date on which a record is taken for the grant, issuance or sale of such Purchase Rights, or, if no such record is taken, the date as of which the record holders of shares of Common Stock are to be determined for the grant, issue or sale of such Purchase Rights (provided, however, that, to the extent that the Holder's right to participate in any such Purchase Right would result in the Holder exceeding the Beneficial Ownership Limitation, then the Holder shall not be entitled to participate in such Purchase Right to such extent (or beneficial ownership of such shares of Common Stock as a result of such Purchase Right to such extent) and such Purchase Right to such extent shall be held in abeyance for the Holder until such time, if ever, as its right thereto would not result in the Holder exceeding the Beneficial Ownership Limitation).

**c) Pro Rata Distributions.** During such time as this Warrant is outstanding, if the Company shall declare or make any dividend or other distribution of its assets (or rights to acquire its assets) to holders of shares of Common Stock, by way of return of capital or otherwise (including, without limitation, any distribution of cash, stock or other securities, property or options by way of a dividend, spin off, reclassification, corporate rearrangement, scheme of arrangement or other similar transaction) (a Distribution), at any time after the issuance of this Warrant, then, in each such case, the Holder shall be entitled to participate in such Distribution to the same extent that the Holder would have participated therein if the Holder had held the number of shares of Common Stock acquirable upon complete exercise of this Warrant (without regard to any limitations on exercise hereof, including without limitation, the Beneficial Ownership Limitation) immediately before the date of which a record is taken for such Distribution, or, if no such record is taken, the date as of which the record holders of shares of Common Stock are to be determined for the participation in such Distribution (provided, however, that, to the extent that the Holder's right to participate in any such Distribution would result in the Holder exceeding the Beneficial Ownership Limitation, then the Holder shall not be entitled to participate in such Distribution to such extent (or in the beneficial ownership of any shares of Common Stock as a result of such Distribution to such extent) and the portion of such Distribution shall be held in abeyance for the benefit of the Holder until such time, if ever, as its right thereto would not result in the Holder exceeding the Beneficial Ownership Limitation).

**d) Fundamental Transaction.** If, at any time while this Warrant is outstanding, (i) the Company, directly or indirectly, in one or more related transactions effects any merger or consolidation of the Company with or into another Person, (ii) the Company (or any Subsidiary), directly or indirectly, effects any sale, lease, license, assignment, transfer, conveyance or other disposition of all or substantially all of its assets in one or a series of related transactions, (iii) any, direct or indirect, purchase offer, tender offer or exchange offer (whether by the Company or another Person) is completed pursuant to which holders of Common Stock are permitted to sell, tender or exchange their shares for other securities, cash or property and has been accepted by the holders of 50% or more of the shares of the outstanding Common Stock or 50% or more of the voting power of the common equity of the Company, (iv) the Company, directly or indirectly, in one or more related transactions effects any reclassification, reorganization or recapitalization of shares of Common Stock or any compulsory share exchange pursuant to which the shares of Common Stock are effectively converted into or exchanged for other securities, cash or property, or (v) the Company, directly or indirectly, in one or more related transactions consummates a stock or share purchase agreement or other business combination (including, without limitation, a reorganization, recapitalization, spin-off, merger or scheme of arrangement) with another Person or group of Persons whereby such other Person or group acquires 50% or more of the outstanding shares of Common Stock or 50% or more of the voting power of the common equity of the Company (each a Fundamental Transaction), then, upon any subsequent exercise of this Warrant, the Holder shall have the right to receive, for each Warrant Share that would have been issuable upon such exercise immediately prior to the occurrence of such Fundamental Transaction, at the option of the Holder (without regard to any limitation in Section 2(e) on the exercise of this Warrant), the number of shares of Common Stock of the successor or acquiring corporation or of the Company, if it is the surviving corporation, and any additional consideration (the Alternate Consideration) receivable as a result of such Fundamental Transaction by a holder of the number of shares of Common Stock for which this Warrant is exercisable immediately prior to such Fundamental Transaction (without regard to any limitation in Section 2(e) on the exercise of this Warrant). For purposes of any such exercise, the determination of the Exercise Price shall be appropriately adjusted to apply to such Alternate Consideration based on the amount of Alternate Consideration issuable in respect of one share of Common Stock in such Fundamental Transaction, and the Company shall apportion the Exercise Price among the Alternate Consideration in a reasonable manner reflecting the relative value of any different components of the Alternate Consideration. If holders of Common Stock are given any choice as to the securities, cash or property to be received in a Fundamental Transaction, then the Holder shall be given the same choice as to the Alternate Consideration it receives upon any exercise of this Warrant following such Fundamental Transaction. The Company shall cause any successor entity in a Fundamental Transaction in which the Company is not the survivor (the Successor Entity) to assume in writing all of the obligations of the Company under this Warrant and the other Transaction

Documents in accordance with the provisions of this Section 3(d) pursuant to written agreements in form and substance reasonably satisfactory to the Holder and approved by the Holder (without unreasonable delay) prior to such Fundamental Transaction and shall, at the option of the Holder, deliver to the Holder in exchange for this Warrant a security of the Successor Entity evidenced by a written instrument substantially similar in form and substance to this Warrant which is exercisable for a corresponding number of shares of capital stock of such Successor Entity (or its parent entity) equivalent to the shares of Common Stock acquirable and receivable upon exercise of this Warrant (without regard to any limitations on the exercise of this Warrant) prior to such Fundamental Transaction, and with an exercise price which applies the exercise price hereunder to such shares of capital stock (but taking into account the relative value of the shares of Common Stock pursuant to such Fundamental Transaction and the value of such shares of capital stock, such number of shares of capital stock and such exercise price being for the purpose of protecting the economic value of this Warrant immediately prior to the consummation of such Fundamental Transaction), 11 Å and which is reasonably satisfactory in form and substance to the Holder. Upon the occurrence of any such Fundamental Transaction, the Successor Entity shall be added to the term “Company” under this Warrant (so that from and after the occurrence or consummation of such Fundamental Transaction, each and every provision of this Warrant and the other Transaction Documents referring to the “Company” shall refer instead to each of the Company and the Successor Entity or Successor Entities, jointly and severally), and the Successor Entity or Successor Entities, jointly and severally with the Company, may exercise every right and power of the Company prior thereto and the Successor Entity or Successor Entities shall assume all of the obligations of the Company prior thereto under this Warrant and the other Transaction Documents with the same effect as if the Company and such Successor Entity or Successor Entities, jointly and severally, had been named as the Company herein. For the avoidance of doubt, the Holder shall be entitled to the benefits of the provisions of this Section 3(d) regardless of (i) whether the Company has sufficient authorized shares of Common Stock for the issuance of Warrant Shares and/or (ii) whether a Fundamental Transaction occurs prior to the Initial Exercise Date. e)Calculations. All calculations under this Section 3 shall be made to the nearest cent or the nearest 1/100th of a share, as the case may be. For purposes of this Section 3, the number of shares of Common Stock deemed to be issued and outstanding as of a given date shall be the sum of the number of shares of Common Stock (excluding treasury shares, if any) issued and outstanding. f)Notice to Holder. i.Adjustment to Exercise Price. Whenever the Exercise Price is adjusted pursuant to any provision of this Section 3, the Company shall promptly deliver to the Holder by email a notice setting forth the Exercise Price after such adjustment and any resulting adjustment to the number of Warrant Shares and setting forth a brief statement of the facts requiring such adjustment. ii.Notice to Allow Exercise by Holder. If (A) the Company shall declare a dividend (or any other distribution in whatever form) on the Common Stock, (B) the Company shall declare a special nonrecurring cash dividend on or a redemption of the Common Stock, (C) the Company shall authorize the granting to all holders of the Common Stock rights or warrants to subscribe for or purchase any shares of capital stock of any class or of any rights, (D) the approval of any stockholders of the Company shall be required in connection with any reclassification of the Common Stock, any consolidation or merger to which the Company (or any of its Subsidiaries) is a party, any sale or transfer of all or substantially all of its assets, or any compulsory share exchange whereby the Common Stock is converted into other securities, cash or property, or (E) the Company shall authorize the voluntary or involuntary dissolution, liquidation or winding up of the affairs of the Company, then, in each case, the Company shall cause to be delivered by email to the Holder at its last email address as it shall appear upon the Warrant Register of the Company, at least 20 calendar days prior to the 12 Å applicable record or effective date hereinafter specified, a notice stating (x) the date on which a record is to be taken for the purpose of such dividend, distribution, redemption, rights or warrants, or if a record is not to be taken, the date as of which the holders of the Common Stock of record to be entitled to such dividend, distributions, redemption, rights or warrants are to be determined or (y) the date on which such reclassification, consolidation, merger, sale, transfer or share exchange is expected to become effective or close, and the date as of which it is expected that holders of the Common Stock of record shall be entitled to exchange their shares of the Common Stock for securities, cash or other property deliverable upon such reclassification, consolidation, merger, sale, transfer or share exchange; provided that the failure to deliver such notice or any defect therein or in the delivery thereof shall not affect the validity of the corporate action required to be specified in such notice. To the extent that any notice provided in this Warrant constitutes, or contains, material, non-public information regarding the Company or any of the Subsidiaries, the Company shall simultaneously file such notice with the Commission pursuant to a Current Report on Form 8-K. The Holder shall remain entitled to exercise this Warrant during the period commencing on the date of such notice to the effective date of the event triggering such notice except as may otherwise be expressly set forth herein. Section 4. Transfer of Warrant. a)Transferability. Subject to compliance with any applicable securities laws and the conditions set forth in Section 4(d) hereof and to the provisions of Section 4.1 of the Purchase Agreement, this Warrant and all rights hereunder (including, without limitation, any registration rights) are transferable, in whole or in part, upon surrender of this Warrant at the principal office of the Company or its designated agent, together with a written assignment of this Warrant substantially in the form attached hereto duly executed by the Holder or its agent or attorney and funds sufficient to pay any transfer taxes payable upon the making of such transfer. Upon such surrender and, if required, such payment, the Company shall execute and deliver a new Warrant or Warrants in the name of the assignee or assignees, as applicable, and in the denomination or denominations specified in such instrument of assignment, and shall issue to the assignor a new Warrant evidencing the portion of this Warrant not so assigned, and this Warrant shall promptly be cancelled. Notwithstanding anything herein to the contrary, the Holder shall not be required to physically surrender this Warrant to the Company unless the Holder has assigned this Warrant in full, in which case, the Holder shall surrender this Warrant to the Company within three (3) Trading Days of the date on which the Holder delivers an assignment form to the Company assigning this Warrant in full. The Warrant, if properly assigned in accordance herewith, may be exercised by a new holder for the purchase of Warrant Shares without having a new Warrant issued. b)New Warrants. This Warrant may be divided or combined with other Warrants upon presentation hereof at the aforesaid office of the Company, together with a written notice specifying the names and denominations in which new Warrants are to be 13 Å issued, signed by the Holder or its agent or attorney. Subject to compliance with Section 4(a), as to any transfer which may be involved in such division or combination, the Company shall execute and deliver a new Warrant or Warrants in exchange for the Warrant or Warrants to be divided or combined in accordance with such notice. All Warrants issued on transfers or exchanges shall be dated the original Issue Date and shall be identical with this Warrant except as to the number of Warrant Shares issuable pursuant thereto. c)Warrant Register. The Company shall register this Warrant, upon records to be maintained by the Company for that purpose (the “Warrant Register”), in the name of the record Holder hereof from time to time. The Company may deem and treat the registered Holder of this Warrant as the absolute owner hereof for the purpose of any exercise hereof or any distribution to the Holder, and for all other purposes, absent actual notice to the contrary. Section 5. Miscellaneous. a)No Rights as Stockholder Until Exercise; No Settlement in Cash. This Warrant does not entitle the Holder to any voting rights, dividends or other rights as a stockholder of the Company prior to the exercise hereof as set forth in Section 2(d)(i), except as expressly set forth in Section 3. Without limiting any rights of a Holder to receive Warrant Shares on a “cashless exercise” pursuant to Section 2(c) or to receive cash payments pursuant to Section 2(d)(i) and Section 2(d)(iv) herein, in no event shall the Company be required to net cash settle an exercise of this Warrant. b)Loss, Theft, Destruction or Mutilation of Warrant. The Company covenants that upon receipt by the Company of evidence reasonably satisfactory to it of the loss, theft, destruction or mutilation of this Warrant or any stock certificate relating to the Warrant Shares, and in case of loss, theft or destruction, of indemnity or security reasonably satisfactory to it (which, in the case of the Warrant, shall not include the posting of any bond), and upon surrender and cancellation of such Warrant or stock certificate, if mutilated, the Company will make and deliver a new Warrant or stock certificate of like tenor and dated as of such cancellation, in lieu of such Warrant or stock certificate. c)Saturdays, Sundays, Holidays, etc. If the last or appointed day for the taking of any action or the expiration of any right required or granted herein shall not be a Business Day, then such action may be taken or such right may be exercised on the next succeeding Business Day. d)Authorized Shares. The Company covenants that, during the period the Warrant is outstanding, it will reserve from its authorized and unissued Common Stock a sufficient number of shares to provide for the issuance of the Warrant Shares upon the exercise of any purchase rights under this Warrant. The Company further covenants that its issuance of this Warrant shall constitute full authority to its officers who are charged with the duty of issuing the necessary Warrant Shares upon the exercise of the purchase rights under this Warrant. The Company will 14 Å take all such reasonable action as may be necessary to assure that such Warrant Shares may be issued as provided herein without violation of any applicable law or regulation, or of any requirements of the Trading Market upon which the Common Stock may be listed. The Company covenants that all Warrant Shares which may be issued upon the exercise of the purchase rights represented by this Warrant will, upon exercise of the purchase rights represented by this Warrant and payment for such Warrant Shares in accordance herewith, be duly authorized, validly

issued, fully paid and nonassessable and free from all taxes, liens and charges created by the Company in respect of the issue thereof (other than taxes in respect of any transfer occurring contemporaneously with such issue). Except and to the extent as waived or consented to by the Holder, the Company shall not by any action, including, without limitation, amending its certificate of incorporation or through any reorganization, transfer of assets, consolidation, merger, dissolution, issue or sale of securities or any other voluntary action, avoid or seek to avoid the observance or performance of any of the terms of this Warrant, but will at all times in good faith assist in the carrying out of all such terms and in the taking of all such actions as may be necessary or appropriate to protect the rights of Holder as set forth in this Warrant against impairment. Without limiting the generality of the foregoing, the Company will (i) not increase the par value of any Warrant Shares above the amount payable therefor upon such exercise immediately prior to such increase in par value, (ii) take all such action as may be necessary or appropriate in order that the Company may validly and legally issue fully paid and nonassessable Warrant Shares upon the exercise of this Warrant and (iii) use commercially reasonable efforts to obtain all such authorizations, exemptions or consents from any public regulatory body having jurisdiction thereof, as may be, necessary to enable the Company to perform its obligations under this Warrant. Before taking any action which would result in an adjustment in the number of Warrant Shares for which this Warrant is exercisable or in the Exercise Price, the Company shall obtain all such authorizations or exemptions thereof, or consents thereto, as may be necessary from any public regulatory body or bodies having jurisdiction thereof. e)Governing Law. All questions concerning the construction, validity, enforcement and interpretation of this Warrant shall be governed by and construed and enforced in accordance with the internal laws of the State of New York, without regard to the principles of conflicts of law thereof. Each party agrees that all legal proceedings concerning the interpretations, enforcement and defense of the transactions contemplated by this Warrant (whether brought against a party hereto or their respective affiliates, directors, officers, shareholders, partners, members, employees or agents) shall be commenced exclusively in the state and federal courts sitting in the City of New York. Each party hereby irrevocably submits to the exclusive jurisdiction of the state and federal courts sitting in the City of New York, Borough of Manhattan for the adjudication of any dispute hereunder or in connection herewith or with any transaction contemplated hereby or discussed herein, and hereby irrevocably waives, and agrees not to assert in any suit, 15  action or proceeding, any claim that it is not personally subject to the jurisdiction of any such court, that such suit, action or proceeding is improper or is an inconvenient venue for such proceeding. Each party hereby irrevocably waives personal service of process and consents to process being served in any such suit, action or proceeding by mailing a copy thereof via registered or certified mail or overnight delivery (with evidence of delivery) to such party at the address in effect for notices to it under this Warrant and agrees that such service shall constitute good and sufficient service of process and notice thereof. Nothing contained herein shall be deemed to limit in any way any right to serve process in any other manner permitted by law. If either party shall commence an action, suit or proceeding to enforce any provisions of this Warrant, the prevailing party in such action, suit or proceeding shall be reimbursed by the other party for their reasonable attorneys fees and other costs and expenses incurred with the investigation, preparation and prosecution of such action or proceeding. f)Restrictions. The Holder acknowledges that the Warrant Shares acquired upon the exercise of this Warrant, if not registered, and the Holder does not utilize cashless exercise, will have restrictions upon resale imposed by state and federal securities laws. g)Nonwaiver and Expenses. No course of dealing or any delay or failure to exercise any right hereunder on the part of Holder shall operate as a waiver of such right or otherwise prejudice the Holders rights, powers or remedies. Without limiting any other provision of this Warrant or the Purchase Agreement, if the Company willfully and knowingly fails to comply with any provision of this Warrant, which results in any material damages to the Holder, the Company shall pay to the Holder such amounts as shall be sufficient to cover any costs and expenses including, but not limited to, reasonable attorneys fees, including those of appellate proceedings, incurred by the Holder in collecting any amounts due pursuant hereto or in otherwise enforcing any of its rights, powers or remedies hereunder. h)Notices. Any and all notices or other communications or deliveries to be provided by the Holders hereunder including, without limitation, any Notice of Exercise, shall be in writing and delivered personally, by e-mail, or sent by a nationally recognized overnight courier service, addressed to the Company, at 2401 4th Avenue, Suite 1050, Seattle Washington 98121, Attention: Daphne Taylor email address: TaylorD2@apvo.com, or such other email address or address as the Company may specify for such purposes by notice to the Holders. Any and all notices or other communications or deliveries to be provided by the Company hereunder shall be in writing and delivered personally, by e-mail, or sent by a nationally recognized overnight courier service addressed to each Holder at the e-mail address or address of such Holder appearing on the books of the Company. Any notice or other communication or deliveries hereunder shall be deemed given and effective on the earliest of (i) the time of transmission, if such notice or communication is delivered via e-mail at the e-mail address set forth in this Section prior to 5:30 p.m. (New York City time) on any date, (ii) the next Trading Day after the time of transmission, if such notice or communication is delivered via e-mail at the e-mail address set forth in this Section on a day that is not a Trading Day or later than 5:30 p.m. (New York City time) on any Trading Day, (iii) the second Trading Day following the date of mailing, if sent by U.S. nationally recognized overnight courier service, or (iv) upon actual 16  receipt by the party to whom such notice is required to be given. To the extent that any notice provided hereunder constitutes, or contains, material, non-public information regarding the Company or any Subsidiaries, the Company shall simultaneously file such notice with the Commission pursuant to a Current Report on Form 8-K. i)Limitation of Liability. No provision hereof, in the absence of any affirmative action by the Holder to exercise this Warrant to purchase Warrant Shares, and no enumeration herein of the rights or privileges of the Holder, shall give rise to any liability of the Holder for the purchase price of any Common Stock or as a stockholder of the Company, whether such liability is asserted by the Company or by creditors of the Company. j)Remedies. The Holder, in addition to being entitled to exercise all rights granted by law, including recovery of damages, will be entitled to specific performance of its rights under this Warrant. The Company agrees that monetary damages would not be adequate compensation for any loss incurred by reason of a breach by it of the provisions of this Warrant and hereby agrees to waive and not to assert the defense in any action for specific performance that a remedy at law would be adequate. k)Successors and Assigns. Subject to applicable securities laws, this Warrant and the rights and obligations evidenced hereby shall inure to the benefit of and be binding upon the successors and permitted assigns of the Company and the successors and permitted assigns of Holder. The provisions of this Warrant are intended to be for the benefit of any Holder from time to time of this Warrant and shall be enforceable by the Holder or holder of Warrant Shares. l)Amendment. This Warrant may be modified or amended or the provisions hereof waived with the written consent of the Company, on the one hand and the Holder or the beneficial owner of this Warrant, on the other hand. m)Severability. Wherever possible, each provision of this Warrant shall be interpreted in such manner as to be effective and valid under applicable law, but if any provision of this Warrant shall be prohibited by or invalid under applicable law, such provision shall be ineffective to the extent of such prohibition or invalidity, without invalidating the remainder of such provisions or the remaining provisions of this Warrant. n)Headings. The headings used in this Warrant are for the convenience of reference only and shall not, for any purpose, be deemed a part of this Warrant.  \*\*\*\*\*  (Signature Page Follows)  17  IN WITNESS WHEREOF, the Company has caused this Warrant to be executed by its officer thereunto duly authorized as of the date first above indicated.  aptevo therapeutics inc.   By:      Name:      Title:   18  NOTICE OF EXERCISE  To: aptevo therapeutics inc.  (1)The undersigned hereby elects to purchase \_\_\_\_\_ Warrant Shares of the Company pursuant to the terms of the attached Warrant (only if exercised in full), and tenders herewith payment of the exercise price in full, together with all applicable transfer taxes, if any. (2)Payment shall take the form of (check applicable box): [ ] in lawful money of the United States; or [ ] if permitted the cancellation of such number of Warrant Shares as is necessary, in accordance with the formula set forth in subsection 2(c), to exercise this Warrant with respect to the maximum number of Warrant Shares purchasable pursuant to the cashless exercise procedure set forth in subsection 2(c). (3)Please issue said Warrant Shares in the name of the undersigned or in such other name as is specified below: \_\_\_\_\_  The Warrant Shares shall be delivered to the following DWAC Account Number:  \_\_\_\_\_  [SIGNATURE OF HOLDER] Name of Investing Entity: \_\_\_\_\_ Signature of Authorized Signatory of Investing Entity: \_\_\_\_\_ Name of Authorized Signatory: \_\_\_\_\_ Title of Authorized Signatory: \_\_\_\_\_ Date: \_\_\_\_\_      EXHIBIT B  ASSIGNMENT FORM (To assign the foregoing Warrant, execute this form and supply required information. Do not use this form to purchase shares.) FOR VALUE RECEIVED, the foregoing Warrant and all rights evidenced thereby are hereby assigned to Name:   (Please Print) Address:    Phone Number:Email Address: (Please Print) \_\_\_\_\_ Dated: \_\_\_\_\_

À Holderâ€™s Signature: À Address: À À EX-18.18 3 apvo-ex\_18.htm EX-18.18 EX-18.18  
 EXHIBIT 4.18 COMMON STOCK PURCHASE WARRANT À aptevo therapeutics inc. Warrant Shares: \_\_\_\_\_ Issue Date: \_\_\_\_, 2024  
 THIS COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, \_\_\_\_\_ or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date that the Stockholder Approval (as defined below) is obtained and deemed effective (the “Initial Exercise Date”) and on or prior to 5:00 p.m. (New York City time) the five year anniversary of the Initial Exercise Date (the “Termination Date”) but not thereafter, to subscribe for and purchase from Aptevo Therapeutics Inc., a Delaware corporation (the “Company”), up to \_\_\_\_\_ shares (as subject to adjustment hereunder, the “Warrant Shares”) of Common Stock. The purchase price of one share of Common Stock under this Warrant shall be equal to the Exercise Price, as defined in Section 2(b). Section 1. Definitions. In addition to the terms defined elsewhere in this Warrant, the following terms have the meanings indicated in this Section 1: “Affiliate” means any Person that, directly or indirectly through one or more intermediaries, controls or is controlled by or is under common control with a Person, as such terms are used in and construed under Rule 405 under the Securities Act. “Bid Price” means, for any date, the price determined by the first of the following clauses that applies: (a) if the Common Stock is then listed or quoted on a Trading Market, the bid price of the Common Stock for the time in question (or the nearest preceding date) on the Trading Market on which the Common Stock is then listed or quoted as reported by Bloomberg L.P. (based on a Trading Day from 9:30 a.m. (New York City time) to 4:02 p.m. (New York City time)), (b) if OTCQB or OTCQX is not a Trading Market, the volume weighted average price of the Common Stock for such date (or the nearest preceding date) on OTCQB or OTCQX as applicable, (c) if the Common Stock is not then listed or quoted for trading on OTCQB or OTCQX and if prices for the Common Stock are then reported on the Pink Open Market (or a similar organization or agency succeeding to its functions of reporting prices), the most recent bid price per share of the Common Stock so reported, or (d) in all other cases, the fair market value of a share of Common Stock as determined by an independent appraiser selected in good faith by the Holders of a majority in interest of the Warrants then outstanding and reasonably acceptable to the Company, the fees and expenses of which shall be paid by the Company. “Board of Directors” means the board of directors of the Company. “Business Day” means any day other than Saturday, Sunday or other day on which commercial banks in The City of New York are authorized or required by law to remain closed; provided, however, for clarification, commercial banks shall not be deemed to be À authorized or required by law to remain closed due to “stay at home”, “shelter-in-place”, “non-essential employee” or any other similar orders or restrictions or the closure of any physical branch locations at the direction of any governmental authority so long as the electronic funds transfer systems (including for wire transfers) of commercial banks in The City of New York generally are open for use by customers on such day. “Commission” means the United States Securities and Exchange Commission. “Common Stock” means the common stock of the Company, par value \$0.001 per share, and any other class of securities into which such securities may hereafter be reclassified or changed. “Common Stock Equivalents” means any securities of the Company or the Subsidiaries which would entitle the holder thereof to acquire at any time Common Stock, including, without limitation, any debt, preferred stock, right, option, warrant or other instrument that is at any time convertible into or exercisable or exchangeable for, or otherwise entitles the holder thereof to receive, Common Stock. “Exchange Act” means the Securities Exchange Act of 1934, as amended, and the rules and regulations promulgated thereunder. À “Person” means an individual or corporation, partnership, trust, incorporated or unincorporated association, joint venture, limited liability company, joint stock company, government (or an agency or subdivision thereof) or other entity of any kind. “Purchase Agreement” means the securities purchase agreement, dated as of \_\_\_\_\_, 2024, by and between the Company and each of the purchasers signatory thereto. “Registration Statement” means the Companyâ€™s registration statement on Form S-1 (File No. 333-\_\_\_\_). “Securities Act” means the Securities Act of 1933, as amended, and the rules and regulations promulgated thereunder. “Stockholder Approval” means such approval as may be required by the applicable rules and regulations of the Nasdaq Capital Market (or any successor entity) from the stockholders of the Company to permit the exercise of the Warrants. “Subsidiary” means any subsidiary of the Company and shall, where applicable, also include any direct or indirect subsidiary of the Company formed or acquired after the date hereof. “Trading Day” means a day on which the Common Stock is traded on a Trading Market. “Trading Market” means any of the following markets or exchanges on which the Common Stock is listed or quoted for trading on the date in question: the NYSE American, À the Nasdaq Capital Market, the Nasdaq Global Market, the Nasdaq Global Select Market, and the New York Stock Exchange, (or any successors to any of the foregoing). “Transfer Agent” means Broadridge the current transfer agent of the Company, with a mailing address of 51 Mercedes Way, Edgewood, NY 11717 and an email address of BCISERM@Broadridge.com, and any successor transfer agent of the Company. “VWAP” means, for any date, the price determined by the first of the following clauses that applies: (a) if the Common Stock is then listed or quoted on a Trading Market, the daily volume weighted average price of the Common Stock for such date (or the nearest preceding date) on the Trading Market on which the Common Stock is then listed or quoted as reported by Bloomberg L.P. (based on a Trading Day from 9:30 a.m. (New York City time) to 4:02 p.m. (New York City time)), (b) if OTCQB or OTCQX is not a Trading Market, the volume weighted average price of the Common Stock for such date (or the nearest preceding date) on OTCQB or OTCQX as applicable, (c) if the Common Stock is not then listed or quoted for trading on OTCQB or OTCQX and if prices for the Common Stock are then reported on the Pink Open Market (or a similar organization or agency succeeding to its functions of reporting prices), the most recent bid price per share of the Common Stock so reported, or (d) in all other cases, the fair market value of a share of Common Stock as determined by an independent appraiser selected in good faith by the holders of a majority in interest of the Warrants then outstanding and reasonably acceptable to the Company, the fees and expenses of which shall be paid by the Company. “Warrants” means this Warrant and other Common Stock purchase warrants issued by the Company pursuant to the Registration Statement. Section 2. Exercise. a) Exercise of Warrant. Exercise of the purchase rights represented by this Warrant may be made, in whole or in part, at any time or times on or after the Initial Exercise Date and on or before the Termination Date by delivery to the Company of a duly executed PDF copy submitted by e-mail (or e-mail attachment) of the Notice of Exercise in the form annexed hereto (the “Notice of Exercise”). Within the earlier of (i) one (1) Trading Day and (ii) the number of Trading Days comprising the Standard Settlement Period (as defined in Section 2(d)(i) herein) following the date of exercise as aforesaid, the Holder shall deliver the aggregate Exercise Price for the shares specified in the applicable Notice of Exercise by wire transfer or cashierâ€™s check drawn on a United States bank unless the cashless exercise procedure specified in Section 2(c) below is specified in the applicable Notice of Exercise. No ink-original Notice of Exercise shall be required, nor shall any medallion guarantee (or other type of guarantee or notarization) of any Notice of Exercise be required. Notwithstanding anything herein to the contrary, the Holder shall not be required to physically surrender this Warrant to the Company until the Holder has purchased all of the Warrant Shares available hereunder and the Warrant has been exercised in full, in which case, the Holder shall surrender this Warrant to the Company for cancellation as soon as reasonably practicable of the date on which the final Notice of Exercise is delivered to the Company. Partial exercises of this Warrant resulting in purchases of a portion of the total number of Warrant Shares available hereunder shall have À the effect of lowering the outstanding number of Warrant Shares purchasable hereunder in an amount equal to the applicable number of Warrant Shares purchased. The Holder and the Company shall maintain records showing the number of Warrant Shares purchased and the date of such purchases. The Company shall deliver any objection to any Notice of Exercise within one (1) Business Day of receipt of such notice. The Holder and any assignee, by acceptance of this Warrant, acknowledge and agree that, by reason of the provisions of this paragraph, following the purchase of a portion of the Warrant Shares hereunder, the number of Warrant Shares available for purchase hereunder at any given time may be less than the amount stated on the face hereof. b) Exercise Price. The exercise price per share of Common Stock under this Warrant shall be \$ \_\_\_\_, subject to adjustment hereunder (the “Exercise Price”). c) Cashless Exercise. If at the time of exercise hereof there is no effective registration statement registering, or the prospectus contained therein is not available for the issuance of the Warrant Shares to the Holder, then this Warrant may also be exercised, in whole or in part, at such time by means of a “cashless exercise” in which the Holder shall be entitled to receive a number of Warrant Shares equal to the quotient obtained by dividing [(A-B) (X)] by (A), where: (A) = as applicable: (i) the VWAP on the Trading Day immediately preceding the date of the applicable Notice of Exercise if such Notice of Exercise is (1) both executed and delivered pursuant to Section 2(a) hereof on a day that is not a Trading Day or (2) both executed and delivered pursuant to Section 2(a) hereof on a Trading Day prior to the opening of “regular trading hours” (as defined in Rule 600(b) of Regulation NMS promulgated under the federal securities laws) on such Trading Day, (ii) at the option of the Holder, either (y) the VWAP on the Trading Day immediately preceding the date of the applicable Notice of Exercise or (z) the Bid Price of the Common Stock on the principal Trading Market as reported by Bloomberg L.P. (“Bloomberg”) as of the time of the Holderâ€™s execution of the applicable Notice of Exercise

if such Notice of Exercise is executed during “regular trading hours” on a Trading Day and is delivered within two (2) hours thereafter (including until two (2) hours after the close of “regular trading hours” on a Trading Day) pursuant to Section 2(a) hereof or (iii) the VWAP on the date of the applicable Notice of Exercise if the date of such Notice of Exercise is a Trading Day and such Notice of Exercise is both executed and delivered pursuant to Section 2(a) hereof after the close of “regular trading hours” on such Trading Day; A (B) = the Exercise Price of this Warrant, as adjusted hereunder; and A (X) = the number of Warrant Shares that would be issuable upon exercise of this Warrant in accordance with the terms of this Warrant if such exercise were by means of a cash exercise rather than a cashless exercise. A If Warrant Shares are issued in such a cashless exercise, the parties acknowledge and agree that in accordance with Section 3(a)(9) of the Securities Act, the Warrant Shares A shall take on the registered characteristics of the Warrants being exercised. The Company agrees not to take any position contrary to this Section 2(c). A Notwithstanding anything herein to the contrary, on the Termination Date, this Warrant shall be automatically exercised via cashless exercise pursuant to this Section 2(c). A d)Mechanics of Exercise. i.Delivery of Warrant Shares Upon Exercise. The Company shall cause the Warrant Shares purchased hereunder to be transmitted by the Transfer Agent to the Holder by crediting the account of the Holder’s or its designee’s balance account with The Depository Trust Company through its Deposit or Withdrawal at Custodian system (“DWAC”) if the Company is then a participant in such system and either (A) there is an effective registration statement permitting the issuance of the Warrant Shares to or resale of the Warrant Shares by the Holder or (B) this Warrant is being exercised via cashless exercise, and otherwise by physical delivery of a certificate, registered in the Company’s share register in the name of the Holder or its designee, for the number of Warrant Shares to which the Holder is entitled pursuant to such exercise to the address specified by the Holder in the Notice of Exercise by the date that is the earlier of (i) one (1) Trading Day after the delivery to the Company of the Notice of Exercise, and (ii) the number of Trading Days comprising the Standard Settlement Period after the delivery to the Company of the Notice of Exercise (such date, the “Warrant Share Delivery Date”). Upon delivery of the Notice of Exercise, the Holder shall be deemed for all corporate purposes to have become the holder of record of the Warrant Shares with respect to which this Warrant has been exercised, irrespective of the date of delivery of the Warrant Shares, provided that payment of the aggregate Exercise Price (other than in the case of a cashless exercise) is received within the earlier of (i) two (2) Trading Days and (ii) the number of Trading Days comprising the Standard Settlement Period following delivery of the Notice of Exercise. If the Company fails for any reason to deliver to the Holder the Warrant Shares subject to a Notice of Exercise by the Warrant Share Delivery Date, the Company shall pay to the Holder, in cash, as liquidated damages and not as a penalty, for each \$1,000 of Warrant Shares subject to such exercise (based on the VWAP of the Common Stock on the date of the applicable Notice of Exercise), \$10 per Trading Day (increasing to \$20 per Trading Day on the third Trading Day after the Warrant Share Delivery Date) for each Trading Day after such Warrant Share Delivery Date until such Warrant Shares are delivered or Holder rescinds such exercise. The Company agrees to maintain a transfer agent that is a participant in the FAST program so long as this Warrant remains outstanding and exercisable. As used herein, “Standard Settlement Period” means the standard settlement period, expressed in a number of Trading Days (including no Trading Days if the settlement date is the trade date), on the Company’s primary Trading A Market with respect to the Common Stock as in effect on the date of delivery of the Notice of Exercise. ii.Delivery of New Warrants Upon Exercise. If this Warrant shall have been exercised in part, the Company shall, at the request of a Holder and upon surrender of this Warrant certificate, at the time of delivery of the Warrant Shares, deliver to the Holder a new Warrant evidencing the rights of the Holder to purchase the unpurchased Warrant Shares called for by this Warrant, which new Warrant shall in all other respects be identical with this Warrant. iii.Rescission Rights. If the Company fails to cause the Transfer Agent to transmit to the Holder the Warrant Shares pursuant to Section 2(d)(i) by the Warrant Share Delivery Date, then the Holder will have the right to rescind such exercise. iv.Compensation for Buy-In on Failure to Timely Deliver Warrant Shares Upon Exercise. In addition to any other rights available to the Holder, if the Company fails to cause the Transfer Agent to transmit to the Holder the Warrant Shares in accordance with the provisions of Section 2(d)(i) above pursuant to an exercise on or before the Warrant Share Delivery Date, and if after such date the Holder is required by its broker to purchase (in an open market transaction or otherwise) or the Holder’s brokerage firm otherwise purchases, shares of Common Stock to deliver in satisfaction of a sale by the Holder of the Warrant Shares which the Holder anticipated receiving upon such exercise (a “Buy-In”), then the Company shall (A) pay in cash to the Holder the amount, if any, by which (x) the Holder’s total purchase price (including brokerage commissions, if any) for the shares of Common Stock so purchased exceeds (y) the amount obtained by multiplying (1) the number of Warrant Shares that the Company was required to deliver to the Holder in connection with the exercise at issue times (2) the price at which the sell order giving rise to such purchase obligation was executed, and (B) at the option of the Holder, either reinstate the portion of the Warrant and equivalent number of Warrant Shares for which such exercise was not honored (in which case such exercise shall be deemed rescinded) or deliver to the Holder the number of shares of Common Stock that would have been issued had the Company timely complied with its exercise and delivery obligations hereunder. For example, if the Holder purchases Common Stock having a total purchase price of \$11,000 to cover a Buy-In with respect to an attempted exercise of shares of Common Stock with an aggregate sale price giving rise to such purchase obligation of \$10,000, under clause (A) of the immediately preceding sentence the Company shall be required to pay the Holder \$1,000. The Holder shall provide the Company written notice indicating the amounts payable to the Holder in respect of the Buy-In and, upon request of the Company, evidence of the amount of such loss. Nothing herein shall limit a Holder’s right to pursue A any other remedies available to it hereunder, at law or in equity including, without limitation, a decree of specific performance and/or injunctive relief with respect to the Company’s failure to timely deliver shares of Common Stock upon exercise of the Warrant as required pursuant to the terms hereof. v.No Fractional Shares or Scrip. No fractional shares or scrip representing fractional shares shall be issued upon the exercise of this Warrant. As to any fraction of a share which the Holder would otherwise be entitled to purchase upon such exercise, the Company shall, at its election, either pay a cash adjustment in respect of such final fraction in an amount equal to such fraction multiplied by the Exercise Price or round up to the next whole share. vi.Charges, Taxes and Expenses. Issuance of Warrant Shares shall be made without charge to the Holder for any issue or transfer tax or other incidental expense in respect of the issuance of such Warrant Shares, all of which taxes and expenses shall be paid by the Company, and such Warrant Shares shall be issued in the name of the Holder or in such name or names as may be directed by the Holder; provided, however, that, in the event that Warrant Shares are to be issued in a name other than the name of the Holder, this Warrant when surrendered for exercise shall be accompanied by the Assignment Form attached hereto as Exhibit B duly executed by the Holder and the Company may require, as a condition thereto, the payment of a sum sufficient to reimburse it for any transfer tax incidental thereto. The Company shall pay all Transfer Agent fees required for same-day processing of any Notice of Exercise and all fees to the Depository Trust Company (or another established clearing corporation performing similar functions) required for same-day electronic delivery of the Warrant Shares. vii.Closing of Books. The Company will not close its stockholder books or records in any manner which prevents the timely exercise of this Warrant, pursuant to the terms hereof. e) Holder’s Exercise Limitations. The Company shall not effect any exercise of this Warrant, and a Holder shall not have the right to exercise any portion of this Warrant, pursuant to Section 2 or otherwise, to the extent that after giving effect to such issuance after exercise as set forth on the applicable Notice of Exercise, the Holder (together with the Holder’s Affiliates, and any other Persons acting as a group together with the Holder or any of the Holder’s Affiliates (such Persons, “Attribution Parties”), would beneficially own in excess of the Beneficial Ownership Limitation (as defined below). For purposes of the foregoing sentence, the number of shares of Common Stock beneficially owned by the Holder and its Affiliates and Attribution Parties shall include the number of shares of Common Stock issuable upon exercise of this Warrant with respect to which such determination is being made, but shall exclude the number of shares of Common A Stock which would be issuable upon (i) exercise of the remaining, non-exercised portion of this Warrant beneficially owned by the Holder or any of its Affiliates or Attribution Parties and (ii) exercise or conversion of the unexercised or non-converted portion of any other securities of the Company (including, without limitation, any other Common Stock Equivalents) subject to a limitation on conversion or exercise analogous to the limitation contained herein beneficially owned by the Holder or any of its Affiliates or Attribution Parties. Except as set forth in the preceding sentence, for purposes of this Section 2(e), beneficial ownership shall be calculated in accordance with Section 13(d) of the Exchange Act and the rules and regulations promulgated thereunder, it being acknowledged by the Holder that the Company is not representing to the Holder that such calculation is in compliance with Section 13(d) of the Exchange Act and the Holder is solely responsible for any schedules required to be filed in accordance therewith. To the extent that the limitation contained in this Section 2(e) applies, the determination of whether this Warrant is exercisable (in relation to other securities owned by the Holder together with any Affiliates and Attribution Parties) and of which portion of this Warrant is exercisable shall be in the sole discretion of the Holder, and the submission of a Notice of Exercise shall be deemed to be the Holder’s

determination of whether this Warrant is exercisable (in relation to other securities owned by the Holder together with any Affiliates and Attribution Parties) and of which portion of this Warrant is exercisable, in each case subject to the Beneficial Ownership Limitation, and the Company shall have no obligation to verify or confirm the accuracy of such determination. In addition, a determination as to any group status as contemplated above shall be determined in accordance with Section 13(d) of the Exchange Act and the rules and regulations promulgated thereunder. For purposes of this Section 2(e), in determining the number of outstanding shares of Common Stock, a Holder may rely on the number of outstanding shares of Common Stock as reflected in (A) the Company's most recent periodic or annual report filed with the Commission, as the case may be, (B) a more recent public announcement by the Company or (C) a more recent written notice by the Company or the Transfer Agent setting forth the number of shares of Common Stock outstanding. Upon the written or oral request of a Holder, the Company shall within one Trading Day confirm orally and in writing to the Holder the number of shares of Common Stock then outstanding. In any case, the number of outstanding shares of Common Stock shall be determined after giving effect to the conversion or exercise of securities of the Company, including this Warrant, by the Holder or its Affiliates or Attribution Parties since the date as of which such number of outstanding shares of Common Stock was reported. The "Beneficial Ownership Limitation" shall be 9.99/4.99% of the number of shares of the Common Stock outstanding immediately after giving effect to the issuance of shares of Common Stock issuable upon exercise of this Warrant. The Holder, upon notice to the Company, may increase or decrease the Beneficial Ownership Limitation provisions of this Section 2(e), provided that the Beneficial Ownership Limitation in no event exceeds 9.99% of the number of shares of the Common Stock outstanding immediately after giving effect to the issuance of shares of Common Stock upon exercise of this Warrant held by the Holder and the provisions of this Section 2(e) shall continue to apply. Any increase in the Beneficial Ownership Limitation will not be effective until the 61st day after such notice is delivered to the Company. The provisions of this paragraph shall be construed and implemented in a manner otherwise than in strict conformity with the terms of this Section 2(e) to correct this paragraph (or any portion hereof) which may be defective or inconsistent with the intended Beneficial Ownership Limitation herein contained or to make changes or supplements necessary or desirable to properly give effect to such limitation. The limitations contained in this paragraph shall apply to a successor holder of this Warrant.

**Section 3. Certain Adjustments.**

**a) Stock Dividends and Splits.** If the Company, at any time while this Warrant is outstanding: (i) pays a stock dividend or otherwise makes a distribution or distributions on shares of its Common Stock or any other equity or equity equivalent securities payable in shares of Common Stock (which, for avoidance of doubt, shall not include any shares of Common Stock issued by the Company upon exercise of this Warrant), (ii) subdivides outstanding shares of Common Stock into a larger number of shares, (iii) combines (including by way of reverse stock split) outstanding shares of Common Stock into a smaller number of shares, or (iv) issues by reclassification of shares of the Common Stock any shares of capital stock of the Company, then in each case the Exercise Price shall be multiplied by a fraction of which the numerator shall be the number of shares of Common Stock (excluding treasury shares, if any) outstanding immediately before such event and of which the denominator shall be the number of shares of Common Stock outstanding immediately after such event, and the number of shares issuable upon exercise of this Warrant shall be proportionately adjusted such that the aggregate Exercise Price of this Warrant shall remain unchanged. Any adjustment made pursuant to this Section 3(a) shall become effective immediately after the record date for the determination of stockholders entitled to receive such dividend or distribution and shall become effective immediately after the effective date in the case of a subdivision, combination or reclassification.

**b) Subsequent Rights Offerings.** In addition to any adjustments pursuant to Section 3(a) above, if at any time the Company grants, issues or sells any Common Stock Equivalents or rights to purchase stock, warrants, securities or other property pro rata to the record holders of any class of shares of Common Stock (the "Purchase Rights"), then the Holder will be entitled to acquire, upon the terms applicable to such Purchase Rights, the aggregate Purchase Rights which the Holder could have acquired if the Holder had held the number of shares of Common Stock acquirable upon complete exercise of this Warrant (without regard to any limitations on exercise hereof, including without limitation, the Beneficial Ownership Limitation) immediately before the date on which a record is taken for the grant, issuance or sale of such Purchase Rights, or, if no such record is taken, the date as of which the record holders of shares of Common Stock are to be determined for the grant, issue or sale of such Purchase Rights (provided, however, that, to the extent that the Holder's right to participate in any such Purchase Right would result in the Holder exceeding the Beneficial Ownership Limitation, then the Holder shall not be entitled to participate in such Purchase Right to such extent (or beneficial ownership of such shares of Common Stock as a result of such Purchase Right to such extent) and such Purchase Right to such extent shall be held in abeyance for the Holder until such time, if ever, as its right thereto would not result in the Holder exceeding the Beneficial Ownership Limitation).

**c) Pro Rata Distributions.** During such time as this Warrant is outstanding, if the Company shall declare or make any dividend or other distribution of its assets (or rights to acquire its assets) to holders of shares of Common Stock, by way of return of capital or otherwise (including, without limitation, any distribution of cash, stock or other securities, property or options by way of a dividend, spin off, reclassification, corporate rearrangement, scheme of arrangement or other similar transaction) (a "Distribution"), at any time after the issuance of this Warrant, then, in each such case, the Holder shall be entitled to participate in such Distribution to the same extent that the Holder would have participated therein if the Holder had held the number of shares of Common Stock acquirable upon complete exercise of this Warrant (without regard to any limitations on exercise hereof, including without limitation, the Beneficial Ownership Limitation) immediately before the date of which a record is taken for such Distribution, or, if no such record is taken, the date as of which the record holders of shares of Common Stock are to be determined for the participation in such Distribution (provided, however, that, to the extent that the Holder's right to participate in any such Distribution would result in the Holder exceeding the Beneficial Ownership Limitation, then the Holder shall not be entitled to participate in such Distribution to such extent (or in the beneficial ownership of any shares of Common Stock as a result of such Distribution to such extent) and the portion of such Distribution shall be held in abeyance for the benefit of the Holder until such time, if ever, as its right thereto would not result in the Holder exceeding the Beneficial Ownership Limitation).

**d) Fundamental Transaction.** If, at any time while this Warrant is outstanding, (i) the Company, directly or indirectly, in one or more related transactions effects any merger or consolidation of the Company with or into another Person, (ii) the Company (or any Subsidiary), directly or indirectly, effects any sale, lease, license, assignment, transfer, conveyance or other disposition of all or substantially all of its assets in one or a series of related transactions, (iii) any, direct or indirect, purchase offer, tender offer or exchange offer (whether by the Company or another Person) is completed pursuant to which holders of Common Stock are permitted to sell, tender or exchange their shares for other securities, cash or property and has been accepted by the holders of 50% or more of the outstanding shares of Common Stock or 50% or more of the voting power of the common equity of the Company, (iv) the Company, directly or indirectly, in one or more related transactions effects any reclassification, reorganization or recapitalization of shares of Common Stock or any compulsory share exchange pursuant to which the shares of Common Stock are effectively converted into or exchanged for other securities, cash or property, or (v) the Company, directly or indirectly, in one or more related transactions consummates a stock or share purchase agreement or other business combination (including, without limitation, a reorganization, recapitalization, spin-off, merger or scheme of arrangement) with another Person or group of Persons whereby such other Person or group acquires 50% or more of the outstanding shares of Common Stock or 50% or more of the voting power of the common equity of the Company (each a "Fundamental Transaction"), then, upon any subsequent exercise of this Warrant, the Holder shall have the right to receive, for each Warrant Share that would have been issuable upon such exercise immediately prior to the occurrence of such Fundamental Transaction, at the option of the Holder (without regard to any limitation in Section 2(e) on the exercise of this Warrant), the number of shares of Common Stock of the successor or acquiring corporation or of the Company, if it is the surviving corporation, and any additional consideration (the "Alternate Consideration") receivable as a result of such Fundamental Transaction by a holder of the number of shares of Common Stock for which this Warrant is exercisable immediately prior to such Fundamental Transaction (without regard to any limitation in Section 2(e) on the exercise of this Warrant). For purposes of any such exercise, the determination of the Exercise Price shall be appropriately adjusted to apply to such Alternate Consideration based on the amount of Alternate Consideration issuable in respect of one share of Common Stock in such Fundamental Transaction, and the Company shall apportion the Exercise Price among the Alternate Consideration in a reasonable manner reflecting the relative value of any different components of the Alternate Consideration. If holders of Common Stock are given any choice as to the securities, cash or property to be received in a Fundamental Transaction, then the Holder shall be given the same choice as to the Alternate Consideration it receives upon any exercise of this Warrant following such Fundamental Transaction. Notwithstanding anything to the contrary, in the event of a Fundamental Transaction, the Company or any Successor Entity (as defined below) shall, at the Holder's option, exercisable at any time concurrently with, or within 30 days after, the consummation of the Fundamental Transaction (or, if later, the date of the public

announcement of the applicable Fundamental Transaction), purchase this Warrant from the Holder by paying to the Holder an amount of cash equal to the Black Scholes Value (as defined below) of the remaining unexercised portion of this Warrant on the date of the consummation of such Fundamental Transaction; provided, however, that, if the Fundamental Transaction is not within the Company's control, including not approved by the Company's Board of Directors, the Holder shall only be entitled to receive from the Company or any Successor Entity the same type or form of consideration (and in the same proportion), at the Black Scholes Value of the unexercised portion of this Warrant, that is being offered and paid to the holders of Common Stock of the Company in connection with the Fundamental Transaction, whether that consideration be in the form of cash, stock or any combination thereof, or whether the holders of Common Stock are given the choice to receive from among alternative forms of consideration in connection with the Fundamental Transaction; provided, further, that if holders of Common Stock of the Company are not offered or paid any consideration in such Fundamental Transaction, such holders of Common Stock will be deemed to have received common stock of the Successor Entity (which entity may be the Company following such Fundamental Transaction) in such Fundamental Transaction. "Black Scholes Value" means the value of this Warrant based on the Black-Scholes Option Pricing Model obtained from the "OV" function on Bloomberg determined as of the day of consummation of the applicable Fundamental Transaction for pricing purposes and reflecting (A) a risk-free interest rate corresponding to the U.S. Treasury rate for a period equal to the time between the date of the public announcement of the applicable contemplated Fundamental Transaction and the Termination Date, (B) an expected volatility equal to the greater of (1) the 30 day volatility, (2) the 100 day volatility or (3) the 365 day volatility, or (4) each of clauses (1)-(3) as obtained from the HVT function on Bloomberg (determined utilizing a 365 day "annualization factor") as of the Trading Day immediately following the public announcement of the applicable contemplated Fundamental Transaction or (5) 100%, (C) the underlying price per share used in such calculation shall be the greater of (i) the sum of the price per share being offered in cash, if any, plus the value of any non-cash consideration, if any, being offered in such Fundamental Transaction and (ii) the highest VWAP during the period beginning on the Trading Day immediately preceding the public announcement of the applicable contemplated Fundamental Transaction (or the consummation of the applicable Fundamental Transaction, if earlier) and ending on the Trading Day of the Holder's request pursuant to this Section 3(e) and (D) a remaining option time equal to the time between the date of the public announcement of the applicable contemplated Fundamental Transaction and the Termination Date and (E) a zero cost of borrow. The payment of the Black Scholes Value will be made by wire transfer of immediately available funds (or such other consideration) within the later of (i) five Business Days of the Holder's election and (ii) the date of consummation of the Fundamental Transaction. The Company shall cause any successor entity in a Fundamental Transaction in which the Company is not the survivor (the "Successor Entity") to assume in writing all of the obligations of the Company under this Warrant and the other Transaction Documents (as defined in the Purchase Agreement) in accordance with the provisions of this Section 3(d) pursuant to written agreements in form and substance reasonably satisfactory to the Holder and approved by the Holder (without unreasonable delay) prior to such Fundamental Transaction and shall, at the option of the Holder, deliver to the Holder in exchange for this Warrant a security of the Successor Entity evidenced by a written instrument substantially similar in form and substance to this Warrant which is exercisable for a corresponding number of shares of capital stock of such Successor Entity (or its parent entity) equivalent to the shares of Common Stock acquirable and receivable upon exercise of this Warrant (without regard to any limitations on the exercise of this Warrant) prior to such Fundamental Transaction, and with an exercise price which applies the exercise price hereunder to such shares of capital stock (but taking into account the relative value of the shares of Common Stock pursuant to such Fundamental Transaction and the value of such shares of capital stock, such number of shares of capital stock and such exercise price being for the purpose of protecting the economic value of this Warrant immediately prior to the consummation of such Fundamental Transaction), and which is reasonably satisfactory in form and substance to the Holder. Upon the occurrence of any such Fundamental Transaction, the Successor Entity shall be added to the term "Company" under this Warrant (so that from and after the occurrence or consummation of such Fundamental Transaction, each and every provision of this Warrant and the other Transaction Documents referring to the "Company" shall refer instead to each of the Company and the Successor Entity or Successor Entities, jointly and severally), and the Successor Entity or Successor Entities, jointly and severally with the Company, may exercise every right and power of the Company prior thereto and the Successor Entity or Successor Entities shall assume all of the obligations of the Company prior thereto under this Warrant and the other Transaction Documents with the same effect as if the Company and such Successor Entity or Successor Entities, jointly and severally, had been named as the Company herein. For the avoidance of doubt, the Holder shall be entitled to the benefits of the provisions of this Section 3(d) regardless of (i) whether the Company has sufficient "authorized shares of Common Stock for the issuance of Warrant Shares and/or (ii) whether a Fundamental Transaction occurs prior to the Initial Exercise Date. e)Calculations. All calculations under this Section 3 shall be made to the nearest cent or the nearest 1/100th of a share, as the case may be. For purposes of this Section 3, the number of shares of Common Stock deemed to be issued and outstanding as of a given date shall be the sum of the number of shares of Common Stock (excluding treasury shares, if any) issued and outstanding. f)Notice to Holder. i.Adjustment to Exercise Price. Whenever the Exercise Price is adjusted pursuant to any provision of this Section 3, the Company shall promptly deliver to the Holder by email a notice setting forth the Exercise Price after such adjustment and any resulting adjustment to the number of Warrant Shares and setting forth a brief statement of the facts requiring such adjustment. ii.Notice to Allow Exercise by Holder. If (A) the Company shall declare a dividend (or any other distribution in whatever form) on the Common Stock, (B) the Company shall declare a special nonrecurring cash dividend on or a redemption of the Common Stock, (C) the Company shall authorize the granting to all holders of the Common Stock rights or warrants to subscribe for or purchase any shares of capital stock of any class or of any rights, (D) the approval of any stockholders of the Company shall be required in connection with any reclassification of the Common Stock, any consolidation or merger to which the Company (or any of its Subsidiaries) is a party, any sale or transfer of all or substantially all of its assets, or any compulsory share exchange whereby the Common Stock is converted into other securities, cash or property, or (E) the Company shall authorize the voluntary or involuntary dissolution, liquidation or winding up of the affairs of the Company, then, in each case, the Company shall cause to be delivered by email to the Holder at its last email address as it shall appear upon the Warrant Register of the Company, at least 20 calendar days prior to the applicable record or effective date hereinafter specified, a notice stating (x) the date on which a record is to be taken for the purpose of such dividend, distribution, redemption, rights or warrants, or if a record is not to be taken, the date as of which the holders of the Common Stock of record to be entitled to such dividend, distributions, redemption, rights or warrants are to be determined or (y) the date on which such reclassification, consolidation, merger, sale, transfer or share exchange is expected to become effective or close, and the date as of which it is expected that holders of the Common Stock of record shall be entitled to exchange their shares of the Common Stock for securities, cash or other property deliverable upon such reclassification, consolidation, merger, sale, transfer or share exchange; provided that the failure to deliver such notice or any defect therein or in the delivery thereof shall not affect the validity of the "corporate action required to be specified in such notice. To the extent that any notice provided in this Warrant constitutes, or contains, material, non-public information regarding the Company or any of the Subsidiaries, the Company shall simultaneously file such notice with the Commission pursuant to a Current Report on Form 8-K. The Holder shall remain entitled to exercise this Warrant during the period commencing on the date of such notice to the effective date of the event triggering such notice except as may otherwise be expressly set forth herein. g)Voluntary Adjustment By Company. Subject to the rules and regulations of the Trading Market, the Company may at any time during the term of this Warrant reduce the then current Exercise Price to any amount and for any period of time deemed appropriate by the board of directors of the Company. h)Stockholder Approval; Charter Amendment. The Company shall use its reasonable best efforts to hold a special meeting of stockholders on or prior to ninety (90) days after the Closing Date (as defined in the Purchase Agreement), for the purpose of obtaining the Stockholder Approval, with the recommendation of the Company's Board of Directors that such proposal be approved, and the Company shall solicit proxies from its stockholders in connection therewith in the same manner as all other management proposals in such proxy statement and all management-appointed proxyholders shall vote their proxies in favor of such proposal. The Company shall use its reasonable best efforts to obtain such Shareholder Approval. i)Share Combination Event Adjustment. In addition to the adjustments set forth in Section 3(a) above, if at any time and from time to time on or after the Issue Date, there occurs any share split, share dividend, share combination recapitalization or other similar transaction involving the Common Stock (each, a "Share Combination Event", and such date thereof, the "Share Combination Event Date") and the lowest VWAP during the period commencing five (5) consecutive Trading Days immediately preceding and ending immediately after the five (5) consecutive Trading Days commencing on the Share Combination Event Date (the "Event Market Price") (provided if the Share Combination Event is effective after close of trading on the primary Trading Market, then

commencing on the next Trading Day which period shall be the “Share Combination Adjustment Period”) is less than the Exercise Price then in effect (after giving effect to the adjustment in Section 3(a) above), then at the close of trading on the primary Trading Market on the last day of the Share Combination Adjustment Period, the Exercise Price then in effect on such fifth (5th) Trading Day shall be reduced (but in no event increased) to the Event Market Price. Notwithstanding the foregoing, if one or more Share Combination Events occur prior to the Shareholder Approval being obtained and a reduction of the Exercise Price did not occur, once the Shareholder Approval is obtained, the Exercise Price will automatically be reduced to equal the lowest Event Market Price with respect to any Share Combination Event that occurred prior to the Shareholder Approval being obtained. For the avoidance of doubt, (a) if the adjustment in the immediately preceding sentence would otherwise result in an increase in the Exercise Price hereunder, no adjustment shall be made, (b) if this Warrant is exercised, on any given exercise date during the Share Combination Adjustment Period, solely with respect to such portion of this Warrant exercised on such applicable exercise date, such applicable Share Combination Adjustment Period shall be deemed to have ended on, and included, the Trading Day immediately prior to such exercise date and the Event Market Price on such applicable exercise date will be the lowest VWAP of the Common Stock during such the Share Combination Adjustment Period immediately prior to such exercise date and ending on, and including the Trading Day immediately prior to such exercise date and (c) all adjustments pursuant to this Section 3(i) shall also be subject to Section 3(a) above, including any Event Market Price.

**Section 4. Transfer of Warrant.**

**a) Transferability.** This Warrant and all rights hereunder (including, without limitation, any registration rights) are transferable, in whole or in part, upon surrender of this Warrant at the principal office of the Company or its designated agent, together with a written assignment of this Warrant substantially in the form attached hereto duly executed by the Holder or its agent or attorney and funds sufficient to pay any transfer taxes payable upon the making of such transfer. Upon such surrender and, if required, such payment, the Company shall execute and deliver a new Warrant or Warrants in the name of the assignee or assignees, as applicable, and in the denomination or denominations specified in such instrument of assignment, and shall issue to the assignor a new Warrant evidencing the portion of this Warrant not so assigned, and this Warrant shall promptly be cancelled. Notwithstanding anything herein to the contrary, the Holder shall not be required to physically surrender this Warrant to the Company unless the Holder has assigned this Warrant in full, in which case, the Holder shall surrender this Warrant to the Company within three (3) Trading Days of the date on which the Holder delivers an assignment form to the Company assigning this Warrant in full. The Warrant, if properly assigned in accordance herewith, may be exercised by a new holder for the purchase of Warrant Shares without having a new Warrant issued.

**b) New Warrants.** This Warrant may be divided or combined with other Warrants upon presentation hereof at the aforesaid office of the Company, together with a written notice specifying the names and denominations in which new Warrants are to be issued, signed by the Holder or its agent or attorney. Subject to compliance with Section 4(a), as to any transfer which may be involved in such division or combination, the Company shall execute and deliver a new Warrant or Warrants in exchange for the Warrant or Warrants to be divided or combined in accordance with such notice. All Warrants issued on transfers or exchanges shall be dated the initial issuance date of the Warrant and shall be identical with this Warrant except as to the number of Warrant Shares issuable pursuant thereto.

**c) Warrant Register.** The Company shall register this Warrant, upon records to be maintained by the Company for that purpose (the “Warrant Register”), in the name of the record Holder hereof from time to time. The Company may deem and treat the registered Holder of this Warrant as the absolute owner hereof for the purpose of any exercise hereof or any distribution to the Holder, and for all other purposes, absent actual notice to the contrary.

**Section 5. Miscellaneous.**

**a) No Rights as Stockholder Until Exercise; No Settlement in Cash.** This Warrant does not entitle the Holder to any voting rights, dividends or other rights as a stockholder of the Company prior to the exercise hereof as set forth in Section 2(d)(i), except as expressly set forth in Section 3. Without limiting any rights of a Holder to receive Warrant Shares on a “cashless exercise” pursuant to Section 2(c) or to receive cash payments pursuant to Section 2(d)(i) and Section 2(d)(iv) herein, in no event shall the Company be required to net cash settle an exercise of this Warrant.

**b) Loss, Theft, Destruction or Mutilation of Warrant.** The Company covenants that upon receipt by the Company of evidence reasonably satisfactory to it of the loss, theft, destruction or mutilation of this Warrant or any stock certificate relating to the Warrant Shares, and in case of loss, theft or destruction, of indemnity or security reasonably satisfactory to it (which, in the case of the Warrant, shall not include the posting of any bond), and upon surrender and cancellation of such Warrant or stock certificate, if mutilated, the Company will make and deliver a new Warrant or stock certificate of like tenor and dated as of such cancellation, in lieu of such Warrant or stock certificate.

**c) Saturdays, Sundays, Holidays, etc.** If the last or appointed day for the taking of any action or the expiration of any right required or granted herein shall not be a Business Day, then such action may be taken or such right may be exercised on the next succeeding Business Day.

**d) Authorized Shares.** The Company covenants that, during the period the Warrant is outstanding, it will reserve from its authorized and unissued Common Stock a sufficient number of shares to provide for the issuance of the Warrant Shares upon the exercise of any purchase rights under this Warrant. The Company further covenants that its issuance of this Warrant shall constitute full authority to its officers who are charged with the duty of issuing the necessary Warrant Shares upon the exercise of the purchase rights under this Warrant. The Company will take all such reasonable action as may be necessary to assure that such Warrant Shares may be issued as provided herein without violation of any applicable law or regulation, or of any requirements of the Trading Market upon which the Common Stock may be listed. The Company covenants that all Warrant Shares which may be issued upon the exercise of the purchase rights represented by this Warrant will, upon exercise of the purchase rights represented by this Warrant and payment for such Warrant Shares in accordance herewith, be duly authorized, validly issued, fully paid and nonassessable and free from all taxes, liens and charges created by the Company in respect of the issue thereof (other than taxes in respect of any transfer occurring contemporaneously with such issue). Except and to the extent as waived or consented to by the Holder, the Company shall not by any action, including, without limitation, amending its certificate of incorporation or through any reorganization, transfer of assets, consolidation, merger, dissolution, issue or sale of securities or any other voluntary action, avoid or seek to avoid the observance or performance of any of the terms of this Warrant, but will at all times in good faith assist in the carrying out of all such terms and in the taking of all such actions as may be necessary or appropriate to protect the rights of Holder as set forth in this Warrant against impairment. Without limiting the generality of the foregoing, the Company will (i) not increase the par value of any Warrant Shares above the amount payable therefor upon such exercise immediately prior to such increase in par value, (ii) take all such action as may be necessary or appropriate in order that the Company may validly and legally issue fully paid and nonassessable Warrant Shares upon the exercise of this Warrant and (iii) use commercially reasonable efforts to obtain all such authorizations, exemptions or consents from any public regulatory body having jurisdiction thereof, as may be, necessary to enable the Company to perform its obligations under this Warrant. Before taking any action which would result in an adjustment in the number of Warrant Shares for which this Warrant is exercisable or in the Exercise Price, the Company shall obtain all such authorizations or exemptions thereof, or consents thereto, as may be necessary from any public regulatory body or bodies having jurisdiction thereof.

**e) Governing Law.** All questions concerning the construction, validity, enforcement and interpretation of this Warrant shall be governed by and construed and enforced in accordance with the internal laws of the State of New York, without regard to the principles of conflicts of law thereof. Each party agrees that all legal proceedings concerning the interpretations, enforcement and defense of the transactions contemplated by this Warrant (whether brought against a party hereto or their respective affiliates, directors, officers, shareholders, partners, members, employees or agents) shall be commenced exclusively in the state and federal courts sitting in the City of New York. Each party hereby irrevocably submits to the exclusive jurisdiction of the state and federal courts sitting in the City of New York, Borough of Manhattan for the adjudication of any dispute hereunder or in connection herewith or with any transaction contemplated hereby or discussed herein, and hereby irrevocably waives, and agrees not to assert in any suit, action or proceeding, any claim that it is not personally subject to the jurisdiction of any such court, that such suit, action or proceeding is improper or is an inconvenient venue for such proceeding. Each party hereby irrevocably waives personal service of process and consents to process being served in any such suit, action or proceeding by mailing a copy thereof via registered or certified mail or overnight delivery (with evidence of delivery) to such party at the address in effect for notices to it under this Warrant and agrees that such service shall constitute good and sufficient service of process and notice thereof. Nothing contained herein shall be deemed to limit in any way any right to serve process in any other manner permitted by law. If either party shall commence an action, suit or proceeding to enforce any provisions of this Warrant, the prevailing party in such action, suit or proceeding shall be reimbursed by the other party for their reasonable attorneys’ fees and other costs and expenses incurred with the investigation, preparation and prosecution of such action or proceeding.

**f) Restrictions.** The Holder acknowledges that the Warrant Shares acquired upon the exercise of this Warrant, if not registered, and the Holder does not utilize cashless exercise, will have restrictions upon resale imposed by state and federal securities laws.

**g) Nonwaiver and Expenses.** No course of dealing or any delay or

failure to exercise any right hereunder on the part of Holder shall operate as a waiver of such right or otherwise prejudice the Holder's rights, powers or remedies. Without limiting any other provision of this Warrant or the Purchase Agreement, if the Company willfully and knowingly fails to comply with any provision of this Warrant, which results in any material damages to the Holder, the Company shall pay to the Holder such amounts as shall be sufficient to cover any costs and expenses including, but not limited to, reasonable attorneys' fees, including those of appellate proceedings, incurred by the Holder in collecting any amounts due pursuant hereto or in otherwise enforcing any of its rights, powers or remedies hereunder. h)Notices. Any and all notices or other communications or deliveries to be provided by the Holders hereunder including, without limitation, any Notice of Exercise, shall be in writing and delivered personally, by e-mail, or sent by a nationally recognized overnight courier service, addressed to the Company, at 2401 4th Avenue, Suite 1050, Seattle, Washington 98121, Attention: Daphne Taylor email address: TaylorD2@apvo.com, or such other email address or address as the Company may specify for such purposes by notice to the Holders. Any and all notices or other communications or deliveries to be provided by the Company hereunder shall be in writing and delivered personally, by e-mail, or sent by a nationally recognized overnight courier service addressed to each Holder at the e-mail address or address of such Holder appearing on the books of the Company. Any notice or other communication or deliveries hereunder shall be deemed given and effective on the earliest of (i) the time of transmission, if such notice or communication is delivered via e-mail at the e-mail address set forth in this Section prior to 5:30 p.m. (New York City time) on any date, (ii) the next Trading Day after the time of transmission, if such notice or communication is delivered via e-mail at the e-mail address set forth in this Section on a day that is not a Trading Day or later than 5:30 p.m. (New York City time) on any Trading Day, (iii) the second Trading Day following the date of mailing, if sent by U.S. nationally recognized overnight courier service, or (iv) upon actual receipt by the party to whom such notice is required to be given. To the extent that any notice provided hereunder constitutes, or contains, material, non-public information regarding the Company or any Subsidiaries, the Company shall simultaneously file such notice with the Commission pursuant to a Current Report on Form 8-K. i)Limitation of Liability. No provision hereof, in the absence of any affirmative action by the Holder to exercise this Warrant to purchase Warrant Shares, and no enumeration herein of the rights or privileges of the Holder, shall give rise to any liability of the Holder for the purchase price of any Common Stock or as a stockholder of the Company, whether such liability is asserted by the Company or by creditors of the Company. j)Remedies. The Holder, in addition to being entitled to exercise all rights granted by law, including recovery of damages, will be entitled to specific performance of its rights under this Warrant. The Company agrees that monetary damages would not be adequate compensation for any loss incurred by reason of a breach by it of the provisions of this Warrant and hereby agrees to waive and not to assert the defense in any action for specific performance that a remedy at law would be adequate. k)Successors and Assigns. Subject to applicable securities laws, this Warrant and the rights and obligations evidenced hereby shall inure to the benefit of and be binding upon the successors and permitted assigns of the Company and the successors and permitted assigns of Holder. The provisions of this Warrant are intended to be for the benefit of any Holder from time to time of this Warrant and shall be enforceable by the Holder or holder of Warrant Shares. l)Amendment. This Warrant may be modified or amended or the provisions hereof waived with the written consent of the Company, on the one hand, and the Holder or the beneficial owner of this Warrant, on the other hand. m)Severability. Wherever possible, each provision of this Warrant shall be interpreted in such manner as to be effective and valid under applicable law, but if any provision of this Warrant shall be prohibited by or invalid under applicable law, such provision shall be ineffective to the extent of such prohibition or invalidity, without invalidating the remainder of such provisions or the remaining provisions of this Warrant. n)Headings. The headings used in this Warrant are for the convenience of reference only and shall not, for any purpose, be deemed a part of this Warrant.

\*\*\*\*\* (Signature Page Follows)

IN WITNESS WHEREOF, the Company has caused this Warrant to be executed by its officer thereunto duly authorized as of the date first above indicated.

Aptevo therapeutics inc. By: \_\_\_\_\_ Name: \_\_\_\_\_ Title: \_\_\_\_\_

NOTICE OF EXERCISE To: aptevo therapeutics inc. (1)The undersigned hereby elects to purchase \_\_\_\_\_ Warrant Shares of the Company pursuant to the terms of the attached Warrant (only if exercised in full), and tenders herewith payment of the exercise price in full, together with all applicable transfer taxes, if any. (2)Payment shall take the form of (check applicable box): [ ] in lawful money of the United States; or [ ] if permitted the cancellation of such number of Warrant Shares as is necessary, in accordance with the formula set forth in subsection 2(c), to exercise this Warrant with respect to the maximum number of Warrant Shares purchasable pursuant to the cashless exercise procedure set forth in subsection 2(c). (3)Please issue said Warrant Shares in the name of the undersigned or in such other name as is specified below: \_\_\_\_\_ The Warrant Shares shall be delivered to the following DWAC Account Number: \_\_\_\_\_ [SIGNATURE OF HOLDER]

Name of Investing Entity: \_\_\_\_\_ Signature of Authorized Signatory of \_\_\_\_\_

Investing Entity: \_\_\_\_\_ Name of Authorized Signatory: \_\_\_\_\_

\_\_\_\_\_ Title of Authorized Signatory: \_\_\_\_\_

\_\_\_\_\_ Date: \_\_\_\_\_

EXHIBIT B ASSIGNMENT FORM (To assign the foregoing Warrant, execute this form and supply required information. Do not use this form to purchase shares.) FOR VALUE RECEIVED, the foregoing Warrant and all rights evidenced thereby are hereby assigned to Name: \_\_\_\_\_ (Please Print) Address: \_\_\_\_\_ Phone Number: \_\_\_\_\_ Email Address: \_\_\_\_\_ (Please Print) Dated: \_\_\_\_\_, \_\_\_\_\_ Holder's

Signature: \_\_\_\_\_ Address: \_\_\_\_\_ EX-5.1 4 apvo-ex5.1.htm EX-5.1 Exhibit 5.1 August 30, 2024 Aptevo Therapeutics Inc. 2401 4th Avenue, Suite 1050 Seattle, WA 98121 Re: Registration Statement on Form S-1 Ladies and Gentlemen: We have acted as counsel to Aptevo Therapeutics Inc., a Delaware corporation (the "Company"), in connection with the preparation and filing with the U.S. Securities and Exchange Commission (the "Commission"), pursuant to the Securities Act of 1933, as amended (the "Securities Act"), of the Registration Statement on Form S-1 of the Company (including all exhibits thereto, the "Registration Statement"), including a related prospectus filed with the Registration Statement (the "Prospectus") relating to the proposed public offering (the "Offering") of (i) up to 13,513,513 shares (the "Shares") of the Company's common stock, \$0.001 par value per share (the "Common Stock"), (ii) common warrants to purchase up to 27,027,026 shares of Common Stock (the "Common Warrants"), (iii) pre-funded warrants to purchase up to 13,513,513 shares of Common Stock (the "Pre-Funded Warrants", and together with the Common Warrants, the "Warrants") and (iv) up to 40,540,539 shares of Common Stock issuable from time to time upon exercise of the Warrants (the "Warrant Shares" and collectively with the Warrants and the Shares, the "Securities"). The Securities are to be sold to the several purchasers pursuant to a securities purchase agreement (the "Securities Purchase Agreement") among the Company and the purchasers signatory thereto (collectively, the "Purchasers"). This opinion letter is being furnished in accordance with the requirements of Item 601(b)(5) of Regulation S-K under the Securities Act. As such counsel and for purposes of our opinions set forth herein, we have examined and relied upon originals or copies, certified or otherwise identified to our satisfaction, of such documents, resolutions, certificates and other instruments of the Company and corporate records furnished to us by the Company, and have reviewed certificates of public officials, statutes, records and such other instruments and documents as we have deemed necessary or appropriate as a basis for the opinion set forth below, including without limitation: (i)the Registration Statement; (ii)the form of Securities Purchase Agreement; (iii) the Amended and Restated Certificate of Incorporation of the Company (the "Certificate of Incorporation"), certified as of August 30, 2024, by the Secretary of State of the State of Delaware and certified by an officer of the Company as of the date hereof, and the Bylaws of the Company as presently in effect (the "Bylaws", and together with the Certificate of Incorporation, the "Company Charter Documents"); (iv) a certificate, dated as of August 30, 2024, from the Secretary of State of the State of Delaware certifying as to the existence and good standing of the Company under the laws of the State of Delaware (the "Good Standing Certificate"); (v)resolutions adopted by the board of directors of the Company or committee thereof, certified by an officer of the Company, relating to, among other things, the approval of the registration, sale and issuance of the Securities (the "Resolutions"); and (vi)a certificate executed by an officer of the Company, dated as of the date hereof, certifying to, among other things, the Company Charter Documents and the Resolutions. In addition to the foregoing, we have made such investigations of law as we have deemed necessary or appropriate as a basis for the opinions set forth in this opinion letter. In such examination and in rendering the opinions expressed below, we have assumed, without independent investigation or verification: (i) the genuineness of all signatures on all agreements, instruments, corporate records, certificates and other documents submitted to us; (ii) the authenticity and completeness of all agreements, instruments, corporate records, certificates and other documents submitted to us as originals; (iii) that all agreements, instruments, corporate records, certificates and other documents submitted to us as certified, electronic, facsimile,

conformed, photostatic or other copies conform to the originals thereof, and that such originals are authentic and complete; (iv) the legal competency, capacity and authority of all persons executing all agreements, instruments, corporate records, certificates and other documents submitted to us; (v) the due authorization, execution and delivery of all agreements, instruments, corporate records, certificates and other documents by all parties thereto (other than the Company); (vi) that no documents submitted to us have been amended or terminated orally or in writing, except as has been disclosed to us in writing; (vii) that the statements contained in the certificates and comparable documents of public officials, officers and representatives of the Company and other persons on which we have relied for the purposes of this opinion letter are true and correct on and as of the date hereof; (viii) that there has not been and there will not be any change in the good standing status of the Company from that reported in the Good Standing Certificate; (ix) that each of the officers and directors of the Company has properly exercised his or her fiduciary duties; (x) that the Securities will not be issued or transferred in violation of any restriction contained in the Certificate of Incorporation and that upon issuance of any of the Shares or Warrant Shares, the total number of shares of Common Stock issued and outstanding will not exceed the total number of shares of Common Stock that the Company is then authorized to issue under the Certificate of Incorporation; (xi) that at or prior to the time of the issuance and delivery of any of the Securities, the Registration Statement will have been declared effective under the Securities Act and such effectiveness shall not have been terminated or rescinded; (xii) that the exercise price of the Warrants will not be adjusted to an amount below the par value of the Common Stock; and (xiii) that the Securities Purchase Agreement to be executed by the Purchasers is in substantially the form previously provided to us to review. We have also assumed that the Securities will be issued and sold as described in the Registration Statement and in accordance with the terms of the Securities Purchase Agreement. With respect to the Warrants and the Warrant Shares, we express no opinion to the extent that, notwithstanding the Company's current reservation of shares of Common Stock, future issuances of securities of the Company, including the Warrant Shares and/or antidilution adjustments to outstanding securities of the Company, including the Warrants, may cause the Warrants to be exercisable for more shares of Common Stock than the number that then remain authorized but unissued. As to all questions of fact material to this opinion letter and as to the materiality of any fact or other matter referred to herein, we have relied (without independent investigation or verification) upon representations and certificates or comparable documents of officers and representatives of the Company. Based upon the foregoing, and in reliance thereon, and subject to the assumptions, limitations, qualifications and exceptions set forth herein, we are of the opinion that:

1. The Shares have been duly authorized by all necessary corporate action on the part of the Company and, when issued and sold in accordance with the Registration Statement and the Prospectus and delivered and paid for in accordance with the terms of the Securities Purchase Agreement, the Shares will be validly issued, fully paid and nonassessable. 2. The Warrants have been duly authorized by all necessary corporate action on the part of the Company and, when issued and sold in accordance with the Registration Statement and the Prospectus and delivered and paid for in accordance with the terms of the Securities Purchase Agreement, the Warrants will constitute valid and binding obligations of the Company, enforceable against the Company in accordance with their terms except as such enforceability may be limited by (i) any applicable bankruptcy, insolvency, reorganization, moratorium or similar laws affecting creditors' rights generally including, without limitation, fraudulent transfer or fraudulent conveyance laws; (ii) public policy considerations, statutes or court decisions that may limit rights to obtain exculpation, indemnification or contribution (including, without limitation, indemnification regarding violations of the securities laws and indemnification for losses resulting from a judgment for the payment of any amount other than in United States dollars); and (iii) general principles of equity (including, without limitation, concepts of materiality, reasonableness, good faith and fair dealing) and the availability of equitable remedies (including, without limitation, specific performance and equitable relief), regardless of whether considered in a proceeding in equity or at law. 3. The Warrant Shares have been duly authorized by all necessary corporate action on the part of the Company and, assuming a sufficient number of authorized but unissued shares of Common Stock are available for issuance when the Warrants are exercised, the Warrant Shares, when and if issued upon exercise of the Warrants in accordance with the terms of the Warrants, will be validly issued, fully paid and nonassessable. With regard to opinion paragraph 2: (i) our opinion is subject to the qualification that the availability of specific performance, an injunction or other equitable remedies is subject to the discretion of the court before which the request is brought; (ii) we express no opinion as to any provision of the Warrants, that (a) provides for liquidated damages, buy-in damages, monetary penalties, prepayment or make-whole payments or other economic remedies to the extent such provisions may constitute unlawful penalties, (b) relates to advance waivers of claims, defenses, rights granted by law, or notice, opportunity for hearing, evidentiary requirements, statutes of limitations, trial by jury, or procedural rights, (c) restricts non-written modifications and waivers, (d) provides for the payment of legal and other professional fees where such payment is contrary to law or public policy, (e) relates to exclusivity, election or accumulation of rights or remedies, (f) authorizes or validates conclusive or discretionary determinations, or (g) provides that provisions of the Warrants are severable to the extent an essential part of the agreed exchange is determined to be invalid and unenforceable; and (iii) we express no opinion as to whether a state court outside of the State of New York or a federal court of the United States would give effect to the choice of New York law provided for in the Warrants. Without limiting any of the other limitations, exceptions, assumptions and qualifications stated elsewhere herein, we express no opinion with regard to the applicability or effect of the laws of any jurisdiction other than the Delaware General Corporation Law and the laws of the State of New York, as in effect on the date of this opinion letter. We are not rendering any opinion as to compliance with any federal or state antifraud law, rule or regulation relating to securities, or to the sale or issuance thereof. This opinion letter deals only with the specified legal issues expressly addressed herein, and you should not infer any opinion that is not explicitly stated herein from any matter addressed in this opinion letter. This opinion letter is rendered solely in connection with the offering of the Securities as described in the Registration Statement. This opinion letter is rendered as of the date hereof, and we assume no obligation to advise you or any other person with regard to any change after the date hereof in the circumstances or the law that may bear on the matters set forth herein, even if the change may affect the legal analysis or a legal conclusion or other matters in this opinion letter. We hereby consent to the filing of this opinion letter as Exhibit 5.1 to the Registration Statement and to the reference to our firm in the Prospectus under the heading "Legal Matters." In giving such consent, we do not hereby admit that we are within the category of persons whose consent is required under Section 7 of the Securities Act or the rules or regulations of the Commission thereunder.

Very truly yours, /s/ Paul Hastings LLP EX-10.48 5 apvo-ex10\_48.htm EX-10.48 EX-10.48 EXHIBIT 10.48 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this "Agreement") is dated as of \_\_\_\_\_, 2024, between Aptevo Therapeutics Inc., a Delaware corporation (the "Company"), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a "Purchaser" and collectively, the "Purchasers"). WHEREAS, subject to the terms and conditions set forth in this Agreement and pursuant to an effective registration statement under the Securities Act (as defined below), the Company desires to issue and sell to each Purchaser, and each Purchaser, severally and not jointly, desires to purchase from the Company, securities of the Company as more fully described in this Agreement. NOW, THEREFORE, IN CONSIDERATION of the mutual covenants contained in this Agreement, and for other good and valuable consideration, the receipt and adequacy of which are hereby acknowledged, the Company and each Purchaser agree as follows:

ARTICLE I. DEFINITIONS

1.1 Definitions. In addition to the terms defined elsewhere in this Agreement, for all purposes of this Agreement, the following terms have the meanings set forth in this Section 1.1: "Acquiring Person" shall have the meaning ascribed to such term in Section 4.5. "Action" shall have the meaning ascribed to such term in Section 3.1(j). "Affiliate" means any Person that, directly or indirectly through one or more intermediaries, controls or is controlled by or is under common control with a Person, as such terms are used in and construed under Rule 405 under the Securities Act. "Board of Directors" means the board of directors of the Company. "Business Day" means any day other than Saturday, Sunday or other day on which commercial banks in The City of New York are authorized or required by law to remain closed; provided, however, for clarification, commercial banks shall not be deemed to be authorized or required by law to remain closed due to a "stay-at-home", "shelter-in-place", "non-essential employee" or any other similar orders or restrictions or the closure of any physical branch locations at the direction of any governmental authority so long as the electronic funds transfer systems (including for wire transfers) of commercial banks in The City of New York are generally open for use by customers on such day. "Closing" means the closing of the purchase and sale of the Securities pursuant to Section 2.1. "Closing Date" means the Trading Day on which all of the Transaction Documents have been executed and delivered by the applicable parties thereto, and all conditions precedent to (i) the Purchasers' obligations to pay the Subscription Amount and (ii) the Company's obligations to deliver the Securities, in each case, have been satisfied or waived, but in no event later than the first (1st) Trading Day following the date hereof (or the second (2nd) Trading Day following the date hereof if this Agreement is signed on a day that is not a Trading Day or after 4:00 p.m. (New York City time) and before

midnight (New York City time) on a Trading Day). “Commission” means the United States Securities and Exchange Commission. “Common Stock” means the common stock of the Company, par value \$0.001 per share, and any other class of securities into which such securities may hereafter be reclassified or changed. “Common Stock Equivalents” means any securities of the Company or the Subsidiaries which would entitle the holder thereof to acquire at any time Common Stock, including, without limitation, any debt, preferred stock, right, option, warrant or other instrument that is at any time convertible into or exercisable or exchangeable for, or otherwise entitles the holder thereof to receive, Common Stock. “Common Warrant Shares” means the shares of Common Stock issuable upon exercise of the Common Warrants. “Common Warrants” means, collectively, the Common Stock purchase warrants delivered to the Purchasers at the Closing in accordance with Section 2.2(a) hereof, which Common Warrants shall be exercisable at any time on or after the date that the Stockholder Approval is obtained and deemed effective. The Common Warrants shall have a term of exercise equal to five (5) years from the initial exercise date. “Company Counsel” means Paul Hastings LLP, with offices located at 2050 M Street NW, Washington DC 20036. “Disclosure Schedules” means the Disclosure Schedules of the Company delivered concurrently herewith. “Disclosure Time” means, (i) if this Agreement is signed on a day that is not a Trading Day or after 9:00 a.m. (New York City time) and before midnight (New York City time) on any Trading Day, 9:01 a.m. (New York City time) on the Trading Day immediately following the date hereof, unless otherwise instructed as to an earlier time by the Placement Agent, and (ii) if this Agreement is signed between midnight (New York City time) and 9:00 a.m. (New York City time) on any Trading Day, no later than 9:01 a.m. (New York City time) on the date hereof, unless otherwise instructed as to an earlier time by the Placement Agent. “EGS” means Ellenoff Grossman & Schole LLP, with offices located at 1345 Avenue of the Americas, New York, New York 10105-0302. 2A “Evaluation Date” shall have the meaning ascribed to such term in Section 3.1(s). “Exchange Act” means the Securities Exchange Act of 1934, as amended, and the rules and regulations promulgated thereunder. “Exempt Issuance” means the issuance of (a) shares of Common Stock or options to employees, officers or directors of the Company pursuant to any stock or option plan duly adopted for such purpose, by a majority of the non-employee members of the Board of Directors or a majority of the members of a committee of non-employee directors established for such purpose for services rendered to the Company, (b) warrants to the Placement Agent in connection with the transactions pursuant to this Agreement and any securities upon exercise of warrants to the Placement Agent, securities upon the exercise or exchange of or conversion of any Securities issued hereunder and/or other securities exercisable or exchangeable for or convertible into shares of Common Stock issued and outstanding on the date of this Agreement, provided that such securities have not been amended since the date of this Agreement to increase the number of such securities or to decrease the exercise price, exchange price or conversion price of such securities (other than in connection with stock splits or combinations) or to extend the term of such securities, and (c) securities issued pursuant to acquisitions or strategic transactions approved by a majority of the disinterested directors of the Company, provided that such securities are issued as “restricted securities” (as defined in Rule 144) and carry no registration rights that require or permit the filing of any registration statement in connection therewith during the prohibition period in Section 4.12(a) herein, and provided that any such issuance shall only be to a Person (or to the equityholders of a Person) which is, itself or through its subsidiaries, an operating company or an owner of an asset in a business synergistic with the business of the Company and shall provide to the Company additional benefits in addition to the investment of funds, but shall not include a transaction in which the Company is issuing securities primarily for the purpose of raising capital or to an entity whose primary business is investing in securities. “FCPA” means the Foreign Corrupt Practices Act of 1977, as amended. “FDA” shall have the meaning ascribed to such term in Section 3.1(ii). “GAAP” shall have the meaning ascribed to such term in Section 3.1(h). “Indebtedness” shall have the meaning ascribed to such term in Section 3.1(aa). “Intellectual Property Rights” shall have the meaning ascribed to such term in Section 3.1(p). “Liens” means a lien, charge pledge, security interest, encumbrance, right of first refusal, preemptive right or other restriction. 3A “Lock-Up Agreement” means the Lock-Up Agreement, dated as of the date hereof, by and among the Company and the directors, officers and 10% stockholders of the Company, in the form of Exhibit A attached hereto. “Material Adverse Effect” shall have the meaning assigned to such term in Section 3.1(b). “Material Permits” shall have the meaning ascribed to such term in Section 3.1(n). “Outstanding Facilities” means the Purchase Agreement with Lincoln Park Capital Fund, LLC. “Per Share Purchase Price” equals \$ \_\_, subject to adjustment for reverse and forward stock splits, stock dividends, stock combinations and other similar transactions of the Common Stock that occur after the date of this Agreement as described in the Common Warrant, provided that the purchase price per Pre-Funded Warrant shall be the Per Share Purchase Price minus \$0.0001. “Person” means an individual or corporation, partnership, trust, incorporated or unincorporated association, joint venture, limited liability company, joint stock company, government (or an agency or subdivision thereof) or other entity of any kind. “Pharmaceutical Product” shall have the meaning ascribed to such term in Section 3.1(hh). “Placement Agent” means Roth Capital Partners, LLC. “Pre-Funded Warrant Shares” means the shares of Common Stock issuable upon exercise of the Pre-Funded Warrants. “Pre-Funded Warrants” means, collectively, the Pre-Funded Common Stock purchase warrants delivered to one or more of the Purchasers at the Closing in accordance with Section 2.2(a)(iv) hereof, in the form of Exhibit B-2 attached hereto, which Pre-Funded Warrants shall be exercisable immediately and will expire when exercised in full. “Preliminary Prospectus” means any preliminary prospectus included in the Registration Statement, as originally filed or as part of any amendment thereto, or filed with the Commission pursuant to Rule 424(a) of the rules and regulations of the Commission under the Securities Act. “Proceeding” means an action, claim, suit, investigation or proceeding (including, without limitation, an informal investigation or partial proceeding, such as a deposition), whether commenced or threatened. “Prospectus” means the final prospectus filed for the Registration Statement. 4A “Prospectus Supplement” means any supplement to the Prospectus complying with Rule 424(b) of the Securities Act that is filed with the Commission and delivered by the Company to each Purchaser at the Closing. “Purchaser Party” shall have the meaning ascribed to such term in Section 4.8. “Registration Statement” means the effective registration statement with the Commission File No. 333-\_\_\_\_\_ which registers the sale of the Shares, the Warrants and the Warrant Shares to the Purchaser, and includes any Rule 462(b) Registration Statement. “Required Approvals” shall have the meaning ascribed to such term in Section 3.1(e). “Rule 144” means Rule 144 promulgated by the Commission pursuant to the Securities Act, as such Rule may be amended or interpreted from time to time, or any similar rule or regulation hereafter adopted by the Commission having substantially the same purpose and effect as such Rule. “Rule 424” means Rule 424 promulgated by the Commission pursuant to the Securities Act, as such Rule may be amended or interpreted from time to time, or any similar rule or regulation hereafter adopted by the Commission having substantially the same purpose and effect as such Rule. “Rule 462(b) Registration Statement” means any registration statement prepared by the Company registering additional Securities, which was filed with the Commission on or prior to the date hereof and became automatically effective pursuant to Rule 462(b) promulgated by the Commission pursuant to the Securities Act. “SEC Reports” shall have the meaning ascribed to such term in Section 3.1(h). “Securities” means the Shares, the Warrants and the Warrant Shares. “Securities Act” means the Securities Act of 1933, as amended, and the rules and regulations promulgated thereunder. “Stockholder Approval” means such approval as may be required by the applicable rules and regulations of the Nasdaq Capital Market (or any successor entity) from the stockholders of the Company to permit the exercise of the Common Warrants. “Shares” means the shares of Common Stock issued or issuable to each Purchaser pursuant to this Agreement. “Short Sales” means all “short sales” as defined in Rule 200 of Regulation SHO under the Exchange Act (but shall not be deemed to include locating and/or borrowing shares of Common Stock). “Subscription Amount” means, as to each Purchaser, the aggregate amount to be paid for Shares and Warrants purchased hereunder as specified below such Purchaser’s 5A name on the signature page of this Agreement and next to the heading “Subscription Amount,” in United States dollars and in immediately available funds (minus, if applicable, a Purchaser’s aggregate exercise price of the Pre-Funded Warrants purchased by such Purchaser, which amounts shall be paid as and when such Pre-Funded Warrants are exercised for cash). “Subsidiary” means any subsidiary of the Company as set forth in the SEC Reports and shall, where applicable, also include any direct or indirect subsidiary of the Company formed or acquired after the date hereof. “Trading Day” means a day on which the principal Trading Market is open for trading. “Trading Market” means any of the following markets or exchanges on which the Common Stock is listed or quoted for trading on the date in question: the NYSE American, the Nasdaq Capital Market, the Nasdaq Global Market, the Nasdaq Global Select Market, the New York Stock Exchange (or any successors to any of the foregoing). “Transaction Documents” means this Agreement, the Warrants, the Lock-Up Agreement, all exhibits and schedules thereto and hereto and any other documents or agreements executed in connection with the transactions contemplated hereunder. “Transfer Agent” means Broadridge, the current transfer agent of the Company, with a mailing address of 51 Mercedes Way, Edgewood, NY 11717, and any

successor transfer agent of the Company. "Variable Rate Transaction" shall have the meaning ascribed to such term in Section 4.12(b). "VWAP" means, for any date, the price determined by the first of the following clauses that applies: (a) if the Common Stock is then listed or quoted on a Trading Market, the daily volume weighted average price of the Common Stock for such date (or the nearest preceding date) on the Trading Market on which the Common Stock is then listed or quoted as reported by Bloomberg L.P. (based on a Trading Day from 9:30 a.m. (New York City time) to 4:02 p.m. (New York City time)), (b) if OTCQB Venture Market ("OTCQB") or OTCQX Best Market ("OTCQX") is not a Trading Market, the volume weighted average price of the Common Stock for such date (or the nearest preceding date) on OTCQB or OTCQX as applicable, (c) if the Common Stock is not then listed or quoted for trading on OTCQB or OTCQX and if prices for the Common Stock are then reported on the Pink Open Market ("Pink Market") operated by OTC Markets, Inc. (or a similar organization or agency succeeding to its functions of reporting prices), the most recent bid price per share of the Common Stock so reported, or (d) in all other cases, the fair market value of a share of Common Stock as determined by an independent appraiser selected in good faith by the Purchasers of a majority in interest of the Securities then outstanding and reasonably acceptable to the Company, the fees and expenses of which shall be paid by the Company. "Warrants" means, collectively, the Common Warrants and the Pre-Funded Warrants. "Warrant Shares" means, collectively, the Common Warrant Shares and the Pre-Funded Warrant Shares.

**ARTICLE II. PURCHASE AND SALE**

**2.1 Closing.** On the Closing Date, upon the terms and subject to the conditions set forth herein, the Company agrees to sell, and the Purchasers, severally and not jointly, agree to purchase, up to an aggregate of \$\_\_\_\_\_ of Shares and Common Warrants. Notwithstanding anything herein to the contrary, to the extent that a Purchaser determines, in its sole discretion, that such Purchaser's Subscription Amount (together with such Purchaser's Affiliates and any Person acting as a group together with such Purchaser or any of such Purchaser's Affiliates) would cause such Purchaser's beneficial ownership of the shares of Common Stock to exceed the Beneficial Ownership Limitation, such Purchaser may elect to purchase Pre-Funded Warrants in lieu of the Shares as determined pursuant to Section 2.2(a). The "Beneficial Ownership Limitation" shall be 4.99% (or, at the election of the Purchaser at Closing, 9.99%) of the number of shares of the Common Stock outstanding immediately after giving effect to the issuance of the Securities on the Closing Date. In each case, the election to receive Pre-Funded Warrants is solely at the option of the Purchaser. Each Purchaser shall deliver to the Company, via wire transfer, immediately available funds equal to such Purchaser's Subscription Amount as set forth on the signature page hereto executed by such Purchaser, and the Company shall deliver to each Purchaser its respective Shares, any Pre-Funded Warrants and a Common Warrant, as determined pursuant to Section 2.2(a), and the Company and each Purchaser shall deliver the other items set forth in Section 2.2 deliverable at the Closing. Upon satisfaction (or waiver) of the covenants and conditions set forth in Sections 2.2 and 2.3, the Closing shall occur at the offices of EGS or such other location (including remotely by electronic transmission) as the parties shall mutually agree. Unless otherwise directed by the Placement Agent, settlement of the Shares shall occur via "Delivery Versus Payment" ("DVP") (i.e., on the Closing Date, the Company shall issue the Shares registered in the Purchaser's names and addresses and released by the Transfer Agent directly to the account(s) at the Placement Agent identified by each Purchaser; upon receipt of such Shares, the Placement Agent shall promptly electronically deliver such Shares to the applicable Purchaser, and payment therefor shall be made by the Placement Agent (or its clearing firm) by wire transfer to the Company). Notwithstanding anything herein to the contrary, if at any time on or after the time of execution of this Agreement by the Company and an applicable Purchaser, through, and including the time immediately prior to the Closing (the "Pre-Settlement Period"), such Purchaser sells to any Person all, or any portion, of the Shares to be issued hereunder to such Purchaser at the Closing (collectively, the "Pre-Settlement Shares"), such Purchaser shall, automatically hereunder (without any additional required actions by such Purchaser or the Company), be deemed to be unconditionally bound to purchase, such Pre-Settlement Shares at the Closing; provided, that the Company shall not be required to deliver any Pre-Settlement Shares to such Purchaser prior to the Company's receipt of the purchase price of such Pre-Settlement Shares hereunder; and provided further that the Company hereby acknowledges and agrees that the forgoing shall not constitute a representation or covenant by such Purchaser as to whether or not during the Pre-Settlement Period such Purchaser shall sell any shares of Common Stock to any Person and that any such decision to sell any shares of Common Stock by such Purchaser shall solely be made at the time such Purchaser elects to effect any such sale, if any. Notwithstanding anything to the contrary herein and a Purchaser's Subscription Amount set forth on the signature pages attached 7A hereto, the number of Shares purchased by a Purchaser (and its Affiliates) hereunder shall not, when aggregated with all other shares of Common Stock owned by such Purchaser (and its Affiliates) at such time, result in such Purchaser beneficially owning (as determined in accordance with Section 13(d) of the Exchange Act) in excess of 4.99/9.99% of the then issued and outstanding Common Stock outstanding at the Closing (the "Beneficial Ownership Maximum"), and such Purchaser's Subscription Amount, to the extent it would otherwise exceed the Beneficial Ownership Maximum immediately prior to the Closing, shall be conditioned upon the issuance of Shares at the Closing to the other Purchasers signatory hereto. To the extent that a Purchaser's beneficial ownership of the Shares would otherwise be deemed to exceed the Beneficial Ownership Maximum, such Purchaser's Subscription Amount shall automatically be reduced as necessary in order to comply with this paragraph. Notwithstanding the foregoing, with respect to any Notice(s) of Exercise (as defined in the Pre-Funded Warrants) delivered on or prior to 12:00 p.m. (New York City time) on the Closing Date, which may be delivered at any time after the time of execution of this Agreement, the Company agrees to deliver the Warrant Shares subject to such notice(s) by 4:00 p.m. (New York City time) on the Closing Date and the Closing Date shall be the Warrant Share Delivery Date (as defined in the Pre-Funded Warrants) for purposes hereunder.

**2.2 Deliveries.** (a) On or prior to the Closing Date, the Company shall deliver or cause to be delivered to each Purchaser the following: (i) this Agreement duly executed by the Company; (ii) a legal opinion of Company Counsel, directed to the Placement Agent and the Purchasers, in form and substance reasonably acceptable to the Placement Agent and Purchasers; (iii) a copy of the irrevocable instructions to the Transfer Agent instructing the Transfer Agent to deliver, on an expedited basis, evidence of the issuance of a number of Shares equal to such Purchaser's Subscription Amount divided by the Per Share Purchase Price as held in DRS book-entry form by the Transfer Agent and registered in the name of such Purchaser; (iv) if applicable, for each Purchaser of Pre-Funded Warrants pursuant to Section 2.1, a Pre-Funded Warrant registered in the name of such Purchaser to purchase up to a number of shares of Common Stock equal to the portion of such Purchaser's Subscription Amount applicable to Pre-Funded Warrant divided by the Per Share Purchase Price minus \$0.0001, with an exercise price equal to \$0.0001; (v) a Common Warrant registered in the name of such Purchaser to purchase up to a number of shares of Common Stock equal to 200% of the sum of such Purchaser's Shares and Pre-Funded Warrant Shares initially issuable upon exercise of such Purchaser's Pre-Funded Warrants, with an exercise price equal to \$\_\_\_\_, subject to adjustment therein; 8A (vi) the Company shall have provided each Purchaser with the Company's wire instructions, on Company letterhead and executed by the Chief Executive Officer or Chief Financial Officer; (vii) the Lock-Up Agreements; (viii) the Preliminary Prospectus and the Prospectus (which may be delivered in accordance with Rule 172 under the Securities Act); and (b) On or prior to the Closing Date, each Purchaser shall deliver or cause to be delivered to the Company the following: (i) this Agreement duly executed by such Purchaser; and (ii) such Purchaser's Subscription Amount, which shall be made available for "Delivery Versus Payment" settlement with the Company or its designee.

**2.3 Closing Conditions.** (a) The obligations of the Company hereunder in connection with the Closing are subject to the following conditions being met: (i) the accuracy in all material respects (or, to the extent representations or warranties are qualified by materiality, in all respects) on the Closing Date of the representations and warranties of the Purchasers contained herein (unless as of a specific date therein in which case they shall be accurate in all material respects (or, to the extent representations or warranties are qualified by materiality, in all respects) as of such date); (ii) all obligations, covenants and agreements of each Purchaser required to be performed at or prior to the Closing Date shall have been performed; and (iii) the delivery by each Purchaser of the items set forth in Section 2.2(b) of this Agreement. (b) The respective obligations of the Purchasers hereunder in connection with the Closing are subject to the following conditions being met: (i) the accuracy in all material respects (or, to the extent representations or warranties are qualified by materiality or Material Adverse Effect, in all respects) on the Closing Date of the representations and warranties of the Company contained herein (unless as of a specific date therein in which case they shall be accurate in all material respects or, to the extent representations or warranties are qualified by materiality or Material Adverse Effect, in all respects) as of such date; 9A (ii) all obligations, covenants and agreements of the Company required to be performed at or prior to the Closing Date shall have been performed; (iii) the delivery by the Company of the items set forth in Section 2.2(a) of this Agreement; (iv) there shall have been no Material Adverse Effect with respect to the Company; and (v) from the date hereof to the Closing Date, trading in the Common Stock shall not have been suspended by the Commission or the Company's principal Trading Market, and, at any time prior to the Closing Date, trading in securities generally as reported by Bloomberg L.P. shall not have been suspended or limited, or minimum prices shall not have been established on securities

whose trades are reported by such service, or on any Trading Market, nor shall a banking moratorium have been declared either by the United States or New York State authorities nor shall there have occurred any material outbreak or escalation of hostilities or other national or international calamity of such magnitude in its effect on, or any material adverse change in, any financial market which, in each case, in the reasonable judgment of such Purchaser, makes it impracticable or inadvisable to purchase the Securities at the Closing.

**ARTICLE III. REPRESENTATIONS AND WARRANTIES**

**3.1 Representations and Warranties of the Company.** Except as set forth in the Disclosure Schedules, which Disclosure Schedules shall be deemed a part hereof and shall qualify any representation or otherwise made herein to the extent of the disclosure contained in the corresponding section of the Disclosure Schedules, the Company hereby makes the following representations and warranties to each Purchaser:

(a) **Subsidiaries.** All of the direct and indirect subsidiaries of the Company are set forth in the SEC Reports. The Company owns, directly or indirectly, all of the capital stock or other equity interests of each Subsidiary free and clear of any Liens, and all of the issued and outstanding shares of capital stock of each Subsidiary are validly issued and are fully paid, non-assessable and free of preemptive and similar rights to subscribe for or purchase securities. If the Company has no subsidiaries, all other references to the Subsidiaries or any of them in the Transaction Documents shall be disregarded.

(b) **Organization and Qualification.** The Company and each of the Subsidiaries is an entity duly incorporated or otherwise organized, validly existing and in good standing under the laws of the jurisdiction of its incorporation or organization, with the requisite power and authority to own and use its properties and assets and to carry on its business as currently conducted. Neither the Company nor any Subsidiary is in violation nor default of any of the provisions of its respective certificate or articles of incorporation, bylaws or other organizational or charter documents. Each of the Company and the Subsidiaries is duly qualified to conduct business and is in good standing as a foreign corporation or other 10<sup>th</sup> entity in each jurisdiction in which the nature of the business conducted or property owned by it makes such qualification necessary, except where the failure to be so qualified or in good standing, as the case may be, could not have or reasonably be expected to result in: (i) a material adverse effect on the legality, validity or enforceability of any Transaction Document, (ii) a material adverse effect on the results of operations, assets, business, prospects or condition (financial or otherwise) of the Company and the Subsidiaries, taken as a whole, or (iii) a material adverse effect on the Company's ability to perform in any material respect its obligations under any Transaction Document (any of (i), (ii) or (iii), a "Material Adverse Effect") and no Proceeding has been instituted in any such jurisdiction revoking, limiting or curtailing or seeking to revoke, limit or curtail such power and authority or qualification.

(c) **Authorization; Enforcement.** The Company has the requisite corporate power and authority to enter into and to consummate the transactions contemplated by this Agreement and each of the other Transaction Documents and otherwise to carry out its obligations hereunder and thereunder. The execution and delivery of this Agreement and each of the other Transaction Documents by the Company and the consummation by it of the transactions contemplated hereby and thereby have been duly authorized by all necessary action on the part of the Company and no further action is required by the Company, the Board of Directors or the Company's stockholders in connection herewith or therewith other than in connection with the Required Approvals. This Agreement and each other Transaction Document to which it is a party has been (or upon delivery will have been) duly executed by the Company and, when delivered in accordance with the terms hereof and thereof, will constitute the valid and binding obligation of the Company enforceable against the Company in accordance with its terms, except (i) as limited by general equitable principles and applicable bankruptcy, insolvency, reorganization, moratorium and other laws of general application affecting enforcement of creditors' rights generally, (ii) as limited by laws relating to the availability of specific performance, injunctive relief or other equitable remedies and (iii) insofar as indemnification and contribution provisions may be limited by applicable law.

(d) **No Conflicts.** The execution, delivery and performance by the Company of this Agreement and the other Transaction Documents to which it is a party, the issuance and sale of the Securities and the consummation by it of the transactions contemplated hereby and thereby do not and will not (i) conflict with or violate any provision of the Company's or any Subsidiary's certificate or articles of incorporation, bylaws or other organizational or charter documents, or (ii) conflict with, or constitute a default (or an event that with notice or lapse of time or both would become a default) under, result in the creation of any Lien upon any of the properties or assets of the Company or any Subsidiary, or give to others any rights of termination, amendment, anti-dilution or similar adjustments, acceleration or cancellation (with or without notice, lapse of time or both) of, any agreement, credit facility, debt or other instrument (evidencing a Company or Subsidiary debt or otherwise) or other understanding to which the Company or any Subsidiary is a party or by which any property or asset of the Company or any Subsidiary is bound or affected, or (iii) subject to the Required Approvals, conflict with or result in a violation of any law, rule, regulation, order, judgment, injunction, decree or other restriction of any court or governmental authority to which the Company or a Subsidiary is subject (including 11<sup>th</sup> federal and state securities laws and regulations), or by which any property or asset of the Company or a Subsidiary is bound or affected; except in the case of each of clauses (ii) and (iii), such as could not have or reasonably be expected to result in a Material Adverse Effect.

(e) **Filings, Consents and Approvals.** The Company is not required to obtain any consent, waiver, authorization or order of, give any notice to, or make any filing or registration with, any court or other federal, state, local or other governmental authority or other Person in connection with the execution, delivery and performance by the Company of the Transaction Documents, other than: (i) the filings required pursuant to Section 4.4 of this Agreement, (ii) the filing with the Commission of the Prospectus Supplement, (iii) application(s) to each applicable Trading Market the listing of the Shares and Warrant Shares for trading thereon in the time and manner required thereby, (iv) Stockholder Approval and (v) such filings as are required to be made under applicable state securities laws (collectively, the "Required Approvals").

(f) **Issuance of the Securities; Registration.** The Securities are duly authorized and, when issued and paid for in accordance with the applicable Transaction Documents, will be duly and validly issued, fully paid and nonassessable, free and clear of all Liens imposed by the Company. The Warrant Shares, when issued in accordance with the terms of the Warrants, will be validly issued, fully paid and nonassessable, free and clear of all Liens imposed by the Company. The Company has reserved from its duly authorized capital stock the maximum number of shares of Common Stock issuable pursuant to this Agreement and the Warrants. The Company has prepared and filed the Registration Statement in conformity with the requirements of the Securities Act, which became effective on \_\_\_\_\_, 2024 (the "Effective Date"), including the Prospectus, and such amendments and supplements thereto as may have been required to the date of this Agreement. The Registration Statement is effective under the Securities Act and no stop order preventing or suspending the effectiveness of the Registration Statement or suspending or preventing the use of the Prospectus has been issued by the Commission and no proceedings for that purpose have been instituted or, to the knowledge of the Company, are threatened by the Commission. The Company, if required by the rules and regulations of the Commission, shall file the Prospectus with the Commission pursuant to Rule 424(b). At the time the Registration Statement and any amendments thereto became effective, at the date of this Agreement and at the Closing Date, the Registration Statement and any amendments thereto conformed and will conform in all material respects to the requirements of the Securities Act and did not and will not contain any untrue statement of a material fact or omit to state any material fact required to be stated therein or necessary to make the statements therein not misleading; and the Prospectus and any amendments or supplements thereto, at the time the Prospectus or any amendment or supplement thereto was issued and at the Closing Date, conformed and will conform in all material respects to the requirements of the Securities Act and did not and will not contain an untrue statement of a material fact or omit to state a material fact necessary in order to make the statements therein, in the light of the circumstances under which they were made, not misleading.

(g) **Capitalization.** The capitalization of the Company as of the date hereof is as set forth on Schedule 3.1(g), which Schedule 3.1(g) shall also include the number of 12<sup>th</sup> shares of Common Stock owned beneficially, and of record, by Affiliates of the Company as of the date thereof. The Company has not issued any capital stock since its most recently filed periodic report under the Exchange Act, other than the release of shares of Common Stock held in abeyance from the exercise of common warrants related to the Company's August 2023 public offering, pursuant to the exercise of employee stock options under the Company's stock option plans, the issuance of shares of Common Stock to employees pursuant to the Company's employee stock purchase plans and pursuant to the conversion and/or exercise of Common Stock Equivalents outstanding as of the date of the most recently filed periodic report under the Exchange Act. No Person has any right of first refusal, preemptive right, right of participation, or any similar right to participate in the transactions contemplated by the Transaction Documents. Except as set forth on Schedule 3.1(g), there are no outstanding options, warrants, scrip rights to subscribe to, calls or commitments of any character whatsoever relating to, or securities, rights or obligations convertible into or exercisable or exchangeable for, or giving any Person any right to subscribe for or acquire, any shares of Common Stock or the capital stock of any Subsidiary, or contracts, commitments, understandings or arrangements by which the Company or any Subsidiary is or may become bound to issue additional shares of Common Stock or Common Stock Equivalents or capital stock of any Subsidiary. The issuance and sale of the Securities will not obligate the Company or any Subsidiary to issue shares of

Common Stock or other securities to any Person (other than the Purchasers). There are no outstanding securities or instruments of the Company or any Subsidiary with any provision that adjusts the exercise, conversion, exchange or reset price of such security or instrument upon an issuance of securities by the Company or any Subsidiary. There are no outstanding securities or instruments of the Company or any Subsidiary that contain any redemption or similar provisions, and there are no contracts, commitments, understandings or arrangements by which the Company or any Subsidiary is or may become bound to redeem a security of the Company or such Subsidiary. The Company does not have any stock appreciation rights or “phantom stock” plans or agreements or any similar plan or agreement. All of the outstanding shares of capital stock of the Company are duly authorized, validly issued, fully paid and nonassessable, have been issued in compliance with all federal and state securities laws, and none of such outstanding shares was issued in violation of any preemptive rights or similar rights to subscribe for or purchase securities. Except for the Stockholder Approval, no further approval or authorization of any stockholder, the Board of Directors or others is required for the issuance and sale of the Securities. There are no stockholders agreements, voting agreements or other similar agreements with respect to the Company’s capital stock to which the Company is a party or, to the knowledge of the Company, between or among any of the Company’s stockholders. (h)SEC Reports; Financial Statements. The Company has filed all reports, schedules, forms, statements and other documents required to be filed by the Company under the Securities Act and the Exchange Act, including pursuant to Section 13(a) or 15(d) thereof, for the two years preceding the date hereof (or such shorter period as the Company was required by law or regulation to file such material) (the foregoing materials, including the exhibits thereto and documents incorporated by reference therein, together with the Preliminary Prospectus and the Prospectus Supplement, being collectively referred to herein as the “SEC Reports”) on a timely basis or has received a valid extension of such 13A time of filing and has filed any such SEC Reports prior to the expiration of any such extension. As of their respective dates, the SEC Reports complied in all material respects with the requirements of the Securities Act and the Exchange Act, as applicable, and none of the SEC Reports, when filed, contained any untrue statement of a material fact or omitted to state a material fact required to be stated therein or necessary in order to make the statements therein, in the light of the circumstances under which they were made, not misleading. The Company has never been an issuer subject to Rule 144(i) under the Securities Act. The financial statements of the Company included in the SEC Reports comply in all material respects with applicable accounting requirements and the rules and regulations of the Commission with respect thereto as in effect at the time of filing. Such financial statements have been prepared in accordance with United States generally accepted accounting principles applied on a consistent basis during the periods involved (“GAAP”), except as may be otherwise specified in such financial statements or the notes thereto and except that unaudited financial statements may not contain all footnotes required by GAAP, and fairly present in all material respects the financial position of the Company and its consolidated Subsidiaries as of and for the dates thereof and the results of operations and cash flows for the periods then ended, subject, in the case of unaudited statements, to normal, immaterial, year-end audit adjustments. (i)Material Changes; Undisclosed Events, Liabilities or Developments. Since the date of the latest audited financial statements included within the SEC Reports, except as set forth on Schedule 3.1(i), (i) there has been no event, occurrence or development that has had or that could reasonably be expected to result in a Material Adverse Effect, (ii) the Company has not incurred any liabilities (contingent or otherwise) other than (A) trade payables and accrued expenses incurred in the ordinary course of business consistent with past practice and (B) liabilities not required to be reflected in the Company’s financial statements pursuant to GAAP or disclosed in filings made with the Commission, (iii) the Company has not altered its method of accounting, (iv) the Company has not declared or made any dividend or distribution of cash or other property to its stockholders or purchased, redeemed or made any agreements to purchase or redeem any shares of its capital stock and (v) the Company has not issued any equity securities to any officer, director or Affiliate, except pursuant to existing Company stock option plans. The Company does not have pending before the Commission any request for confidential treatment of information. Except for the issuance of the Securities contemplated by this Agreement or as set forth on Schedule 3.1(i), no event, liability, fact, circumstance, occurrence or development has occurred or exists or is reasonably expected to occur or exist with respect to the Company or its Subsidiaries or their respective businesses, prospects, properties, operations, assets or financial condition that would be required to be disclosed by the Company under applicable securities laws at the time this representation is made or deemed made that has not been publicly disclosed at least 1 Trading Day prior to the date that this representation is made. (j)Litigation. Except as set forth on Schedule 3.1(j), there is no action, suit, inquiry, notice of violation, proceeding or investigation pending or, to the knowledge of the Company, threatened against or affecting the Company, any Subsidiary or any of their respective properties before or by any court, arbitrator, governmental or administrative agency or regulatory authority (federal, state, county, local or foreign) (collectively, an “Action”). None of the Actions set forth on Schedule 3.1(j), (i) adversely affects or challenges the legality, validity or enforceability of any of the Transaction Documents or the Securities or (ii) could, if there were an unfavorable decision, have or reasonably be expected to result in a Material Adverse Effect. Neither the Company nor any Subsidiary, nor any director or officer thereof, is or has been the subject of any Action involving a claim of violation of or liability under federal or state securities laws or a claim of breach of fiduciary duty. There has not been, and to the knowledge of the Company, there is not pending or contemplated, any investigation by the Commission involving the Company or any current or former director or officer of the Company. The Commission has not issued any stop order or other order suspending the effectiveness of any registration statement filed by the Company or any Subsidiary under the Exchange Act or the Securities Act. (k)Labor Relations. No labor dispute exists or, to the knowledge of the Company, is imminent with respect to any of the employees of the Company, which could reasonably be expected to result in a Material Adverse Effect. None of the Company’s or its Subsidiaries’ employees is a member of a union that relates to such employee’s relationship with the Company or such Subsidiary, and neither the Company nor any of its Subsidiaries is a party to a collective bargaining agreement, and the Company and its Subsidiaries believe that their relationships with their employees are good. To the knowledge of the Company, no executive officer of the Company or any Subsidiary is, or is now expected to be, in violation of any material term of any employment contract, confidentiality, disclosure or proprietary information agreement or non-competition agreement, or any other contract or agreement or any restrictive covenant in favor of any third party, and the continued employment of each such executive officer does not subject the Company or any of its Subsidiaries to any liability with respect to any of the foregoing matters. The Company and its Subsidiaries are in compliance with all U.S. federal, state, local and foreign laws and regulations relating to employment and employment practices, terms and conditions of employment and wages and hours, except where the failure to be in compliance could not, individually or in the aggregate, reasonably be expected to have a Material Adverse Effect. (l)Compliance. Neither the Company nor any Subsidiary: (i) is in default under or in violation of (and no event has occurred that has not been waived that, with notice or lapse of time or both, would result in a default by the Company or any Subsidiary under), nor has the Company or any Subsidiary received notice of a claim that it is in default under or that it is in violation of, any indenture, loan or credit agreement or any other agreement or instrument to which it is a party or by which it or any of its properties is bound (whether or not such default or violation has been waived), (ii) is in violation of any judgment, decree, or order of any court, arbitrator or other governmental authority or (iii) is or has been in violation of any statute, rule, ordinance or regulation of any governmental authority, including without limitation all foreign, federal, state and local laws relating to taxes, environmental protection, occupational health and safety, product quality and safety and employment and labor matters, except in each case as could not have or reasonably be expected to result in a Material Adverse Effect. (m) Environmental Laws. The Company and its Subsidiaries (i) are in compliance with all federal, state, local and foreign laws relating to pollution or protection 15A of human health or the environment (including ambient air, surface water, groundwater, land surface or subsurface strata), including laws relating to emissions, discharges, releases or threatened releases of chemicals, pollutants, contaminants, or toxic or hazardous substances or wastes (collectively, “Hazardous Materials”) into the environment, or otherwise relating to the manufacture, processing, distribution, use, treatment, storage, disposal, transport or handling of Hazardous Materials, as well as all authorizations, codes, decrees, demands, or demand letters, injunctions, judgments, licenses, notices or notice letters, orders, permits, plans or regulations, issued, entered, promulgated or approved thereunder (“Environmental Laws”); (ii) have received all permits licenses or other approvals required of them under applicable Environmental Laws to conduct their respective businesses; and (iii) are in compliance with all terms and conditions of any such permit, license or approval where in each clause (i), (ii) and (iii), the failure to so comply could be reasonably expected to have, individually or in the aggregate, a Material Adverse Effect. (n)Regulatory Permits. The Company and the Subsidiaries possess all certificates, authorizations and permits issued by the appropriate federal, state, local or foreign regulatory authorities necessary to conduct their respective businesses as described in the SEC Reports, except where the failure to possess such permits could not reasonably be expected to result in a Material Adverse Effect (“Material Permits”), and neither the Company nor any Subsidiary has received any notice of

proceedings relating to the revocation or modification of any Material Permit. (o)Title to Assets. The Company and the Subsidiaries have good and marketable title in fee simple to all real property owned by them and good and marketable title in all personal property owned by them that is material to the business of the Company and the Subsidiaries, in each case free and clear of all Liens, except for (i) Liens as do not materially affect the value of such property and do not materially interfere with the use made and proposed to be made of such property by the Company and the Subsidiaries and (ii) Liens for the payment of federal, state or other taxes, for which appropriate reserves have been made therefor in accordance with GAAP and the payment of which is neither delinquent nor subject to penalties. Any real property and facilities held under lease by the Company and the Subsidiaries are held by them under valid, subsisting and enforceable leases with which the Company and the Subsidiaries are in compliance. (p)Intellectual Property. The Company and the Subsidiaries have, or have rights to use, all patents, patent applications, trademarks, trademark applications, service marks, trade names, trade secrets, inventions, copyrights, licenses and other intellectual property rights and similar rights necessary or required for use in connection with their respective businesses as described in the SEC Reports and which the failure to so have could have a Material Adverse Effect (collectively, the “Intellectual Property Rights”). None of, and neither the Company nor any Subsidiary has received a notice (written or otherwise) that any of, the Intellectual Property Rights has expired, terminated or been abandoned, or is expected to expire or terminate or be abandoned, within two (2) years from the date of this Agreement. Neither the Company nor any Subsidiary has received, since the date of the latest audited financial statements included within the SEC Reports, a written notice of a claim or otherwise has any knowledge that the Intellectual Property Rights violate or infringe upon the rights of any Person, except as could not have or reasonably be expected to not have a Material Adverse Effect. To the knowledge of the Company, all such Intellectual Property Rights are enforceable and there is no existing infringement by another Person of any of the Intellectual Property Rights. The Company and its Subsidiaries have taken reasonable security measures to protect the secrecy, confidentiality and value of all of their intellectual properties, except where failure to do so could not, individually or in the aggregate, reasonably be expected to have a Material Adverse Effect. (q)Insurance. The Company and the Subsidiaries are insured by insurers of recognized financial responsibility against such losses and risks and in such amounts as are prudent and customary in the businesses in which the Company and the Subsidiaries are engaged, including, but not limited to, directors and officers insurance coverage at least equal to the aggregate Subscription Amount. Neither the Company nor any Subsidiary has any reason to believe that it will not be able to renew its existing insurance coverage as and when such coverage expires or to obtain similar coverage from similar insurers as may be necessary to continue its business without a significant increase in cost. (r)Transactions with Affiliates and Employees. Except as set forth on Schedule 3.1(r), none of the officers or directors of the Company or any Subsidiary and, to the knowledge of the Company, none of the employees of the Company or any Subsidiary is presently a party to any transaction with the Company or any Subsidiary (other than for services as employees, officers and directors), including any contract, agreement or other arrangement providing for the furnishing of services to or by, providing for rental of real or personal property to or from, providing for the borrowing of money from or lending of money to or otherwise requiring payments to or from any officer, director or such employee or, to the knowledge of the Company, any entity in which any officer, director, or any such employee has a substantial interest or is an officer, director, trustee, stockholder, member or partner, in each case in excess of \$120,000 other than for (i) payment of salary or consulting fees for services rendered, (ii) reimbursement for expenses incurred on behalf of the Company and (iii) other employee benefits, including stock option agreements under any stock option plan of the Company. (s)Sarbanes-Oxley; Internal Accounting Controls. The Company and the Subsidiaries are in compliance with any and all applicable requirements of the Sarbanes-Oxley Act of 2002, as amended, that are effective as of the date hereof, and any and all applicable rules and regulations promulgated by the Commission thereunder that are effective as of the date hereof and as of the Closing Date. The Company and the Subsidiaries maintain a system of internal accounting controls sufficient to provide reasonable assurance that: (i) transactions are executed in accordance with management’s general or specific authorizations, (ii) transactions are recorded as necessary to permit preparation of financial statements in conformity with GAAP and to maintain asset accountability, (iii) access to assets is permitted only in accordance with management’s general or specific authorization, and (iv) the recorded accountability for assets is compared with the existing assets at reasonable intervals and appropriate action is taken with respect to any differences. The Company and the Subsidiaries have established disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 17A 15d-15(e)) for the Company and the Subsidiaries and designed such disclosure controls and procedures to ensure that information required to be disclosed by the Company in the reports it files or submits under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the Commission’s rules and forms. The Company’s certifying officers have evaluated the effectiveness of the disclosure controls and procedures of the Company and the Subsidiaries as of the end of the period covered by the most recently filed periodic report under the Exchange Act (such date, the “Evaluation Date”). The Company presented in its most recently filed periodic report under the Exchange Act the conclusions of the certifying officers about the effectiveness of the disclosure controls and procedures based on their evaluations as of the Evaluation Date. Since the Evaluation Date, there have been no changes in the internal control over financial reporting (as such term is defined in the Exchange Act) of the Company and its Subsidiaries that have materially affected, or is reasonably likely to materially affect, the internal control over financial reporting of the Company and its Subsidiaries. (t)Certain Fees. Except for fees payable by the Company to the Placement Agent, no brokerage or finder’s fees or commissions are or will be payable by the Company or any Subsidiary to any broker, financial advisor or consultant, finder, placement agent, investment banker, bank or other Person with respect to the transactions contemplated by the Transaction Documents. The Purchasers shall have no obligation with respect to any fees or with respect to any claims made by or on behalf of other Persons for fees of a type contemplated in this Section that may be due in connection with the transactions contemplated by the Transaction Documents. (u)Investment Company. The Company is not, and is not an Affiliate of, and immediately after receipt of payment for the Securities, will not be or be an Affiliate of, an “investment company” within the meaning of the Investment Company Act of 1940, as amended. The Company shall conduct its business in a manner so that it will not become an “investment company” subject to registration under the Investment Company Act of 1940, as amended. (v)Registration Rights. Except as set forth on Schedule 3.1(v), no Person has any right to cause the Company or any Subsidiary to effect the registration under the Securities Act of any securities of the Company or any Subsidiary. (w)Listing and Maintenance Requirements. The Common Stock is registered pursuant to Section 12(b) or 12(g) of the Exchange Act, and the Company has taken no action designed to, or which to its knowledge is likely to have the effect of, terminating the registration of the Common Stock under the Exchange Act nor has the Company received any notification that the Commission is contemplating terminating such registration. Except as set forth on Schedule 3.1(w), the Company has not, in the 12 months preceding the date hereof, received notice from any Trading Market on which the Common Stock is or has been listed or quoted to the effect that the Company is not in compliance with the listing or maintenance requirements of such Trading Market. To the Company’s knowledge it is, and has no reason to believe that it will not in the foreseeable future continue to be, in compliance with all such listing and maintenance requirements. The Common Stock is currently eligible for electronic transfer through the Depository Trust Company or another established clearing corporation and the Company is current in payment of the fees to the Depository Trust Company (or such other established clearing corporation) in connection with such electronic transfer. (x)Application of Takeover Protections. The Company and the Board of Directors have taken all necessary action, if any, in order to render inapplicable any control share acquisition, business combination, poison pill (including any distribution under a rights agreement) or other similar anti-takeover provision under the Company’s certificate of incorporation (or similar charter documents) or the laws of its state of incorporation that is or could become applicable to the Purchasers as a result of the Purchasers and the Company fulfilling their obligations or exercising their rights under the Transaction Documents, including without limitation as a result of the Company’s issuance of the Securities and the Purchasers’ ownership of the Securities. (y)Disclosure. Except with respect to the material terms and conditions of the transactions contemplated by the Transaction Documents, the Company confirms that neither it nor any other Person acting on its behalf has provided any of the Purchasers or their agents or counsel with any information that it believes constitutes or might constitute material, non-public information. The Company understands and confirms that the Purchasers will rely on the foregoing representation in effecting transactions in securities of the Company. All of the disclosure furnished by or on behalf of the Company to the Purchasers regarding the Company and its Subsidiaries, their respective businesses and the transactions contemplated hereby, including the Disclosure Schedules to this Agreement, is true and correct and does not contain any untrue statement of a material fact or omit to state any material fact necessary in order to make the statements made therein, in the light of the circumstances under which they were made, not misleading. The press releases disseminated by the Company during the twelve months preceding the date of this Agreement taken as a whole do not contain any untrue statement of a material fact or omit to state a

material fact required to be stated therein or necessary in order to make the statements therein, in the light of the circumstances under which they were made and when made, not misleading. The Company acknowledges and agrees that no Purchaser makes or has made any representations or warranties with respect to the transactions contemplated hereby other than those specifically set forth in Section 3.2 hereof. (z)No Integrated Offering. Assuming the accuracy of the Purchasers' representations and warranties set forth in Section 3.2, neither the Company, nor any of its Affiliates, nor any Person acting on its or their behalf has, directly or indirectly, made any offers or sales of any security or solicited any offers to buy any security, under circumstances that would cause this offering of the Securities to be integrated with prior offerings by the Company for purposes of any applicable shareholder approval provisions of any Trading Market on which any of the securities of the Company are listed or designated. (aa)Solvency. Based on the consolidated financial condition of the Company as of the Closing Date, after giving effect to the receipt by the Company of the proceeds from the sale of the Securities hereunder, (i) the fair saleable value of the Company's assets exceeds the amount that will be required to be paid on or in respect of the Company's 19A existing debts and other liabilities (including known contingent liabilities) as they mature, (ii) the Company's assets do not constitute unreasonably small capital to carry on its business as now conducted and as proposed to be conducted including its capital needs taking into account the particular capital requirements of the business conducted by the Company, consolidated and projected capital requirements and capital availability thereof, and (iii) the current cash flow of the Company, together with the proceeds the Company would receive, were it to liquidate all of its assets, after taking into account all anticipated uses of the cash, would be sufficient to pay all amounts on or in respect of its liabilities when such amounts are required to be paid. The Company does not intend to incur debts beyond its ability to pay such debts as they mature (taking into account the timing and amounts of cash to be payable on or in respect of its debt). The Company has no knowledge of any facts or circumstances which lead it to believe that it will file for reorganization or liquidation under the bankruptcy or reorganization laws of any jurisdiction within one year from the Closing Date. Schedule 3.1(aa) sets forth as of the date hereof all outstanding secured and unsecured Indebtedness of the Company or any Subsidiary, or for which the Company or any Subsidiary has commitments. For the purposes of this Agreement, "Indebtedness" means (x) any liabilities for borrowed money or amounts owed in excess of \$50,000 (other than trade accounts payable incurred in the ordinary course of business), (y) all guaranties, endorsements and other contingent obligations in respect of indebtedness of others, whether or not the same are or should be reflected in the Company's consolidated balance sheet (or the notes thereto), except guaranties by endorsement of negotiable instruments for deposit or collection or similar transactions in the ordinary course of business; and (z) the present value of any lease payments in excess of \$50,000 due under leases required to be capitalized in accordance with GAAP. Neither the Company nor any Subsidiary is in default with respect to any Indebtedness. (bb)Tax Status. Except for matters that would not, individually or in the aggregate, have or reasonably be expected to result in a Material Adverse Effect, the Company and its Subsidiaries each (i) has made or filed all United States federal, state and local income and all foreign income and franchise tax returns, reports and declarations required by any jurisdiction to which it is subject, (ii) has paid all taxes and other governmental assessments and charges that are material in amount, shown or determined to be due on such returns, reports and declarations and (iii) has set aside on its books provision reasonably adequate for the payment of all material taxes for periods subsequent to the periods to which such returns, reports or declarations apply. There are no unpaid taxes in any material amount claimed to be due by the taxing authority of any jurisdiction, and the officers of the Company or of any Subsidiary know of no basis for any such claim. (cc)Foreign Corrupt Practices. Neither the Company nor any Subsidiary, nor to the knowledge of the Company or any Subsidiary, any agent or other person acting on behalf of the Company or any Subsidiary, has (i) directly or indirectly, used any funds for unlawful contributions, gifts, entertainment or other unlawful expenses related to foreign or domestic political activity, (ii) made any unlawful payment to foreign or domestic government officials or employees or to any foreign or domestic political parties or campaigns from corporate funds, (iii) failed to disclose fully any contribution made by the Company or any Subsidiary (or made by any person acting on its behalf of which the Company is aware) which is in violation of law or (iv) violated in any material respect any provision of FCPA. (dd)Accountants. The Company's accounting firm is as set forth in the SEC Reports. To the knowledge and belief of the Company, such accounting firm (i) is a registered public accounting firm as required by the Exchange Act and (ii) shall express its opinion with respect to the financial statements to be included in the Company's Annual Report for the fiscal year ending December 31, 2023. (ee)No Disagreements with Accountants and Lawyers. There are no disagreements of any kind presently existing, or reasonably anticipated by the Company to arise, between the Company and the accountants and lawyers formerly or presently employed by the Company and the Company is current with respect to any fees owed to its accountants and lawyers which could affect the Company's ability to perform any of its obligations under any of the Transaction Documents. (ff) Acknowledgment Regarding Purchasers' Purchase of Securities. The Company acknowledges and agrees that each of the Purchasers is acting solely in the capacity of an arm's length purchaser with respect to the Transaction Documents and the transactions contemplated thereby. The Company further acknowledges that no Purchaser is acting as a financial advisor or fiduciary of the Company (or in any similar capacity) with respect to the Transaction Documents and the transactions contemplated thereby and any advice given by any Purchaser or any of their respective representatives or agents in connection with the Transaction Documents and the transactions contemplated thereby is merely incidental to the Purchasers' purchase of the Securities. The Company further represents to each Purchaser that the Company's decision to enter into this Agreement and the other Transaction Documents has been based solely on the independent evaluation of the transactions contemplated hereby by the Company and its representatives. (gg)Acknowledgment Regarding Purchasers' Trading Activity. Anything in this Agreement or elsewhere herein to the contrary notwithstanding (except for Sections 3.2(f) and 4.13 hereof), it is understood and acknowledged by the Company that: (i) none of the Purchasers has been asked by the Company to agree, nor has any Purchaser agreed, to desist from purchasing or selling, long and/or short, securities of the Company, or "derivative" securities based on securities issued by the Company or to hold the Securities for any specified term, (ii) past or future open market or other transactions by any Purchaser, specifically including, without limitation, Short Sales or "derivative" transactions, before or after the closing of this or future private placement transactions, may negatively impact the market price of the Company's publicly-traded securities, (iii) any Purchaser, and counter-parties in "derivative" transactions to which any such Purchaser is a party, directly or indirectly, presently may have a "short" position in the Common Stock and (iv) each Purchaser shall not be deemed to have any affiliation with or control over any arm's length counter-party in any "derivative" transaction. The Company further understands and acknowledges that (y) one or more Purchasers may engage in hedging activities at various times during the period that the Securities are outstanding, including, without limitation, during the periods that the value of the Warrant Shares deliverable with respect to Securities are being determined, and (z) such hedging activities (if any) could reduce the value of the existing stockholders' equity interests in the Company at and after the time that the hedging activities are being conducted. The Company acknowledges that such aforementioned hedging activities do not constitute a breach of any of the Transaction Documents. (hh)Regulation M Compliance. The Company has not, and to its knowledge no one acting on its behalf has, (i) taken, directly or indirectly, any action designed to cause or to result in the stabilization or manipulation of the price of any security of the Company to facilitate the sale or resale of any of the Securities, (ii) sold, bid for, purchased, or paid any compensation for soliciting purchases of, any of the Securities, or (iii) paid or agreed to pay to any Person any compensation for soliciting another to purchase any other securities of the Company, other than, in the case of clauses (ii) and (iii), compensation paid to the Placement Agent in connection with the placement of the Securities. (ii)FDA. As to each product subject to the jurisdiction of the U.S. Food and Drug Administration ("FDA") under the Federal Food, Drug and Cosmetic Act, as amended, and the regulations thereunder ("FDCA") that is manufactured, packaged, labeled, tested, distributed, sold, and/or marketed by the Company or any of its Subsidiaries as of the date hereof (each such product, a "Pharmaceutical Product"), such Pharmaceutical Product is being manufactured, packaged, labeled, tested, distributed, sold and/or marketed by the Company in compliance with all applicable requirements under FDCA and similar laws, rules and regulations relating to registration, investigational use, premarket clearance, licensure, or application approval, good manufacturing practices, good laboratory practices, good clinical practices, product listing, quotas, labeling, advertising, record keeping and filing of reports, except where the failure to be in compliance would not have a Material Adverse Effect. There is no pending, completed or, to the Company's knowledge, threatened, action (including any lawsuit, arbitration, or legal or administrative or regulatory proceeding, charge, complaint, or investigation) against the Company or any of its Subsidiaries, and none of the Company or any of its Subsidiaries has received any notice, warning letter or other communication from the FDA or any other governmental entity, which (i) contests the premarket clearance, licensure, registration, or approval of, the uses of, the distribution of, the manufacturing or packaging of, the testing of, the sale of, or the labeling and promotion of any Pharmaceutical Product, (ii) withdraws its approval of, requests the recall, suspension, or seizure of, or withdraws or orders the

withdrawal of advertising or sales promotional materials relating to, any Pharmaceutical Product, (iii) imposes a clinical hold on any clinical investigation by the Company or any of its Subsidiaries, (iv) enjoins production at any facility of the Company or any of its Subsidiaries, (v) enters or proposes to enter into a consent decree of permanent injunction with the Company or any of its Subsidiaries, or (vi) otherwise alleges any violation of any laws, rules or regulations by the Company or any of its Subsidiaries, and which, either individually or in the aggregate, would have a Material Adverse Effect. The properties, business and operations of the Company have been and are being conducted in all material respects in accordance with all applicable laws, rules and regulations of the FDA. The Company has not been informed by the FDA that the FDA will prohibit the marketing, sale, license or use in the United States of any product proposed to be developed, produced or marketed by the Company nor has the FDA expressed any concern as to approving or 22 clearing for marketing any product being developed or proposed to be developed by the Company. (jj)Stock Option Plans. Each stock option granted by the Company under the Company's stock option plan was granted (i) in accordance with the terms of the Company's stock option plan and (ii) with an exercise price at least equal to the fair market value of the Common Stock on the date such stock option would be considered granted under GAAP and applicable law. No stock option granted under the Company's stock option plan has been backdated. The Company has not knowingly granted, and there is no and has been no Company policy or practice to knowingly grant, stock options prior to, or otherwise knowingly coordinate the grant of stock options with, the release or other public announcement of material information regarding the Company or its Subsidiaries or their financial results or prospects. (kk)Cybersecurity. (i)(x) There has been no security breach or other compromise of or relating to any of the Company's or any Subsidiary's information technology and computer systems, networks, hardware, software, data (including the data of its respective customers, employees, suppliers, vendors and any third party data maintained by or on behalf of it), equipment or technology (collectively, "IT Systems and Data") and (y) the Company and the Subsidiaries have not been notified of, and has no knowledge of any event or condition that would reasonably be expected to result in, any security breach or other compromise to its IT Systems and Data; (ii) the Company and the Subsidiaries are presently in compliance with all applicable laws or statutes and all judgments, orders, rules and regulations of any court or arbitrator or governmental or regulatory authority, internal policies and contractual obligations relating to the privacy and security of IT Systems and Data and to the protection of such IT Systems and Data from unauthorized use, access, misappropriation or modification, except as would not, individually or in the aggregate, have a Material Adverse Effect; (iii) the Company and the Subsidiaries have implemented and maintained commercially reasonable safeguards to maintain and protect its material confidential information and the integrity, continuous operation, redundancy and security of all IT Systems and Data; and (iv) the Company and the Subsidiaries have implemented backup and disaster recovery technology consistent with industry standards and practices. (ll)Office of Foreign Assets Control. Neither the Company nor any Subsidiary nor, to the Company's knowledge, any director, officer, agent, employee or affiliate of the Company or any Subsidiary is currently subject to any U.S. sanctions administered by the Office of Foreign Assets Control of the U.S. Treasury Department ("OFAC"). (mm)U.S. Real Property Holding Corporation. The Company is not and has never been a U.S. real property holding corporation within the meaning of Section 897 of the Internal Revenue Code of 1986, as amended, and the Company shall so certify upon Purchaser's request. (nn)Bank Holding Company Act. Neither the Company nor any of its Subsidiaries or Affiliates is subject to the Bank Holding Company Act of 1956, as amended (the "BHCA") and to regulation by the Board of Governors of the Federal Reserve System ("Federal Reserve"). Neither the Company nor any of its Subsidiaries or Affiliates owns or controls, directly or indirectly, five percent (5%) or more of the outstanding shares of any class of voting securities or twenty-five percent or more of the total equity of a bank or any entity that is subject to the BHCA and to regulation by the Federal Reserve. Neither the Company nor any of its Subsidiaries or Affiliates exercises a controlling influence over the management or policies of a bank or any entity that is subject to the BHCA and to regulation by the Federal Reserve. (oo)Money Laundering. The operations of the Company and its Subsidiaries are and have been conducted at all times in compliance with applicable financial record-keeping and reporting requirements of the Currency and Foreign Transactions Reporting Act of 1970, as amended, applicable money laundering statutes and applicable rules and regulations thereunder (collectively, the "Money Laundering Laws"), and no Action or Proceeding by or before any court or governmental agency, authority or body or any arbitrator involving the Company or any Subsidiary with respect to the Money Laundering Laws is pending or, to the knowledge of the Company or any Subsidiary, threatened. 3.2Representations and Warranties of the Purchasers. Each Purchaser, for itself and for no other Purchaser, hereby represents and warrants as of the date hereof and as of the Closing Date to the Company as follows (unless as of a specific date therein, in which case they shall be accurate as of such date): (a)Organization; Authority. Such Purchaser is either an individual or an entity duly incorporated or formed, validly existing and in good standing under the laws of the jurisdiction of its incorporation or formation with full right, corporate, partnership, limited liability company or similar power and authority to enter into and to consummate the transactions contemplated by the Transaction Documents and otherwise to carry out its obligations hereunder and thereunder. The execution and delivery of the Transaction Documents and performance by such Purchaser of the transactions contemplated by the Transaction Documents have been duly authorized by all necessary corporate, partnership, limited liability company or similar action, as applicable, on the part of such Purchaser. Each Transaction Document to which it is a party has been duly executed by such Purchaser, and when delivered by such Purchaser in accordance with the terms hereof, will constitute the valid and legally binding obligation of such Purchaser, enforceable against it in accordance with its terms, except (i) as limited by general equitable principles and applicable bankruptcy, insolvency, reorganization, moratorium and other laws of general application affecting enforcement of creditors' rights generally, (ii) as limited by laws relating to the availability of specific performance, injunctive relief or other equitable remedies and (iii) insofar as indemnification and contribution provisions may be limited by applicable law. (b)Understandings or Arrangements. Such Purchaser is acquiring the Securities as principal for its own account and has no direct or indirect arrangement or understandings with any other persons to distribute or regarding the distribution of such Securities (this representation and warranty not limiting such Purchaser's right to sell the Securities pursuant to the Registration Statement or otherwise in compliance with 24 applicable federal and state securities laws). Such Purchaser is acquiring the Securities hereunder in the ordinary course of its business. (c)Purchaser Status. At the time such Purchaser was offered the Securities, it was, and as of the date hereof it is, and on each date on which it exercises any Warrants, it will be an "accredited investor" as defined in Rule 501(a)(1), (a)(2), (a)(3), (a)(7), (a)(8), (a)(9), (a)(12), or (a)(13) under the Securities Act. (d)Experience of Such Purchaser. Such Purchaser, either alone or together with its representatives, has such knowledge, sophistication and experience in business and financial matters so as to be capable of evaluating the merits and risks of the prospective investment in the Securities, and has so evaluated the merits and risks of such investment. Such Purchaser is able to bear the economic risk of an investment in the Securities and, at the present time, is able to afford a complete loss of such investment. (e)Access to Information. Such Purchaser acknowledges that it has had the opportunity to review the Transaction Documents (including all exhibits and schedules thereto) and the SEC Reports and has been afforded (i) the opportunity to ask such questions as it has deemed necessary of, and to receive answers from, representatives of the Company concerning the terms and conditions of the offering of the Securities and the merits and risks of investing in the Securities; (ii) access to information about the Company and its financial condition, results of operations, business, properties, management and prospects sufficient to enable it to evaluate its investment; and (iii) the opportunity to obtain such additional information that the Company possesses or can acquire without unreasonable effort or expense that is necessary to make an informed investment decision with respect to the investment. Such Purchaser acknowledges and agrees that neither the Placement Agent nor any Affiliate of the Placement Agent has provided such Purchaser with any information or advice with respect to the Securities nor is such information or advice necessary or desired. Neither the Placement Agent nor any Affiliate has made or makes any representation as to the Company or the quality of the Securities and the Placement Agent and any Affiliate may have acquired non-public information with respect to the Company which such Purchaser agrees need not be provided to it. In connection with the issuance of the Securities to such Purchaser, neither the Placement Agent nor any of its Affiliates has acted as a financial advisor or fiduciary to such Purchaser. (f)Certain Transactions and Confidentiality. Other than consummating the transactions contemplated hereunder, such Purchaser has not, nor has any Person acting on behalf of or pursuant to any understanding with such Purchaser, directly or indirectly executed any purchases or sales, including Short Sales, of the securities of the Company during the period commencing as of the time that such Purchaser first received definitive pricing terms from the Company or any other Person representing the Company setting forth the material pricing terms of the transactions contemplated hereunder and ending immediately prior to the execution hereof. Notwithstanding the foregoing, in the case of a Purchaser that is a multi-managed investment vehicle whereby separate portfolio managers manage separate portions of such Purchaser's assets and the portfolio managers have no direct knowledge of the investment decisions made by the portfolio managers managing other portions of such

Purchaser's assets, the representation set forth above shall only apply with respect to the portion of assets managed by the portfolio manager that made the investment decision to purchase the Securities covered by this Agreement. Other than to other Persons party to this Agreement or to such Purchaser's representatives, including, without limitation, its officers, directors, partners, legal and other advisors, employees, agents and Affiliates, such Purchaser has maintained the confidentiality of all disclosures made to it in connection with this transaction (including the existence and terms of this transaction). Notwithstanding the foregoing, for the avoidance of doubt, nothing contained herein shall constitute a representation or warranty, or preclude any actions, with respect to locating or borrowing shares in order to effect Short Sales or similar transactions in the future. The Company acknowledges and agrees that the representations contained in this Section 3.2 shall not modify, amend or affect such Purchaser's right to rely on the Company's representations and warranties contained in this Agreement or any representations and warranties contained in any other Transaction Document or any other document or instrument executed and/or delivered in connection with this Agreement or the consummation of the transactions contemplated hereby. Notwithstanding the foregoing, for the avoidance of doubt, nothing contained herein shall constitute a representation or warranty, or preclude any actions, with respect to locating or borrowing shares in order to effect Short Sales or similar transactions in the future.

**ARTICLE IV. OTHER AGREEMENTS OF THE PARTIES**

**4.1 Warrant Shares.** If all or any portion of a Warrant is exercised at a time when there is an effective registration statement to cover the issuance or resale of the Warrant Shares or if the Warrant is exercised via cashless exercise, the Warrant Shares issued pursuant to any such exercise shall be issued free of all legends. If at any time following the date hereof the Registration Statement (or any subsequent registration statement registering the sale or resale of the Warrant Shares) is not effective or is not otherwise available for the sale or resale of the Warrant Shares, the Company shall immediately notify the holders of the Warrants in writing that such registration statement is not then effective and thereafter shall promptly notify such holders when the registration statement is effective again and available for the sale or resale of the Warrant Shares (it being understood and agreed that the foregoing shall not limit the ability of the Company to issue, or any Purchaser to sell, any of the Warrant Shares in compliance with applicable federal and state securities laws). The Company shall use best efforts to keep a registration statement (including the Registration Statement) registering the issuance or resale of the Warrant Shares effective during the term of the Warrants.

**4.2 Furnishing of Information.** Until the earliest of the time that (i) no Purchaser owns Securities or (ii) the Warrants have expired, the Company covenants to timely file (or obtain extensions in respect thereof and file within the applicable grace period) all reports required to be filed by the Company after the date hereof pursuant to the Exchange Act even if the Company is not then subject to the reporting requirements of the Exchange Act.

**4.3 Integration.** The Company shall not sell, offer for sale or solicit offers to buy or otherwise negotiate in respect of any security (as defined in Section 2 of the Securities Act) that would be integrated with the offer or sale of the Securities for purposes of the rules and regulations of any Trading Market such that it would require shareholder approval prior to the closing of such other transaction unless shareholder approval is obtained before the closing of such subsequent transaction.

**4.4 Securities Laws Disclosure; Publicity.** The Company shall (a) by the Disclosure Time, issue a press release disclosing the material terms of the transactions contemplated hereby, and (b) file a Current Report on Form 8-K, including the Transaction Documents as exhibits thereto, with the Commission within the time required by the Exchange Act. From and after the issuance of such press release, the Company represents to the Purchasers that it shall have publicly disclosed all material, non-public information delivered to any of the Purchasers by the Company or any of its Subsidiaries, or any of their respective officers, directors, employees, Affiliates or agents, including, without limitation, the Placement Agent, in connection with the transactions contemplated by the Transaction Documents. In addition, effective upon the issuance of such press release, the Company acknowledges and agrees that any and all confidentiality or similar obligations under any agreement, whether written or oral, between the Company, any of its Subsidiaries or any of their respective officers, directors, agents, employees, Affiliates or agents, including, without limitation, the Placement Agent, on the one hand, and any of the Purchasers or any of their Affiliates on the other hand, shall terminate and be of no further force or effect. The Company understands and confirms that each Purchaser shall be relying on the foregoing covenant in effecting transactions in securities of the Company. The Company and each Purchaser shall consult with each other in issuing any other press releases with respect to the transactions contemplated hereby, and neither the Company nor any Purchaser shall issue any such press release nor otherwise make any such public statement without the prior consent of the Company, with respect to any press release of any Purchaser, or without the prior consent of each Purchaser, with respect to any press release of the Company, which consent shall not unreasonably be withheld or delayed, except if such disclosure is required by law, in which case the disclosing party shall promptly provide the other party with prior notice of such public statement or communication. Notwithstanding the foregoing, the Company shall not publicly disclose the name of any Purchaser, or include the name of any Purchaser in any filing with the Commission or any regulatory agency or Trading Market, without the prior written consent of such Purchaser, except (a) as required by federal securities law in connection with the filing of final Transaction Documents with the Commission and (b) to the extent such disclosure is required by law or Trading Market regulations, in which case the Company shall provide the Purchasers with prior notice of such disclosure permitted under this clause (b) and reasonably cooperate with such Purchaser regarding such disclosure.

**4.5 Shareholder Rights Plan.** No claim will be made or enforced by the Company or, with the consent of the Company, any other Person, that any Purchaser is an "Acquiring Person" under any control share acquisition, business combination, poison pill (including any distribution under a rights agreement) or similar anti-takeover plan or arrangement in effect or hereafter adopted by the Company, or that any Purchaser could be deemed to trigger the provisions of any such plan or arrangement, by virtue of receiving Securities under the Transaction Documents or under any other agreement between the Company and the Purchasers.

**4.6 Non-Public Information.** Except with respect to the material terms and conditions of the transactions contemplated by the Transaction Documents, which shall be disclosed pursuant to Section 4.4, the Company covenants and agrees that neither it, nor any other Person acting on its behalf will provide any Purchaser or its agents or counsel with any information that constitutes, or the Company reasonably believes constitutes, material non-public information, unless prior thereto such Purchaser shall have consented in writing to the receipt of such information and agreed in writing with the Company to keep such information confidential. The Company understands and confirms that each Purchaser shall be relying on the foregoing covenant in effecting transactions in securities of the Company. To the extent that the Company, any of its Subsidiaries, or any of their respective officers, directors, agents, employees or Affiliates delivers any material, non-public information to a Purchaser without such Purchaser's consent, the Company hereby covenants and agrees that such Purchaser shall not have any duty of confidentiality to the Company, any of its Subsidiaries, or any of their respective officers, directors, employees, Affiliates or agents, including, without limitation, the Placement Agent, or a duty to the Company, any of its Subsidiaries or any of their respective officers, directors, employees, Affiliates or agents, including, without limitation, the Placement Agent, not to trade on the basis of, such material, non-public information, provided that the Purchaser shall remain subject to applicable law. To the extent that any notice provided pursuant to any Transaction Document constitutes, or contains, material, non-public information regarding the Company or any Subsidiaries, the Company shall simultaneously with the delivery of such notice file such notice with the Commission pursuant to a Current Report on Form 8-K. The Company understands and confirms that each Purchaser shall be relying on the foregoing covenant in effecting transactions in securities of the Company.

**4.7 Use of Proceeds.** The Company shall use the net proceeds from the sale of the Securities hereunder for working capital purposes and shall not use such proceeds: (a) for the satisfaction of any portion of the Company's debt (other than payment of trade payables in the ordinary course of the Company's business and prior practices), (b) for the redemption of any Common Stock or Common Stock Equivalents, (c) for the settlement of any outstanding litigation or (d) in violation of FCPA or OFAC regulations.

**4.8 Indemnification of Purchasers.** Subject to the provisions of this Section 4.8, the Company will indemnify and hold each Purchaser and its directors, officers, shareholders, members, partners, employees and agents (and any other Persons with a functionally equivalent role of a Person holding such titles notwithstanding a lack of such title or any other title), each Person who controls such Purchaser (within the meaning of Section 15 of the Securities Act and Section 20 of the Exchange Act), and the directors, officers, shareholders, agents, members, partners or employees (and any other Persons with a functionally equivalent role of a Person holding such titles notwithstanding a lack of such title or any other title) of such controlling persons (each, a "Purchaser Party") harmless from any and all losses, liabilities, obligations, claims, contingencies, damages, costs and expenses, including all judgments, amounts paid in settlements, court costs and reasonable attorneys' fees and costs of investigation that any such Purchaser Party may suffer or incur as a result of or relating to (a) any breach of any of the representations, warranties, covenants or agreements made by the Company in this Agreement or in the other Transaction Documents or (b) any action instituted against the Purchaser Parties in any capacity, or any of them or their respective Affiliates, by any stockholder of the Company who is not an Affiliate of such Purchaser Party, with respect to any of the transactions contemplated by the Transaction Documents unless

such action is solely based upon a material breach of such Purchaser Party's representations, warranties or covenants under the Transaction Documents or any agreements or understandings such Purchaser Party may have with any such stockholder or 28. Any violations by such Purchaser Party of state or federal securities laws or any conduct by such Purchaser Party which is finally judicially determined to constitute fraud, gross negligence or willful misconduct. If any action shall be brought against any Purchaser Party in respect of which indemnity may be sought pursuant to this Agreement, such Purchaser Party shall promptly notify the Company in writing, and, the Company shall have the right to assume the defense thereof with counsel of its own choosing reasonably acceptable to the Purchaser Party. Any Purchaser Party shall have the right to employ separate counsel in any such action and participate in the defense thereof, but the fees and expenses of such counsel shall be at the expense of such Purchaser Party except to the extent that (i) the employment thereof has been specifically authorized by the Company in writing, (ii) the Company has failed after a reasonable period of time to assume such defense and to employ counsel or (iii) in such action there is, in the reasonable opinion of counsel a material conflict on any material issue between the position of the Company and the position of such Purchaser Party, in which case the Company shall be responsible for the reasonable fees and expenses of no more than one such separate counsel. The Company will not be liable to any Purchaser Party under this Agreement (y) for any settlement by a Purchaser Party effected without the Company's prior written consent, which shall not be unreasonably withheld or delayed; or (z) to the extent, but only to the extent that a loss, claim, damage or liability is attributable to any Purchaser Party's breach of any of the representations, warranties, covenants or agreements made by such Purchaser Party in this Agreement or in any other Transaction Documents. The indemnification required by this Section 4.8 shall be made by periodic payments of the amount thereof during the course of the investigation or defense, as and when bills are received or are incurred. The indemnity agreements contained herein shall be in addition to any cause of action or similar right of any Purchaser Party against the Company or others and any liabilities the Company may be subject to pursuant to law. 4.9Reservation of Common Stock. As of the date hereof, the Company has reserved and the Company shall continue to reserve and keep available at all times, free of preemptive rights, a sufficient number of shares of Common Stock for the purpose of enabling the Company to issue Shares pursuant to this Agreement and Warrant Shares pursuant to any exercise of the Warrants. 4.10Listing of Common Stock. The Company hereby agrees to use best efforts to maintain the listing or quotation of the Common Stock on the Trading Market on which it is currently listed, and concurrently with the Closing, the Company shall apply to list or quote all of the Shares and Warrant Shares on such Trading Market and promptly secure the listing of all of the Shares and Warrant Shares on such Trading Market. The Company further agrees, if the Company applies to have the Common Stock traded on any other Trading Market, it will then include in such application all of the Shares and Warrant Shares, and will take such other action as is necessary to cause all of the Shares and Warrant Shares to be listed or quoted on such other Trading Market as promptly as possible. The Company will then take all action reasonably necessary to continue the listing and trading of its Common Stock on a Trading Market and will comply in all respects with the Company's reporting, filing and other obligations under the bylaws or rules of the Trading Market. The Company agrees to maintain the eligibility of the Common Stock for electronic transfer through the Depository Trust Company or another established clearing corporation, including, without limitation, by timely payment of fees to the Depository Trust Company or such other established clearing corporation in connection with such electronic transfer. 29. 4.11Stockholder Approval. The Company shall use its reasonable best efforts hold a special meeting of stockholders on or prior to ninety (90) days after the Closing date for the purpose of obtaining Stockholder Approval with respect to the terms of the Warrants, with the recommendation of the Company's Board of Directors that such proposal is approved, and the Company shall solicit proxies from its stockholders in connection therewith in the same manner as all other management proposals in such proxy statement and all management-appointed proxyholders shall vote their proxies in favor of such proposal. If the Company does not obtain Stockholder Approval with respect to the terms of the Warrants at the first special meeting of the stockholders, the Company shall call a meeting every sixty (60) days thereafter to seek such Stockholder Approval until the date on which Stockholder Approval is obtained or the Warrants are no longer outstanding. 4.12Subsequent Equity Sales. (a)From the date hereof until 60 days after the Closing Date, neither the Company nor any Subsidiary shall (i) issue, enter into any agreement to issue or announce the issuance or proposed issuance of any shares of Common Stock or Common Stock Equivalents or (ii) file any registration statement or any amendment or supplement thereto other than the Prospectus Supplement or filing a registration statement on Form S-8 in connection with any employee benefit plan. (b)From the date hereof until 180 days after the Closing Date, the Company shall be prohibited from effecting or entering into an agreement to effect any issuance by the Company or any of its Subsidiaries of Common Stock or Common Stock Equivalents (or a combination of units thereof) involving a Variable Rate Transaction. "Variable Rate Transaction" means a transaction in which the Company (i) issues or sells any debt or equity securities that are convertible into, exchangeable or exercisable for, or include the right to receive additional shares of Common Stock either (A) at a conversion price, exercise price or exchange rate or other price that is based upon and/or varies with the trading prices of or quotations for the shares of Common Stock at any time after the initial issuance of such debt or equity securities, or (B) with a conversion, exercise or exchange price that is subject to being reset at some future date after the initial issuance of such debt or equity security or upon the occurrence of specified or contingent events directly or indirectly related to the business of the Company or the market for the Common Stock (other than any reset to the exercise price of any Common Stock purchase warrants existing on or before the date hereof) or (ii) enters into, or effects a transaction under, any agreement, including, but not limited to, an equity line of credit or an "at-the-market offering", whereby the Company may issue securities at a future determined price regardless of whether shares pursuant to such agreement have actually been issued and regardless of whether such agreement is subsequently canceled; provided, however, that, following the three (3) month anniversary of the Closing Date, the Outstanding Facilities shall not be deemed a Variable Rate Transaction. No amendments or modifications shall be made to the Outstanding Facilities from the date hereof until 180 days after the Closing Date. Any Purchaser shall be entitled to obtain injunctive relief against the Company to preclude any such issuance, which remedy shall be in addition to any right to collect damages. 30. (c)Notwithstanding the foregoing, this Section 4.12 shall not apply in respect of an Exempt Issuance, except that no Variable Rate Transaction shall be an Exempt Issuance. 4.13Equal Treatment of Purchasers. No consideration (including any modification of the Transaction Documents) shall be offered or paid to any Person to amend or consent to a waiver or modification of any provision of the Transaction Documents unless the same consideration is also offered to all of the parties to the Transaction Documents. For clarification purposes, this provision constitutes a separate right granted to each Purchaser by the Company and negotiated separately by each Purchaser, and is intended for the Company to treat the Purchasers as a class and shall not in any way be construed as the Purchasers acting in concert or as a group with respect to the purchase, disposition or voting of Securities or otherwise. 4.14Certain Transactions and Confidentiality. Each Purchaser, severally and not jointly with the other Purchasers, covenants that neither it, nor any Affiliate acting on its behalf or pursuant to any understanding with it will execute any purchases or sales, including Short Sales, of any of the Company's securities during the period commencing with the execution of this Agreement and ending at such time that the transactions contemplated by this Agreement are first publicly announced pursuant to the initial press release as described in Section 4.4. Each Purchaser, severally and not jointly with the other Purchasers, covenants that until such time as the transactions contemplated by this Agreement are publicly disclosed by the Company pursuant to the initial press release as described in Section 4.4, such Purchaser will maintain the confidentiality of the existence and terms of this transaction and the information included in the Disclosure Schedules (other than as disclosed to its legal and other representatives). Notwithstanding the foregoing and notwithstanding anything contained in this Agreement to the contrary, the Company expressly acknowledges and agrees that (i) no Purchaser makes any representation, warranty or covenant hereby that it will not engage in effecting transactions in any securities of the Company after the time that the transactions contemplated by this Agreement are first publicly announced pursuant to the initial press release as described in Section 4.4, (ii) no Purchaser shall be restricted or prohibited from effecting any transactions in any securities of the Company in accordance with applicable securities laws from and after the time that the transactions contemplated by this Agreement are first publicly announced pursuant to the initial press release as described in Section 4.4 and (iii) no Purchaser shall have any duty of confidentiality or duty not to trade in the securities of the Company to the Company, any of its Subsidiaries, or any of their respective officers, directors, employees, Affiliates or agent, including, without limitation, the Placement Agent after the issuance of the initial press release as described in Section 4.4. Notwithstanding the foregoing, in the case of a Purchaser that is a multi-managed investment vehicle whereby separate portfolio managers manage separate portions of such Purchaser's assets and the portfolio managers have no direct knowledge of the investment decisions made by the portfolio managers managing other portions of such Purchaser's assets, the covenant set forth above shall only apply with respect to the portion of assets managed by the portfolio manager that made the investment decision to purchase the Securities covered by this Agreement. 4.15Acknowledgment of Dilution. The

Company acknowledges that the issuance of the Securities may result in dilution of the outstanding shares of Common Stock, which dilution may be substantial under certain market conditions. The Company further acknowledges that its obligations under the Transaction Documents, including, without limitation, its obligation to issue 31A the Shares and Warrant Shares pursuant to the Transaction Documents, are unconditional and absolute and not subject to any right of set off, counterclaim, delay or reduction, regardless of the effect of any such dilution or any claim the Company may have against any Purchaser and regardless of the dilutive effect that such issuance may have on the ownership of the other stockholders of the Company. 4.16Exercise Procedures. The form of Notice of Exercise included in the Warrants set forth the totality of the procedures required of the Purchasers in order to exercise the Warrants. No additional legal opinion, other information or instructions shall be required of the Purchasers to exercise their Warrants. Without limiting the preceding sentences, no ink-original Notice of Exercise shall be required, nor shall any medallion guarantee (or other type of guarantee or notarization) of any Notice of Exercise form be required in order to exercise the Warrants. The Company shall honor exercises of the Warrants and shall deliver Warrant Shares in accordance with the terms, conditions and time periods set forth in the Transaction Documents. 4.17Lock-Up Agreements. The Company shall not amend, modify, waive or terminate any provision of any of the Lock-Up Agreements except to extend the term of the lock-up period and shall enforce the provisions of each Lock-Up Agreement in accordance with its terms. If any party to a Lock-Up Agreement breaches any provision of a Lock-Up Agreement, the Company shall promptly use its best efforts to seek specific performance of the terms of such Lock-Up Agreement. ARTICLE V.MISCELLANEOUS 5.1Termination. This Agreement may be terminated by any Purchaser, as to such Purchaser's obligations hereunder only and without any effect whatsoever on the obligations between the Company and the other Purchasers, by written notice to the other parties, if the Closing has not been consummated on or before the fifth (5th) Trading Day following the date hereof; provided, however, that no such termination will affect the right of any party to sue for any breach by any other party (or parties). 5.2Fees and Expenses. Except as expressly set forth in the Transaction Documents to the contrary, each party shall pay the fees and expenses of its advisers, counsel, accountants and other experts, if any, and all other expenses incurred by such party incident to the negotiation, preparation, execution, delivery and performance of this Agreement. The Company shall pay all Transfer Agent fees (including, without limitation, any fees required for same-day processing of any instruction letter delivered by the Company and any exercise notice delivered by a Purchaser), stamp taxes and other taxes and duties levied in connection with the delivery of any Securities to the Purchasers. 5.3Entire Agreement. The Transaction Documents, together with the exhibits and schedules thereto, the Preliminary Prospectus and the Prospectus Supplement, contain the entire understanding of the parties with respect to the subject matter hereof and thereof and supersede all prior agreements and understandings, oral or written, with respect to such matters, which the parties acknowledge have been merged into such documents, exhibits and schedules. 32A 5.4Notices. Any and all notices or other communications or deliveries required or permitted to be provided hereunder shall be in writing and shall be deemed given and effective on the earliest of: (a) the time of transmission, if such notice or communication is delivered via email attachment at the email address as set forth on the signature pages attached hereto at or prior to 5:30 p.m. (New York City time) on a Trading Day, (b) the next Trading Day after the time of transmission, if such notice or communication is delivered via email attachment at the email address as set forth on the signature pages attached hereto on a day that is not a Trading Day or later than 5:30 p.m. (New York City time) on any Trading Day, (c) the second (2nd) Trading Day following the date of mailing, if sent by U.S. nationally recognized overnight courier service or (d) upon actual receipt by the party to whom such notice is required to be given. The address for such notices and communications shall be as set forth on the signature pages attached hereto. 5.5Amendments; Waivers. No provision of this Agreement may be waived, modified, supplemented or amended except in a written instrument signed, in the case of an amendment, by the Company and Purchasers which purchased at least 50.1% in interest of the Shares and Pre-Funded Warrants based on the initial Subscription Amounts hereunder (or, prior to the Closing, the Company and each Purchaser) or, in the case of a waiver, by the party against whom enforcement of any such waived provision is sought, provided that if any amendment, modification or waiver disproportionately and adversely impacts a Purchaser (or multiple Purchasers), the consent of such disproportionately impacted Purchaser (or at least 50.1% in interest of such multiple Purchasers) shall also be required. No waiver of any default with respect to any provision, condition or requirement of this Agreement shall be deemed to be a continuing waiver in the future or a waiver of any subsequent default or a waiver of any other provision, condition or requirement hereof, nor shall any delay or omission of any party to exercise any right hereunder in any manner impair the exercise of any such right. Any proposed amendment or waiver that disproportionately, materially and adversely affects the rights and obligations of any Purchaser relative to the comparable rights and obligations of the other Purchasers shall require the prior written consent of such adversely affected Purchaser. Any amendment effected in accordance with this Section 5.5 shall be binding upon each Purchaser and holder of Securities and the Company. 5.6Headings. The headings herein are for convenience only, do not constitute a part of this Agreement and shall not be deemed to limit or affect any of the provisions hereof. 5.7Successors and Assigns. This Agreement shall be binding upon and inure to the benefit of the parties and their successors and permitted assigns. The Company may not assign this Agreement or any rights or obligations hereunder without the prior written consent of each Purchaser (other than by merger). Any Purchaser may assign any or all of its rights under this Agreement to any Person to whom such Purchaser assigns or transfers any Securities, provided that such transferee agrees in writing to be bound, with respect to the transferred Securities, by the provisions of the Transaction Documents that apply to the "Purchasers." 5.8No Third-Party Beneficiaries. The Placement Agent shall be the third-party beneficiary of the representations and warranties of the Company in Section 3.1 and the representations and warranties of the Purchasers in Section 3.2. This Agreement is intended for the benefit of the parties hereto and their respective successors and permitted assigns and is not for the benefit of, nor may any provision hereof be enforced by, any other Person, except as otherwise set forth in Section 4.8 and this Section 5.8. 33A 5.9Governing Law. All questions concerning the construction, validity, enforcement and interpretation of the Transaction Documents shall be governed by and construed and enforced in accordance with the internal laws of the State of New York, without regard to the principles of conflicts of law thereof. Each party agrees that all legal Proceedings concerning the interpretations, enforcement and defense of the transactions contemplated by this Agreement and any other Transaction Documents (whether brought against a party hereto or its respective affiliates, directors, officers, shareholders, partners, members, employees or agents) shall be commenced exclusively in the state and federal courts sitting in the City of New York. Each party hereby irrevocably submits to the exclusive jurisdiction of the state and federal courts sitting in the City of New York, Borough of Manhattan for the adjudication of any dispute hereunder or in connection herewith or with any transaction contemplated hereby or discussed herein (including with respect to the enforcement of any of the Transaction Documents), and hereby irrevocably waives, and agrees not to assert in any Action or Proceeding, any claim that it is not personally subject to the jurisdiction of any such court, that such Action or Proceeding is improper or is an inconvenient venue for such Proceeding. Each party hereby irrevocably waives personal service of process and consents to process being served in any such Action or Proceeding by mailing a copy thereof via registered or certified mail or overnight delivery (with evidence of delivery) to such party at the address in effect for notices to it under this Agreement and agrees that such service shall constitute good and sufficient service of process and notice thereof. Nothing contained herein shall be deemed to limit in any way any right to serve process in any other manner permitted by law. If any party shall commence an Action or Proceeding to enforce any provisions of the Transaction Documents, then, in addition to the obligations of the Company under Section 4.8, the prevailing party in such Action or Proceeding shall be reimbursed by the non-prevailing party for its reasonable attorneys' fees and other costs and expenses incurred with the investigation, preparation and prosecution of such Action or Proceeding. 5.10Survival. The representations and warranties contained herein shall survive the Closing and the delivery of the Securities. 5.11Execution. This Agreement may be executed in two or more counterparts, all of which when taken together shall be considered one and the same agreement and shall become effective when counterparts have been signed by each party and delivered to each other party, it being understood that the parties need not sign the same counterpart. In the event that any signature is delivered by e-mail delivery of a "pdf" format data file, such signature shall create a valid and binding obligation of the party executing (or on whose behalf such signature is executed) with the same force and effect as if such "pdf" signature page were an original thereof. 5.12Severability. If any term, provision, covenant or restriction of this Agreement is held by a court of competent jurisdiction to be invalid, illegal, void or unenforceable, the remainder of the terms, provisions, covenants and restrictions set forth herein shall remain in full force and effect and shall in no way be affected, impaired or invalidated, and the parties hereto shall use their commercially reasonable efforts to find and employ an alternative means to achieve the same or substantially the same result as that contemplated by such term, provision, covenant or restriction. It is hereby stipulated and declared to be the intention of the parties that they would have executed the remaining terms, provisions, covenants and restrictions without including any of such that may be hereafter declared invalid, illegal, void or unenforceable.

34Â 5.13Rescission and Withdrawal Right. Notwithstanding anything to the contrary contained in (and without limiting any similar provisions of) any of the other Transaction Documents, whenever any Purchaser exercises a right, election, demand or option under a Transaction Document and the Company does not timely perform its related obligations within the periods therein provided, then such Purchaser may rescind or withdraw, in its sole discretion from time to time upon written notice to the Company, any relevant notice, demand or election in whole or in part without prejudice to its future actions and rights; provided, however, that, in the case of a rescission of an exercise of a Warrant, the applicable Purchaser shall be required to return any shares of Common Stock subject to any such rescinded exercise notice concurrently with the return to such Purchaser of the aggregate exercise price paid to the Company for such shares and the restoration of such Purchaser's right to acquire such shares pursuant to such Purchaser's Warrant (including, issuance of a replacement warrant certificate evidencing such restored right). 5.14Replacement of Securities. If any certificate or instrument evidencing any Securities is mutilated, lost, stolen or destroyed, the Company shall issue or cause to be issued in exchange and substitution for and upon cancellation thereof (in the case of mutilation), or in lieu of and substitution therefor, a new certificate or instrument, but only upon receipt of evidence reasonably satisfactory to the Company of such loss, theft or destruction. The applicant for a new certificate or instrument under such circumstances shall also pay any reasonable third-party costs (including customary indemnity) associated with the issuance of such replacement Securities. 5.15Remedies. In addition to being entitled to exercise all rights provided herein or granted by law, including recovery of damages, each of the Purchasers and the Company will be entitled to specific performance under the Transaction Documents. The parties agree that monetary damages may not be adequate compensation for any loss incurred by reason of any breach of obligations contained in the Transaction Documents and hereby agree to waive and not to assert in any Action for specific performance of any such obligation the defense that a remedy at law would be adequate. 5.16Payment Set Aside. To the extent that the Company makes a payment or payments to any Purchaser pursuant to any Transaction Document or a Purchaser enforces or exercises its rights thereunder, and such payment or payments or the proceeds of such enforcement or exercise or any part thereof are subsequently invalidated, declared to be fraudulent or preferential, set aside, recovered from, disgorged by or are required to be refunded, repaid or otherwise restored to the Company, a trustee, receiver or any other Person under any law (including, without limitation, any bankruptcy law, state or federal law, common law or equitable cause of action), then to the extent of any such restoration the obligation or part thereof originally intended to be satisfied shall be revived and continued in full force and effect as if such payment had not been made or such enforcement or setoff had not occurred. 5.17Independent Nature of Purchasers' Obligations and Rights. The obligations of each Purchaser under any Transaction Document are several and not joint with the obligations of any other Purchaser, and no Purchaser shall be responsible in any way for the performance or non-performance of the obligations of any other Purchaser under any Transaction Document. Nothing contained herein or in any other Transaction Document, and no action taken by any Purchaser pursuant hereto or thereto, shall be deemed to constitute the Purchasers as a partnership, an association, a joint venture or any other kind of entity, or create a presumption that the Purchasers are in any way acting in concert or as a group with respect to such obligations or the transactions contemplated by the Transaction Documents. Each Purchaser shall be entitled to independently protect and enforce its rights including, without limitation, the rights arising out of this Agreement or out of the other Transaction Documents, and it shall not be necessary for any other Purchaser to be joined as an additional party in any Proceeding for such purpose. Each Purchaser has been represented by its own separate legal counsel in its review and negotiation of the Transaction Documents. For reasons of administrative convenience only, each Purchaser and its respective counsel have chosen to communicate with the Company through EGS. EGS does not represent any of the Purchasers and only represents the Placement Agent. The Company has elected to provide all Purchasers with the same terms and Transaction Documents for the convenience of the Company and not because it was required or requested to do so by any of the Purchasers. It is expressly understood and agreed that each provision contained in this Agreement and in each other Transaction Document is between the Company and a Purchaser, solely, and not between the Company and the Purchasers collectively and not between and among the Purchasers. 5.18Liquidated Damages. The Company's obligations to pay any partial liquidated damages or other amounts owing under the Transaction Documents is a continuing obligation of the Company and shall not terminate until all unpaid partial liquidated damages and other amounts have been paid notwithstanding the fact that the instrument or security pursuant to which such partial liquidated damages or other amounts are due and payable shall have been canceled. 5.19Saturdays, Sundays, Holidays, etc. If the last or appointed day for the taking of any action or the expiration of any right required or granted herein shall not be a Business Day, then such action may be taken or such right may be exercised on the next succeeding Business Day. 5.20Construction. The parties agree that each of them and/or their respective counsel have reviewed and had an opportunity to revise the Transaction Documents and, therefore, the normal rule of construction to the effect that any ambiguities are to be resolved against the drafting party shall not be employed in the interpretation of the Transaction Documents or any amendments thereto. In addition, each and every reference to share prices and shares of Common Stock in any Transaction Document shall be subject to adjustment for reverse and forward stock splits, stock dividends, stock combinations and other similar transactions of the Common Stock that occur after the date of this Agreement. 5.21WAIVER OF JURY TRIAL. IN ANY ACTION, SUIT, OR PROCEEDING IN ANY JURISDICTION BROUGHT BY ANY PARTY AGAINST ANY OTHER PARTY, THE PARTIES EACH KNOWINGLY AND INTENTIONALLY, TO THE GREATEST EXTENT PERMITTED BY APPLICABLE LAW, HEREBY ABSOLUTELY, UNCONDITIONALLY, IRREVOCABLY AND EXPRESSLY WAIVES FOREVER TRIAL BY JURY. (Signature Pages Follow) 36 IN WITNESS WHEREOF, the parties hereto have caused this Securities Purchase Agreement to be duly executed by their respective authorized signatories as of the date first indicated above. aptevo therapeutics inc. Address for Notice: By: Name: Title: With a copy to (which shall not constitute notice): Email: [REMAINDER OF PAGE INTENTIONALLY LEFT BLANK SIGNATURE PAGE FOR PURCHASER FOLLOWS] 37A [PURCHASER SIGNATURE PAGES TO APVO SECURITIES PURCHASE AGREEMENT] IN WITNESS WHEREOF, the undersigned have caused this Securities Purchase Agreement to be duly executed by their respective authorized signatories as of the date first indicated above. Name of Purchaser: Signature of Authorized Signatory of Purchaser: Name of Authorized Signatory: Title of Authorized Signatory: Email Address of Authorized Signatory: Address for Notice to Purchaser: Address for Delivery of Securities to Purchaser (if not same as address for notice): Subscription Amount: \$ Shares: Pre-Funded Warrant Shares: Beneficial Ownership Blocker i 4.99% or i 9.99% Common Warrant Shares: Beneficial Ownership Blocker i 4.99% or i 9.99% EIN Number: Notwithstanding anything contained in this Agreement to the contrary, by checking this box (i) the obligations of the above-signed to purchase the securities set forth in this Agreement to be purchased from the Company by the above-signed, and the obligations of the Company to sell such securities to the above-signed, shall be unconditional and all conditions to Closing shall be disregarded, (ii) the Closing shall occur on the first (1st) Trading Day following the date of this Agreement(the second (2nd) Trading Day following the date hereof in the event this Agreement is signed on a day that is not a Trading Day or after 4:01 p.m. (New York City time) and before midnight (New York City time) on a Trading Day) and (iii) any condition to Closing contemplated by this Agreement (but prior to being disregarded by clause (i) above) that required delivery by the Company or the above-signed of any agreement, instrument, certificate or the like or purchase price (as applicable) shall no longer be a condition and shall instead be an unconditional obligation of the Company or the above-signed (as applicable) to deliver such agreement, instrument, certificate or the like or purchase price (as applicable) to such other party on the Closing Date. [SIGNATURE PAGES CONTINUE] 38A EX-10.49 6 apvo-ex10\_49.htm EX-10.49 EX-10.49 EXHIBIT 10.49 PLACEMENT AGENCY AGREEMENT , 2024 Roth Capital Partners, LLC 888 San Clemente Drive, Suite 400 Newport Beach, CA 92660 Ladies and Gentlemen: Introduction. Subject to the terms and conditions herein (this "Agreement"), Aptevo Therapeutics Inc. a Delaware corporation (the "Company"), hereby agrees to sell up to an aggregate of \$ of registered securities (the "Securities") of the Company, including, but not limited to, shares (the "Shares") of the Company's common stock, \$0.001 par value per share (the "Common Stock"), pre-funded common stock purchase warrants to purchase up to an aggregate of shares of Common Stock (the "Pre-Funded Warrants"), and common stock purchase warrants to purchase up to an aggregate of shares of Common Stock (the "Common Warrants" and, collectively with the Pre-Funded Warrants, the "Warrants"), and together with the Shares and the shares of common stock issuable upon exercise of the Warrants, the "Securities") directly to various investors (each, an "Investor" and, collectively, the "Investors") through Roth Capital Partners, LLC (the "Placement Agent") as placement agent. The documents executed and delivered by the Company and the Investors in connection with the Offering (as defined below), including, without limitation, a securities

purchase agreement (the "Purchase Agreement"), shall be collectively referred to herein as the "Transaction Documents." The purchase price to the Investors for each Share is \$ \_\_\_\_\_ and the exercise price to the Investors for each share of common stock issuable upon exercise of the Common Warrants is \$ \_\_\_\_\_. The Placement Agent may retain other brokers or dealers to act as sub-agents or selected-dealers on its behalf in connection with the Offering. The Company hereby confirms its agreement with the Placement Agent as follows:

Section 1. Agreement to Act as Placement Agent.

(a) On the basis of the representations, warranties and agreements of the Company herein contained, and subject to all the terms and conditions of this Agreement, the Placement Agent shall be the exclusive placement agent in connection with the offering and sale by the Company of the Securities pursuant to the Company's registration statement on Form S-1 (File No. 333-\_\_\_\_\_) (the "Registration Statement"), with the terms of such offering (the "Offering") to be subject to market conditions and negotiations between the Company, the Placement Agent and the prospective Investors. The Placement Agent will act on a reasonable best efforts basis and the Company agrees and acknowledges that there is no guarantee of the successful placement of the Securities, or any portion thereof, in the prospective Offering. Under no circumstances will the Placement Agent or any of its "Affiliates" (as defined below) be obligated to underwrite or purchase any of the Securities for its own account or otherwise provide any financing. The Placement Agent shall act solely as the Company's agent and not as principal. The Placement Agent shall have no authority to bind the Company with respect to any prospective offer to purchase Securities and the Company shall have the sole right to accept offers to purchase Securities and may reject any such offer, in whole or in part. Subject to the terms and conditions hereof, payment of the purchase price for, and delivery of, the Securities shall be made at one or more closings (each a "Closing" and the date on which each Closing occurs, a "Closing Date"). As compensation for services rendered, on each Closing Date, the Company shall pay to the Placement Agent the fees and expenses set forth below:

(i) A cash fee (the "Cash Fee") equal to 7.0% of the gross proceeds received by the Company from the sale of the Securities at the closing of the Offering (the "Closing").

(ii) The Company also agrees to reimburse Placement Agent's expenses (with supporting invoices/receipts) of \$100,000 payable immediately upon the Closing of the Offering.

(b) The term of the Placement Agent's exclusive engagement will be until the completion of the Offering (the "Exclusive Term"); provided, however, that a party hereto may terminate the engagement with respect to itself at any time upon 10 days written notice to the other parties. Notwithstanding anything to the contrary contained herein, the provisions concerning confidentiality, indemnification and contribution contained herein and the Company's obligations contained in the indemnification provisions will survive any expiration or termination of this Agreement, and the Company's obligation to pay fees actually earned and payable and to reimburse expenses actually incurred and reimbursable pursuant to Section 1 hereof and which are permitted to be reimbursed under FINRA Rule 5110(f)(2)(D), will survive any expiration or termination of this Agreement. Nothing in this Agreement shall be construed to limit the ability of the Placement Agent or its Affiliates to pursue, investigate, analyze, invest in, or engage in investment banking, financial advisory or any other business relationship with Persons (as defined below) other than the Company. As used herein (i) "Persons" means an individual or corporation, partnership, trust, incorporated or unincorporated association, joint venture, limited liability company, joint stock company, government (or an agency or subdivision thereof) or other entity of any kind and (ii) "Affiliate" means any Person that, directly or indirectly through one or more intermediaries, controls or is controlled by or is under common control with a Person as such terms are used in and construed under Rule 405 under the Securities Act of 1933, as amended (the "Securities Act").

Section 2. Representations, Warranties and Covenants of the Company. The Company hereby represents, warrants and covenants to the Placement Agent as of the date hereof, and as of each Closing Date, as follows:

(a) Securities Law Filings. The Company has filed with the Securities and Exchange Commission (the "Commission") the Registration Statement under the Securities Act, which was filed on \_\_\_\_\_, 2024 and declared effective on \_\_\_\_\_, 2024 for the registration of the Securities under the Securities Act. Following the determination of pricing among the Company and the prospective Investors introduced to the Company by Placement Agent, the Company will file with the Commission pursuant to Rules 430A and 424(b) under the Securities Act, and the rules and regulations (the "Rules and Regulations") of the Commission 2A promulgated thereunder, a final prospectus relating to the placement of the Securities, their respective pricings and the plan of distribution thereof and will advise the Placement Agent of all further information (financial and other) with respect to the Company required to be set forth therein. Such registration statement, at any given time, including the exhibits thereto filed at such time, as amended at such time, is hereinafter called the "Registration Statement"; such prospectus in the form in which it appears in the Registration Statement at the time of effectiveness, together with any preliminary prospectus supplement relating to the Offering, is hereinafter called the "Base Prospectus"; the preliminary prospectus supplement in the form in which it was filed with the Commission pursuant to Rule 424(b) is hereinafter called the "Preliminary Prospectus"; and the final prospectus, in the form in which it will be filed with the Commission pursuant to Rules 430A and/or 424(b) (including the Base Prospectus as it may be amended or supplemented) is hereinafter called the "Final Prospectus." The Registration Statement at the time it originally became effective is hereinafter called the "Original Registration Statement." Any reference in this Agreement to the Registration Statement, the Original Registration Statement, the Base Prospectus, the Preliminary Prospectus or the Final Prospectus shall be deemed to refer to and include the documents incorporated by reference therein (the "Incorporated Documents"), if any, which were or are filed under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), at any given time, as the case may be; and any reference in this Agreement to the terms "amend," "amendment" or "supplement" with respect to the Registration Statement, the Original Registration Statement, the Base Prospectus, the Preliminary Prospectus or the Final Prospectus shall be deemed to refer to and include the filing of any document under the Exchange Act after the date of this Agreement, or the issue date of the Base Prospectus, the Preliminary Prospectus or the Final Prospectus, as the case may be, deemed to be incorporated therein by reference. All references in this Agreement to financial statements and schedules and other information which is "contained," "included," "described," "referenced," "set forth" or "stated" in the Registration Statement, the Base Prospectus, the Preliminary Prospectus Supplement or the Final Prospectus (and all other references of like import) shall be deemed to mean and include all such financial statements and schedules and other information which is or is deemed to be incorporated by reference in the Registration Statement, the Base Prospectus, the Preliminary Prospectus or the Final Prospectus, as the case may be. As used in this paragraph and elsewhere in this Agreement, "Time of Sale Disclosure Package" means the Base Prospectus, any preliminary prospectus, any subscription agreement between the Company and the Investors, and any issuer free writing prospectus as defined in Rule 433 of the Act (each, an "Issuer Free Writing Prospectus"), if any, that the parties hereto shall hereafter expressly agree in writing to treat as part of the Time of Sale Disclosure Package. The term "any Prospectus" shall mean, as the context requires, the Base Prospectus, the Final Prospectus, and any supplement to either thereof. The Company has not received any notice that the Commission has issued or intends to issue a stop order suspending the effectiveness of the Registration Statement or the use of the Base Prospectus or the Prospectus or intends to commence a proceeding for any such purpose.

(b) Assurances. The Original Registration Statement, as amended, (and any further documents to be filed with the Commission) contains all exhibits and schedules as required by the Securities Act. Each of the Registration Statement and any post-effective amendment thereto, at the time it became effective, complied in all material respects with the Securities 3A Act and the applicable Rules and Regulations and did not contain any untrue statement of a material fact or omit to state a material fact required to be stated therein or necessary to make the statements therein not misleading. The Base Prospectus, and the Final Prospectus, each as of its respective date, comply or will comply in all material respects with the Securities Act and the applicable Rules and Regulations. Each of the Base Prospectus and the Final Prospectus, as amended or supplemented, did not and will not contain as of the date thereof any untrue statement of a material fact or omit to state a material fact necessary in order to make the statements therein, in light of the circumstances under which they were made, not misleading. The Incorporated Documents, when they were filed with the Commission, conformed in all material respects to the requirements of the Exchange Act and the applicable Rules and Regulations promulgated thereunder, and none of such documents, when they were filed with the Commission, contained any untrue statement of a material fact or omitted to state a material fact necessary to make the statements therein (with respect to Incorporated Documents incorporated by reference in the Base Prospectus or Final Prospectus), in light of the circumstances under which they were made not misleading. No post-effective amendment to the Registration Statement reflecting any facts or events arising after the date thereof which represent, individually or in the aggregate, a fundamental change in the information set forth therein is required to be filed with the Commission. Except for this Agreement, there are no documents required to be filed with the Commission in connection with the transaction contemplated hereby that (x) have not been filed as required pursuant to the Securities Act or (y) will not be filed within the requisite time period. Except for this Agreement, there are no contracts or other documents required to be described in the Base Prospectus or Final Prospectus, or to be filed as exhibits or schedules to the Registration Statement, which have not been described or

filed as required. Â (c)Offering Materials. Neither the Company nor any of its directors and officers has distributed and none of them will distribute, prior to each Closing Date, any offering material in connection with the offering and sale of the Securities other than the Time of Sale Disclosure Package. Â (d)Authorization; Enforcement. The Company has the requisite corporate power and authority to enter into and to consummate the transactions contemplated by this Agreement and the Time of Sale Disclosure Package and otherwise to carry out its obligations hereunder and thereunder. The execution and delivery of each of this Agreement by the Company and the consummation by it of the transactions contemplated hereby and thereby and under the Base Prospectus have been duly authorized by all necessary action on the part of the Company and no further action is required by the Company, the Companyâ€™s Board of Directors (the â€œBoard of Directorsâ€) or the Companyâ€™s stockholders in connection therewith other than in connection with the Required Approvals (as defined below). This Agreement has been duly executed by the Company and, when delivered in accordance with the terms hereof, will constitute the valid and binding obligation of the Company enforceable against the Company in accordance with its terms, except (i) as limited by general equitable principles and applicable bankruptcy, insolvency, reorganization, moratorium and other laws of general application affecting enforcement of creditorsâ€™ rights generally, (ii) as limited by laws relating to the availability of specific performance, injunctive relief or other equitable remedies and (iii) insofar as indemnification and contribution provisions may be limited by applicable law. 4Â Â (e)No Conflicts. The execution, delivery and performance by the Company of this Agreement and the transactions contemplated pursuant to the Time of Sale Disclosure Package, the issuance and sale of the Securities and the consummation by it of the transactions contemplated hereby and thereby to which it is a party do not and will not (i) conflict with or violate any provision of the Companyâ€™s or any Subsidiaryâ€™s certificate or articles of incorporation, bylaws or other organizational or charter documents, or (ii) conflict with, or constitute a default (or an event that with notice or lapse of time or both would become a default) under, result in the creation of any Lien upon any of the properties or assets of the Company or any Subsidiary, or give to others any rights of termination, amendment, acceleration or cancellation (with or without notice, lapse of time or both) of, any agreement, credit facility, debt or other instrument (evidencing a Company or Subsidiary debt or otherwise) or other understanding to which the Company or any Subsidiary is a party or by which any property or asset of the Company or any Subsidiary is bound or affected, or (iii) subject to the Required Approvals, conflict with or result in a violation of any law, rule, regulation, order, judgment, injunction, decree or other restriction of any court or governmental authority to which the Company or a Subsidiary is subject (including federal and state securities laws and regulations), or by which any property or asset of the Company or a Subsidiary is bound or affected; except in the case of each of clauses (ii) and (iii), such as could not have or reasonably be expected to result in a Material Adverse Effect. Â (f)Certificates. Any certificate signed by an officer of the Company and delivered to the Placement Agent or to counsel for the Placement Agent shall be deemed to be a representation and warranty by the Company to the Placement Agent as to the matters set forth therein. Â (g)Reliance. The Company acknowledges that the Placement Agent will rely upon the accuracy and truthfulness of the foregoing representations and warranties and hereby consents to such reliance. Â (h)Forward-Looking Statements. No forward-looking statements (within the meaning of Section 27A of the Securities Act and Section 21E of the Exchange Act) contained in the Time of Sale Disclosure Package has been made or reaffirmed without a reasonable basis or has been disclosed other than in good faith. Â (i)Statistical or Market-Related Data. Any statistical, industry-related and market-related data included or incorporated by reference in the Time of Sale Disclosure Package, are based on or derived from sources that the Company reasonably and in good faith believes to be reliable and accurate, and such data agree with the sources from which they are derived. Â (j)FINRA Affiliations. There are no affiliations with any FINRA member firm that is participating in the Offering among the Companyâ€™s officers, directors or, to the knowledge of the Company, any five percent (5%) or greater stockholder of the Company. Â (k)Representations and Warranties Incorporated by Reference. Each of the representations and warranties (together with any related disclosure schedules thereto) made 5Â to the Investors in the Purchase Agreement is hereby incorporated herein by reference (as though fully restated herein) and is hereby made to, and in favor of, the Placement Agent. Â Section 3. Delivery and Payment. Each Closing shall occur at the offices of the Ellenoff Grossman & Schole LLP, 1345 Avenue of the Americas, New York, New York 10105 (â€œPlacement Agent Counselâ€) (or at such other place as shall be agreed upon by the Placement Agent and the Company). Subject to the terms and conditions hereof, at each Closing payment of the purchase price for the Securities sold on such Closing Date shall be made by Federal Funds wire transfer, against delivery of such Securities, and such Securities shall be registered in such name or names and shall be in such denominations, as the Placement Agent may request at least one business day before the time of purchase (as defined below). Â Deliveries of the documents with respect to the purchase of the Securities, if any, shall be made at the offices of Placement Agent Counsel. All actions taken at a Closing shall be deemed to have occurred simultaneously. Â Section 4. Covenants and Agreements of the Company. The Company further covenants and agrees with the Placement Agent as follows: Â (a)Registration Statement Matters. The Company will advise the Placement Agent promptly after it receives notice thereof of the time when any amendment to the Registration Statement has been filed or becomes effective or any supplement to the Base Prospectus or the Final Prospectus has been filed and will furnish the Placement Agent with copies thereof. The Company will file promptly all reports and any definitive proxy or information statements required to be filed by the Company with the Commission pursuant to Section 13(a), 14 or 15(d) of the Exchange Act subsequent to the date of any Prospectus and for so long as the delivery of a prospectus is required in connection with the Offering. The Company will advise the Placement Agent, promptly after it receives notice thereof (i) of any request by the Commission to amend the Registration Statement or to amend or supplement any Prospectus or for additional information, and (ii) of the issuance by the Commission of any stop order suspending the effectiveness of the Registration Statement or any post-effective amendment thereto or any order directed at any Incorporated Document, if any, or any amendment or supplement thereto or any order preventing or suspending the use of the Base Prospectus or the Final Prospectus or any prospectus supplement or any amendment or supplement thereto or any post-effective amendment to the Registration Statement, of the suspension of the qualification of the Securities for offering or sale in any jurisdiction, of the institution or threatened institution of any proceeding for any such purpose, or of any request by the Commission for the amending or supplementing of the Registration Statement or a Prospectus or for additional information. The Company shall use its best efforts to prevent the issuance of any such stop order or prevention or suspension of such use. If the Commission shall enter any such stop order or order or notice of prevention or suspension at any time, the Company will use its best efforts to obtain the lifting of such order at the earliest possible moment, or will file a new registration statement and use its best efforts to have such new registration statement declared effective as soon as practicable. Additionally, the Company agrees that it shall comply with the provisions of Rules 424(b), 430A, 430B and 430C, as applicable, under the Securities Act, including with respect to the timely filing of documents thereunder, and 6Â will use its reasonable efforts to confirm that any filings made by the Company under such Rule 424(b) are received in a timely manner by the Commission. Â (b)Blue Sky Compliance. The Company will cooperate with the Placement Agent and the Investors in endeavoring to qualify the Securities for sale under the securities laws of such jurisdictions (United States and foreign) as the Placement Agent and the Investors may reasonably request and will make such applications, file such documents, and furnish such information as may be reasonably required for that purpose, provided the Company shall not be required to qualify as a foreign corporation or to file a general consent to service of process in any jurisdiction where it is not now so qualified or required to file such a consent, and provided further that the Company shall not be required to produce any new disclosure document. The Company will, from time to time, prepare and file such statements, reports and other documents as are or may be required to continue such qualifications in effect for so long a period as the Placement Agent may reasonably request for distribution of the Securities. The Company will advise the Placement Agent promptly of the suspension of the qualification or registration of (or any such exemption relating to) the Securities for offering, sale or trading in any jurisdiction or any initiation or threat of any proceeding for any such purpose, and in the event of the issuance of any order suspending such qualification, registration or exemption, the Company shall use its best efforts to obtain the withdrawal thereof at the earliest possible moment. Â (c)Amendments and Supplements to a Prospectus and Other Matters. The Company will comply with the Securities Act and the Exchange Act, and the rules and regulations of the Commission thereunder, so as to permit the completion of the distribution of the Securities as contemplated in this Agreement, the Incorporated Documents and any Prospectus. If during the period in which a prospectus is required by law to be delivered in connection with the distribution of Securities contemplated by the Incorporated Documents or any Prospectus (the â€œProspectus Delivery Periodâ€), any event shall occur as a result of which, in the judgment of the Company or in the opinion of the Placement Agent or counsel for the Placement Agent, it becomes necessary to amend or supplement the Incorporated Documents or any Prospectus in order to make the statements therein, in the light of the circumstances under which they were made, as the case may be, not misleading, or if it is necessary at any time to amend or supplement the Incorporated Documents or any Prospectus or to file under the Exchange Act any Incorporated Document to comply with any law, the Company will promptly prepare

and file with the Commission, and furnish at its own expense to the Placement Agent and to dealers, an appropriate amendment to the Registration Statement or supplement to the Registration Statement, the Incorporated Documents or any Prospectus that is necessary in order to make the statements in the Incorporated Documents and any Prospectus as so amended or supplemented, in the light of the circumstances under which they were made, as the case may be, not misleading, or so that the Registration Statement, the Incorporated Documents or any Prospectus, as so amended or supplemented, will comply with law. Before amending the Registration Statement or supplementing the Incorporated Documents or any Prospectus in connection with the Offering, the Company will furnish the Placement Agent with a copy of such proposed amendment or supplement and will not file any such amendment or supplement to which the Placement Agent reasonably objects. Â 7Â (d)Copies of any Amendments and Supplements to a Prospectus. The Company will furnish the Placement Agent, without charge, during the period beginning on the date hereof and ending on the later of the last Closing Date of the Offering, as many copies of any Prospectus or prospectus supplement and any amendments and supplements thereto, as the Placement Agent may reasonably request. Â (e)Free Writing Prospectus. The Company covenants that it will not, unless it obtains the prior written consent of the Placement Agent, make any offer relating to the Securities that would constitute an Company Free Writing Prospectus or that would otherwise constitute a "free writing prospectus" (as defined in Rule 405 of the Securities Act) required to be filed by the Company with the Commission or retained by the Company under Rule 433 of the Securities Act. In the event that the Placement Agent expressly consents in writing to any such free writing prospectus (a "Permitted Free Writing Prospectus"), the Company covenants that it shall (i) treat each Permitted Free Writing Prospectus as an Company Free Writing Prospectus, and (ii) comply with the requirements of Rule 164 and 433 of the Securities Act applicable to such Permitted Free Writing Prospectus, including in respect of timely filing with the Commission, legending and record keeping. Â (f)Transfer Agent. The Company will maintain, at its expense, a registrar and transfer agent for the Common Stock. Â (g)Earnings Statement. As soon as practicable and in accordance with applicable requirements under the Securities Act, but in any event not later than 18 months after the last Closing Date, the Company will make generally available to its security holders and to the Placement Agent an earnings statement, covering a period of at least 12 consecutive months beginning after the last Closing Date, that satisfies the provisions of Section 11(a) and Rule 158 under the Securities Act. Â (h)Periodic Reporting Obligations. During the Prospectus Delivery Period, the Company will duly file, on a timely basis, with the Commission and the Trading Market all reports and documents required to be filed under the Exchange Act within the time periods and in the manner required by the Exchange Act. Â (i)Additional Documents. The Company will enter into any subscription, purchase or other customary agreements as the Placement Agent or the Investors deem necessary or appropriate to consummate the Offering, all of which will be in form and substance reasonably acceptable to the Placement Agent and the Investors. The Company agrees that the Placement Agent may rely upon, and each is a third party beneficiary of, the representations and warranties, and applicable covenants, set forth in any such purchase, subscription or other agreement with Investors in the Offering. Â (j)No Manipulation of Price. The Company will not take, directly or indirectly, any action designed to cause or result in, or that has constituted or might reasonably be expected to constitute, the stabilization or manipulation of the price of any securities of the Company. Â 8Â (k)Acknowledgment. The Company acknowledges that any advice given by the Placement Agent to the Company is solely for the benefit and use of the Board of Directors of the Company and may not be used, reproduced, disseminated, quoted or referred to, without the Placement Agent's prior written consent. Â (l)Announcement of Offering. The Company acknowledges and agrees that the Placement Agent may, subsequent to the Closing, make public its involvement with the Offering. Â (m)Reliance on Others. The Company confirms that it will rely on its own counsel and accountants for legal and accounting advice. Â (n)Research Matters. By entering into this Agreement, the Placement Agent does not provide any promise, either explicitly or implicitly, of favorable or continued research coverage of the Company and the Company hereby acknowledges and agrees that the Placement Agent's selection as a placement agent for the Offering was in no way conditioned, explicitly or implicitly, on the Placement Agent providing favorable or any research coverage of the Company. In accordance with FINRA Rule 2711(e), the parties acknowledge and agree that the Placement Agent has not directly or indirectly offered favorable research, a specific rating or a specific price target, or threatened to change research, a rating or a price target, to the Company or inducement for the receipt of business or compensation. Â Section 5. Conditions of the Obligations of the Placement Agent. The obligations of the Placement Agent hereunder shall be subject to the accuracy of the representations and warranties on the part of the Company set forth in Section 2 hereof, in each case as of the date hereof and as of each Closing Date as though then made, to the timely performance by each of the Company of its covenants and other obligations hereunder on and as of such dates, and to each of the following additional conditions: Â (a)Accountant's Comfort Letter. On the date hereof, the Placement Agent shall have received, and the Company shall have caused to be delivered to the Placement Agent, a letter from Moss Adams LLP (the independent registered public accounting firm of the Company), addressed to the Placement Agent, dated as of the date hereof, in form and substance satisfactory to the Placement Agent. The letter shall not disclose any change in the condition (financial or other), earnings, operations, business or prospects of the Company from that set forth in the Incorporated Documents or the applicable Prospectus or prospectus supplement, which, in the Placement Agent's sole judgment, is material and adverse and that makes it, in the Placement Agent's sole judgment, impracticable or inadvisable to proceed with the Offering of the Securities as contemplated by such Prospectus. Â (b)Compliance with Registration Requirements; No Stop Order; No Objection from the FINRA. Each Prospectus (in accordance with Rule 424(b)) and "free writing prospectus" (as defined in Rule 405 of the Securities Act), if any, shall have been duly filed with the Commission, as appropriate; no stop order suspending the effectiveness of the Registration Statement or any part thereof shall have been issued and no proceeding for that purpose shall have been initiated or threatened by the Commission; no order preventing or suspending the use of any Prospectus shall have been issued and no proceeding for that purpose shall have been initiated or threatened by the Commission; no order having the effect of ceasing or suspending the distribution of the Securities or any other securities of the Company shall have been issued by any securities commission, securities regulatory authority or stock exchange and no proceedings for that purpose shall have been instituted or shall be pending or, to the knowledge of the Company, contemplated by any securities commission, securities regulatory authority or stock exchange; all requests for additional information on the part of the Commission shall have been complied with; and the FINRA shall have raised no objection to the fairness and reasonableness of the placement terms and arrangements. Â (c)Corporate Proceedings. All corporate proceedings and other legal matters in connection with this Agreement, the Registration Statement and each Prospectus, and the registration, sale and delivery of the Securities, shall have been completed or resolved in a manner reasonably satisfactory to the Placement Agent's counsel, and such counsel shall have been furnished with such papers and information as it may reasonably have requested to enable such counsel to pass upon the matters referred to in this Section 5. Â (d)No Material Adverse Change. Subsequent to the execution and delivery of this Agreement and prior to each Closing Date, in the Placement Agent's sole judgment after consultation with the Company, there shall not have occurred any Material Adverse Effect or any material adverse change or development involving a prospective material adverse change in the condition or the business activities, financial or otherwise, of the Company from the latest dates as of which such condition is set forth in the Registration Statement and Prospectus ("Material Adverse Change"). Â (e)Opinion of Counsel for the Company. The Placement Agent shall have received on each Closing Date the favorable opinion of US legal counsel to the Company, dated as of such Closing Date, including, without limitation, a negative assurance letter addressed to the Placement Agent and in form and substance satisfactory to the Placement Agent. Â (f)Officers' Certificate. The Placement Agent shall have received on each Closing Date a certificate of the Company, dated as of such Closing Date, signed by the Chief Executive Officer and Chief Financial Officer of the Company, to the effect that, and the Placement Agent shall be satisfied that, the signers of such certificate have reviewed the Registration Statement, the Incorporated Documents, the Prospectus, and this Agreement and to the further effect that: Â (i)The representations and warranties of the Company in this Agreement are true and correct, as if made on and as of such Closing Date, and the Company has complied with all the agreements and satisfied all the conditions on its part to be performed or satisfied at or prior to such Closing Date; Â (ii)No stop order suspending the effectiveness of the Registration Statement or the use of any Prospectus has been issued and no proceedings for that purpose have been instituted or are pending or, to the Company's knowledge, threatened under the Securities Act; no order having the effect of ceasing or suspending the distribution of the Securities or any other securities of the Company has been issued by any securities commission, 10Â securities regulatory authority or stock exchange in the United States and no proceedings for that purpose have been instituted or are pending or, to the knowledge of the Company, contemplated by any securities commission, securities regulatory authority or stock exchange in the United States; Â (iii)When the Registration Statement became effective, at the time of sale, and at all times subsequent thereto up to the delivery of such certificate, the Registration Statement and the Incorporated Documents, if any, when such documents became effective or were filed with the Commission, and any Prospectus, contained all material

information required to be included therein by the Securities Act and the Exchange Act and the applicable rules and regulations of the Commission thereunder, as the case may be, and in all material respects conformed to the requirements of the Securities Act and the Exchange Act and the applicable rules and regulations of the Commission thereunder, as the case may be, and the Registration Statement and the Incorporated Documents, if any, and any Prospectus, did not and do not include any untrue statement of a material fact or omit to state a material fact required to be stated therein or necessary to make the statements therein, in the light of the circumstances under which they were made, not misleading (provided, however, that the preceding representations and warranties contained in this paragraph (iii) shall not apply to any statements or omissions made in reliance upon and in conformity with information furnished in writing to the Company by the Placement Agent expressly for use therein) and, since the effective date of the Registration Statement, there has occurred no event required by the Securities Act and the rules and regulations of the Commission thereunder to be set forth in the Incorporated Documents which has not been so set forth; and Â (iv) Subsequent to the respective dates as of which information is given in the Registration Statement, the Incorporated Documents and any Prospectus, there has not been: (a) any Material Adverse Change; (b) any transaction that is material to the Company and the Subsidiaries taken as a whole, except transactions entered into in the ordinary course of business; (c) any obligation, direct or contingent, that is material to the Company and the Subsidiaries taken as a whole, incurred by the Company or any Subsidiary, except obligations incurred in the ordinary course of business; (d) any material change in the capital stock (except changes thereto resulting from the exercise of outstanding stock options or warrants) or outstanding indebtedness of the Company or any Subsidiary; (e) any dividend or distribution of any kind declared, paid or made on the capital stock of the Company; or (f) any loss or damage (whether or not insured) to the property of the Company or any Subsidiary which has been sustained or will have been sustained which has a Material Adverse Effect. Â (g) Bring-down Comfort Letter. On each Closing Date, the Placement Agent shall have received from Moss Adams LLP, or such other independent registered public accounting firm of the Company, a letter dated as of such Closing Date, in form and substance satisfactory to the Placement Agent, to the effect that they reaffirm the statements made in the letter furnished pursuant to subsection (a) of this Section 5, except that the specified date referred to therein for the carrying out of procedures shall be no more than three business days prior to such Closing Date. 11Â Â (h) Lock-Up Agreements. On the date hereof, the Placement Agent shall have received the executed lock-up agreement, in the form attached hereto as Exhibit A, from each of the directors and officers of the Company. Â (i) Stock Exchange Listing. The Common Stock shall be registered under the Exchange Act and shall be listed on the Trading Market, and the Company shall not have taken any action designed to terminate, or likely to have the effect of terminating, the registration of the Common Stock under the Exchange Act or delisting or suspending from trading the Common Stock from the Trading Market, nor shall the Company have received any information suggesting that the Commission or the Trading Market is contemplating terminating such registration or listing. Â (j) Additional Documents. On or before each Closing Date, the Placement Agent and counsel for the Placement Agent shall have received such information and documents as they may reasonably require for the purposes of enabling them to pass upon the issuance and sale of the Securities as contemplated herein, or in order to evidence the accuracy of any of the representations and warranties, or the satisfaction of any of the conditions or agreements, herein contained. Â If any condition specified in this Section 5 is not satisfied when and as required to be satisfied, this Agreement may be terminated by the Placement Agent by notice to the Company at any time on or prior to a Closing Date, which termination shall be without liability on the part of any party to any other party, except that Section 6 (Payment of Expenses), Section 7 (Indemnification and Contribution) and Section 8 (Representations and Indemnities to Survive Delivery) shall at all times be effective and shall survive such termination. Â Section 6. Payment of Expenses. The Company agrees to pay all costs, fees and expenses incurred by the Company in connection with the performance of its obligations hereunder and in connection with the transactions contemplated hereby, including, without limitation: (i) all expenses incident to the issuance, delivery and qualification of the Securities (including all printing and engraving costs); (ii) all fees and expenses of the registrar and transfer agent of the Common Stock; (iii) all necessary issue, transfer and other stamp taxes in connection with the issuance and sale of the Securities; (iv) all fees and expenses of the Company's counsel, independent public or certified public accountants and other advisors; (v) all costs and expenses incurred in connection with the preparation, printing, filing, shipping and distribution of the Registration Statement (including financial statements, exhibits, schedules, consents and certificates of experts), the Base Prospectus, the Final Prospectus and all amendments and supplements thereto, and this Agreement; (vi) all filing fees, reasonable attorneys' fees and expenses incurred by the Company or the Placement Agent in connection with qualifying or registering (or obtaining exemptions from the qualification or registration of) all or any part of the Securities for offer and sale under the state securities or blue sky laws or the securities laws of any other country, and, if requested by the Placement Agent, preparing and printing a "Blue Sky Survey," an "International Blue Sky Survey" or other memorandum, and any supplements thereto, advising the Placement Agent of such qualifications, registrations and exemptions; provided, however, that any such fees shall be subject to the overall expense cap set forth in Section 1(a); (vii) if applicable, the filing fees incident to 12Â the review and approval by the FINRA of the Placement Agent's participation in the offering and distribution of the Securities; (viii) the fees and expenses associated with including the Shares and shares of Common Stock issuable upon exercise of the Warrants on the Trading Market; (ix) all costs and expenses incident to the travel and accommodation of the Company's and the Placement Agent's employees on the "roadshow," if any; and (x) all other fees, costs and expenses referred to in Part II of the Registration Statement. Â Section 7. Indemnification and Contribution. Â (a) The Company agrees to indemnify and hold harmless the Placement Agent, its affiliates and each person controlling the Placement Agent (within the meaning of Section 15 of the Securities Act), and the directors, officers, agents and employees of the Placement Agent, its affiliates and each such controlling person (the Placement Agent, and each such entity or person. an "Indemnified Person") from and against any losses, claims, damages, judgments, assessments, costs and other liabilities (collectively, the "Liabilities"), and shall reimburse each Indemnified Person for all fees and expenses (including the reasonable fees and expenses of one counsel for all Indemnified Persons, except as otherwise expressly provided herein) (collectively, the "Expenses") as they are incurred by an Indemnified Person in investigating, preparing, pursuing or defending any Actions, whether or not any Indemnified Person is a party thereto, (i) caused by, or arising out of or in connection with, any untrue statement or alleged untrue statement of a material fact contained in the Registration Statement, any Incorporated Document, or any Prospectus or by any omission or alleged omission to state therein a material fact necessary to make the statements therein, in light of the circumstances under which they were made, not misleading (other than untrue statements or alleged untrue statements in, or omissions or alleged omissions from, information relating to an Indemnified Person furnished in writing by or on behalf of such Indemnified Person expressly for use in the Incorporated Documents) or (ii) otherwise arising out of or in connection with advice or services rendered or to be rendered by any Indemnified Person pursuant to this Agreement, the transactions contemplated thereby or any Indemnified Person's actions or inactions in connection with any such advice, services or transactions; provided, however, that, in the case of clause (ii) only, the Company shall not be responsible for any Liabilities or Expenses of any Indemnified Person that are finally judicially determined to have resulted solely from such Indemnified Person's (x) gross negligence or willful misconduct in connection with any of the advice, actions, inactions or services referred to above or (y) use of any offering materials or information concerning the Company in connection with the offer or sale of the Securities in the Offering which were not authorized for such use by the Company and which use constitutes gross negligence or willful misconduct. The Company also agrees to reimburse each Indemnified Person for all Expenses as they are incurred in connection with enforcing such Indemnified Person's rights under this Agreement. Â (b) Upon receipt by an Indemnified Person of actual notice of an Action against such Indemnified Person with respect to which indemnity may be sought under this Agreement, such Indemnified Person shall promptly notify the Company in writing; provided that failure by any Indemnified Person so to notify the Company shall not relieve the Company from any liability which the Company may have on account of this indemnity or otherwise to such Indemnified Person, except to the extent the Company shall have been prejudiced by such 13Â failure. The Company shall, if requested by the Placement Agent, assume the defense of any such Action including the employment of counsel reasonably satisfactory to the Placement Agent, which counsel may also be counsel to the Company. Any Indemnified Person shall have the right to employ separate counsel in any such action and participate in the defense thereof, but the fees and expenses of such counsel shall be at the expense of such Indemnified Person unless: (i) the Company has failed promptly to assume the defense and employ counsel or (ii) the named parties to any such Action (including any impeded parties) include such Indemnified Person and the Company, and such Indemnified Person shall have been advised in the reasonable opinion of counsel that there is an actual conflict of interest that prevents the counsel selected by the Company from representing both the Company (or another client of such counsel) and any Indemnified Person; provided that the Company shall not in such event be responsible hereunder for the fees and expenses of more than one firm of separate counsel for all Indemnified Persons in connection with any Action or related Actions,

in addition to any local counsel. The Company shall not be liable for any settlement of any Action effected without its written consent (which shall not be unreasonably withheld). In addition, the Company shall not, without the prior written consent of the Placement Agent (which shall not be unreasonably withheld), settle, compromise or consent to the entry of any judgment in or otherwise seek to terminate any pending or threatened Action in respect of which indemnification or contribution may be sought hereunder (whether or not such Indemnified Person is a party thereto) unless such settlement, compromise, consent or termination includes an unconditional release of each Indemnified Person from all Liabilities arising out of such Action for which indemnification or contribution may be sought hereunder. The indemnification required hereby shall be made by periodic payments of the amount thereof during the course of the investigation or defense, as such expense, loss, damage or liability is incurred and is due and payable. Â (c) In the event that the foregoing indemnity is unavailable to an Indemnified Person other than in accordance with this Agreement, the Company shall contribute to the Liabilities and Expenses paid or payable by such Indemnified Person in such proportion as is appropriate to reflect (i) the relative benefits to the Company, on the one hand, and to the Placement Agent and any other Indemnified Person, on the other hand, of the matters contemplated by this Agreement or (ii) if the allocation provided by the immediately preceding clause is not permitted by applicable law, not only such relative benefits but also the relative fault of the Company, on the one hand, and the Placement Agent and any other Indemnified Person, on the other hand, in connection with the matters as to which such Liabilities or Expenses relate, as well as any other relevant equitable considerations; provided that in no event shall the Company contribute less than the amount necessary to ensure that all Indemnified Persons, in the aggregate, are not liable for any Liabilities and Expenses in excess of the amount of fees actually received by the Placement Agent pursuant to this Agreement. For purposes of this paragraph, the relative benefits to the Company, on the one hand, and to the Placement Agent on the other hand, of the matters contemplated by this Agreement shall be deemed to be in the same proportion as (a) the total value paid or contemplated to be paid to or received or contemplated to be received by the Company in the transaction or transactions that are within the scope of this Agreement, whether or not any such transaction is consummated, bears to (b) the fees paid to the Placement Agent under this Agreement. Notwithstanding the above, no person guilty of fraudulent misrepresentation within the meaning of Section 11(f) of the 14Â Securities Act, as amended, shall be entitled to contribution from a party who was not guilty of fraudulent misrepresentation. Â (d) The Company also agrees that no Indemnified Person shall have any liability (whether direct or indirect, in contract or tort or otherwise) to the Company for or in connection with advice or services rendered or to be rendered by any Indemnified Person pursuant to this Agreement, the transactions contemplated thereby or any Indemnified Person's actions or inactions in connection with any such advice, services or transactions except for Liabilities (and related Expenses) of the Company that are finally judicially determined to have resulted solely from such Indemnified Person's gross negligence or willful misconduct in connection with any such advice, actions, inactions or services. Â (e) The reimbursement, indemnity and contribution obligations of the Company set forth herein shall apply to any modification of this Agreement and shall remain in full force and effect regardless of any termination of, or the completion of any Indemnified Person's services under or in connection with, this Agreement. Â Section 8. Representations and Indemnities to Survive Delivery. The respective indemnities, agreements, representations, warranties and other statements of the Company or any person controlling the Company, of its officers, and of the Placement Agent set forth in or made pursuant to this Agreement will remain in full force and effect, regardless of any investigation made by or on behalf of the Placement Agent, the Company, or any of its or their partners, officers or directors or any controlling person, as the case may be, and will survive delivery of and payment for the Securities sold hereunder and any termination of this Agreement. A successor to a Placement Agent, or to the Company, its directors or officers or any person controlling the Company, shall be entitled to the benefits of the indemnity, contribution and reimbursement agreements contained in this Agreement. Â Section 9. Notices. All communications hereunder shall be in writing and shall be mailed, hand delivered or e-mailed and confirmed to the parties hereto as follows: Â If to the Placement Agent to the address set forth above, attention: James Antonopoulos email: ecm@roth.com Â With a copy to: Â Ellenoff Grossman & Schole LLP 1345 Avenue of the Americas, 11th Floor New York, New York 10105 E-mail: capmkt@egsllp.com Â If to the Company: Â Aptevo Therapeutics Inc 2401 4th Avenue, Suite 1050 Seattle, WA 98121 15Â e-mail: KwonS@apvo.com Attention: SoYoung Kwon Â With a copy to: Â Paul Hastings LLP 200 Park Avenue New York, NY 10166 e-mail: SeanDonahue@paulhastings.com Attention: Sean Donahue Â Any party hereto may change the address for receipt of communications by giving written notice to the others. Â Section 10. Successors. This Agreement will inure to the benefit of and be binding upon the parties hereto, and to the benefit of the employees, officers and directors and controlling persons referred to in Section 7 hereof, and to their respective successors, and personal representative, and no other person will have any right or obligation hereunder. Â Section 11. Partial Unenforceability. The invalidity or unenforceability of any section, paragraph or provision of this Agreement shall not affect the validity or enforceability of any other section, paragraph or provision hereof. If any Section, paragraph or provision of this Agreement is for any reason determined to be invalid or unenforceable, there shall be deemed to be made such minor changes (and only such minor changes) as are necessary to make it valid and enforceable. Â Section 12. Governing Law Provisions. This Agreement shall be deemed to have been made and delivered in New York City and both this engagement letter and the transactions contemplated hereby shall be governed as to validity, interpretation, construction, effect and in all other respects by the internal laws of the State of New York, without regard to the conflict of laws principles thereof. Each of the Placement Agent and the Company: (i) agrees that any legal suit, action or proceeding arising out of or relating to this engagement letter and/or the transactions contemplated hereby shall be instituted exclusively in New York Supreme Court, County of New York, or in the United States District Court for the Southern District of New York, (ii) waives any objection which it may have or hereafter to the venue of any such suit, action or proceeding, and (iii) irrevocably consents to the jurisdiction of the New York Supreme Court, County of New York, and the United States District Court for the Southern District of New York in any such suit, action or proceeding. Each of the Placement Agent and the Company further agrees to accept and acknowledge service of any and all process which may be served in any such suit, action or proceeding in the New York Supreme Court, County of New York, or in the United States District Court for the Southern District of New York and agrees that service of process upon the Company mailed by certified mail to the Company's address shall be deemed in every respect effective service of process upon the Company, in any such suit, action or proceeding, and service of process upon the Placement Agent mailed by certified mail to the Placement Agent's address shall be deemed in every respect effective service process upon the Placement Agent, in any such suit, action or proceeding. Notwithstanding any provision of this engagement letter to the contrary, the Company agrees that neither the Placement Agent nor its affiliates, and the respective officers, directors, employees, 16Â agents and representatives of the Placement Agent, its affiliates and each other person, if any, controlling the Placement Agent or any of its affiliates, shall have any liability (whether direct or indirect, in contract or tort or otherwise) to the Company for or in connection with the engagement and transaction described herein except for any such liability for losses, claims, damages or liabilities incurred by us that are finally judicially determined to have resulted from the willful misconduct or gross negligence of such individuals or entities. If either party shall commence an action or proceeding to enforce any provision of this Agreement, then the prevailing party in such action or proceeding shall be reimbursed by the other party for its reasonable attorney's fees and other costs and expenses incurred with the investigation, preparation and prosecution of such action or proceeding. Â Section 13. General Provisions. Â (a) This Agreement constitutes the entire agreement of the parties to this Agreement and supersedes all prior written or oral and all contemporaneous oral agreements, understandings and negotiations with respect to the subject matter hereof. Notwithstanding anything herein to the contrary, the Engagement Agreement, dated August 29, 2024, (the "Engagement Agreement"), between the Company and Roth Capital Partners, LLC shall continue to be effective and the terms therein shall continue to survive and be enforceable by the Placement Agent in accordance with its terms, provided that, in the event of a conflict between the terms of the Engagement Agreement and this Agreement, the terms of this Agreement shall prevail. This Agreement may be executed in two or more counterparts, each one of which shall be an original, with the same effect as if the signatures thereto and hereto were upon the same instrument. This Agreement may not be amended or modified unless in writing by all of the parties hereto, and no condition herein (express or implied) may be waived unless waived in writing by each party whom the condition is meant to benefit. Section headings herein are for the convenience of the parties only and shall not affect the construction or interpretation of this Agreement. Â (b) The Company acknowledges that in connection with the offering of the Securities: (i) the Placement Agent has acted at arms length, are not agents of, and owe no fiduciary duties to the Company or any other person, (ii) the Placement Agent owes the Company only those duties and obligations set forth in this Agreement and (iii) the Placement Agent may have interests that differ from those of the Company. The Company waives to the full extent permitted by applicable law any claims it may have against the Placement Agent arising from an alleged breach of fiduciary duty in connection with the offering of the Securities Â [The remainder of this page has been intentionally left blank.] 17Â Â Â If the foregoing is in accordance with your understanding of our agreement, please

[illegible]









[illegible]



[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

M^M73.;GAN9\_UJ<|8I%>R\A\_#7\_(RZ?\_-=EKV20\$!^NDLM9L\F0XCCF5F/H\_M\_|I7L3:E8I\$LK7ENL?\_  
=8R#|^!E3@9)196+3YD33\_P#^O)\_N^!5>%5IK/\_O\MR?|A\_E7A51C\_+/S\*P?4I=|^2\BI8\_1\_OVKSSQ:2?%-\_GKO'\_H(KT/P=\_R\*\_  
MECI'\_P#0VKB?^EFUOXB?:^R7\$S:N#I@:3\_(?G3Q)OAXOT\_(5)\_OI?,TOAOMH\_M4<\_>VQX^F6S\_  
\$KT^O(^>|LHVH\_?2)BU40W+?5\$VSAU^REM+A+T4JH6^1HUAS^\_I/75K:PM1\_MH\_LJ00\*K85MC4\_  
4L1\*BCDO9A\$DCI(%)/|7M1\*Z:0DGKH8\DX\_MM:FFL>#-=2TR1GAC:ZMNSQC+>ZI?  
Z5@1R202AXW>\_13PRD@>@UJE#/#\_G^\*X:V\$23G:G72Q+;49\_M(S?"WC\*=|H.PU-Q(LAVQSG@>@|@WK|\_|^O"(RRR\*4SN:|&/6O=Q6  
SUK7|U93\_MBU+H9XJFHM-=0HHHKM\_4\*\*\*\*\_\"BBB@\_HHHH\_\*\*\*\*\_\"BBB@\_HHHH\_\*\*\*\*\_\"BB@\_HHHH\_\*\*\*\*\_\"BBB@\_HHHH\_\*\*\*\*  
)+?\_CYB\_P!|?SKT7XG\_/\_EI\_|UT?^\_M0KSJW\_X^8O|\_?^|Z|%^)\_P#OY:??\_=-'\_D\*Y:O|\_&A|SHI\_P|\_(VHHHKJ|\_|<\_M\*\*\*\*\_\"BBB@\_HHHH\_\*\*\*\*  
\*\*\*\*\_\"BBB@\_HHHH\_\*\*\*\*\_\"BBB@\_HHHH\_\*\*\*\*\_\"BBB@\_HHHH\_\*\*\*\*\_\"BBB@\_HHHH\_\*\*\*\*\_\"BBB@\_HHHH\_\*\*\*\*\_\"BBB@\_HHHH\_\*\*\*\*  
\"BB\_MB@\_HHHH\_\*\*\*\*\_\"BBB@\_HHHH\_\*\*\*\*\_\"BBB@\_HHHH\_\*\*\*\*\_\"BBB@\_HHHH\_\*\*\*\*\_\"BBB@\_HHHH\_\*\*\*\*\_\"BBB@\_HHHH\_\*\*\*\*\_\"BBB@\_HHHH\_\*\*\*\*  
\"BBB@\_HHHH\_\*\*\*\*\_\"BBB@\_HHHH\_M\*\*\*\*\_\"BBB@\_HHHH\_\*\*\*\*\_\"BBB@\_HHHH\_\*\*\*\*\_\"BBB@\_HHHH\_\*\*\*\*\_\"BBB@\_HHHH\_\*\*\*\*\_\"N^^(W\_M\_#  
|+\_KJW|H6N^^(W\_(LO^NK?RKGO7?1MA\_XB.(T;\_D:??\_UQ\_|H0KV\_MRO\$|&\_Y#FG\_|J??\_\*\$|JK#\_?\"S;&\_H^|<|3D6Q\_  
J&>OG&O8Z|H<6;6OB2\_M63;A+A5D4\_A@\_|J^K^X|\_|/S/A^H1D66E7V|H:S9VSS|\_|MG;-6\_|A%G|\_P^@\_M\_A\_D^T\_VL0Z;J4MO|84\_-  
\"K\"|H36M7G\_M3E:VAX|\_|(OK?|\_T#9\_R%=7X^T34\_A\_O:FXO+>=H4;8H;J3D^E=E/W452LM7L\_0MUGM|J)E(R06\_M  
#\_4=JRI9|8-=I2E(W)WAP\$^FFD^0UX9-=|?D\_M\_71OYU|\_|S^YMHU|&D0:|HFO\$;O\_C|G\_ZZ\_-|N^|1.K|H|2\_A\_R+0\_MZ|\_|  
\$KJ^Y?P#\_R+0\_Z|\_|2NHKKH?PH^ASUOXG/S=5\_Y#%|\_|?%G\_HIKT+X\_M>\_|\_|(O2\_I?+?^@K7GNJ|\_AB|\_P^OB3\_T|UZX%|\_|  
^1>E\_Z^6\_|H6O/PG|9\_|I\_M\_1\_|)\"/W\_(M^KL6|\_|TM|A\_C|@\_ZZ+\_|#KTOO|\_R+1\_Z|)\_6O+3\_C|@\_ZZ\_M+\_|.C&?Q0PO|  
#|AY4G^L7ZBO=Z|(3\_6+|17N|<>\_ ^U|C|QGV3PR|R;R?|=HS&S^=>C\_#\_MW\_|PC|V.OVEL\_P#?^UPWB\*S:Q|07L)7  
J=|HUN1\_|MWP^K<-C/874HCCF(M;\_F\_&Z9|QCV|QPI4\*UI&U9<|P^Z/2\*X^XG|?LNGY^|O?^TP\_TKMFD1(R|\_M|H|DL3@  
5Y9XSUN+5|3C2V??:VZE5;LS^J|1<?|J|<?^DUW\_3#1;J)|C;T#\_M/\_OZ=MZ\_:8\_0A7|\_BO\_D5|\_P^ZY\_U^<^X^L&N\_4/|U|AW\_\"\"  
|3\_KBG\_H(KP|O<?\_MY|=I\_P\_|4\_|012P&|BL9LCQ6|R;R?|=HS&S^=>C\_#\_W\_|P\_(CK|\_|/\_?^\*U\_MPWB\*S:Q|07L)7\_|I=|A\_=?D?  
SK=|ZW#8SS6%U^\*(XYB&C9C@|NA&?^<8\_\*LL\_MU^M:|H67/2NCTBN^^(^W^|+I^?O\_WQ|\_|#|/19|52\_NSH^9+X^%>6>\_|BU\_M?  
4XTMGWV|NI56|QZD>W\_\*NW%S2I=SDPT6ZB?8S\_-S\_P\_|#IVWK|H\_C\_P#0\_MA7|J^B>Q@O|\_N4N)5B6;>8LC=%8=A/QK@O  
|@UWXBCF(S;\_\*9&/OT^ZG/X5T\_M^Q&N)4L;\_\*|21%(|\_|^Y\_&|^\_|^\_|N:A|N^E)HWK>|6C%G|\_|\$|MM.D|\_|E)8V^#P\_MZ@UTC>|/M9\_  
OY>+8\_C^FB|OKUQ^E4/#\_&EP;J6U9%;W;\_J\_ZH^#^)^TS75B\_MR|\_|O+N\$D\_SV\_|@?SK^C&?  
+>?TOF:5910\_4;G\_P07617HCB1Y|B5L|0SH\_NPH|>34&ES>|\_|<>5|HUBK\_QB\_UW\_4UL5VX:@|J^O7NS  
MEKUG2UD5M1|TU#3KBTU^|A7/H|>Q\_|UXE+|\$SQ2+M=&\*L/O\_C@U|M7EOCK\_M3OL6O&X1<|W2^8/|X<-  
\_O\_C6>|WBHB|\_|S<3H=&U\_R\_GZ)8#3?%M;3&+!|O\_P|X|G|2;T\*\*\*|J^459^EMW=|MV%|%%|04444\_%%|%%|\_1110\_4444\_%%|%%|  
\_1110\_4444\_%%|%%|\_1110\_4444\_M%%|%%|\_1110\_4444\_%%|%%|\_1110\_4444\_%%|%%|\_1110\_4444\_%%|%%|\_1110\_4\_M444\_%%|%%|\_1110  
4444\_%%|%%|\_1110\_4444\_%%|%%|\_1110\_4444\_%%|%%|\_111\_M10\_4444\_%%|%%|\_1110\_4444\_%%|%%|\_1110\_4444\_%%|%%|\_1110\_4444\_%%|%%|  
\_M+1110\_4444\_%%|%%|\_1110\_4444\_%%|%%|\_1110\_4444\_%%|%%|\_1110\_5|?X6\_M\_P^17TW\_  
\*X+7B%>W^O^17TW\_K@M<\_|/|^!>IUX3XF:|%%|%%>6>@<3|3/^0+9\_M|?^+\*\_|OKU#XF?|@6S\_P^OC\_V4UY?  
7L8/^<CS\_5\_\$\"BBBNHYPHHHH\_\*\*\*\*\_M\_\"BBB@\_HHHH\_\*\*\*\*\_\"BBB@\_HHHH\_\*\*\*\*\_\"BBB@\_HHHH\_\*\*\*\*\_\"BBB@\_HHHH\_\*\*\*\*\_\"BBB@\_HHHH\_\*\*\*\*  
M^\*Q|\$7ARWUZW&3Y=U&|WY|\_ZFBM;\_.\$C3?>|LZN)E\_6M9^!\_\$2W\_MGE>ODCAD=%5PS\*I(|XZUC^\_|.6X\_X2:VE|B3RT#|FVG  
^4CD\_C7JE%.6&4JOM\_M+B6(|FE@KB?B);S306#Q1.ZH9-Q520N=N\_D:|BMJM|VD|\$RISY)\*1Y\_X0\_MM;@^|K\_Q)|L1F+\_  
L\_%&T|37|JL23PO#(NZ\_12K#U|X\_/HJ^\_\*4HAM|E5;OM)\_M7/(<=<|\_WVC7+\_|NGEM2?DF5W\$^!&\_4J\_|05|?3|)BW\_M|\_|+3?>VC\_  
<|L\$KWA^QNL7|2N>3V/AC5\_4BGO)DE2\_8V?^?\"6E(&0\_!SZU\_MG6%I\_8)\_GLI5MP  
MPVCH;J9HKHKT?:QY;V:55V;O8XGX=V|T;%^|D3HKF|64@-C=G^YBNVHH|J\_M5/V<%\$FI/GDY%74;&+4M/GLYON2KMSZ^L?  
P\_#7D6JZ?Z?T;Q\_QC|^651E&\_M^U\_I7L|9U|X|KY.TI5G3|O=M&\*42BB^O;WMTD9X\$;2L|^\_|K1C|^ZF^E7&H  
MSPRIA%#)&5)>0DC/4#&3S7K^PQ^Y=8T#^N%&;?6;<\$OM2N:O%|/L>1>%K;  
M<^)>+A#)A9\_L=IP^CO7KM%%;T^/LHVOZTUD5OAE#W&;R|X\_|WS)V-^>\*E%6:MN>&V|M/=2\".WADE<\_P  
\*\*6/Z5Z7X^T&ZT>VN);O0DMQMQ^G)4#&7WYK|J%54&\_M%4^0#%+3HX14YGO^|BBDDG\$<4;2>B\_MH\_D\_A7M6D026VC64\$HO^'  
BL/0A1D5:5\$3\_Q57/H\_4ZC#X;V3;O<=;O|2RL>\_M>^)?|4ZW\$EYI4?F1=|S0+U0\_|/J;N\_DCGM9=LB20R^LP^D5H361^\_|JMCU  
M&;S|8^\_G>+L5#2BK25QO|V|F\_|H^F@QV^F0G|U=|^V/ZG=ZC;2+9RI^DJLT\_MDB|O\_#D|>OX5ZRD;47^KC1|UO0^?  
4QP20>4KE2Q>EHH^|F7VMP|P^3Q^UXY@\_DT\_MREGV6G#;\_\*AKUFBN901HK^EO8PI5?9NICB?AW;S0P7R|L\_BN8H9I\_V3D9^O1O\_  
H%\_&C\_|0\_%.51DDX|5XX+6X+|\_|+OZ;=AS7N\_M=%95|\_JK3O8UHU\_9H|Q4TI&CT>QC=2KK;OAE(P00HXKRWO|H6H:J|=S^|O|C|  
M#RLZ2H;J03D9\";\_\*J>E>S&W@+;C#&6|2HS4E(M\_|MK1|52|\_\*\"B)Z;A\_CR/OK5HKM|G^EY.AS<|Y  
MN;|>^7EC=6\$QBN|^>2^P>CC&?H>D;VEQ>W^P6T3R2;<\_\*U|BR|XPRAAZ\$9H\_M550850H\_|5Q?4%?XM#|^N\_VPR12;=U^|V\$?  
7BQ\$^M+V\_0QO;R|X\_|^I0@U|G\_M1717PZJVM8QHUO9WT;PG%|\_|X8LHY8VC<^V588(RQ(XIWB^O|HM=T\_R6(29#  
MNBDO|T^A|C6106GLURE4\_\"3|@#)\_M>|TQ8HU\_5C4^U\_KC>5|\_|4L8|H|P|\_|&=1N=3M;N6;H+;&19^T@VEL'. \_MIKK?  
&NDW6JZ3&+1/DADWE^P1O|UTM%=\$\_&\_\*#N8RKRE\_2|AX>^TV4J&\_MN+63N\_60TDL|YJ\$JB66>YDZ+O8N?  
PKVIDI0AU5A|C-)^%|\_|\$1OH@|%&\*Y\_J+|MVYM#;ZVM^74|^|^\*^|EKR^\_U^\*(PQ1\$;D3|\_|  
|\_|ID=A|\_|\$HHKKI4HTHV\_B\_|=C16=2^/|Q|EPGR24CQ61+2YDURQV6|K;|B;G^\"|@|ADFO9J^\*BA0|D  
MEKw+K5?\_-.P5C^(|M|BUZQ\$3\_|YXSF^3&<^N#|&M|BBM914ERLSC)O=T>+ZCH6\_ML;6Y6ZM)%4?  
|M%&Y#^<(X|H>=W\_\"E8KB;3U^\_0^|SJ(V|\_|8;88|COM%<+P\_O\_MNR.M8O3WD>\*16U|H\_G|H>Y<|952QK|TP9I5UI6C/^=IY5:OX7U  
M^2)6W0M;Y^6:~|2U;1|VSB\_|M97&U\_/KW\_\"O8C%&6W&\_|<|13ZYHX|7|Z1N|8|\_|(BM81;6D\_|.1\$BIGUP;5X\_MO?VES?  
SK);R|WF\_P4(|U|1717PZJ^|K&\_\*LZ;M>YS?>@>^6#PXJ51/&QE\_M9@^?|X|YK|^\*UA^DBH|C^>Q;Z>LW@>WE7\_|D90|C<>\_|  
|P2P>\_M^W\$T3QEIv8|U(R\_|S^E=116%+\*#G/GN;5^|G^EL5F|Q>A/>O;\_\*V%52?<^\*6(=|+8^P|&4\_L\_AFY2&\_  
MY^W(=J#)P&&WZ^Z)QYHN/^06=S+\_.B1V|K.6^R|A|KW&BBL;%#V\_M|W:U;VEM#G?%|AE<@66\$JEY\$;\_\*QZ\_|/H\_H\_|SOM+OM\_  
D^7EK)\$1W^\_\*PH\_M>AKVZD(#\_@@\$^L\_FMA8U^S+1C8B4%;=^A|=BH4L=HZ#^/%;FF>=3U611|\_|.M|9ZRR#;@^U|\_|(5|  
+>%6W+\*#&|0HS4E8QP^OIS-7C^1|&9H>BP\_8^\"WA\_|V\_M.Z20CEV\_P|H9XFBDG\_|7T<2;  
H^A52>16M17;R+DY^L4OG&T|G6R.\"K+&H(8X%6^\*QH8?V5W>|S2M6H;0YWQ3X937(%E\_MA^I>1#^L>CC^Z?Z&O;  
H^H39^EY;R1\$=RORGZ^H;|N|^P(|H|E6PL\_CY\_MEHOTL1^\"MNCNP@N04^6.T=|GBM33/^N|ZK(H@MG6;199|M0#Z|\_PKV  
6|^MN6\_M&\_-ZAIFF^QC@%?WF;O&\_VB\_S0|%@T\_P^O^=|L=TDA^+M\_A|5F>\_|C3H|\_|H\_M4O^YS  
J^#|AWSZ>OUKH|P^^(#2^Q^JOG8(%V?3)S^M;8A|JG1M%>1E13G4NV<MY;6=Q?W26UM\$9)7.%45L\_  
X+U|20+\$/43)\_C5CP3|ECIFIS&|81^\_|M24CA>\_MB\_VQ|FS?\_^-IMZY|H64A>3U\_FM6G^5HH^\"\$-P+|^+N96DAD|\$18Y^\_|G&?  
0U5|\_ZY9ZM<6T\_FPD2#\_M=NEQP2<<#^J|>\"\_|2Z|2V|H#L@S(Y|C\_4BHA^|K|4W=+M;4=^9XD+SVS>8H\_Y(Z\_|RY\_\"NCK  
|8:E\_9WA^8^V);C|RGX|3^6?TKTZUO9O\_MFV\_\"E?G5CR600\_AW|\_EVE\$J^#F50+Z^D\_J^TKST\_LP5022<\_#O7M>CV(TW2\_M+6S  
YCC\_W^J?U)KSL^#FGS=CMQ4|0MW+M%G%>L>=<5%CR6%\_|1110\_4444\_%%|%%|\_M^%\_|1110\_4444\_%%|%%|\_1110\_4444\_%%|%%|\_1110\_4444\_%%|%%|  
4444\_%%|%%|\_1110\_4444\_M\_%%|%%|\_1110\_4444\_%%|%%|\_1110\_4444\_%%|%%|\_1110\_4444\_%%|%%|\_1110\_4444\_%%|%%|\_1110\_4444\_%%|%%|  
M^%\_|1110\_4444\_%%|%%|\_1110\_4444\_%%|%%|\_17M\_A\_|D5|\_|ZX+7B%>W^O^17  
MTW\_K@M<\_|/|^!>IUX3XF:|%%|%%>6>@<3|3/^0+9\_P#7Q\_|^\_|OKU#XF?|@6S\_Z^M\_|937E|>Q@\_X2/Q7|O\*\*\*\*ZCG\"BBB@\_HHHH  
\*\*\*\*\_\"BBB@\_HHHH\_\*\*\*\*\_\"B\_MBB@\_HHHH\_\*\*\*\*\_\"BBB@\_HHHH\_\*\*\*\*\_\"BBB@\_HHHH\_\*\*\*\*\_\"BBB@\_HHHH\_\*\*\*\*\_\"BBB@\_HHHH\_\*\*\*\*  
\"BBB@\_HHHH\_\*\*\*\*\_\"BBB@\_HHHH\_\*\*\*\*\_\"BBB@\_HHHH\_\*\*\*\*\_\"BBB@\_HHHH\_\*\*\*\*\_\"BBB@\_HHHH\_\*\*\*\*\_\"BBB@\_HHHH\_\*\*\*\*\_\"BBB@\_HHHH\_\*\*\*\*  
\"BBB@\_MHHHH\_\*\*\*\*\_\"BBB@\_HHHH\_\*\*\*\*\_\"BBB@\_HHHH\_\*\*\*\*\_\"BBB@\_HHHH\_\*\*\*\*\_\"B\_MBB@\_HHHH\_\*\*\*\*\_\"BBB@\_HHHH\_\*\*\*\*  
\"BBB@\_HHHH\_DM\_^/F+\_|?^|Z|%^)\_|MOY:??\_P!=-'\_D^|ZM\_^/F+\_|?^|Z|%^)\_|OY:??\_P!=-'\_D^Y:O|\_|S.BG\_\"G|CS\_M;BBBNHYPHHHH  
\*\*\*\*\_\"BBB@\_HHHH\_\*\*\*\*\_\"BBB@\_HHHH\_\*\*\*\*\_\"BBB@\_HHHH\_M\_\*\*\*\*\_\"BBB@\_HHHH\_\*\*\*\*\_\"BBB@\_HHHH\_\*\*\*\*\_\"BBB@\_HHHH\_\*\*\*\*  
\"BBB@\_MHHHH\_\*\*\*\*\_\"BBB@\_HHHH\_\*\*\*\*\_\"BBB@\_HHHH\_\*\*\*\*\_\"BBB@\_HHHH\_\*\*\*\*\_\"B\_MBB@\_HHHH\_\*\*\*\*\_\"BBB@\_HHHH\_\*\*\*\*  
\"BBB@\_HHHH\_\*\*\*\*\_\"BBB@\_HHHH\_\*\*\*\*\_\"M\"\_\"BBB@\_HHHH\_\*\*\*\*\_\"BBB@\_HHHH\_\*\*\*\*\_\"BBB@\_HHHH\_\*\*\*\*\_\"BBB@\_HHHH\_M\_\*\*\*\*  
\"BBB@\_HHHH\_\*\*\*\*\_\"BBB@\_HHHH\_\*\*\*\*\_\"BBB@\_HHHH\_\*\*\*\*\_\"BBB@\_MHHHH\_\*\*\*\*\_\"BBB@\_HHHH\_\*\*\*\*\_\"BBB@\_HHHH\_\*\*\*\*\_\"L?  
7\_#MMKUNJR;8IX\_M|7^HSCV(|BMBBIE%25I;%1DXNZ/+>+KP)K4#^R4BN%|&\_0#1&Q51?^&O<#3V

#&+!-607J\*Y7@::ZLZ%BYGF=E/I4G8&[DAMD]HIV (L5J95\*TVZ,\*XKOKH^KZK>6YM+?S:\*\*/H' (8GG@GT-M KM:\*NK352/\*R:XOX%A@A82\$%U8L1R!@\$)=:-!HHI M4J,:2M\$=2!\*HIL\*\*\*\*U,PHHHH \*\*\*\* "BBB@ HHHH \*\*\*\* "BBB@ HHHH \*\*\*  
M\*\* "BBB@ HHHH \*\*\*\* "BBB@ HHHH \*\*\*\* "BBB@ HHHH \*\*\*\* "BBB@ HHH MH \*\*\*\* "BBB@ HHHH \*\*\*\* "BBB@ HHHH \*\*\*\*  
"BBB@ HHHH \*\*\*\* "BBB@ M HHHH \*\*\*\* "BBB@ HHHH \*\*\*\* "BBB@ HHHH \*\*\*\* "BBB@ HHHH \*\*\*\* "MBBB@ HHHH \*\*\*\*  
"BBB@ HHHH \*\*\*\* "BBB@ HHHH \*\*\*\* "BBB@ HHHH \*\* M\*\* "BBB@ HHHH \*|O|+?BOIO 7!:0KV PM P BOIO %P6N!"  
+U.O"?MS\$7HHHKRST\*B?B9 R:/ KX JE->7UV Q9I4:19>K&5KR4-<@8A8.IC=0 M^Q07D7 ">.) ?G H&OAPM6\$::4F>?B\*) ?  
G \_ 1H X3 MS1/I | WZ-= /MZ7R/8U.OTU% ME \_ @IC4I'345SA PGFB?WY ^ 1H P"\$IT3 ^ / I ^ C1 > E \_ @IC4I'345S/ M ">.) ?  
G P" 1H X3S1/I \_ 'Z-'MZ7R#V-3L=-17\_P#">.) ?G H&C M (3S1/I P#WZ-'MZ7R#V-3L=-17\_ )YHG|^? +I&C A/- \$ OS |+?  
HT> MWI?S(8U.OTU%WI?S(8U.OTU%< MS PGFB?WY | OT:/^\$IT3 ^ / P|^C1>E \_ @IC4I'345SA PGFB?WY ^ 1H  
M P"\$IT3 ^ / I ^ C1 > E \_ @IC4I'345S/ ">.) ?G P" 1H X3S1/I \_ 'Z-'MZ7R#V-3L=-17\_P#">.) ?G H&C (3S1/I P#WZ-  
'MZ7R#V-3L=-17\_ )YHG|^? +I&C A/- \$ OS |+? HT> WI?S(8U.OTU%WI?S(8U.OTU%E \_ @IC4I'345SA PGFB?  
WY ^ 1H P"\$IT3 ^ / I ^ C1 > E \_ @IC4I'345S/ ">.) ?G P" 1H X3S1/I \_ 'Z-'MZ7R#V-3L=-17\_P#">.) ?G I MI&C  
(3S1/I P#WZ-'MZ7R#V-3L=-17\_ )YHG|^? +I&C A/- \$ OS |+? MT> WI?S(8U.OTU%WI?S(8U.Q MTU%E \_ @IC4I'345SA  
PGFB?WY M ^ 1H P"\$IT3 ^ / I ^ C1 > E \_ @IC4I'345S/ ">.) ?G P" 1H X3S1/I \_ M 'Z-'MZ7R#V-3L=-17\_P#">.) ?G H&C  
(3S1/I P#WZ-'MZ7R#V-3 ML=-17\_ )YHG|^? +I&C A/- \$ OS |+? HT> WI?S(8U.OTU%WI?S(8U.OTU%E \_ @IC4I'345SA PGFB?  
WY ^ 1H P"\$IT3 ^ / I ^ C1 > E \_ @IC M4I'345S/ ">.) ?G P" 1H X3S1/I \_ 'Z-'MZ7R#V-3L=-17\_P#">.) ?G H&C  
(3S1/I P#WZ-'MZ7R#V-3L=-17\_ )YHG|^? +I&C A/- \$ OS |+? HT> WI?S(8U.OTU%WI?S(8U.OTU%E \_ @IC4I'345SA PGFB?  
WY ^ 1H P"\$IT3 ^ / I ^ C1 > E \_ @IC M4I'345S/ ">.) ?G P" 1H X3S1/I \_ 'Z-'MZ7R#V-3L=-17\_P#">.) ?G H&C  
(3S1/I P#WZ-'MZ7R#V-3L=-17\_ )YHG|^? +I&C A/- \$ OS |+? HT> WI?S(8U.OTU%WI?S(8U.OTU%E \_ @IC4I'345SA PGFB?  
WY ^ 1H P"\$IT3 ^ / I ^ C1 > E \_ M \_ @IC4I'345S/ ">.) ?G P" 1H X3S1/I \_ 'Z-'MZ7R#V-3L=-17\_P#">.) ?G H&C  
(3S1/I P#WZ-'MZ7R#V-3L=-17\_ )YHG|^? +I&C A/- \$ O MS |+? HT> WI?S(8U.OTU%WI?S(/ M8U.OTU%E \_ @IC4I'345SA PGFB  
M?WY ^ 1H P"\$IT3 ^ / I ^ C1 > E \_ @IC4I'345S/ ">.) ?G P" 1H X3S1/MI \_ 'Z-'MZ7R#V-3L=-17\_P#">.) ?G H&C  
(3S1/I P#WZ-'MZ7R M#V-3L=-17\_ )YHG|^? +I&C A/- \$ OS |+? HT> WI?S(8U.OTU%WI?S(8U.OTU%E \_ @IC4I'345SA PGFB?  
WY ^ 1H P"\$IT3 ^ / I ^ C1 > E \_ M \_ @IC4I'345S/ ">.) ?G P" 1H X3S1/I \_ 'Z-'MZ7R#V-3L=-17\_P#">.) ?G H&C  
(3S1/I P#WZ-'MZ7R#V-3L=-17\_ )YHG|^? +I&C A/- \$ OS |+? HT> WI?S(8U.OTU%WI?S(8U.OTU%E \_ @IC4I'345 SA  
MPGFB?WY ^ 1H P"\$IT3 ^ / I ^ C1 > E \_ @IC4I'345S/ ">.) ?G P" 1H X M3S1/I \_ 'Z-'MZ7R#V-3L=-17\_P#">.) ?G H&C  
(3S1/I P#WZ-'M MZ7R#V-3L=-17\_ )YHG|^? +I&C A/- \$ OS |+? HT> WI?S(8U.OTU%WI?S(8U.OTU%E \_ @IC4I'345SA PGFB?  
WY ^ 1H P"\$IT3 ^ / I ^ C1 MJ>E \_ @IC4I'345S/ ">.) ?G P" 1H X3S1/I \_ 'Z-'MZ7R#V-3L=-17\_P#">.) ?G H&C  
(3S1/I P#WZ-'MZ7R#V-3L=-17\_ )YHG|^? +I&C MC A/- \$ OS |+? HT> WI?S(8U.OTU%WI?S(8U.OTU%E \_ @IC4I'345 MS/A  
PGFB?WY ^ 1H P"\$IT3 ^ / I ^ C1 > E \_ @IC4I'345S/ ">.) ?G P" MIH X3S1/I \_ 'Z-'MZ7R#V-3L=-17\_P#">.) ?G H&C  
(3S1/I P#W MZ-'MZ7R#V-3L=-17\_ )YHG|^? +I&C A/- \$ OS |+? HT> WI?S(8U.OU5 MO QIQ?FX G7HOQ/\_ /+3 |  
KH /A7B>7C|0TF1C)/@."W1KK &WO@)Z| M6B64UV6B=BV^ KU KFJ58.K/H7-X4YJG>=BG17 \_ ">.) ?G \_ 1H X3 MS1/I |  
WZ-= /MZ7R/8U.OTU% ME \_ @IC4I'345SA PGFB?WY ^ 1H P"\$IT3 ^ / I ^ C1 > E \_ @IC4I'345S/ M ">.) ?G P" 1H X3S1/I \_ 'Z-  
'MZ7R#V-3L=-17\_P#">.) ?G H&C M (3S1/I P#WZ-'MZ7R#V-3L=-17\_ )YHG|^? +I&C A/- \$ OS |+? HT> MWI?  
S(8U.OTU%WI?S(8U.OTU%< MS PGFB?WY | OT:/^\$IT3 ^ / P|^C1>E \_ @IC4I'345SA PGFB?WY ^ 1H M P"\$IT3 ^ /  
I ^ C1 > E \_ @IC4I'345S/ ">.) ?G P" 1H X3S1/I \_ 'Z-'M'MZ7R#V-3L=-17\_P#">.) ?G H&C (3S1/I P#WZ-'MZ7R#V-3L=-1  
M7\_ )YHG|^? +I&C A/- \$ OS |+? HT> WI?S(8U.OTU%WI?S(8U.OTU%E \_ @IC4I'345SA PGFB?WY ^ 1H P"\$IT3 ^ /  
I ^ C1 > E \_ @IC4I'345S/ ">.) ?G P" 1H X3S1/I \_ 'Z-'MZ7R#V-3L=-17\_P#">.) ?G I MI&C (3S1/I P#WZ-'MZ7R#V-  
3L=-17\_ )YHG|^? +I&C A/- \$ OS |+? MT> WI?S(8U.OTU%WI?S(8U.OTU%E \_ @IC4I'345SA PGFB?WY M ^ 1H P"\$IT3 ^ /  
I ^ C1 > E \_ @IC4I'345S/ ">.) ?G P" 1H X3S1/I \_ M 'Z-'MZ7R#V-3L=-17\_P#">.) ?G H&C (3S1/I P#WZ-'MZ7R#V-3  
ML=-17\_ )YHG|^? +I&C A/- \$ OS |+? HT> WI?S(8U.OTU%WI?S(8U.OTU%E \_ @IC4I'345SA PGFB?WY ^ 1H P"\$IT3 ^ /  
I ^ C1 > E \_ @IC M4I'345S/ ">.) ?G P" 1H X3S1/I \_ 'Z-'MZ7R#V-3L=-17\_P#">.) ?G H&C (3S1/I P#WZ-'MZ7R#V-  
3L=-17\_ )YHG|^? +I&C A/- \$ O MS |+? HT> WI?S(8U.OTU%WI?S(/ M8U.OTU%E \_ @IC4I'345SA PGFB M?WY ^ 1H P"\$IT3 ^ /  
I ^ C1 > E \_ @IC4I'345S/ ">.) ?G P" 1H X3S1/MI \_ 'Z-'MZ7R#V-3L=-17\_P#">.) ?G H&C (3S1/I P#WZ-'MZ7R M#V-  
3L=-17\_ )YHG|^? +I&C A/- \$ OS |+? HT> WI?S(8U.OTU%WI?S(8U.OTU%E \_ @IC4I'345SA PGFB?WY ^ 1H P"\$IT3 ^ /  
I ^ C1 > E \_ M \_ @IC4I'345S/ ">.) ?G P" 1H X3S1/I \_ 'Z-'MZ7R#V-3L=-17\_P#">.) ?G H&C (3S1/I P#WZ-'MZ7R#V-  
3L=-17\_ )YHG|^? +I&C A/- \$ OS |+? HT> WI?S(8U.OTU%WI?S(8U.OTU%E \_ @IC4I'345SA MPGFB?WY ^ 1H P"\$IT3 ^ /  
I ^ C1 > E \_ @IC4I'345S/ ">.) ?G P" 1H X M3S1/I \_ 'Z-'MZ7R#V-3L=-17\_P#">.) ?G H&C (3S1/I P#WZ-'M MZ7R#V-  
3L=-17\_ )YHG|^? +I&C A/- \$ OS |+? HT> WI?S(8U.OTU%WI?S(8U.OTU%E \_ @IC4I'345SA PGFB?WY ^ 1H P"\$IT3 ^ /  
I ^ C1 MJ>E \_ @IC4I'345S/ ">.) ?G P" 1H X3S1/I \_ 'Z-'MZ7R#V-3L=-17\_P#">.) ?G H&C (3S1/I P#WZ-'MZ7R#V-  
3L=-17\_ )YHG|^? +I&C MC A/- \$ OS |+? HT> WI?S(8U.OTU%WI?S(8U.OTU%E \_ @IC4I'345 MS/A PGFB?WY ^ 1H P"\$IT3 ^ /  
I ^ C1 > E \_ @IC4I'345S/ ">.) ?G P" MIH X3S1/I \_ 'Z-'MZ7R#V-3L=-17\_P#">.) ?G H&C (3S1/I P#W MZ-'MZ7R#V-  
3L=-17\_ )YHG|^? +I&C A/- \$ OS |+? HT> WI?S(8U.OTU M%WI?S(8U.OTU%E \_ @IC4I'345SA PGFB?WY ^ 1H P"\$IT3 ^ /  
MI ^ C1 > E \_ @IC4I'345S/ ">.) ?G P" 1H X3S1/I \_ 'Z-'MZ7R#V-3L= M-17\_P#">.) ?G H&C (3S1/I P#WZ-'MZ7R#V-  
3L=-17\_ )YHG|^? M +I&amp

[illegible]



^@U"5W8JHD>#5V6PY1\*Z)XJUGD)JNK-2 YCM47#7 ZG M#G@?3&?2050BOX"L15T"XUC3I6+4K-  
3\*YB3'G1CIP(4@<@I>5H0S2VTI M<L1C1RQ1IU."K Y!%#7\*100<^S+&QM=L8,\*R@2"VA7;'&@P%6\*YSP-XD'  
MBKPE9ZD2M&WRI@#M\*O#?GP?H171ULB HHHH \*\*\*\* "BBB@ HHHH \*\*\*\* "B MBB@ HHHH \*\*\*\* "BBB@ HHHH \*\*\*\* "BBB@  
HHHH \*\*\*\* "BBB@ HHHH \*\*\*\* "BBB@ HHHH \*\*\*\* "BBB@ HHHH \*\*\*\* "BBB@ HHHH \*\*\*\* "BBB@ HHHH \*\*\*\* "BBB@  
)\$2X I' '\$G\_H\$=#13/^2<:W\_P! KN-&Q M/?D6J?1N7+|01^(KNJ^>OCEKGV1Q5:Z3&V8M/BRX\_Z:/@G\_P="?F:F3LA MK<|  
fT:3)=9UNRTR\_674RQ^F3@G!S^%:78EM:Q6EK#;0KMBA01HHH!@ "OC M6QOKK3;R:1LKB2WN8|  
D8VPRY&#-0FMK\_A/!%G\_\$.6I?I @0U9QDD4U<I' MXYZ)IB4VVK1KB\_APYQ\_P M\$P#\_..E/R-87PIUS^Q/"UEO?;!>YM)/^!/?=  
M\_P#^@OZUSFI^(!:UJ%(M3U.ZNXXVW(LTA8^?F1FLY:.19\$8JZD%6'4\$=Z3> MMPMH?:M>0 'W\_D!Z/\_UO\_Z#7H\_A?  
65!0^&-.U52\_W\$ (9P\_@<=<P8\$5YXQ? M?0^0\_H+UO\_@.UK+X25N/>=>\$^1QT/\_L(0?^C%KZ\_KY!)\_P#(XZ^-A" M#\_T8M?  
7I33(\*L\_U^/+\*?E@AQN.H\*1H!)G^8KU\_O OCIXABOM:LM\$MYXL5 M.DY7M(CV,+10!\_P"/54MA+<1HB0R3(B)S\_#ZUJ5)C^".  
\*\_6O&ND604LK7\*O M( (4fF\_0&OKP7\*KF'3T:Y:/3=T4?7)!\_X#7.^\_M:/B+Q=J6IALQRS\$1?\_7-?E7!\_\*MI:7KNJZ(93I>H7%F9<>88)"N|&<9Q|34MZW^0^QR\_C|Z5|B^|\_!\$ P"\$>18: MGI@7;%%,6B'\_ \$S;YE\_0BI?  
^\$|16?1#%J7\_@0U9&HZI?\_O=? M1NYKJ?\_?R M5B58'09-.4DP2L>P\_77/^0GH\_C^EW#"^0\_..R?K7M=?)/@?7/^\$=19:9J+ M-  
MA64)>WEM|K?D#G|^\*MJJ#T)EN?\_?QJ\_Y^)+\_U1?R-9\_!D:KK=|!#>|/3^9I MFE01S\_|  
>0F23I&?)X8JN50<5TC5<=<B7N4M9\_Y>H?I>TG\_\*\*,:^<RM9\_Y>H?I>TG\_H)KXUJ M\*A43Z>^\$^)\_M+\_WIO\_ T:15?  
C5\_R3N;\_KYB\_F:M?#"\_)EI?I\_03?<C7JK\_M:O^2=S2I?7I5\$?99\_U/FNGR121\$"2-D)Z:AC\_KF-EL:LL;W=O%/"Z\_-'  
M\*^92,>AK,..E-V/C,8R,G\_!^A/A9X&+6UG#X@M+X:M=\$861DVK;MW\_0!AO M<\_AC->8?\$\_PPD?  
\*%\_19\_#GQ;J%E!>6NBRR6|Z^2-Q(@W\*1D'E02N7KZ MY|S?B)H'\_8/|\_+0!645\_2"1TY\_&NQHK112);N%QI,DD1@\_M2%^DKN"  
OTZD(P=)7SA|80%Q|N^?)?+MLV6FDH<^AYOXC^W1|ZT2=D)\* MYYO3HV^2\*Y57"D^W0^QKN?  
A5X03Q3XGWWDF/:9+YDX1V/"I^!)Y^BFN?I M%WAV;PMXFO\_\*F#%(WW0N?XXSRK?EUJP:RMI  
+\_+Q9|@U:7P|=28M|TF2W)\_AF\_Y'\_(#P/6O?JV MB|HS:L%#%, HHHH \*\*\*\* "BBB@ HHHH \*\*\*\* "BBB@ HHHH \*\*\*\* "BBB@  
HHHH \*\*\*\* "BBB@ HHHH \*\*\*\* "BBB@ HHHH \*\*\*\* "BBB@ HHHH \*\*\*\* "BBB@ HHHH \*\*\*\* "BBB@ HHHH \*\*\*\* "BBB@  
P\_..Y'+5\_P#KT\_-T8M>^5X^| M#^A D^5M#8B6X44450@HHHH \*\*\*\* "BBB@ HHHH \*\*\*\* M"BBB@ HHHH \*\*\*\* "BBB@ HHHH \*\*\*\*  
"BBB@ HHHH \*\*\*\* "BBB@ HHHH \*\*\*\* M\*\*\* "BBB@ HHHH \*\*\*\* "BBB@ HHHH \*\*\*\* "BBB@ HHHH \*\*\*\* "BBB@ HHHH \*\*\*\*  
"BBB@ HHHH \*\*\*\* "BBB@ HHHH \*\*\*\* "BBB@ HHHH \*\*\*\* "BBB@ HHHH \*\*\*\* "BBB@ HHHH \*\*\*\* "BBB@ HHHH \*\*\*\*  
"BBB@ HHHH \*\*\*\* M"BBB@ HHHH \*\*\*\* "BBB@ HHHH \*\*\*\* "BBB@ HHHH \*\*\*\* "BBB@ HHHH \*\*\*\* "BBB@ HHHH \*\*\*\*  
(5UK\_KA'\_Z\$;100/^&X\_ZYM\_\*O\$/@#\_P\_A760^N\$?\_\*\$E|H: MV/=J\*\*\*H04444 %%%% !1110 4444 %%%% !1110 4444 %%%%  
!1110 444 M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 M 4444 %%%% !1110 5X5|>=<|  
f4=.T\*)\_E@0W\_P|YN%|JP\_3\_P\*O=:+|\_ M"SQ7KWC#4=4@^R30W\$@-C-M(4 @CJ\_\*F5!:#6YQOPR/Q^(\_%G;7,\*R  
MYD(XGIAD%5Z\_CT+1%1^\_?0W\_@?A^Z%W3?\_ =:YOX5^+SP=#?7J\_-V\_MZVHJO-N"(GKCJ2?T?>BT1C9:@V<|\_P@?A/\_  
\*%W3?I\_P'6O?C1X2LM^O=-\_MU#2!\_UM+A&ADCA4^H=3D"J0?I\_QVOH:N8|?^%F7>\$Y!A:-+I766W:3IH\_M<>OU!8?  
C1)70)GS9X-UL^?%FZF6(CBF\_E\_ZYMAK?H37UM^O;=R#D#UK#@^CZ5\_MW\_+\*518?|/\_P(^%?<  
06@V5U9&+!L=0D62ZAMDBF="2&8\*>3U^M\*M\*T\$C\_MZXKUKP(15M\*)^<8=)N|!"FECD=R16W:1QSW(JH<\_  
OO.ES(MOFF\_I\_P!O\_B:A\*2\*.3.MO?C|HRP|!HEU)-V\$|BHH\_M\_+=FO)O%7C#5\_&%^+G4YAL3(B@C&(X@?0>ON>:  
f\*X\$^)^Y"#+>Z7\$N>?WKD\_ MD\$Q^M=5HGP\_TVVE676=3E00.?)A3RE^A.22/IBG:3%HC\$+P#X(NO&6MK^M:/ M3H6#74^\_  
/H/H/X\_IUKZGBBC@A2&)\_D<:A451@\*IP\_\*@TF3K/2;\*&RT^VCM|\_M:(82..8\_P3|HZ?>I+8W\$=JZQW#1,L3MT5B\_-?  
Q|XQ|N)Y\_M\_\$G7/H?>Z\_MC8X/<#;\_M^9K/P4!8%R/+LCS|H1Q|>E>X^"/#?\_ BGA.STIV1YT!>9TZ,I)QI#@?0\_M5,4fW8V|  
\_X0/PG\_-\_"HO\_X#K1\_P'(X3\_A=TW\_P'6NAHJH(D^3\_(@Z\_M"OASOMJ-C%&SMB\_G0\*.@1^0!H#)X5U?P-US|XIN-  
D:6\$H190\$ \_P+1+D\_M^EOR%=S|5AY?>+YK&\_TDP?<:H\$\*596VTSE<^8E0SKB\_#GPD|7Z5XETV\_M86<26|RDKOY^<##DC  
\_1D8|ZSLU(HT>C\_%\_P#Y)EJG^|\_#\_C4KYAKZS|>M:!=>)|MH-D|27\$VPH920ORNK8)/85XE!\$ \_%R|66Q12>7:XXY#\_-;8  
M19|"-\_R|/\_O:/\_T\$5=J"QMS::?6S,&.,2QDCO@\_5/6A(4444 %?/\_QI\_M\_P"1JTW\_\*O\_9VKZ\_KRSXJ?#S6?%VJ65\_136S"&#R7CE??:  
O\$Y^&#U\_2IDK MH:W/?A'\_P\_E/T?\_+;?>B9\*^H:4^OPL|0^\_&5GJ^I&TCM|8295)=S.61\_ME&#\_..S^>UT05D\$@KYU^\_O\_<  
"/=M\_V#X+T\_2OHJO|BC|\_15^C;74J\*\_M:V>-.986CDDV\_&8YZ8(^B2N@6YPWP5\_P"2B1?I>TOA7TH7COPT^&>O>?&?M%  
(U74S:I"D+QA\$EW\_Q;MC^XU!1:60/<^0%G\_(XZY\_V\$)\_1C5|H^|\_O^0^MK'\_7RC\_H-<|XC^#OBB|2:E>6GV.6%"YN9)D/G;2  
S\$@S\$=>+;|^%O@W40!VC MWD\_10\_9KF82|(6+0!CDX^3%\_XV|\*O&4,I5@""\_ \$'O7R3XVT\_&2%>H:~(C\_MA23?76-  
N5\_ ("U!KZWKS7X1\_#R|7M97VE&\_7MNIBD65MN^J\_L"4/\_?55\_M-70DSB|/@=XC^P^(+C0YWO#?K0BR>DJCI^\*Y\_IY%?0-  
?/6B\_""QEI^N6\_ZILH\_M&MYTE\$AGSC!!Z<\_2OH6B%|:@PHHHJA|1110 4444 %%%% !1110 4444 %%% M% % !1110 4444 %%%%  
!1110 4444 %%%% !1110 4444 %%%% !1110 444 M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444 M4  
M^!2\_ "(EQ\_V\$)/A\_T".NA^G)\_-;\_ZX#\_T(5SWP+\_Y\$2X\_I' '\$G\_\*!4\_-'MT/3:\*\*\*H04444 %%%% !1110 4444 %%%% !1110 4444  
%% % !1110 444 M4 %%%% !1110 4444 %%%% !1110 4444 0W=@\_8V4JW<\_LA@C:21O15&2?R M?>L:E-K.LWN13-  
\_MNHE(STRHZ\_MOI=M=S7BK&9X@O6?\*\_^H/XUW7\_!/\_&A=TW\_P\_IUK7TRPBTk2K3X|H\_M5;0I^GN%  
\_I\*M5:22)NFI2NY(%##(Z@|C7RQJFGS:3JU\_MWIUP,36TS1/!E3C\_?9E>-?\$.X5:OKWBF351%LT=RB^=)|L8\_!C/3&"/Q\$  
M4SCV&F2\_?7/TO4\_#D;Y|>Q<0@G^!N&|@0#\_P\*G?\_W\_D!Z/\_UO\_Z#5;X<M?#?Q/X7?PZE>\_98f01/,"\$FW\_X(X^IX\*?  
PKL/B;X+N\_&>AVT^A\_#'=6TW\_MF\*)B0K\_C|&0#@|#1KR^#?\_NBWJ:9KNGW|JL=K\_%>Y?|+ZT\_M'\_H%:E^4?\_Q5<3\_PHIQ9\_P|+  
-|\_M\_132CX&^+^0/-TT>YG\_-XFI7\_MANS\_-M+Q#|=Z|MY+?0|/%EN!"VF9H|>JKC\_/US7DLLMQ\_1LKO)+ (Q9G8DLQ/4D|  
MS7K\_M|18D?\_ \$\_6;&!<18\$>4\_D0M>B^%0A9X+1,31W8C>10TY6>YP0A|54<\_M#Z|D>M^+)|A=(P\_@\_P")M:|LWUS4XC'?  
7<>V&%AAH8^O|AH8^8#W(K|B:B\_K\_MGI@^|J0F1H|POV:'GG<^|QIA@\_#\_NOKSOXK^#|<|V7>FPZ2T!CMW=Y8Y7VD  
MD@!2.W\$?G5VLM;L^\_D1H)1%+Q\_4#J37U-H\_PY-V6BV5M=Z)87%\$%"BS  
M2R0JS.^/F)/US7G^@|X.ZY8^&\_&\_U@6J6=K\*)BJ2IV=EY4\_8I0\_YI5|M4PCW\_M|LY|\_A\_-"T+NF\_P#@.MTMKVWC|!AB"L00+&CK  
ME<|>N\*P!&570HZAE88(X|JVD\*Y14U16\_#G7A\_A(/\_NFW3MNGB3|/D|IT\_MXR?+26S|QC"QGP=F>\_01UQ7H\_P\_\*?\_M^<\$\_=J&WU  
M=H|!/\*DD,<4fL0^&)|<+^51%\_IV/+?C5\_R427\_KVB\_D:M?\_K\_)NY\_I!\_MIG\_H<==112\_AGKWB:Q0=5TLVKPO"D92238RD9H8J?  
X7?#C6\_"GBX&U/56MD\_MC:V:%8XY-|EE>\_F/EHL^8+Z^K=%%\$A1110 5145|KUWS\_+Q;\_Z1?Q\_MF0Y7\$^\_  
P^A&B\_-?"GI7P2\_Y)|^ON7\_P|EKT\_N2^/AFH)^\_?TFW4^A>X\_ MSRMY+|J\_<8&2|Z5UM4MA|JOQ|\_Y\_MW-\_UQ?S\_-  
(#T"Z|>#K'2\_UXGN=(Y\$=(2C\_MU9|<07!1HXHY-Y5AD\$|\_#(Q^5>CU:VU)84444P///C5\_R3N;\_KYB\_F: ^:Z^K M?B^X:N\_?%  
A\*^3+&2)+@R)(OFDA3M/(R<5XQ#|O\$OTD|HXL8E)Y=|@?D":S\_MFFV4F?1T/^HC\_P!T?RH-1=D:KG\_!3JT)"O:OCI\_PAS1\_^O9-  
\*\$O>\_!V\_M^\*7PIU^OE+HUI&^#M=B|\_&\*F6)H7\_MFCMBY:\$\_G\*\_O?ZUZ|\_POW2\_<@>?I\_5KD/^%>+|^>FF+?I0\_ (FC\_A1W  
MBS\_GHO\_-'\_P")J\$S+8:LSL8\_CYI+2\*!T:15"0&82\*<#UQ79\_!\$@\_PYU|E\_M.5:U)|1D5XZ6P-15%U#S:~JDMYS'  
\_|YKW37|\_ \$MGPK>Z,DOEF>W^2,X\_M..?Q?JE=K43L?I>Z>?^C/X+\_,ZW33\_P!MV|\_B:/^%>+|^>FF+?I0\_ (FH2DBG9G>?  
+|X|+|\_M|AK'?+P\_ P".5N>?>B?H?B\_5CMC|20W\_C\_@TQHH8&0^KGFO)\_P^A1WBS\_M\_GHO\_?IO\_B:Z\_X\_ ##6\_ "WBK^U-  
3EM)2!T589"Q+^J!QC\_6G\*Y+2.O^(\_ MBL>\$\_-'\_ %P%XH16^(\_M(+FP:VDL880D4;R|2C9RQ(|I?)  
@:16=X\$^#^J:XFMM3U|H+>T;S(XHY-Y>0 M?>SQ@\_'GZ@4D)MC321Z|/?"PV)^\$K:SD4"IE\_?71/\_1NWX#\_ #WKF?C3X4  
M\_M;P^FN6R9NM;|S\_Y>\$GG\_OD|\_3=7I?\_EBCCA>5%>-U^NK#(8^@U=M+!\$W\_MU/B^WN);6YBN0&CFBPXGTU11161  
M9|M\_S\_D^!2\_ "(EQ\_V\$)/A\_T".NA^G)\_-;\_ZX#\_T(5SWP+\_Y\$2X\_I' '\$G\_\*!4\_-'MT/3:\*\*\*H04444 %%%% !1110 4444 %%%% !1110  
4444 %%%% !1110 M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444  
%% % !1110 4444 %%%% !1110 4444 %%% M% % !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444 M4  
%% % !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%  
!1110 4444 %>&^%/\_M^3G\_/\_M|N\_+T1)7N5>&^%/\_^3G\_^WN|\_!\$E1/8<3Z:HHHK(L^6\_@9\_R.6K\_M\_P#7HW\_HQ:HKP/X&?I  
(Y\_Q\_P!>C?I\_HQ:HK&Q\$MPHHHJA|1110 4444 M% % !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4  
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11 M10 4444 %%%% !1110 4444 %%%% !1110 4444  
%% % !1110 4444 %%%% M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444  
%% % !1110 4444 %%%% !1110 4444 %%%% !1110 4 M444 07G\_!XW\_7-OY5XA|\_?^OKK7\_7"/T(U?>?I>-Q\_US\_<5>C?\_D^Z  
MU\_UPC\_+0C4O=#6Q|M1115""BBB@ HHHH \*\*\*\* "BBB@ HHHH \*\*\*\* "BBB@ M HHHH \*\*\*\* "BBB@ HHHH \*\*\*\* "BBB@ HHHH

\*\*\* "BBB@ HHHH \*\*\* "MBBB@ HHHH \*\*\* "BBB@ HHHH \*\*\* "BBB@ HHHH \*\*\* "BBB@ HHHH \*\*\* "M\*" "BBB@ HHHH \*\*\*  
"BBB@ HHHH \*\*\* "BBB@ HHHH \*\*\* "BBB@ HHHH MH \*\*\* "BBB@ HHHH \*\*\* "BBB@ HHHH \*\*\* "BBB@ HHHH \*\*\*  
"BBB@ M HHHH \*\*\* "BBB@ HHHH \*\*\* "BBB@ HHHH \*\*\* "BBB@ HHHH \*\*\* "MBBB@ HHHH \*\*\* "BBB@ HHHH \*\*\*  
3^G )-; ZX# T(5SWP+ Y\$2X I M"\$G \*!70 \$S DG&M I Z!6F D |151 POK70^@5IOY/ P#%51+447<-#YI X7UKW MW 0\*TWG P#BJA A260?I K3?R?  
MZ!6F D \_51 P +ZUI \_\*!6F D \_P 57TM11=IPT/FG A260?I 0\*TWG ^ M\*H X7UKW 0\*TWG  
/BJ^EJ\*+ON&A I T | +ZUI H %;; ^3 P#Q5' ^"M> Z!6F M D \_57TM11=IPT/FG (7UKW 0\*TWG | B I / ^ %! : I T "M - ) P! K3?R? XJOL BBH AH? / " ^ M > Z!6F D P # 151 POK70 ^ @ 5IOY / / % 51 + 447 ? < - # Y I X7UKW MW 0 \* T W G P # B J A A 260 ? I K 3 ? R ?  
\_ P " \* K Z 6 H H N ^ X : ' S 3 \_ P + Z U I \_ \* ! 6 F D \_ M P 51 POK70 ^ @ 5IOY / \_ % 51 + 447 ? < - # Y I X7UKW 0 \* T W G \_ B J / ^ % ! : I T " M - ) |  
XJOL BBH AH? / A POK70 ^ @ 5IOY / P # % 4 ? | " ^ M > P " @ 5IOY / | M % 51 + 447 ? < - # Y I X7UKW \_ \$ " M - ) \_ B J / ^ % ! : I T " M - )  
\_ P # XJOL BBH AH? / M / " ^ M > Z!6F D | 151 POK70 ^ @ 5IOY / P # % 51 + 447 ? < - # Y I P " % ! : I T " M - ) \_ ( J C A 260 ? I  
0 \* T W G ^ \* K Z 6 H H N ^ X : ' S 3 \_ POK70 ^ @ 5IOY / \_ % 4 ? | + Z U I H % ; ; ^ M 3 | Q 5 ? 2 U % % W W # 0 ^ : ? ^ % ! : I T " M - ) | X J C  
( 7 U K W \_ 0 \* T W G | M B J ^ E J \* + O N & A I T | " ^ M > P " @ 5IOY / | % 4 ? | + Z U I H % ; ; ^ 3 / Q 5 ? 2 U % % W W # 0 ^ : ? ^ % ! : I T " M - ) P # X J C A 2  
60 ? I K 3 ? R ? \_ \* K Z 6 H H N ^ X : ' S 3 \_ + Z U I H M % ; ; ^ 3 | Q 5 ' OK70 I H % ; ; ^ 3 \_ ! 5 ? 2 U % % W W # 0 ^ : ? ^ % ! : I P ! K 3 ? R ? X J M C A 260 ? I  
K 3 ? R ? | ^ \* K Z 6 H H N ^ X : ' S 3 \_ POK70 ^ @ 5IOY / / % 4 ? | + Z U I H % ; ; ^ M 3 | Q 5 ? 2 U % % W W # 0 ^ : ? ^ % ! : I A 260 ? I K 3 ? R ? P " \* H X7UKW \_ \$ " M - )  
\_ B J ^ E J \* + M O N & A I T | + Z U I H % ; ; ^ 3 / Q 5 ' ^ " M > Z!6F D | 157TM11=IPT/FG A260?I M I K3?R? \_ \* H P " % ! : I T " M - ) \_  
( J O I : B B H A H ? / \_ O K 70 I H % ; ; ^ 3 \_ M ! 5 ' ^ " M > Z!6F D P # 157TM11=IPT/FG A260?I K3?R? | ^ H X7UKW 0 \*  
M T W G P # B J ^ E J \* + O N & A I T P # " ^ M > Z!6F D \_ 51 P + Z U I \_ \* ! 6 F D \_ P 5 M 7 T M 11 = I P T / F G A 260 ? I  
0 \* T W G ^ \* H X7UKW 0 \* T W G \_ B J ^ E J \* + O N & A I T \_ M | + Z U I H % ; ; ^ 3 P # Q 5 ' ^ " M > Z!6F D \_ 57TM11=IPT/FG (7UKW 0\*TW  
M G | B I / ^ % ! : I P ! K 3 ? R ? X J O I : B B H A H ? / \_ " ^ M > Z!6F D P # 151 POK70 M ^ @ 5IOY / / % 51 + 447 ? < - # Y I X7UKW 0 \* T W G P # B J A  
A 260 ? I K 3 ? R ? P " \* M K Z 6 H H N ^ X : ' S 3 \_ P + Z U I \_ \* ! 6 F D \_ P 51 POK70 ^ @ 5IOY / \_ % 51 + 447 ? < - # M Y I X7UKW 0 \* T W G  
/ B J / ^ % ! : I T " M - ) | X J O I : B B H A H ? A POK70 ^ @ 5 MIOY / P # % 4 ? | " ^ M > P " @ 5IOY / | % 51 + 447 ? < - # Y I X7UKW \_ \$ " M - ) \_ B J /  
M ^ % ! : I T " M - ) P # XJOL BBH AH? / " ^ M > Z!6F D | 151 POK70 ^ @ 5IOY / P # % 51 + 447 ? < - # Y I P " % ! : I T " M - ) \_ ( J C A 260 ? I  
0 \* T W G ^ \* K Z 6 H H N ^ M X : ' S 3 \_ POK70 ^ @ 5IOY / \_ % 4 ? | + Z U I H % ; ; ^ 3 P # Q 5 ? 2 U % % W W # 0 ^ : ? ^ % ! : I T " M - ) | X J C  
( 7 U K W \_ 0 \* T W G | B J ^ E J \* + O N & A I T | " ^ M > P " @ 5IOY / | M % 4 ? | + Z U I H % ; ; ^ 3 / Q 5 ? 2 U % % W W # 0 ^ : ? ^ % ! : I T " M - ) P # X J C A 260 ? I  
K 3 M ? R ? \_ \* K Z 6 H H N ^ X : ' S 3 \_ + Z U I H % ; ; ^ 3 | Q 5 ' OK70 I H % ; ; ^ 3 \_ ! 5 ? 2 U % % W W # 0 ^ : ? ^ % ! : I P ! K 3 ? R ? X J C A 260 ? I K 3 ? R ? |  
^ \* K Z 6 H H N ^ X : ' S 3 \_ P MOK70 ^ @ 5IOY / / % 4 ? | + Z U I H % ; ; ^ 3 | Q 5 ? 2 U % % W W # 0 ^ : ? ^ % ! : I A 260 ? I K 3 ? R ? M P " \* H X7UKW \_ \$ " M - )  
\_ B J ^ E J \* + O N & A I T | + Z U I H % ; ; ^ 3 / Q 5 ' ^ " M > Z!6F D | 157TM11=IPT/FG A260?I K3?R? \_ \* H P " % ! : I T " M - ) \_ ( J O  
M I : B B H A H ? / \_ O K 70 I H % ; ; ^ 3 \_ ! 5 ' ^ " M > Z!6F D P # 157TM11=IPT/FG A260?I K3?R? | ^ H X7UKW 0 \* T W G P # B J ^ E J \* + O N & A I T P # " ^ M > Z!6F M D \_ 51 P + Z U I \_ \* ! 6 F D \_ P 57TM11=IPT/FG A260?I  
0 \* T W G ^ \* H X M 7 U K W 0 \* T W G \_ B J ^ E J \* + O N & A I T | + Z U I H % ; ; ^ 3 P # Q 5 ' ^ " M > Z!6F D \_ M 57TM11=IPT/FG  
( 7 U K W \_ 0 \* T W G | B J / ^ % ! : I P ! K 3 ? R ? X J O I : B B H A M H ? / \_ " ^ M > Z!6F D P # 151 POK70 ^ @ 5IOY / / % 51 + 447 ? < - # Y I X7UKW 0 \*  
M T W G P # B J A A 260 ? I K 3 ? R ? P " \* K Z 6 H H N ^ X : ' S 3 \_ P + Z U I \_ \* ! 6 F D \_ P 5 M 1 POK70 ^ @ 5IOY / \_ % 51 + 447 ? < -  
# Y I X7UKW 0 \* T W G \_ B J / ^ % ! : I T " M - ) | X J O I : B B H A H ? A POK70 ^ @ 5IOY / P # % 4 ? | " ^ M > P " @ 5IOY / | % 51 + M 447 ? < -  
# Y I X7UKW \_ \$ " M - ) \_ B J / ^ % ! : I T " M - ) P # XJOL BBH AH? / \_ " ^ M M > Z!6F D | 151 POK70 ^ @ 5IOY / P # % 51 + 447 ? < -  
# Y G E ^ . ^ N R P O & = + T X I U \* M D @ / W P " ! 5 R 7 @ S Q Q ? > " F I F L K 6 W G : Y 1483 ; L # ! ) X P 1 Z U I ? 7 W ! X 7 / 7 ) O Y & O M ! / V = / ^ O O K O I  
U P B ! " D I W R P # A 260 ? I K 3 ? R ? \_ \* H P " % ! : I T " M - ) \_ M ( J O I : B G = I P T / F G ( 7 U K W \_ 0 \* T W G | B J / ^ % ! : I P ! K 3 ? R ? X J O I : B B H A  
M H ? / \_ " ^ M > Z!6F D P # 151 POK70 ^ @ 5IOY / / % 51 + 447 ? < - # Y I X7UKW 0 \* M T W G P # B J A A 260 ? I K 3 ? R ?  
\_ P " \* K Z 6 H H N ^ X : ' S 3 \_ P + Z U I \_ \* ! 6 F D \_ P 5 M 1 POK70 ^ @ 5IOY / \_ % 51 + 447 ? < - # Y I X7UKW 0 \* T W G \_ B J / ^ % ! : I T " M - ) M |  
XJOL BBH AH? / A POK70 ^ @ 5IOY / P # % 4 ? | " ^ M > P " @ 5IOY / | % 51 + M 447 ? < - # Y I X7UKW \_ \$ " M - ) \_ B J / ^ % ! : I T " M - )  
\_ P # XJOL BBH AH? / \_ " ^ M M > Z!6F D | 151 POK70 ^ @ 5IOY / P # % 51 + 447 ? < - # Y I P " % ! : I T " M - ) \_ M ( J C A 260 ? I  
0 \* T W G ^ \* K Z 6 H H N ^ X : ' S 3 \_ POK70 ^ @ 5IOY / \_ % 4 ? | + Z U I H % M ; ; ^ 3 P # Q 5 ? 2 U % % W W # 0 ^ : ? ^ % ! : I T " M - ) | X J C  
( 7 U K W \_ 0 \* T W G | B J ^ E M J \* + O N & A I T | " ^ M > P " @ 5IOY / | % 4 ? | + Z U I H % ; ; ^ 3 / Q 5 ? 2 U % % W W # 0 ^ : ? ^ % ! : I T " M - ) P # X J C A 2  
60 ? I K 3 ? R ? \_ \* K Z 6 H H N ^ X : ' S 3 \_ + Z U I H % ; ; ^ M 3 | Q 5 ' OK70 I H % ; ; ^ 3 \_ ! 5 ? 2 U % % W W # 0 ^ : ? ^ % ! : I P ! K 3 ? R ? X J C A 2 M 60 ? I  
K 3 ? R ? | ^ \* K Z 6 H H N ^ X : ' S 3 \_ POK70 ^ @ 5IOY / / % 4 ? | + Z U I H % ; ; ^ 3 | M Q 5 ? 2 U % % W W # 0 ^ : ? ^ % ! : I A 260 ? I K 3 ? R ? P " \* H X7UKW \_ \$ " M - )  
\_ B J ^ E J \* + O N & A M I T | + Z U I H % ; ; ^ 3 / Q 5 ' ^ " M > Z!6F D | 157TM11=IPT/FG A260?I K3?R? \_ \* H P " % ! : I T " M - ) \_  
( J O I : B B H A H ? / \_ O K 70 I H % ; ; ^ 3 \_ ! 5 ' M ^ " M > Z!6F D P # 157TM11=IPT/FG A260?I K3?R? | ^ H X7UKW 0 \* T W G  
M P # B J ^ E J \* + O N & A I T P # " ^ M > Z!6F D \_ 51 P + Z U I \_ \* ! 6 F D \_ P 57TM1 M 1 = I P T / F G A 260 ? I 0 \* T W G ^ \* H X7UKW 0 \* T W G  
/ B J ^ E J \* + O N & A I T | + Z U M I H % ; ; ^ 3 P # Q 5 ' ^ " M > Z!6F D \_ 57TM11=IPT/FG (7UKW 0\*TWG | M B J / ^ % ! : I P ! K 3 ? R ?  
\_ X J O I : B B H A H ? / \_ " ^ M > Z!6F D P # 151 POK70 ^ @ 5I MOY / / % 51 + 447 ? < - # Y I X7UKW 0 \* T W G P # B J A A 260 ? I K 3 ? R ? P " \* K Z 6 H  
M H N ^ X : ' S 3 \_ P + Z U I \_ \* ! 6 F D \_ P 51 POK70 ^ @ 5IOY / \_ % 51 + 447 ? < - # Y I X M 7 U K W 0 \* T W G \_ B J / ^ % ! : I T " M - ) | X J O I : B B H A H ? A  
POK70 ^ @ 5IOY / M P # % 4 ? | " ^ M > P " @ 5IOY / | % 51 + 447 ? < - # Y I X7UKW \_ \$ " M - ) \_ B J / ^ % ! : I T " M - ) \_ P # XJOL BBH AH? /  
\_ " ^ M > Z!6F D | 151 POK70 ^ @ 5IOY / P # % M 51 + 447 ? < - # Y I P " % ! : I T " M - ) \_ ( J C A 260 ? I 0 \* T W G ^ \* K Z 6 H H N ^ X : ' S  
M 3 \_ POK70 ^ @ 5IOY / \_ % 4 ? | + Z U I H % ; ; ^ 3 P # Q 5 ? 2 U % % W W # 0 ^ : ? ^ % ! : I T " M - ) M | X J C ( 7 U K W \_ 0 \* T W G | B J ^ E J \* + O N & A I T |  
" ^ M > P " @ 5IOY / | % 4 ? | M + Z U I H % ; ; ^ 3 / Q 5 ? 2 U % % W W # 0 ^ : ? ^ % ! : I T " M - ) P # X J C A 260 ? I K 3 ? R ? M \_ \* K Z 6 H H N ^ X : ' S 3  
\_ + Z U I H % ; ; ^ 3 | Q 5 ' OK70 I H % ; ; ^ 3 \_ ! 5 ? 2 U % % M W W # 0 ^ : ? ^ % ! : I P ! K 3 ? R ? X J C A 260 ? I K 3 ? R ? | ^ \* K Z 6 H H N ^ X : ' S 3 \_ POK70  
M ^ @ 5IOY / / % 4 ? | + Z U I H % ; ; ^ 3 | Q 5 ? 2 U % % W W # 0 ^ : ? ^ % ! : I A 260 ? I K 3 ? R ? P " \* M H X7UKW \_ \$ " M - )  
\_ B J ^ E J \* + O N & A I T | + Z U I H % ; ; ^ 3 / Q 5 ' ^ " M > Z!6F M D | 157TM11=IPT/FG A260?I K3?R? \_ \* H P " % ! : I T " M - ) \_ ( J O I : B B  
M I A H ? / \_ O K 70 I H % ; ; ^ 3 \_ ! 5 ' ^ " M > Z!6F D P # 157TM11=IPT/FG A260?I K3?R? | ^ H X7UKW 0 \* T W G P # B J ^ E J \* + O N & A I T P # " ^ M > Z!6F D \_ M 51 P + Z U I \_ \* ! 6 F D \_ P 57TM11=IPT/FG A260?I  
0 \* T W G ^ \* H X7UKW M 0 \* T W G \_ B J ^ E J \* + O N & A I T | + Z U I H % ; ; ^ 3 P # Q 5 ' ^ " M > Z!6F D \_ 57 M T M 11 = I P T / F G  
( 7 U K W \_ 0 \* T W G | B J / ^ % ! : I P ! K 3 ? R ? X J O I : B B H A H ? / M \_ " ^ M > Z!6F D P # 151 POK70 ^ @ 5IOY / / % 51 + 447 ? < -  
# Y I X7UKW 0 \* T W G M P # B J A A 260 ? I K 3 ? R ? P " \* K Z 6 H H N ^ X : ' S 3 \_ P + Z U I \_ \* ! 6 F D \_ P 51 P O M K 70 ^ @ 5IOY / \_ % 51 + 447 ? < -  
# Y I X7UKW 0 \* T W G \_ B J / ^ % ! : I T " M - ) | M X J O I : B B H A H ? A POK70 ^ @ 5IOY / P # % 4 ? | " ^ M > P " @ 5IOY / | % 51 + 447 ? M < -  
# Y I X7UKW \_ \$ " M - ) \_ B J / ^ % ! : I T " M - ) P # XJOL BBH AH? / \_ " ^ M > Z M ! 6 F D | 151 POK70 ^ @ 5IOY / P # % 51 + 447 ? < -  
# Y I P " % ! : I T " M - ) \_ ( J C M A 260 ? I 0 \* T W G ^ \* K Z 6 H H N ^ X : ' S 3 \_ POK70 ^ @ 5IOY / \_ % 4 ? | + Z U I H % ; ; ^ 3 M P # Q 5 ? 2 U % % W W # 0 ^ : ?  
^ % ! : I T " M - ) | X J C ( 7 U K W \_ 0 \* T W G | B J ^ E J \* + O M N & A I T | " ^ M > P " @ 5IOY / | % 4 ? | + Z U I H % ; ; ^ 3 / Q 5 ? 2 U % % W W # 0 ^ : ? ^ % ! :  
M I T " M - ) P # X J C A 260 ? I K 3 ? R ? \_ \* K Z 6 H H N ^ X : ' S 3 \_ + Z U I H % ; ; ^ 3 | M Q 5 ' OK70 I H % ; ; ^ 3 \_ ! 5 ? 2 U % % W W # 0 ^ : ? ^ % ! : I P ! K 3 ?  
R ? X J C A 260 ? I M K 3 ? R ? | ^ \* K Z 6 H H N ^ X : ' S 3 \_ POK70 ^ @ 5IOY / / % 4 ? | + Z U I H % ; ; ^ 3 | Q 5 ? 2 M U % % W W # 0 ^ : ? ^ % ! : I A 260 ? I K 3 ? R ?  
\_ P " \* H X7UKW \_ \$ " M - ) \_ B J ^ E J \* + O N & A I T | M + Z U I H % ; ; ^ 3 / Q 5 ' ^ " M > Z!6F D | 157TM11=IPT/FG A260?I K3?R? \_ M  
\_ \* H P " % ! : I T " M - ) \_ ( J O I : B B H A H ? / \_ O K 70 I H % ; ; ^ 3 \_ ! 5 ' ^ " M > Z!6F D P # 157TM11=IPT/FG A260?I K3?R? |  
^ H X7UKW 0 \* T W G P # B M J ^ E J \* + O N & A I L : | & + 6 / \$ & A 7 > D W & G 6 , < 5 R F O G C W I @ , @ : 9 ; V J C X 0 ^ ) V I ^ # = ? M 3 ; R M ) X G F : 8 M -  
N S D @ # ! " R U I " % 3 D E . O ? I P " @ 5IOY / | % 51 + 447 ? < - # Y I X7UKW \_ \$ " M - ) \_ B J / ^ % ! : I M I T " M - ) P # XJOL BBH AH? /  
\_ " ^ M > Z!6F D | 151 POK70 ^ @ 5IOY / P # % M 51 + 447 ? < - # Y I P " % ! : I T " M - ) \_ ( J C A 260 ? I 0 \* T W G ^ \* K Z 6 H H N ^ X : ' S  
M 3 \_ POK70 ^ @ 5IOY / \_ % 4 ? | + Z U I H % ; ; ^ 3 P # Q 5 ? 2 U % % W W # 0 ^ : ? ^ % ! : I T " M - ) M | X J C ( 7 U K W \_ 0 \* T W G | B J ^ E J \* + O N & A I T |  
" ^ M > P " @ 5IOY / | % 4 ? | M + Z U I H % ; ; ^ 3 / Q 5 ? 2 U % % W W # 0 ^ : ? ^ % ! : I T " M - ) P # X J C A 260 ? I K 3 ? R ? M \_ \* K Z 6 H H N ^ X : ' S 3  
\_ + Z U I H % ; ; ^ 3 | Q 5 ' OK70 I H % ; ; ^ 3 \_ ! 5 ? 2 U % % M W W # 0 ^ : ? ^ % ! : I P ! K 3 ? R ? X J C A 260 ? I K 3 ? R ? | ^ \* K Z 6 H H N ^ X : ' S 3 \_ POK70  
M ^ @ 5IOY / / % 4 ? | + Z U I H % ; ; ^ 3 | Q 5 ? 2 U % % W W # 0 ^ : ? ^ % ! : I A 260 ? I K 3 ? R ? P " \* M H X7UKW \_ \$ " M - )  
\_ B J ^ E J \* + O N & A I T | + Z U I H % ; ; ^ 3 / Q 5 ' ^ " M > Z!6F M D | 157TM11=IPT/FG A260?I K3?R? \_ \* H P " % ! : I T " M - ) \_ ( J O I : B B  
M I A H ? / \_ O K 70 I H % ; ; ^ 3 \_ ! 5 ' ^ " M > Z!6F D P # 157TM11=IPT/FG A260?I K3?R? |  
^ H X7UKW 0 \* T W G P # B J ^ E J \* + O N & A I T P # " ^ M > Z!6F D \_ M 51 P + Z U I \_ \* ! 6 F D \_ P 57TM11=IPT/FG A260?I  
0 \* T W G ^ \* H X7UKW M 0 \* T W G \_ B J ^ E J \* + O N & A I T | + Z U I H % ; ; ^ 3 P # Q 5 ' ^ " M > Z!6F D \_ 57 M T M 11 = I P T / F G  
( 7 U K W \_ 0 \* T W G | B J / ^ % ! : I P ! K 3 ? R ? X J O I : B B H A H ? / M \_ " ^ M > Z!6F D P # 151 POK70 ^ @ 5IOY / / % 51 + 447 ? < -







```

<?P-1#*XRI+*1P.XX.2:O:OCIX:U??"UI=Z M=|:3.TDL.8RQ1A@LWQ@?@3Z5Y?X#^,%|X*!_!&|AU*#5?%2 MOQQPL)
(1%7#EV'3>1QCO@$Y|X|W8_P|HRO+ #S?#EPH|E:16_|E%:_E_'SPI>
MS|)%>07|@6.#))&'C7ZE23_X|1H&IZ15>ROK74K.*|KBP*XM1N26|@RL/8B MK%42%%%%_1110_4444_%%%%_1110_4444
%%%%_1110_4444_%%%%_111 M10_4444_%%%%_1110!|?2|_!<_!'"LZ?A?7?>N$7_H34GN/H?05%%%,0444_%%%%_1110_444
M4_%%%%_1110_4444_%%%%_1110_4444_%%%%_1110_4444_%%%%_1110_4444_%%%%_1110_4444_%%%%_1110_4444_%%%%_1110_4444
&OH_A:7@7_H88|/^-4 MG_O-2BF=I7S3^T:00>|6>|+>|BQ1Y0.I(9U|X_#_@>|ZL:16GVSO:Z MA)23_96&W@<C%_O;
H_.OGSQ|K.K?;$OH_A+9I+JZ<0VUM'SL0?>7/MR2?J>_M*#P1|Y|Y9I|A|'L:R.ZE6+|W(ARU<|T7_R"-
_"Z|_R_@K7|O@OPXGA3 MPEI^CJP9X|RN.C2,=S$>V2<>V*|R_:+P_01H7_ %WE_P#05H>PNH?L|_|
MB#??|A23_P!%15Z|XB_Y%6C5O^O_:_P!->*HM>BC_T34$57<=>%F08P_M?
3*A2/7|I*#&HG3;E:W2|Z25@RS0I(&'<%0<_K5F0%OA_15=>70+?0=08|_M.YM!Y=O/;<1R1_P@MT4J_|.<#&*
|30A5?>_@V+SC5|4|L?|N|>OE65G/H2N0 MOU)IW"OYU^T= P?^AS_+^C<=>9|:O^2;C_K|E_P#9:1%|7^)-9|::A)KN MH(ZVH?
R(57/E0|9"***>YOR>_Z5|U|O| DEF_X|Z|_2_9:2W+|CTZBBBB|'OC?O MX#*#1M2|'(U&9L?|)#K|I(KY4^&B2Z3|1KVX*#6|1^%N(FOP>
&_UW_F*EC1_M|5*P90RD$9!>EKRWX>?%G0=1_.6EGK.IOV.IVT.PR&Z<(LN!@.&/'C_<<MYIWC?XT:'H=C):H5S#JFIN;
(8CNAC_VF8<'Z#|*=>PL>_,%_) *IKG^_%_Z* M2OJ3P|_R+&D_|>?|
MDFY_Z_(O_9|)'|^&^+M4|%ZRNIZ>2|7"7$#$DE_NGT|P>WYT<_A|EU4U2|_M33|)O+V1@J6|_#RLS=_%4G^E^|D6%D|EB-2J":
MX#XN?%32KW0I?#V@70NWN<"YN8_N(@.=JGN3<9QQC/KP|BL>6_#BV>Z^C_A^M-
|DB|JWCI_X_H*^X^O:~>|@X5ENM;N$T|>+T5H;=C_*PPQ?T4D?|KZ|I(M&%%%%4|F_:$ _P"1L?^PI'_BI:S/V=^A D$:_P!=XO|
T?123OCQ8R?P MX|Z_2PM+R*9|=AADS^&BO.?@XRTOPUJ616&KQ26L_Z|_(-<(K|NX)|9#>3_MZ5/4KH?2E>4?M_V|2^
:6502(=0C908%"|R*|:#OUX6NM7MM*M=7Q5X0U^1|@23O9B8|_!|W(3|9_S|9IB|OV M<|O%N?%$D6&|TAE5<|X4N&/_-(M>|U|
<^>_?00A|XU2|EMG$EL|07=LQVEE_MZ,OU!&1|@5|_:12?|&LVB3P_|90EAS%=3+|(H"K$9Q|9^O23:G55|F_&_|
M6|_&*KE&#)%Y40(|5C7C|/^->W^+2C|X:|Z?+|_9H|JFH%3Y,5LXD3=V+... M/HU#&CZ=|&6CV^@C0K6_M08DBL(5<>C;|G|:W*
|@<M13)"L'QO_R(B/_+|=S_*MZLSO_9|7A_M?5K&)=TES930|/4LA_G0|AU_|_)*=9_|7"_:--?4|?7P|00>??"6
_MFZI>A:1.R38|1564J3COC_*PKZRTG7HTXD1K28^X^9/S!|?JH1UD170@JPR"XKCOBMH?|O?_M#K5(43=
_|HJB|A|P|WZCW/EH<=4C_P_45E26HS<_>T?_D#_MZZB_WK_5O_T_P#;E_PQ?7|!&B|G8_|HB3?M|J4|T^X|@H^E=+5-%_M
MSXS4T)GRA|9|=H/BGJS_#ME6&12>X|I|_&OHW P%>|)? M#_0|T8_-H$2,0?XE4*WZ@UYA|? PG-<1V?B>UB+K_GV>
|Q_"NJL|S@GD$=R<^RV8^A|5@<^KM;#P+K MURS|=EA,%)_O%"%YD4A|<>$Q;^?_P)|+^EXSG|'G|G&_YS|=+4^+WQ2L_M?
$=BN@:#(|EGY>@YN<%1+MZ*H)7?)|@8|MB_9^#_H|U4=^91E8!+^Y|_(MV_4BOK^O&?@_
X_GTRPN|$M|8Y;U!%:JPP1%G)_@1_Q|+GO7LU!"A1113$ M?_?|0G_(-6/_&'X_P#T+7LGPKY^&.@_P#7_|H:5Y-
|T18R|XGTF_*GRI_MK_PAO=)_(|_@KJ|@_10_A|6VC:GJEK8W=DSJ/M4@C5T+@%05<=>R>+U3U_M*Z'L>2?&
|QW>^>_&|UT72|F@N|Y&DFG0X:~+.%8L<|L>|>A+XLT^O%=W M=M&I0WDMH%,WE9*=@_
G&&QANAZ$XUC^T|MPGB/2M4V;..2T^SA|~;ZQJ=D:ZHI"/! M:H_8|JR/XFN>3^0K_&#^CG1#X.M=|O+Z"SO|_
64)_X02JSE@5X)^&.&O&:_M3Q_1|/#/AFQ_XNM3@FEQF.YMH|)(?0_CZG_I^P:GS5|2_#UAX7|<7>E::L MBVL21LHD?<?^2;G_
*_(O_9|Y|_IG#_F9O^W7_P|K4=1=#W>CH3)_M8_-A>_DCF;K$9;*Y=D=0Y4D|_M&V|CG|V^&QR
001D_M7R_XPT&^&GCYA;HEAG%UTN;@INROUQC|_E#&CWG_M_A27@7_H&3_^!O|VC74_~))P|^OR7^2UA?M%
MV_DFD:2JH<=$L3-Z%U4C_T6:H?_IQSHVD:>_JH_#9A_<0R3ML1@RJF M_|OX||7|K2ZCZ^O5%86G>_#FL_PVDZ;J|_M>7BQ&4I
2Z|00"=X^7N_YK%_M|_#NP|_#Q|MG|_E/+>=H$O/$|F@_#Y3|H|<C&_11_X|&^ACQ:SSWEF;
M>|_K=V|'2$ _|7&&_$$UX/X|^&NK>"H#J4$XOM+&_&=%VO^2>-Z|AGC(/7TR*_M^B-+|=>%M8A62RUZP?>T1YA&X^J-
AA^5<7|6?B#H$@V_P|(L|0M|V_O4$2Q_MV|B0H|+|P:P.N2/K2=@12^/C^<^UY+CP_JTW%$S;|>=;SN^<^&?
#G@H^5|6MC_DWDD@C9^VE5P>_?0U/4KH>Z5RGO_M
M(+SX;Z|<=J6C2J6_O)_R_CD^J^K_*SP(B^CX@B(|V^4G|@M>5_%#XPVWB+ M2I-
|/T+24C1=2KM_BCG;J|O.XR3@|8Q3;$D8Y^5FJ_CZGV-?0)_SX|M^&_-"4CP_|?B5|B5|= #?_D|A_|Z_$K|S|HB#|FOH|3_
|ZQ_|P;_UO6K|_#O^28VG_7 M>;_T_UO_!"/X|J$C|D*@W+|O+?/_#T4|@/OP1^~0_IYA^SE=)M|069_M|+C7K@|SU/3
MHUXCX4(T?Q4T1&&&6:0$>A|MZ'N_~U01115$A7D|I0R$^#=#_?L_O_~P#_ MO7JX#XS:)+K7PXO/(00+92+=A0_DA"O$ _PU_N-
_OB6_9D&3&P|ROCN|E@<<|V^<@KGXE>#>+6P_MXWB*P=_(H0A|M@^_|J*28_Y_XZ_P#)-
|O^O|+^9KB_V<^/_O|_P|1_|+7SSH_|7O#|=27$4&_S49PD_*G(1*8Y|I^<(VJ93$MMJ3RH#QD_IRG|1@_C4L_/LFBN2L?B9X_O=*2_|
M|P|8%?|FAFF^R|>XV^DGZ_UOZ1|J|AKVEO:G|EP+BSG|_+&#HDP&4^F<O?|)*|+X7?S2?|'"M=#|0W2V=U:((H|B4_NY4
M"Y_&$@<<|<9SV1+0|GM%>OBO/_GOAT+6M)@M|OH:U2_DIN&V1R MD#|X<|H/C&4+W(1""2_!|?
G4|_MHZ:|KEX|_DMQ$#ZE%)A_Z&*|P|=^*KOX_MC^_HY+^VF_7%M8VW5R_12|_ $2>?P'|OI3P#X7^A#P=9:4VTW"@R7#+T:5N3^
M7_'L|26X^AA_&M"WPLU_C^&2_G_OZH_K7G^T.T@'B76(^_M9JWY_A:|F|>_M)_X@|'"ZOID^IYY;I_F*?42?|DEC|L'B33Q^C_U|O|A
MO@_~E>)_ $CXG7?GB|H|H|V|OSC2D#22D^0|P$&XEAVO_$X|LGT#;$B#X|?E$ MD_Z|?)T)*^G^&8_@%_R423_KPE_P#0DKZ'?|
D6_)_P^O'_T_M4+<=&5%>%4(****_D+X|?|E_U|_KN/_0%KZUL>=|MO^N2_R%?_0OCL9+X MH:L74A+CRYHS_>|103^88?
A7NG@|X^&-0!6#W>M65G=PVZ<0W_PC8_J@'_M_8_&C(OFI6Y3_&KY|_&'CV^&6|/"FGSM":P|O&0X_K_P4G^Z_1QW).>E>
MWZ%|XBTGO+927FCWBW=O^T+2^K_|P_2_O?/3FOF+XR;=>_2|3_3DF1A";
M
```



[illegible]

[illegible]



[illegible]

[illegible]

[illegible]



[illegible]













I"l>K: P-BYIG %Z2 P#H!KYO^\$? "4 1|MMM Z)DKZ4U>"2ZT6 MX5W2RVAB(N<9)4@!O! AEX-1Z9|0!O+!1KNWMH/-  
MR65-JC.3J.> )2B6Z!J?Q%!\\$1>.M\*\*Q!4U.V!>UD?UO^Q-0X/K7A7@? MQ>^ ^ \$S^?^(+9G|F^MB.\$8..X O^< J.1?4!>2?  
%CX;3:S(-T.VAR^X6YM MTP#\*.SC ^AT|J.>G))=4"70J5M+NWOL^!M95FMYDQR(H.2?8@^M=16M(  
MU#60!#VVVFLEU.MQY^K<8RVT9R0. 6FW>=(3R#K%Q#?I.H% L668 M  
DQ%=VUL=Q!QSW-!^E^OX.J".>WE26&10R2(P\*L#T((ZUX3X9^\$=QK7@N|3 M4|633-76Z+6LLRX+)M7Y6'7;G/N#^(\.G!?  
B/X.DDM;2+5X8S\_%#Q!X=1&W:"8+?7J&"W0YCNX9OH 3SZX|!^?#6BR.G MX|AO-IC3XVF->#?""CX-T06-J3)\*YWW\$|#!E?7Y  
|#!^N3|K)W#9&Y=VT=Y9SVLHS' ^MT.CV(P?YUE6|E|X+|9H|J|=9=X9>F|< \$?0C/X&OKNO\_ B+|8.2%Y&HZ?(MEMJR%?)?  
|DZCH&QT(|V/3%25|A)G<5JMEK6FP:AIZ56TRIE9?Y'T(JBK\_ M.%4LO 4#)|/ %?.\$/A\_XB>#|B065EJ|OG))XQ9W\$  
M.NSP|\_\*CQ1-J2<?QI<\_D%\_A\_P 6%/47B?Q9Y=E^". Q3R877D.QY=A|9P|^ M @|Z|O| AQH.GAWP-HG.A2Y4SS\*1@JS|XN!|@?  
A7%< ^/|@=^?Q(=6|F^6X MC(>^S0|E1AT+GH2/0<YKU^B^=|L&^AYS|?^2? K|B\_P#9?Y|G|GW\_F80| MMV |JUV?9?T4-  
!\$/\$Z:R7.ZW\$S M%P8!%YR|2VWS|=^XA^=V^OZ^K-<|5\_-29.S\_NQ?^C4K|JY?XBZ;>:MX|U6\_MQL(&GN9439&O5L2\*3C|  
J|F"1Y|A|A D:M2\_P^O+\_V=;|N(\$NK:6WE&8Y4 M\*/A\$8->\_!PQK>BZ\_J^UJ>F7-I|KY:M.FW+;E\_#ST|KVJE#8;W/DJRDN M?  
OCV)KE.F73+O\$BC^0<!"U4|245|5Z=J|JVGWPUC.D|M.NY)\$|/|#!=J.MXCXB?#.#QB|?V4J6VK1|%WO|R91T#8Y|'8\_AZ8|CAV?<  
\$?P=ZV-JT)RWV M+L\_!Y^9YB|5XCW|VH)KRU|MI8H|H|F^29M|2/((+GT4J?I7SI\_?Q7U(" M-1KY#?+NCM6C' 2048\_.MKP?<  
|+>= BBQU0?Y|LZVUPEQGFV:0J0P|/|<= MS^%FOLA6/>\*\*\*\*L0444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !  
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !  
\*!4\_.'T/3:\*\*\*H M04444 %%%% 'SS|>^1XLO|L&Q^C^).:|^&?)-.\$\_ZX\_ T(UY|90"VNZS MX|JL|W3=+N;NW%DL1>%-  
Y&#N2!"ST85Z9X"L+K2\_VDV5|T-S%#AXVZ|=Q// MYU^")C>QT=2.70Q\_Y^Z/ KQC\_P#0GKZ-KPKXP>=>U?  
QC%>=15U=VYM\$3S(C4W\_&L.G44YH|'<10^W\_)M" Z|SK|PO!=EQQWQOLGNO\_\*S("L.WD|DD|8XW.MN05'N0V?^<  
FO<=2TZVU;3+G3|R?2;W\$9CD7V|Z&OF\_O)^?\*\$WA^\_9|U^UG&  
M#9AGM+|+..;H/F|/C O^G1)-Z|6|JO^C/M^X^L=2MSX.TODN%24/O1WOP|T9XW#>7Y+8|A^D^JQ\_BE|Y\_&%G;WFFL@U^T5E".  
<M^9?#SMSV(3MR;Z|/O M63XY-\*?<(DS|E^Y?IC<^?US7H7PDTKQ-96^K7GB0W8DNWB|L;N4L\_RALD@  
MG(SD#GTK0^)/@%?&>F1RVK)%|MJ#Y+OPKJ>J?U|!ZFJ>J\$M&3\_K:T/PX  
MTD6A4@\*PEQC(DW'=GW\_IBNMN+B"TMV+BYF2&&-2SR2,%51ZDGI7S/9:9|1\_! M4|HL|+5.96/|P01>=\$O|2\_&4\_6M1-^)?<  
C^5(-6>|ALPV6:|7R(Q|^6-O|\_M#|124M+6"ORGCW6+37\_&^J.G8LS6LSJ(V88+|45060H?3(7M|L MX95VR1P(C#T(4  
T13N|@S|>1-X|UUA4&3|BD|ER?Y5X5|&R.T|-(ENDCA? MM\$SD^Y|MCYNHB)=M/N6CGC\_V>4?X\$X\_@JVS0+4+.\*  
|M|DEMYE#QR(56^B\_\$CP=(T=C:;O;IG) M6Y|U|+>6L-Q%;RW\_<|W\$4|\_T'4|U?G|J\_%C5 (U&O|7^7<K0IM^?A9U|\*3  
MV(|^Y#Z<DKH\$SL= UNT|+;:G92\*4R-D Y\*-W4^X%62;QK-AH.FRZAJ5RE MO:1CEFF/H^W)!7S;:100"5U)96.M6C-  
SVY7\*M6Q8>? ?C MB\_CFUQ|RW@4X\_<HDY0=PL9Y\_0#WI-M|GW|U|^\_D0=|\_P^O&+ \_T\$5X\_0?AE=Z=|  
I5OX;TBYNK:VVS31KN=Y=Q M9L>V/M7L\_@^SN^A';9W<1BN(2-)(SU5@HR#1%.^H/8VJ\*\*\*L1Y5|>6E M'A+3PN?\*\_+<  
^/78V/ZUF?%K3|K2Y7|6C)|QGR^H9SG^\*H|3>K/Q3H M-O|5Z)\*I(CS^X^ZP^GZ|BOGN?P^X|Z^N;C3;2|=XR?+NM/R^?H<  
<=<="\*MAZ.XUM8^FZ^?C?X@T|5|9T^Q|9L0/8+)(W3E0S?E|H|>?3/UJ+KX|X^X M\_P"SV75A\$XVL6@%L|^<%JY|QF|H?<  
^#VH-X3MYK6\*74M?>X^GK;E8|HX4 M=6YODX =TVVM|H6|0O@K\_R3N^KYE\_F^ZCOE\_R\_C#\_+|MQ\_Z+L/X4;3? MZ-  
X%@M=1M9+;X.TC^7C\_3QD=JZ+O^SWWA/6\_VC;D|C/%&@-S.A\_YF MK6Q/4^??@S\_R4>U\_ZX2\_@U|+UX%|\*"/B'2O'4-  
YJ&D75K;Q12\*TDJ;1DC MQGK^%>^U\_-ARW(+S\_CQN/^N;?RKY;^&?)1|\$\_Z|G\_T%J^IKE&DM9D499D8  
M>^\*^=\_A\_X)|2Z=X^TNYO-%NX(02TDLB851M/?H?PHEN@1|&UYA>HE;PK|L MH^RK>|3^\*  
C^1KUBL^QCX9B|6^<K62|F\$30AX92;D|T/TZ@^Q-4U="1Y| MKR-M|UBOWCS462;WVLN\_<  
CM>PU|M2^#?/A4GEM+\*48Y8|J+G3PS|E^J M|CBIB^@VNIZX MR\_Y\$?Q|\_V#;C\_P|0M7@?P9\_Y^/|<)?\_0:~@O\$|K|?<  
>\$|9L;R3SV|4: MXW.R\$ \_?F4|F^A^#Q#0^I7CJ M|B2+JUMXHX%25-HR1@8SU\_ "B6Z|OM?2?WQ M<\_Y^PK'&Q\_!\$QU|0U\_?&?<  
P9XBU7XE7MW9:/@Y|Z MT3V^)|Z|A\_O|CXDTBWTN9DM|4M8A&82<"55& RYZ|=1U^TKT&O#/&\_P=OK6^M?5"/<  
|XBV|V:OM>\$|77%,5E9S++Z17\_ (FB^S6;\$+0L^|OLV/NK^OTZU|T MJA5"J %P|P!1%.|V#?0|K^FBR7OAJSU6)-<  
Q|B)|#HCX&?^E7|ZYSX^M^X+|NO#|L:73"6U+G\_E\_N?4@+C\_?>O<|JU@O;2:UN8EE@F0D|PX9 M2.\$&O\_/0P7U?<  
3KN2XV+|OLE.5BW@31#TYP&N.?B2:=T^VL?0E<|XT4V MOA/PY|C|2#D4 M^S^'OCOQAJ^W&IPW<0\_A|G4W^E1Z|6^Z<  
#THYNR^Q2^&NB3^C\_ 'UDSAGBM MY?M=PY&1A3N&?JV|^\_?4M6|>8Y;\*[WP-CL&W(WY8-75&@:W>=(M\$MM3LI%>\*9 M-2|<  
<.K0IM^?A9U|\*3V(|^#ZCORTVCX@^K M|2.RL=;M&8X?L^<QN>W^Y5JG6+^N?3L;S8:#|LNH;ENHL/COQQ?QS:X|Y;P^<&?<  
42<MH.X6\_|H|U=^(|PRN|FTJW\_|Z1&YDMKN\_%;9B<+D\_|9N>G?M69|9/"NNZUXMLK03+^N;N 6 M21%X4W<  
J)|L&%;1?|FZGT73|0T2-8M06TB%W8NP7=(\$&XJW0'/4COFL M|W16ECW^O^OCGXG@N|BSV|6LRR?9F|T%.0KXP|\_4<  
L3|H7+|+3K2+^SL>M)50?\*\$5)6X'96 Z?0XK3|)"#7-.04NM=BDT^QW;W|T\_O|24|>J\_5OR-#;>B M!^QVWP\*T;2R|WNJ2J5-  
\_CR|JY&?^E^F8?A1|>6E'A+3PN?\*\_+^/78V/Z MUZ=9V=OHE#9VL2O6|""\_.%Z^H&\_\*S\_\$WAZS|4Z#<5>C"2C\*2 GMG.?<  
PKVBOF2P^X|Z^N;C3;2 M|=XR?+NM/R^?H.<=<="\*OBZ^+|B>/^SV75A\$XVL6@%L|^<%JY|QF|4K^M^UAM W+|QO|0=J^LZ?<  
8V.XGBL?D\$|HRH9BOR@|R-O|GZUZ|H?^2=P|J\_0Q?G MNO|P^?P+10=O-0\_Q2ZEHW|L8\$K%M^C|JW\_ G^X#OZ=|\*\_\*<  
)O|&|^P6NHV MLEM<^1\_+D&^&)XR.U^OS78GL0\_WU;P|^<21NDL9%N@!UVC(|E8G|\*|M M^#7BFWT#Q-  
-8WL|J06NHHJ>8QPIR\*3LR>P.6^U(KZ.=%&1U#\*PP5(R^"|#|: M?|C4K6|EO/#48NK)V+?9=P\$D7L\_|/3O|>M.2=|H^V/?;QO\$?<  
BK2|MB;K5; M|8|\_ZN>9)#Z^O?Z|H^?J+|2|B6QM|\_ \$D2\_4B\$|\_R<^#CM6EL|PL M|8^=0%WK;36D;X.ES?7E8>RD|L\_7<  
HYGT06/H32M1@U?2;34K8;C|J?9D#\_MC#\_X/O7S3|7A-DI^L?|L?\_1=2?VEZ=#I&DVF66^|R;6%84+=2%&GWKP M7XG>#?<  
\$>I\$+4+VOT>|N:|X|KRY8DW^<1(JY'3D^K18|G|M5E|UK|\_@JST^<  
M^A66V+N&)|\$<|^H@U|V^<^<^H^W@J|32\*8W\$UE=\*\_U|XU^O^C^AKZ@\_MT>"2YT2P@F7;+%;1HZ^A"@5D>-O"-<  
KXQ|V6\_VU+E/GMR.8W\_P/O^C^H%.4 M;H\$|?@3OE;>\_1Z27^>PX2Z@^X\_X J|D|1^H^5U?>-A+0'?@IQ7%<6VA M7K@-<  
Y4Z^N8Y8|C=T|P<|<5|41=UJ#1;Z)|LNAZY9;I#&LDEK\*|LH1^C8/2 MOJWPOX|TSQ;I^?V62@G\_\$L+YXF|&^J>AKPOP|1-  
M6G|6|V\_B#0KF/3?+E69 MY%V|'48\*5;N=V.8IVM\_#3Q=X.U-KSP^UW=0\_N|B0)\$P^IUD7G|L^C^51&Z&|<  
M\_<AKR|M|LY;H|F2&WA4O)|CP%\_I|U|G:J%QXR|75U;HSRW|R\$MT/7;D^@-<  
M("M2Z|OB)X|F9+2|M=NT#8"3ONL8/OG^@YKU/X;?"S\_ (J=8UHDJ8^F M%#E8.C)|=L<>@|^M-WD&QZ-I=BFEZ19;?<  
&AUS;M|&7A MB+|M&GP3W21G;5UH>|^ CYP?^9H|J\_%.8-\_/01DXPP6WD##10N1;2 MDUHQV/1C5XM@L= /A^VG5KV|<  
(ZJ M)|A=Z5-=Z)=PPV|RKRR|F\$4#J=W0\_A1+= CZ2HHH|JO'R\_-R4Z3\_L.G\_P|\_ M5|95|VS>|O\$Y^ (SW<  
T2L|U0S";9|FSS=V|=TQCFOI^H@.1|1?'#1)++Q=%J\_MH3|Q?PC+^\_GH@D?H|F|^\$WBFWU|P?;6+2(+<  
|3H0|)%GDHHP|C8|8^U|K|M2\$WANP|5Z++|FH?+8|DD7|T.CHR^\_|>O M4^%C+PO|V62XYK|8R3%=: M>Y\$@\_P" @|@?<  
ID>|N#G<-T?2M.EFB@B:6:1(XU&6=V^N37S>NO\_99|F^Z M^6^Z;M^B^/KLS2KX(^C^C^96U-  
\_P1DYWZC.55/HAY^X+1S=D%CZ.@GBN8\$G@\_ME26&0|DDC8;K#U|45)63X8T8^\_SI^DM\_|FM8@C2 8#^J<>V36M5B^BBB M@<  
HHHH\_\*|\*?|G/P#;W=^B)\*|RKRPW|P R<|\_JO=W P^B)\*|RKRPW|P R<\_P#JO=W\_.B)\*B>PXGTU|11619|5>"|HQ79:O=R>%K:;<  
M>|L(B98K<2D)'N8@XYQ7;|^0\_&7\_H%7W\_@M7\_XFG\_L\_P#\_.^L|+7FW\_M^6OHF|5R6?2|<  
PD/OE\_Z|5|X+5^H)X2^XR\_P#0^OO\_6K\_P#XU&4 M4|P^X^SG\_)|#|9?^5?2^U?\_B:/^\$A^O|\_T^K|\_P%J|\_O?2IE%&O<#YS<  
M\_P"\$A^O\_0^OO\_|\_X\_O^\_|\_0\_&7\_?|5|X+5|\_B:~^C^\*>X^SG\_P)#|9?M^<5?2^U?\_B:/^\$A^O\_?K|\_P6K|\_XU|&44;|P/G|^A?<  
C+T^K|\_.%J M\_P#Q^\_|\_0\_&7\_H%7W\_@M7\_XFOHRBC7N|Y|Y)|#|9?^<5?2|\_@M7\_)H\_P"\$M^A^O\_0^OO\_|\_O\_O?<

1E%&O<#YS X2'XR P#0\*OO\_6K P#\$T?l "0 &7 H% M7W @M7 XFOHRBC7N\Y )#19?l H%7W @M7 P")H X2'XR I J^ P#!:O  
M|37T911KW ^<\_P#A(?C+\_PI J^-|%J -!-' "0 &7 H%7W\_(+5\_P#B:^C\*M\*->X'SG\_)#19?^@5??^"U? B:/^\$A^,OI T^KI P\_%J|^  
Q-?1E%&O<#YS M\_P"\$A^,O 0\*OO !:O Q-' "0 &7 \*15l X+5 |B:^C\*\*->X'SG\_P)#19? M^@5??^"U? B:/^\$A^,O\_\$"KI\_P6K|^  
\$UI&44:IP/G/\_A(?C+\_T^KI\_,%J M\_P#Q-' "0 &7 H%7W @M7 XFOHRBC7N\Y )#19?^@5??l @M7\_)H\_P"\$  
MA^,O 0\*OO !:O Q-?1E%&O<#YS X2'XR P#0\*OO\_6K P#\$T?l "0 &7 H% M7W @M7 XFOHRBC7N\Y )#19?l  
H%7W @M7 P")H X2'XR I J^ P#!:O|M37T911KW ^<\_P#A(?C+\_PI J^-|%J -!-' "0 &7 H%7W\_(+5\_P#B:^C\*M\*->X'SG\_  
)#19?^@5??^"U? B:/^\$A^,OI T^KI P\_%J|^Q-?1E%&O<#YS M\_P"\$A^,O 0\*OO !:O Q-' "0 &7 \*15l X+5 |B:^C\*\*->X'SG\_P)#19?  
M^@5??^"U? B:/^\$A^,O\_\$"KI\_P6K|^\$UI&44:IP/G/\_A(?C+\_T^KI\_,%J M\_P#Q-' "0 &7 H%7W @M7 XFOHRBC7N\Y )#19?  
^@5??l @M7\_)H\_P"\$ MA^,O 0\*OO !:O Q-?1E%&O<#YS X2'XR P#0\*OO\_6K P#\$T?l "0 &7 H%  
M7W @M7 XFOHRBC7N\Y )#19?l H%7W @M7 P")H X2'XR I J^ P#!:O|M37T911KW ^<\_P#A(?C+\_PI J^-|%J -!-  
' "0 &7 H%7W\_(+5\_P#B:^C\*M\*->X'SG\_)#19?^@5??^"U? B:/^\$A^,OI T^KI P\_%J|^Q-?1E%&O<#YS M\_P"\$A^,O 0\*OO !:O Q-  
' "0 &7 \*15l X+5 |B:^C\*\*->X'SG\_P)#19? M^@5??^"U? B:/^\$A^,O\_\$"KI\_P6K|^\$UI&44:IP/G/\_A(?C+\_T^KI\_,%J M\_P#Q-  
' "0 &7 H%7W @M7 XFOHRBC7N\Y )#19?^@5??l @M7\_)H\_P"\$ MA^,O 0\*OO !:O Q-?1E%&O<#YS X2'XR P#0\*OO\_  
6K P#\$T?l "0 &7 H% M7W @M7 XFOHRBC7N\Y )#19?l H%7W @M7 P")H X2'XR I J^ P#!:O|M37T911KW ^<\_P#A(?C+\_P  
J^-|%J -!-' "0 &7 H%7W\_(+5\_P#B:^C\*M\*->X'SG\_)#19?^@5??^"U? B:/^\$A^,OI T^KI P\_%J|^Q-?1E%&O<#YS  
M\_P"\$A^,O 0\*OO !:O Q-' "0 &7 \*15l X+5 |B::~C\*\*->X'SG\_P)#19? M^@5??^"U? B:/^\$A^,O\_\$"KI\_P6K|^\$UI&44:IP/G/\_A(?  
C+\_T^KI\_,%J M\_P#Q-' "0 &7 H%7W @M7 XFOHRBC7N\Y )#19?^@5??l @M7\_)H\_P"\$ MA^,O 0\*OO !:O Q-  
?1E%&O<#YS X2'XR P#0\*OO\_6K P#\$T?l "0 &7 H% M7W @M7 XFOHRBC7N\Y )#19?l H%7W @M7 P")H X2'XR I J^ P#!:O  
|M37T911KW ^<\_P#A(?C+\_PI J^-|%J -!-' "0 &7 H%7W\_(+5\_P#B:^C\*M\*->X'SG\_)#19?^@5??^"U? B:/^\$A^,OI T^KI P\_%J|^  
Q-?1E%&O<#YS M\_P"\$A^,O 0\*OO !:O Q-' "0 &7 \*15l X+5 |B::~C\*\*->X'SG\_P)#19? M^@5??^"U? B:/^\$A^,O\_\$"KI\_P6K|^  
\$UI&44:IP/G/\_A(?C+\_T^KI\_,%J M\_P#Q-' "0 &7 H%7W @M7 XFOHRBC7N\Y )#19?^@5??l @M7\_)H\_P"\$  
MA^,O 0\*OO !:O Q-?1E%&O<#YS X2'XR P#0\*OO\_6K P#\$T?l "0 &7 H% M7W @M7 XFOHRBC7N\Y )#19?l  
H%7W @M7 P")H X2'XR I J^ P#!:O|M37T911KW ^<\_P#A(?C+\_PI J^-|%J -!-' "0 &7 H%7W\_(+5\_P#B:^C\*M\*->X'SG\_  
)#19?^@5??^"U? B:/^\$A^,OI T^KI P\_%J|^Q-?1E%&O<#YS M\_P"\$A^,O 0\*OO !:O Q-' "0 &7 \*15l X+5 |B::~C\*\*->X'SG\_P)#19?  
M^@5??^"U? B:/^\$A^,O\_\$"KI\_P6K|^\$UI&44:IP/G/\_A(?C+\_T^KI\_,%J M\_P#Q-' "0 &7 H%7W @M7 XFOHRBC7N\Y )#19?  
^@5??l @M7\_)H\_P"\$ MA^,O 0\*OO !:O Q-?1E%&O<#YS X2'XR P#0\*OO\_6K P#\$T?l "0 &7 H%  
M7W @M7 XFOHRBC7N\Y )#19?l H%7W @M7 P")H X2'XR I J^ P#!:O|M37T911KW ^<\_P#A(?C+\_PI J^-|%J -!-  
' "0 &7 H%7W\_(+5\_P#B::~C\*M\*->X'SG\_)#19?^@5??^"U? B:/^\$A^,OI T^KI P\_%J|^Q-?1E%&O<#YS M\_P"\$A^,O 0\*OO !:O Q-  
' "0 &7 \*15l X+5 |B::C\*\*->X'SG\_P)#19? M^@5??^"U? B:/^\$A^,O\_\$"KI\_P6K|^\$UI&44:IP/G/\_A(?C+\_T^KI\_,%J M\_P#Q-  
' "0 &7 H%7W @M7 XFOHRBC7N\Y )#19?^@5??l @M7\_)H\_P"\$ MA^,O 0\*OO !:O Q-?1E%&O<#YS X2'XR P#0\*OO\_  
X:XWP.?^+K&ZO&|)6TTIK(HG\$5N)<+DXSD"..^NKI CPN?^N3?RM->"?LZ?A?7?^N\$7 H34G>X%7 A(?C+\_J^-|!:O \_31\_P  
)#19?^@5? M?^"U? B::C\*\*->O<#YS X2'XR P#0\*OO\_6K P#\$T?l "0 &7 H%7W @M7 X MFOHRBC7N\Y )#19?l  
H%7W @M7 P")H X2'XR I J^ P#!:O|M37T911K MW ^<\_P#A(?C+\_PI J^-|%J -!-' "0 &7 H%7W\_(+5\_P#B::~C\*\*->X'SG\_M  
)#19?^@5??^"U? B:/^\$A^,OI T^KI P\_%J|^Q-?1E%&O<#YS P"\$A^,O M 0\*OO !:O Q-' "0 &7 \*15l X+5 |B::C\*\*->X'SG\_P)#19?  
^@5??^"U M? B:/^\$A^,O\_\$"KI\_P6K|^\$UI&44:IP/G/\_A(?C+\_T^KI\_,%J P#Q-' " M0 &7 H%7W @M7 XFOHRBC7N\Y )#19?  
^@5??l @M7\_)H\_P"\$A^,O 0\*O MO !:O Q-?1E%&O<#YS X2'XR P#0\*OO\_6K P#\$T?l "0 &7 H%7W @M7 X  
MFOHRBC7N\Y )#19?l H%7W @M7 P")H X2'XR I J^ P#!:O|M37T911K MW ^<\_P#A(?C+\_PI J^-|%J -!-' "0 &7 H%7W\_  
(+5\_P#B::C\*\*->X'SG\_M)#19?^@5??^"U? B:/^\$A^,OI T^KI P\_%J|^Q-?1E%&O<#YS P"\$A^,O M 0\*OO !:O Q-' "0 &7  
\*15l X+5 |B::C\*\*->X'SG\_P)#19?^@5??^"U M? B:/^\$A^,O\_\$"KI\_P6K|^\$UI&44:IP/G/\_A(?C+\_T^KI\_,%J P#Q-' "  
M0 &7 H%7W @M7 XFOHRBC7N\Y )#19?^@5??l @M7\_)H\_P"\$A^,O 0\*O MO !:O Q-?1E%&O<#YS X2'XR P#0\*OO\_  
6K P#\$T?l "0 &7 H%7W @M7 X MFOHRBC7N\Y )#19?l H%7W @M7 P")H X2'XR I J^ P#!:O|M37T911K MW ^<\_P#A(?  
C+\_PI J^-|%J -!-' "0 &7 H%7W\_(+5\_P#B::C\*\*->X'SG\_M)#19?^@5??^"U? B:/^\$A^,OI T^KI P\_%J|^Q-?  
1E%&O<#YS P"\$A^,O M 0\*OO !:O Q-' "0 &7 \*15l X+5 |B::C\*\*->X'SG\_P)#19?^@5??^"U M? B:/^\$A^,O\_\$"KI\_P6K|^  
\$UI&44:IP/G/\_A(?C+\_T^KI\_,%J P#Q-' " M0 &7 H%7W @M7 XFOHRBC7N\Y )#19?^@5??l @M7\_)H\_P"\$A^,O 0\*O  
MO !:O Q-?1E%&O<#YS X2'XR P#0\*OO\_6K P#\$T?l "0 &7 H%7W @M7 X MFOHRBC7N\Y )#19?l  
H%7W @M7 P")H X2'XR I J^ P#!:O|M37T911K MW ^<\_P#A(?C+\_PI J^-|%J -!-' "0 &7 H%7W\_(+5\_P#B::C\*\*->X'SG\_M  
)#19?^@5??^"U? B:/^\$A^,OI T^KI P\_%J|^Q-?1E%&O<#YS P"\$A^,O M 0\*OO !:O Q-' "0 &7 \*15l X+5 |B::C\*\*->X'SG\_P)#19?  
^@5??^"U M? B:/^\$A^,O\_\$"KI\_P6K|^\$UI&44:IP/G/\_A(?C+\_T^KI\_,%J P#Q-' " M0 &7 H%7W @M7 XFOHRBC7N\Y )#19?  
^@5??l @M7\_)H\_P"\$A^,O 0\*O MO !:O Q-?1E%&O<#YS X2'XR P#0\*OO\_6K P#\$T?l "0 &7 H%7W @M7 X  
MFOHRBC7N\Y )#19?l H%7W @M7 P")H X2'XR I J^ P#!:O|M37T911K MW ^<\_P#A(?C+\_PI J^-|%J -!-' "0 &7 H%7W\_  
(+5\_P#B::C\*\*->X'SG\_M)#19?^@5??^"U? B:/^\$A^,OI T^KI P

[illegible]

[illegible]



5CZIX6T/Q/"FM;=%>"\$DQE|@IG<\$\$'G M \*MBB@ "AH^BZ=H&GK8:5:1VMJH+"-.F3U)SR35B|LK:4:\*.SO(\$GMIE\*21N  
M.A@>QJ>B@# T/P3X;|W;W>D:3!;W#J4.BEF:2"1DDXZ"M^BB@ "M?V%JEC M-8WUO<6LR|9(!E6%9>@ #/#OAF>2?  
1M^AM)I5V/(I9F\*Y|ODD9\_\*MVB@ M JHJ6F66L?+8:C;1W;| BD&0V#D?J;MT4P/0?|\_A PQ+)|HVFOVCS\*  
MHJ68L(3)XKZ+;3WQ(9I6S\_Q P"1G;Z#J^Z\*B@05EZYXB@ IDL:50"!T:21."KHZ@JP/8@L:213 XJ|\_A)X&U^5I9;BB=N|  
MOA(0'T56"-I3M.^%'@C3)EEAT""20#K<|P/ 7)'Z5V=%\*PQI(D4:QOHJ(H MPJH. #T IU%0%;1|@^)+Z3O9|4;C^T)V2\*741;|B?|5\$)-  
@Q6I@<-7-?6UA86 MNEV\$%C90H;0(\$CC0<^17@'Q0^\$>KIKMWKGA^U;JM+J0S2V|(S+\$Y.6POI0) MY&.1G|OFL33?  
C|XZ|;0+HXP5QY8V^N|6|>8H^N^T|XYJ=BMSZBKYQ.^"LL MM0\$^G36|I)23P.UT\$P^P!\_1F?P  
F&?;H+CX| ^.=07H/8V>GP2N,\*T.#N^?8.MQ5+JGA\_X9^+|^NM\_P|H|+JUMYG#SW=X-LCCT13STZ>G\_-  
MU=7KWA0/0\$YA;6=,ANVA|0\$;2"H/49|H05\_3-M M="TRVZTRB\$5M;1B;-|V\_F?>K=;13TO2K#1-/BL--M8f;UBSLBC" R44AG-  
Z+|V|"GAZ99M.T.UFB4V65P974\$S.21^4K|\*\*\*|7/ZSX+| M>G|;|5=(@NKE5^B1L@D#H#@C/XUT%  
%2|TNPOI/;GWEE|/9E0OD21ADP.G M|H\*XY^@SX#DG|TZ(0#U1;J8\*?\_N/PKO\*\*|F;HV@:3X>M3;:1H09Q!|81)@ ML?  
5CU8^YK2HHHB" LW60#VD>(K46VKZ?;WD0Y42KDJ?53U|^E:5%(#A(O@WX#  
MAN|;NA|L\$\$(|S^RC|^W|XYKL|6QM+&S2SM+6&^U0:5ABC"H|Z #BK%% SG=(\_M|)">@-|U'^T+T:WMKO!\_E7)\*@|  
<9;|^.=%110(CYGA0A|X3U?4WU\_\*P|#MHN M0@O=(PW^U|(P?RKI54^H50\_#M2T4\_9>N>^-(12VB6NL6\$5W"C;T5|@J>F  
M01@BET3P\_I|ANR;TT>QBM(&?>ROY^9L\_9)|X K3HH\_Z)|D?T;J&1|@0RL;@&  
M|C7;:7V|"FBZFFHZ=HEO!>H24D|8|<@X|;P3TKI\_\*"BBB|S;O| #SPE M;ZNNJP;.%:I>D|YJR#.%?2.OP7.<|I^Z:BBD  
4444P"FR1I+&T=V0^NIB|\_M8W|CZUWE%\*PS.TGP|HVA)MTK2|2SSU;\_05F^IZG|;TZ\*\*||7+ZQ|;O".O7#W  
M&H;.%|;YRID>Z)F|J2A&3|FNHHH X\_2/A;X+T6X6XM=#A>=>0|P|38/J Y(| MJP^VM=|;+XFMXH\_9T^\*  
|CB8M&)|4GK@|@UK44#\*FF:99;-|T.GZ=;);6D(| M|CB0<+DY/ZDG|;DO^YVU&RFLR|);E92DD;C(8^L;GHH\$8&A^"?#?ANI>|TC  
M28+6X=2AD4LS;202.DG^05OT44\_5K^PM-4L9K&^MX|BUF7;)|;JPK+T^P9X M=|;SR3Z-I4-I^\*NOY%+;O7(|;DGC(Y5NT4\_%5-  
2TRRUC3Y;#4;:Y)|M|@M|R&P48?>2S%AZ9|%;E%0%('F5^|GA)-M7|KH5J+T2<^)|FP^SG=MSC;>E=-110\_5S-  
M|/!"5HZZK;Z;QWJ2>:L@S M^A7SG(7.<^U=-10\_4=;\_\*8;P^W|);9JB;G9;^0W<;;DD7=|H0;X^X^NF MHHI\_4|3TG3|9LYM-  
3LH+NW)SYN0E^#?@:82G0|OJJ7;J?P# MPT>W@ MO|L|N\_O7&R\_!KP^+YAT0KS MDJEU\*%X;N/PQ7>44AFH?  
@|P|X;YTC2+;UDQCS0NZ3^O;+?K6Y110(\*\*\*\* M8|1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444  
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4 M444 %%%% !1110 4444 %?7AK\_DZ9^OR|\_  
/1\$E?0M?7AK\_DZ9\_|K|N\_M\_1\$E3(|/I>BBB|/F3|G\_P#Y?6?^O\_0\_1BU|S|U|^?L\_P#(|ZS->:;?^C%MKZ)JEL2PHHHJA|1110  
4444 %%%% !1110 4444 %%%% !1110 4444 %%%% M |1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444  
M%%%% 'Q7|JPMO&E|;06\$6HR:0^")JL\_P"^(BM) Z\_-|P\_4KQ358N%&U| M^=DFHR(V;N#(17T^ PH+P= SUU3\_P^"%\_|  
B:A7\*9D?|-%:3\_T;W\_OZE5|\_M\_P#;|T|TZZM5T;5IH7C#&5<#((S^M;\_P#PH+P=\_P|=4\_|"%\_)J|KJ7P^M(VFEW=S)J?  
F0P/(N9UQD\*2/X;>HM#QWX5\_|E.T\_KN?\_0&KZ|KY^"%?)3M\_M|\_Z|G\_T|H^O:((SS;XB?"^?  
QYXATV;IK;6=O"815Y%G^|G^CISG/H.M;&D M?"P7L\_|L\_9\*WL@ZRWG&IF\_#|H\_"NSN|NVL;62ZN|B\*WMXON>65PH/4D|^"  
MO.M5^\_G@W3|&CMY+|S4&";""Y^KE?S&?>@WQ+|(^?NMZ7+9Z9|HUX%/DS MVR|\_-CC&O3I9W.A;Z%G<(#P5=MC^N"O?  
J7|H|G M1.C|OW>AWI+ZM@(|/Y^C0Q|<\_HLRH|JAI<@?K4L;LZO?|VC MO^/CPY\_N7^XZ|ZKP7|H|\_CX|;?IEQ\_..J>PD=A|")O|  
DFD|\_7U+;\_5T.N\_#MGPGEU)MIU?25N+ME^\_OY(|@=;A6<|I"O^2:0\_P#7U+;\_5Z50M@|B|^S| M7\_A.O|\_  
|K\_1/|3CR|Q^YYNW& M27.WE|3|L^(@#)).#^5>:\_P#\*1EW\_-|W|\_X%G\_XFG<5CWZBO A^T;=;AN|-0 MXSSB|A  
|17O44@FA25\_IAN3\_-TOL2OC05?^2JW MO\_8;D\_|YK|;\$|G|^2VCO|CX|;?IEQ\_..NP^!7\_)^(?^OJ7^8KC\_VCO^/C  
MPY\_N7^XZ|^X%?^)|^(?^OJ7^8HZAT.AUWX<^\$ \_\$NI\_|KZ2MO=LH|H|/D M#ID\*P|KY7\_L^U\_X3K^S?  
\*\_T3^T^O;MOG>G?;^T;^\_FIO\_?&? M\_?U#|T;\_P\_\*|@\_P#(|R?\_+KK;NYLO#^AS7+A8;PMRVU1P|J(O0?  
M@;5>KX\_XTWCVPPU+4;9WBAS|P3^@(|B|/8AK^Q8^B(K+5(EO)"2>62VA^M\_/0#Z9|137T7HOP|G+H=J-  
\$L|OP/GG085F=SZY8^T&|7SH\_-&|MX\$U MF|U&;3G07FM\_(0+\*\$V@L&8\_W17I?\_#1EI T+<\_ (C%P")I^PV;00\$^#VB  
MWN7.H>^D;+4;:R#+;).|R5V|CC."/ U<+|^"?<^F>\*3H\$TA-EJ(O13T2\_M9|D\$>F0"#Z+Z5T|;LR\_PU;1\_U|C\_)KR3P+  
(5^(|OAH^8\_ZE>0|D M/Z\$T\_295%%42%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444 M4 %%%% !1110 4444  
%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 M 4444 07W\_!A<|7)OY&O|V=|^00KO\_7^+ P|^O>|H\_CPN?|KDW|C7@G  
M|\_G\_")=|ZX1?|H34GN/H?05%%0444 %%%% !1110 4444 %%%% !11 M10 4444 %%%% !1110 4444 %%%% !1110 4444  
%%%% !1110 4444 %%%% M |1110 4444 %%%% !1110 4444 %%%% !1110 4444 M%%%% !1110 4444  
%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4 M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%  
!11 M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% M |1110 4444 %=\$D0HZ|JRG|&0=10  
R\_\*%=L4;HL<\*;"GT44 %%%% !1 M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% M% |1110 4444  
%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%  
!1110 M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1 M110 4444 %%%% !1110 4444 %%%% !1110  
4444 %%%% !1110 4444 %%%% M% |1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 M %?7AK\_)F?  
\_K|N\_|T1)7T+7SUX;\_Y.F?\_K|N\_P#T1)4R&CZ7HHHJ2CYD\_M\_9\_.1WUG\_KS;\_T8M?1-?W|A\_P\_COK/\_  
%YM\_P"C%KZ)JEL2PHHHJA|1 M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%% M% |1110 4444  
%%%% !1110 4444 %%%% !1110 4444 %%%% 'QA?2^C|<\_ MJA10\_HK|/KXPOO^1^N?^PHW\_HTUIGU\*\*850US\_D  
\_E\_UZR^@FK|4<\_P^0\_M|J7\_%ZR\_P#H|DGR|C\_P#DIV@\_|=S\_@\_7U|7R%|\*P#DIV@\_|=S\_@\_M7U|2B-GS+|\_@H46B6  
MFH^(|GOKVXC|A+E8H@PR|@8)|YR<?>W>O?>C\_H5U|O^Q|2-A;Z@1/|)C MAOE 8?4-GCT(|;|;|&|PU>Z|:0ZQ?  
#3|HAC6.595;8YCN5@^")?S^="7 M4?0ZFX<>#(EVKX;TGC?FA#|^7\_)BMOB=Y\$;QQ|ZSL1&|B;\_KVGO6 M=-(|+)|  
|;PPWV^<^<8\$|I8H0?Y@^Q|H8|^U>^ZP.H)\*MX|\_#)\*5PV MYG#9(|3G|XT;\$?->\_ M^?|\_OX<\_P|RX\_G^7O5>\_ M^?  
|?^AS\_E5YK|\_O| DFD|\_7U+;\_5Z50@9|;\_U\_|CA|6K| M(KXW\_P^;F\_|<9\_IK5|D4D#\*J\_-INMVRVJ6%O>0J|V4GC#@\_ZC?DUD?|  
M^O?^W\_0M;7\_X#^+ A72T4Q\_K|O^|ZL&^AK2|@Y^C+^ A72444\_?>J\_|E5O? M^PW|\_P^CS7V|7QW|Q\_)5;W\_L\_R?^CS7V|213|/?  
VCO|CX|;?IEQ\_..NP^!7\_M\_)^(?^OJ7^8KC\_VCO^/CPY\_N7^XZ|^X%?^)|^(?^OJ7^8HZAT/2|^\_&^F\_MIQG\_-K5|D5|\_|+3?  
^XS\_|6H8D?9%>?>F&S>|^&^HL@R8^BEQ|P#^A)KT  
M^|H|;=:ZOI5W|UVNZWNHFB|LPQO|TP/G#X%V6DZGXJO|^5=/LKP/9F2);J^ M9 &5USMW|X;MZ5|Y\_PA^A/\_\*%?1?|P7Q?  
\_\$\_U|MW\_KK?PO|=Q|RL;NOEWQ\_M.5.R>|D>JL;@^G(ZBO>\_>^\_/A#4K9#?W\$NF7)'S13L\_ZY|F4\$?2%)#9UG\_M\_A^A\_Z%?1?\_1?  
%\_|\$U8L\_"WAF|3K|+JOT^2|6X3.V6^SC1U^A\_R^Y;J^- M^@6SB9DU9|HQ\_P\_LX+;0D\_0L\_OZU2|^?  
%Z^QGXQ.CVFD2P6OD(|L|@+|DKC|MH&\_?4H>@CTRBBBF(\*\*\*\* "BBB@ HHHH \*\*\*\* "BBB@ HHHH \*\*\*\* "BBB@ M HHHH \*\*\*\*  
"BBB@ HHHH \*\*\*\* "BBB@ HHHH \*\*\*\* "BBB@ HHHH \*\*\*\* "BBBB@ HHHH @O@/^Y\_ZY\_(UX)^S|\_R|)=\_ZX1?^A-  
7O=|\_OX7|\_%R;^1KP\_M3|G3\_D+Z|\_UPB\_|OFI<3^"2K;20N.F1ZTAGK\_%%%0444 %%%% M|1110 4444 %%%% !1110 4444  
%|4M3|UC3=0%MA<^P^VUG^3M#SRA\_3Z#4 MT 7?^IZ;JVG;S;:=OK>|@S@R02|P#Z^0U=W^V=6/O|HJ&UMT^|+;(\$4 M?  
B;K;5KVD;XCOI6IVEZ(^|^SS^WZ@^B@1HT45Y#|=|>Q;FB\_V|\*(GO|;B MX^U#^DOMW;-OZ;J|GKU%%0444 %%%% !1110  
4444 %%%9?B/6H\_#OAV^U M>6%IDM(C(8U;"WMGM7\$>\_|B|^XYUZ32CHKV;BPM;K\_.1^"0\_Y5QU|Z0STN\_MBBBF(\*\*\*\* "BBB@  
HHHH \*\*\*\*|Q)=\_&+P5XB\_L<(|ZXB61Y/M(B W=@\_K9\_M2D;|HK|T+5DUW0;#58HFB2|@281L%|HC|&108|"?  
3|/Z5PT^|L\_P#|FAD^GK^>Y91^<\_I1<=CW>BJ&B; MO;|IHEG|JMH'\$%W\$)4#C#\_L?<=^OTQ|114-W<+9V<|RX)6&-I^|U(  
S0|-17 MD\_A+XW0^?2%5KHT&2U^TS^DWVH|C^EN5VCT|;J8|#"BLG4\_<^Z+<);ZGK%  
MC9S;B;=>4;K@G|HUP517\$^3021+^X#&5@>X(ZB0^O^BBN|!\$0?M&DS\_Z1X9 A)ZQWN64?BG/  
MZ5|HFKVVO;)9ZK;!Q|=Q^5\_XPP|^W^2BX0^BBBF(\*\*\*\* "BBB@ HHHK)U/O M/H.BW^6^IZO8V|(#6HID;T5Q^DT\$J2Q;  
R.C|E8^N^;H| M| HHHH \*\*\*\* "BBB@ HHHH \*\*\*\* "BBB@ HHHH \*\*\*\*KWU\_9Z9;|=W|U#;VZ M?>EFD^"/Q-  
%BB|I2M>TC7\$=|^U.T01^P\_V>97V\_4\_5HT@^BBBF 4444 %%% M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%  
!1110 444 M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 M 4444 %?7AK\_DZ9\_P#K|N\_-  
\$|)7T+7SUX;\_P^3|G\_Z\_+O\_-\$25;AH^EZ\* M^DH^9/V?|\_D=|9\_P^O^O|T8M?1-?W|/\_R\_|L|>?^C%KZ)JEL2PHH MHHJA|1110  
4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444 M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444  
%%%% 'F;WP\_M\_|S>(7U9KW4@7N#<(\$2)MW%MV;|C;?6+^U&:6V8M%\*Z;\_M&=)|5:8;#5|19X<|E.<\_&WJK#D&O\_KO|G?

1'DS9ZU?PKG(LJ)QI0%KV2BBP M'G A7X/>&/#%REX8Y-104.4EN%4/J 8!|SDTFI ""015!9GQ+->7ZSM.DI M0HRI"RXQ #G'  
I'M>@T46"X5R'CGX=Z7X!6S.H7-W!);.+.W91D-C.00?H MKKZ"!&'X2!+67@f08l(L)9Y84=G+SL"Q9CDI!6Y110!YG PI#PI\_P)-  
-7 MVW4M\_P!J^U>303;OW;L9VYVY"">O3\*\*\*!A1113\$%%%"FES!\$O#USXHDUO MKI(4A))=&f.\$:FW>6W59VYQ6!?  
>02Z\*\*0SDP/PITOQXMF=0N;N"2TW^6UNRC MG<&@& W16GX2!+67@f08l(L)9Y84=G+SL"Q9CDI!6Y110!YG PI#PI\_P)-M-  
-7VW4M\_P!J^U>303;OW;L9VYVY"">O3\*\*\*"BBBF(Q \$/A;10%5B+36;&. MY10+W16C0Y9&.RUF\_MU/19523"-H-  
>QT4K#"/+/!6G0H MW4WFLA.HZK&J1Y/X@!5Z%X;1#^'O"\*L="TY(9G7:|f\$O(P!-QY X' P\*Z&B MBP7"BBBF(\*\*\*\*"BBB@ HHHH  
\*\*\*\*"BBB@ HHHH \*\*\*\*"BBB@ HHHH \*\*\*\*M\*"BBB@ HHHH \*\*\*\*"BBB@ HHHH \*\*\*\*"BBB@ HHHH \*\*\*\*"BBB@ HHHH M  
@OO^/"Y\_P"N3?R->"?LZ? (7UW\_KA%\_P"A-70=|\_QX7A UR;^1KP3!G3\_M)"^N\_|7"+-".D!Q!#Z"HHHHB"BBB@ HHHH \*\*\*\*  
"BBB@ HHHH \*\*\*\*M"BBB@ HHHH \*\*\*\*"BBB@ HHHH \*\*\*\*"BBB@ HHHH \*\*\*\*"BBB@ HHHH \*\*\*\*M\*\*\*\*"BBB@ HHHH \*\*\*\*/?  
CG>W-E!F\$S3\$9KN.\*0HQ!92&!)@5!|^&/M!FM^)+F/L:9)FM@K2A!53;..fYZ&O??C|\_D!C\_Z\_XO!T%ZY+IG/\_C\_|M02!  
7\*#^\_U+W\*Z")X.\$"U^>'2|DCGRKR(" ?0JE+J'O#!"3KHN-9T;L  
M+YS.T+VSE&\_6OKBH+RRM=1M)+2!MXKBWE&UXI4#\*PIP;.+N>0> ?CG#JUS% MIGB=(Z2X?"QWD?3MZ/X3H/I7LU?\*7Q6!  
+X)UV.2QW'2KT%K?<^#7L7P5!7R^)"3V-!9+!3&\$3.QR7B.=A/OP5\_X"/6A/H#/2Z\*\*J.MZC!J5C!  
E)>.C=PVMM!JZ69PJC|^\_M5"+5%>;7GQS!%6LOCCN+RZ\_-!L)/&.@^\$X%O#DUG4(f=G&8XAEf^BCG|\_M>E(9NT5YM;?'3P5/<>4H  
I N!F2VQV\_7Y2QC|^!L\_0L!4LH!RPN8KFVE&4 MEB<K?B\*+-%8/B3QGH'A\*%7UC4(X'^92%06D?Z\*.<>\_2N4M/CGX\*N;@1/<7  
MEL">2.W.W.QTD\_10!Z314E>VNHV<5W9?5\$QO;2CQ63TO!117'Z!M4/"AV=|>U9)+E#AH;93RGT.. ?8G-  
(#L\*\*!QB^//@R23:OU".?WWM^/T M)/Z5VN@^\*!|3PF71M3@NPO+(I\*NOU0X8?B\*+C-FBBJN!E::1HMQJ%\_-C6  
MW0R2R\$5\$!5^L\_3^%\_1.HKF\_#^CSP!XOGG@T;I;:::0!B-"Z\$\*3C/(&>\_J^)/B  
M7X5!+7#6VH.D'NU^!\_VZFU^N.%^A(I#.NHKSO3/C9X\*U&X6!RXLV8X#74)\_M5?  
Q(R!^.\*!BECFB26)UDC@!1%4!4U;3!%L70=30C6V3!T MDK8'T!J9-/#\_BV'15T/ M4/M9MFF.O!F2/;NV8^HST/2AL\$>U>  
<\*>\_/#G1K-9-9B3-"T1DWX(.0<# M/7TKIZ|^\$7Q"|>%.!CZ?K;J?9KHW  
MPYX5B^&'GAWO?/!HUZFTF"AY\$%T(4G>0\_|T".DHKA\$'Q>|(^KH&> M!ENKF;f9\$M(fX0^A;(&?8\$XK;|\*>~%|9VDUQH  
fOY!"S1R(4;G..CWP>F> ME SH\*\*ANKNVL;9!fIN(K>!!EY97\*HJR>!7"ZE!;?!.GR&=1ENV'7f+ S#|\_MS@!^#0!Z!17FUT<\_!-  
S(\$EN+RU!\_TUL2/\_!W=7?Z=J5CJE">Z==PW5M) M!V6%PRGVX|^U%JN7!>^X\_WAU=5>R;+SK\_L2R;.2&.2<^4HJZ&^O;?3  
M;"XOKN416UO&TLLAZ\*!C)/M7A?Q@^/(A?Q3X@L\_&U3!5P^4^SRIA0C@ MG+!U(H8(1%^7Q"3Q\_7TPTUK%  
f!T5E.WFAMP."#M!Z5VU?\_P6!;>'O"5 MGK\$>N;A!D;XDB.0!F23<  
&S!O3C!M>PZ3!3\_VN;H!NG;R)KN:C=PVMM!JZ69PJC|^\_M3\$6J!VO/CGX\*MM9C"<7ET  
<\_X;8X\_P#\*B\*T=\$^+G@WZ^A+>+4\_LTHD!8!M#^D^FHOMU!78  
M!BBCK13\$%%5=1U\*RTBQDO=1NHK6VC&6EE8\*!\_P#7!J!\_N\_C!X\*MIC"/>W(! MQOAMCM\_|)/Z4AGI5?&\_BG\_D!NM?IAF?  
\_P!\_-7U)X9!>>/%N4TG44DG49;W MD!20#UVG!/<9%?+?BG\_D!NM?IAF?\_P!\_-28T?9%%%42%%-DDCAG;25U2-1 MEF8X\_!30  
ZBN%U7XP>="E;3;L+!0^!%I&9^A @0^4\_@:S;2X|^"Y!LDE M\_/!EMD?^\_DG!^5QV/3\*\*SM&U!2O\$-  
D+S2+&@/Z%HVY4^C#HJB!6C3\$%\_M8GB7Q;HOA&SBNM;NS!\*\_EQ!8V\$4XZCK0(XGOM;(\_!\_BF?1!H3WA@5"!QNA'Y0W  
V/!H176FWHJAE!P M(A!F%)@/ZJ&4^ZUE!\_6\_!1!>/!0U2KCI!9S+\$\$DV.F<1HX8\_10>U>Y M;H7\_UEXA  
M!GB7Q9HJOA&RBN!;NS;OROY<>(VU;#@?@:X5UOPWIVKRZQ;26@NWB\_M!F&0C=|H;+\$\$=f!@\_?202M<\_Y  
&f!>LO\_H)JKX;4Z/XMT!H!W1KHW\$;1A\_NCD#W;126PV=%17F MMM|=?!4!XC>\_!MU)QYDML=OU^4D\_!7?  
Z;J=CJHC">Z==175K(fEB;<#\_P#7\_MJH8BW1113\$%%?IAEV?\_M\$O"\_W\_LXQ\_Z%G!^5QGIU%<fX>|<^&\_%Y:1JL\_TP&3\_V4D'\_  
%@"?J\_\*Z@\_M0445G;UKVE>'K\$WFKWT\_HG\_0!L20\_9R\_?P7'\_Y;R7!BYQYB M6WR\_J0?TKLO#OBW00%=LT^C;A%  
<L;X^5=|Y3R/KTI7&?\_P!\_Y\*)X>\_P"O M^+T(51D5!\_!\_Y)X>\_Z\_XO!T(5!>7U!::87%|>2>5;6;2RO@G;fC)  
M;R>2D@98HKD!^!\_A/P+JL>F;J3>2 F;2!T!WX&3@D8S@SUU!0445RO  
MB3XC>@/"FH+8;M!CNF02>6D3N54!"=H(C!H0!U5%5=-U&TU?3;?4+&7SK6X\_M0212;2-RGO@!C!;M4P"BBB@#Y<^\_O\_)2YO!  
KUA\_D;|^~^O\_"3OP!\_UX1?^ M@BO ?CK\_&F F\_Z!8?Y&O?OA!\_R3OP!\_UX1?^@BI6Y3V;?\_C/X!;" 67;PXSUP6'%  
fY/K7L&O;\_IOAK2!3U;X!BUC(4OM+!\$D!\_f!ACQOH^C#f!0\_%O#\_MUOMU6B9"H<\_Y@\_!#TH!^0U;V/\_)3;\_L\_K\_Z.%29%?  
&fC\_R4VV\_|#\*^MCA28(^R\*\*\*R!^!Z1X8T\_P"W;Q>L\_V^!f;I8\$EF!H)/T%;1J45S^AGX@^&\_M%U!+9Z/?/<11^T;0NGR9  
SDC^4C|ZZ>@\_HKU\_07H7A>!9M9U\*^T#?<1B6 M=-HHR3^\_KBF^//@Q9=@.HLN?  
OBW&U;Z47&>G45S7A00fX;15MY>DZG^<8 MR;0&0?L>?PS72T""BBBF!R?Q\_Y!K\_ %ZG^8KP\_P" 7\_)1)A KPE  
M!"2O\$O\_H25+W\*6Q!45R7B/XE^%?" MUPUMJ&fHKM?O6!NID=?KC@?0D5D;9!;f6HW"PO>7%FS'\_ZA^K^)&0/OQ3N  
M(f\$HID4LA!|T^F(\*J:CJEA!%HUWJ5Y;6Z!9)I @^G M/?VKA+|XW^;\_5DCO+FIQWM|=L?FV\*0ST;BO;|^\_O@F^E6-  
fVXLROP#L^!\_TF?/2OA!\_R3OP!\_UX1?^@BN@NKA;2TFN7^Y#&TC\_M?0#-<|\_#W\_DG?A!\_KPB\_P#016#XL^)\_@^WT!6M6;60-  
f2&>W!H6!H0+M\*|=MP7;UXZXI@?\_A6-QXZ!VUM=S\_YNIW9>XD!Y"DEG(S!X\_"OI?^X51X(-B+M0^!f?8!C?  
N;S/KOSG!^\_AKK&G;f!0=+U/59\_(LH#\*9)-C\_MS\$ZCA02>2\_U M?1EK!7/ U!>0VL&NAHG6;\_&UF4B<#DH\_>Y!G;fTC2K71-  
M|=L49+;YC M\$<89LG\_135VBB!)J&N?@P#^40^067\_T\$U?JAGK\_(U+\_\*!9?\_032^5?A+ M\_E!T+KJ!  
Z+;OKFOD;X2\_|E!T+KJ\_P#Z+;OKFE\$;/G#XK> ?%6!f\$&^U M&QTHY0;2Z!LQ20C=C""H!^\_#UKV?X=;/?\_!X TG3-  
279>0QMYB;@VW<f;\_MR.. 0/PIGB+XC^%\_"NI#3!6U!HKHH";0N^U3T)(\*&Z.POK;4!M!^SE\$MM<M1K+%(  
fN4C!\_#R/O!@NKA;2TFN7^Y#&TC?0#-?>A6-QXZ!VUM=S\_YNIW9 M>XD!Y"DEG(S!X\_"OH;Q9!3\_?;Z=K6D-  
K(&H!#;^4+>4XEVE=NX+MZ!<=M5X!|-8T!0/B#f!>fZK/Y^E 93))L9MN8G4<\*3R!VL\_/!#\_(51X(-B+0^!M!f?8!C?  
N;S/KOSG!^Z72\_\*M=\$fFUTRO!DMK;1OAFR<#U-WD\_K!K MH::9UCC!M9E!8G\_Y\*#GN;f\_F(\*SM9U!2O#UD;S5K^&S@S@-  
\*Y"O!\_!L\*MX\_X^\_@N&A!8!\_H\_CGML\_H\$!^\*^/3\_\*Y!PH3/"?B;X6VL\_45;A8+A3 MS\$23!/L"3774""BBBF 5!X?  
%;P#XJU+X@WVHV.E7-f.77EF\*2\$;L815(C\_A MP0>M?HPOK;4!M!^SE\$MM<1K+%(fN4C!\_#R/  
MOJHKVOZ;X9T!34!6N/(M4(4ML+!\$D!\_f\$@#3HK#|^+|!\$7VLUQH MV9T@<)  
M(&C9^f(X8"L70BWX^A/W3VLVHFYN\$)#QVB>9M/H6^fGV\$0!W%<^HOQA!&MZW!E.\$^f!E1^!K\_O.M !1113\$%%%"O!EO^K-  
ZT.E MP" T+!\$SD@=3H!.\*0!T5FVVOZ5=Z"FN1WL0TOX\_-%S(=BA?4fL8\_&N)O/CCX\_M\*M;HPI^O^R-8^HI+\*@W/X\*2\*7  
M;2>1<9%;5Y>VNG6DE>W\$5O;Q#<fLK!54>Y-B>BO-KOXY^!K;Z,\*7%Y<#\*# MRPVYV?\_CQ!\_2N!>-/\_#\_BV)FT?  
4(YW09>@!4D3Z!>>\_2BX\$?KSKXS^\_7 M!2^>8+2!X&N)H+M9G@0@%EVL;J<%AQ7HM9NO;\_IOAK2!3U;X!BUC(4OM+!\$  
MD!\_f\$@#Q\_X^>#/\$A\_?ZEJNGS65JH8%6;Y6=RZG.WKP%)!fIRKGO#^C\_M?0/&^V@;+>&=K?\_YJM\$R%0W;/S;&\_!J^XC1/BWX-  
UR=+>5!;3N<M+!^=H8LGTW^Y?UKM^M @HHKE/\$7Q(f^%YVM!H!U!M2!>3(X^H7fOXXH\_ZN MBO;H?COX;DEV.VH1+?>  
YR/T)/Z5W6B>(M(26?YK!H0AO(fPOC^\*GT93ROX MB@9Tf444Q!1110\_4444 %%%%"1110\_4444 %%%%"1110\_4444 %%%%"  
!11\_M10\_4444 %%%%"1110\_4444 %%%%"1110\_4444 %%%%"1110\_4444 %%%%"M !7SUX\_Y.F?\_K!N\_P#T1)7T+7SUX\_Y.F?  
\*\_+O\_T1)4R&CZ7HHHJ2CYD\_M9\_|^1WUG\_KS;T8M?1-2.W!/\_R\_!\_P#7FW\_HQ;^B;f;L\$\*\*\*H04444 M%%%"1110\_4444  
%%%"1110\_4444 %%%%"1110\_4444 %%%%"1110\_4444 M4444 %%%%"1110\_4444 %%%%"1110\_4444 %%%%"1110\_4444 %%%%"  
!11\_M10\_4444 %%%%"1110\_4444 %%%%"1110\_4444 %%%%"1110\_4444 %%%%"M !1110\_4444 %%%%"1110\_4444 %%%%"  
!1110\_4444 %%%%"1110\_4444 M%%%"1110\_4444 %%%%"1110\_4444 %%%%"1110\_4444 %%%%"1110\_4 M4444 %%%%"  
\$%|\_P>%S\_UR;^1KP3!G3\_D+Z!\_-<(O\_0FKWN^\_P"/Y\_ZY-(MUX)^S!\_R!|=ZX1?^A-2>X^A!4444Q!1110\_4444 %%%%"  
!1110\_4444 %%%%"M%%"1110\_4444 %%%%"1110\_4444 %%%%"1110\_4444 %%%%"1110\_444 M4 %%%%"1110\_4444 %%%%"  
'EWQ!\_P"2=Q\_|^7\_\*!8?\_">W!>W-H#^fNK!)C\_5E(f;OSKV^XO\_M2"/X6;X3W2-?  
SE05XE(fHC)!2X6^+\_UE8\_D!6!>Y70^G;N!@L+\*>N9!^M!&TLCGHJH\_D^\*4=>UW7?  
BQXVAM+;=LEE\*65JS82%.I9L=|#+^V^@KW+XUZ MB!A!  
fU(R0UU+;Y^H6W^PI^XUXY!O\$WA\_PGK>H:CKEPT+M;B&W\*PLY;+M=F;3!\_?#5M8(NJ7%Y>79\_I R1)/+0'\_&0!G^U)KC/B-  
f!%X\_#FC MRZUH\_U/!6XW7%O<\$ZKGIRD\_9 SR"!SDUZ3\_PNWP+\_-!\_?P\$D\_P!Qf^Q MC!WVFW5H^H5%9X7B(-  
f)@A@1Z>|&@M3FO@3XZN;O!/"NI3+Y4!DL9;2%\_MWH\_?Y^H\_1Z5!A7R#|+;E!7XF;#(A(+7^EGZ;f4\_H\_^OJ\$#/C#^UIM!G  
MH;5P!\_O%=2\_VG0/#+JPCD0!&4RX^\_O!J\_-(HUCCL4C0!551@^!T%)G/\_MG!Q\$!#(=\$T&?5=  
OKFX^RH9)K>YVEB@&6\*EO!UQC!W!>^&#\_ \$;5?\_T6H16;  
MB>\*ZBPD4K^9+QB3^TSD<9X!^\*NI(TEB>.10R."K">A;ZU!9^%+""X!>Z/87\_M4;S0/J;44B-T=2;







1U M%?./ "DO%/A T'I3 OY+ A1 PI+Q3 T'I3 OY+ A19I@T/HZBOG' A27BG H M/VG 'IE P \*^/%>\*?^@\_:?I )?I\*+/L&A I'45IX\_

"DO%/\_0?M/A OY+ \_M (4?I\*2I4 |0?M/^ DO M^%%GV#0^CJ\*^\*?^@\_:?I )?I\*^/%>\*?^@\_:?I ?R7\_ HL^P:T=17

MSC PI+Q3 P!|^T I^2 X4?I "DO%/\_0?M/A OY+ \_ (4678-#Z.HKYQ X4EXI M P"@\_:?I )?I\*^/A27BG H/VG ?R7\_ "BSI!H?

1U%?./ "DO%/A T'I3 OY+ M A1 PI+Q3 T'I3 OY+ A19I@T/HZBOG' A27BG H/VG 'IE P \*^/%>\*?^ M@\_:?I )?I\*+/L&A I'45IX\_

"DO%/\_0?M/A OY+ \_ (4?I\*2I4 |0?M/^ DO M^%%GV#0^CJ\*^\*?^ M@\_:?I )?I\*^/%>\*?^@\_:?I ?R7\_

HL^P:T=17SC PI+Q3 P!|^T I^2 X M4?I "DO%/\_0?M/A OY+ \_ (4678-#Z.HKYQ X4EXI P"@\_:?I )?I\*^/A27B MG H/VG\_?

R7\_ "BSI!H?1U>6VOP(I,P.RNH37NI7(675?)ED3:QSG#\$+DC\JX/M A27BG H/VG 'IE P \*^/%>\*?^@\_:?I )?

|\*+/L I'45IX P#"DO%/\_0?M M/^ DO^% ' "DO%/A T'I3 OY+ A19I@T/HZBOG' A27BG H/VG ?R7\_ "C A27 MBG H/VG 'IE P

\*+/L&A I'45IX |\*2I4 |0?M/^ DO^% ' I+Q3 T'I3 \_M +^2 P^%%GV#0^CJ\*^\*?I H/VG ?R7\_ "C (4EXI Z#H WIE PHL^

MP:T=17SC PI+Q3 \_|^T I^2 X4?I\*2I4 I|^T I^2 X4678-#Z.HKYQ X4 MEXI Z#H P I )?I "C A27BG H/VG ?R7\_ "BSI!H?1U%?./

I+Q3 T'I3 \_M +^2 P^% ' "DO%/\_ \$'I3 OY+ A19I@T/HZBOG' (4EXI Z#H WIE PH X M4EXI P"@\_:?I )?

|\*+/L&A I'45IX P#"DO%/\_0?M/^ DO^% ' "DO%/A T'I3 M OY+ A19I@T/HZBOG' A27BG H/VG ?R7\_ "C A27BG H/VG 'IE P \*+/L&

MAI'45IX |\*2I4 |0?M/^ DO^% ' I+Q3 T'I3 \_ +^2 P^%%GV#0^CJ\*^\*?I H/VG ?R7\_ "C (4EXI Z#H WIE PHL^P:T=17SC PI+Q3

\_|^T I^2 X4?I\*2I4 I|^T I^2 X4678-#Z.HKYQ X4EXI Z#H P I )?I "C A M27BG H/VG ?R7\_ "BSI!H?1U%?./ I+Q3 T'I3

\_ +^2 P^% ' "DO%/\_ \$'I M3 OY+ A19I@T/HZBOG' (4EXI Z#H WIE PH X4EXI P"@\_:?I )?I\*+/L M&A I'45IX P#"DO%/\_0?

M/^ DO^% ' "DO%/A T'I3 OY+ A19I@T/HZBOG' A M27BG H/VG ?R7\_ "C A27BG H/VG 'IE P \*+/L&A I'45IX |\*2I4 |0?M/

M^ DO^% ' I+Q3 T'I3 \_ +^2 P^%%GV#0^CJ\*^\*?I H/VG ?R7\_ "C \_M (4EXI Z#H WIE PHL^P:T=17SC PI+Q3 \_|^T I^2 X4?

|\*2I4 I|^T M I^2 X4678-#Z.HKYQ X4EXI Z#H P I )?I "C A27BG H/VG ?R7\_ "BSI!H M?1U%?./ I+Q3 T'I3 \_ +^2 P^% ' "DO%/\_

\$'I3 OY+ A19I@T/HZBOG' \_M (4EXI Z#H WIE PH X4EXI P"@\_:?I )?I\*+/L&A I'45IX P#"DO%/\_0?M M/^ DO^% ' "DO%/A

T'I3 OY+ A19I@T/HZBOG' A27BG H/VG ?R7\_ "C A27 MBG H/VG 'IE P \*+/L&A I'45IX |\*2I4 |0?M/^ DO^% ' I+Q3 T'I3 \_M

\_ +^2 P^%%GV#0^CJ\*^\*?I H/VG ?R7\_ "C (4EXI Z#H WIE PHL^MP:T=17SC PI+Q3 \_|^T I^2 X4?I\*2I4 I|^T I^2 X4678-

#Z.HKYQ X4 MEXI Z#H P I )?I "C A27BG H/VG ?R7\_ "BSI!H?1U%?./ I+Q3 T'I3 \_M +^2 P^% ' "DO%/\_

\$'I3 OY+ A19I@T/HZBOG' (4EXI Z#H WIE PH X M4EXI P"@\_:?I )?I\*+/L&A I'45IX P#"DO%/\_0?M/^ DO^% ' "DO%/A T'I3

M OY+ A19I@T/HZBOG' A27BG H/VG ?R7\_ "C A27BG H/VG 'IE P \*+/L& MAI'45IX |\*2I4 |0?M/^ DO^% ' I+Q3 T'I3

\_ +^2 P^%%GV#0^CJ\*^\*?I H/VG ?R7\_ "C (4EXI Z#H WIE PHL^P:T=17SC PI+Q3 \_|^T I^2 X4?I\*2I4 I|^T I^2 X4678-

#Z.HKYQ X4EXI Z#H P I )?I "C A M27BG H/VG ?R7\_ "BSI!H?1U%?./ I+Q3 T'I3 \_ +^2 P^% ' "DO%/\_ \$'I

M3 OY+ A19I@T/HZBOG' (4EXI Z#H WIE PH X4EXI P"@\_:?I )?I\*+/L M&A I'45IX P#"DO%/\_0?M/^ DO^% ' "DO%/A

T'I3 OY+ A19I@T/HZBOG' A M27BG H/VG ?R7\_ "C A27BG H/VG 'IE P \*+/L&A I'45IX |\*2I4 |0?M/M^ DO^% ' I+Q3 T'I3

\_ +^2 P^%%GV#0^CJ\*^\*?I H/VG ?R7\_ "C \_M (4EXI Z#H WIE PHL^P:T=17SC PI+Q3 \_|^T I^2 X4?I\*2I4 I|^T M I^2 X4678-

#Z.HKYQ X4EXI Z#H P I )?I "C A27BG H/VG ?R7\_ "BSI!H M?1U%?./ I+Q3 T'I3 \_ +^2 P^% ' "DO%/\_

\$'I3 OY+ A19I@T/HZBOG' \_M (4EXI Z#H WIE PH X4EXI P"@\_:?I )?I\*+/L&A I'45IX P#"DO%/\_0?M M/^ DO^% ' "DO%/A

T'I3 OY+ A19I@T/HZBOG' A27BG H/VG ?R7\_ "C A27 MBG H/VG 'IE P \*+/L&A I'45IX |\*2I4 |0?M/^ DO^% ' I+Q3 T'I3 \_M

\_ +^2 P^%%GV#0^CJ\*^\*?I H/VG ?R7\_ "C (4EXI Z#H WIE PHL^MP:T=17SC PI+Q3 \_|^T I^2 X4?I\*2I4 I|^T I^2 X4678-

#Z.HKYQ X4 MEXI Z#H P I )?I "C A27BG H/VG ?R7\_ "BSI!H?1U%?./ I+Q3 T'I3 \_M +^2 P^% ' "DO%/\_

\$'I3 OY+ A19I@T/HZBOG' (4EXI Z#H WIE PH X M4EXI P"@\_:?I )?I\*+/L&A I'45IX P#"DO%/\_0?M/^ DO^% ' "DO%/A T'I3

M OY+ A19I@T/HZBOG' A27BG H/VG ?R7\_ "C A27BG H/VG 'IE P \*+/L& MAI'45IX |\*2I4 |0?M/^ DO^% ' I+Q3 T'I3

\_ +^2 P^%%GV#0^CJ\*^\*?I H/VG ?R7\_ "C (4EXI Z#H WIE PHL^P:T=17SC PI+Q3 \_|^T I^2 X4?I\*2I4 I|^T I^2 X4678-

#Z.HKYQ X4EXI Z#H P I )?I "C A M27BG H/VG ?R7\_ "BSI!H?1U%?./ I+Q3 T'I3 \_ +^2 P^% ' "DO%/\_ \$'I

M3 OY+ A19I@T/HZBOG' (4EXI Z#H WIE PH X4EXI P"@\_:?I )?I\*+/L M&A I'45IX P#"DO%/\_0?M/^ DO^% ' "DO%/A

T'I3 OY+ A19I@T/HZOGKPU MR= \_7Y= P#HB2JW "DO%/A T'I3 OY+ A5#X7Z9/HWQIT 3:F599I:6YC>1 M22&(@DYVYI.XT?

5I)%%2,^6 @9\_R.6K\_/7HW\_HO:|KP/X&?|CEJ\_|UZ\_ MZ,6O?\*VAL1+<\*\*\*\*H04444 %%%% !1110 4444 %%%% !1110 4444

%%%% M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 % M%%% !1110 4444 %%%% !1110 4444

%%%% !1110 4444 %%%% !1110 44 M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111 M0 4444

%%%% !1110 4444 M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% \$%Y\_OXW\_7-

OY5XA! ?^OKK7 7"/\_M P I ">WWG\_ 'C144450@HHHH M \*\*\*\* "BBB@ HHHH \*\*\*\* "BBB@ HHHH \*\*\*\* "BBB@ HHHH \*\*\*\* "BBB@

MHHHH \*\*\*\* "BBB@ HHHH \*\*\*\* "BBB@ HHHH \*\*\*\* "BBB@ HHHH \*\*\*\* "B MBB@ HHHH \*\*\*\* "BBB@ HHHH \*\*\*\* "BBB@

HHHH \*\*\*\* "BBB@ HHHH \*\*\*\* M\* "BBB@ HHHH \*\*\*\* "BBB@ HHK.N?

\$&BV=WIDNM8T^"YX\_TASCS)Y5C7/HDF@ "S15>RU"RU\*W^T6\_WI=0YOYD\$@=< M^F0<58H \*\*\*\* "BBB@ HHHH \*\*\*\* "BBB@

HHHH \*\*\*\* "BHKFZMI\_ \$S74I4 M\$0ZO\*X51^ )MI?6E\_ \$9\_:Z@N(P<%X9\_XS10!/\_1110 4444 %%%% !1110 4 M444 %%%% !1110

4444 %%%% !115:~U&QTR#S|^MI2'\_|GE6-<^F2: +-M%5I+4+4K?I18W<%U#G^F02!USZ9!05B@ HHHH \*\*\*\* "BBB@

HHHH \*\*\*\* M"BBB@ HHHH \*\*\*\* "BBB@ HHHH \*\*\*\* "BBB@ HHHH \*\*\*\* "BBB@ HHHH \*\*\*\* M\*\*\*\*

"BJ@|KND:7.L.H:K8VDK#\*I<7"1DCV|QI|(DL:R1NKHX#\*RG((/0@T M.HHHH \*\*\*\* "BBB@ HHHH \*\*\*\* "BBB@ HHHH

\*\*9+ +!\$TLTB1OJL|L/\_MJO\_-\$25IE7AOA3\_DY\_MIN\_P#T1)43V/'\$^FJ\*\*\*\*R+/EOX&?|CEJ\_|UZ\_ MZ,6O?^I#^!G\_ ".6K|7HW\_

\*\_6O?^VAL1+<\*\*\*\*H04444 %%%% !1110 4 M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11 M10

4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% M!1110 4444 %%%% !1110 4444 %%%% !1110 4444

%%%% !1110 4444 M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4 M444 %%%% !1110 4444

%%%% !1110 4444 %%%% !1110 4444 %%%% \$%Y M P >-Q US;^5>(? \_D^ZU UPC\_I">WWG\_ 'C144450@HHHH X?

XE^\_.GP3IEG)96L.IS=2,J^=G8H4\_DD @GJ.MXKS' A?BC GPT? \_+|R P#QRNA^/\_|OXZ%\_ P!=9OY)3?@|H.CZKX:U"74=

M\*L;R1+S:KW^NDA V^< L#O6;NY612M8P/^>|^?#1 \_^\_ O\_P TF.1"&5TLHP5(Z\$""T NXKHV\*\*\*\*L04444 %%%% !1110 4444

%%%% M!1110 4444 %%%% !1110 4CJ|7=@|H.DDX%+61XK\_P"1.US\_ +|P#Z M+:@":R10:+|J5P:>PU>PNI@.F."Y1V

^@\_:T:~9@|Y\_R4JP\_ZY3?^BS7TW4Q= MT#5@HHHJ@ "BBB@ HHHH HZAK6E:2R+J6IV5F7&4%S.L>|Z:B.U:@N(CJ|I)>

M6:~(OE)(V#P101UKP#X| (XZ? P!@|?I T8I>|?I \_DFNB |7)\_ \$8U M2GK8=M#KZX3XK^ )|3I+>>8;G2I!>

<3W?P^<4#~\*V1QP#D9^7^= W534M+L-8 MLFLIM(KJW8@F.59C@R EFQTR3R:UJ\$FEJ#"BBBF 4444 M%%% !1110 4444

%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4 M444 %%%% !1110 4444 %%%% !7RA1\_ ^2B:Y\_UG^0KZOKYO^ ( )I-

<Z^ M3 (\$\$IAO/JBS\_P"/&W\_ZYK\_\*IZ@L\_P#COM ^N: RJ>K\$%%% !1110 4444 M%%% !1110 4444 %%%%

|2.RHA=V"JHR2X@ 4M9'BO\_ )\$|7A L'S\_ /HM MJ )K+O|HNI7MI#5I"ZF R8X+E'8#Z YK1KYD^#G )2K#\_KE\_ Z+?3=3%W0 M-

6"OG+Q140%MMXNU\*^TU|\_VMU)#' (4("JO7G0)...^C:Y^ ^|^#&-2U( MZA>+:373P(T=\$O9-3T#3K^9 DMS:Q3.HZ

LH)ZUYA M??^0'H\_7R\_H>NJHH50%4#& !7D7QI P^0'H\_ ^|O\_P^@T2V&MR?X M" \_ (J-E P! ?W\_LBUZ+XBU"72?#6IZC

@>:UM9)D4I"54D9IN^Z^O \_"N MI?I 7I |M>JNB2QM'(BNC JRL @|011'8'N?@"\_XH>+ +OOEIEK>ZCJHMK MNZ2&2)H4 PS

9& ".9S^%?1-8G>"/#\_DZB+^QT:UAN@7\_ 'C\_D1I+ \_L)1\_|HN6L MKX ?I>\_N P#76^ ^3UJ?'C\_D1I+ \_L)1\_ ^BY:R @!\_OXZ| P!=8?

Y/4?;T/9: M\*\*\*L051U#6M\*TED74M3LK.N.H+F=8IWTW\$9JH7SYI>?^1OT\_ L'K\_P"C I2=

MD"5SW^"XANH\$GMY8YH7&4DC8.K#U!^6I\*Y#X7?I )= % P"N3\_|HQJZ^F@" MBBB@ HHHH \*\*\*\* "BBB@ HHHH \*\*\*\* "O(?

CI\_R I' \_Z^7\_IKUZO(C|\_R MI' \_Z^7\_IJ9: MR?X" \_BH7\_7I\_|M>B^ (M0ETGPIU>HP(FM;629/0E5) M&?BO.O@+\_R\*NI?I?

W\_LBUZJZ)&T|H\_00!67? MC+3+6IU!5;7=TD.D30H/AF R\_ \$8SGI^M^B:P\_.\$&=&)U\$7ICHUK# =Y615 M)VG\_

&0> % "M^B\*W\$PHHHJ@ "BBB@ HHHH \*\*\*\* /+ C#XOUGPO#1^&CS\_9F MNC(TDY06.%VX49|QH^52?HQ?

K'BBQU\_/6)OL:#I7B"V6WU:QANXE.5\$@Y4^H/4?A2Z1H>EZ#:&UTJRAM(2=S+&O^U)ZD\_M\_6IL|W" ^AH44450!1110 4444

%%%% !1110 57O+ZTTZW-Q?74%K IP99Y MBC|3Q5BO.OCI\_P B);\_|A"/\_ -DI-V0(I" L-4T\_58FETZ\_M;R-3AGMYED /MH2I-6Z|: ^

\_ |XZ| UUA DI>RT)W5P>@4444P"BBB@ HHHH \*\*\*\* /FOXU? MAE\$E\_P"O: +^1KW/P'\_R|\_@\_ |>\_7\_ \*\*X|\_ ^-7\_)1)I?

KVB\_D|S|\_|B#H/M\_7C%\_ P"@BHC|3&|CH:\*\*\*\*L05S/Q|UR|\_|>="OU.PP+I(L;H8(6<+NP?3/Y

MUTU0W=I;WH+ /W<\$<IO^NUXY%W\*PI00P/\$AC|I|\$NL>--;2I30OM=K'I N7N=+ TJWMW!!D4\$M@10"<@DDXYKZ-

KGHP/X8U+4C1%YHMI- =S.R\_ ?I MPZ?I3DFIA(T=\$O9-3T#3K^9 DMS:Q3.HZ LH)ZU?I?544"H" I|@\_ # I.H M HHHH \*\*\*\*

"BBB@ HHHH \*\*\*\* "BBB@ #\_E|1:)>\_8IM9T^ |#;?(>Z029I M-I.G>"O"OAV MZ|Z+<7&@Z7- )9OL|DEG&S,2HR22,DUN\_|













4  
1.1999YBB1@/XOJ?PO4)R9321REI?=26< M&T2TDASR(9&1@/JA\CT-N<5Y+))M9ETGO\_81JY\$-Z3;2KGAM MP^7\FQ^M.  
I3LQ6311044458@HHHHH \*\*\*\* "BBB@ HHHH \*\*\*\* "BBB@ HHHH M \*\*\*\* "BBB@ HHHH \*\*\*\* "BBB@ HHHH \*\*\*\* "BBB@ HHHH  
\*\*\*\* "BBB@ MHHHH \*\*\*\* "BBB@ HHHH \*\*\*\* "O#?G )S\_ /VIW? Z(DKW\*O#?G "<\_ M P!O=W Z(DJ)I#B?  
35%#%9%GRW\#/^1RU? ZI&\_J&+7OE>\_ S\_ )+5 | MKT;\_&+7OE;0V(EN%#%4(\*\*\*\* "BBB@ HHHH \*\*\*\* "BBB@ HHHH \*\*\*\*  
M"BBB@ HHHH \*\*\*\* "BBB@ HHHH \*\*\*\* "BBB@ HHHH \*\*\*\* "BBB@ HHHH \*\*\*\* "BBB@ HHHH \*\*\*\* "BBB@ HHHH \*\*\*\*  
"BBB@ HHHH \*\*\*\* "BBB@ HH MHH \*\*\*\* "BBB@ HHHH \*\*\*\* "BBB@ HHHH \*\*\*\* "BBB@ HHHH \*\*\*\* "BBB M@ HHHH \*\*\*\*  
"BBB@ HHHH \*\*\*\* "BBB@ HHHH \*\*\*\* "BBB@ HHHH \*\*\*\* M"BBB@ HHHH \*\*\*\* "BBB@ HHHH \*\*\*\*  
"BBB@ "" P!&X ZYM \*O\$@# R% M=; ZX1 ^A&O;IS CQN/^N;?RKO#X\_ | (5UK KA' P"A&I>Z&MCW:BBB)\$%# M%% 1110  
4444 %%% 1110 4444 %%% 1110 4444 %%% 1110 4444 M4 %%% 1110 4444 %%% 1110 4444 %%% 1110 4444 %%% 1110 4444  
%% 1110 M!E^?>15UC KRF\_1-?/@S1;Q%XTN;2;MY4MJEV5VA(##"D)S^CMZ5I3>) M?^15UC KRF\_1-?>  
PN\_Y5HO 71 P#T6U9SW12V3KXS";A3?MU\_4(I;? M9MD@S!@;I KO^?7AGXNC+K\$MW!^AE\*XY4&1D?  
4=B;OJZO/OC!X;M^# M);V/-WLZ\$#DQ\_QCZ8^; @\_-45;ZF=%X\_46\_B\_PY|JD"B.ODI#G/ER#  
MJ/TF(IB\*WZ^=O@GXC.F>\*GTB9I6^HIA03P)5R5\_ ;A<5I\$TXNZ\$U8^3\_B+= M=- \$/7)^6Z:A\_ /E'Z+7@&!\_#7%?>JT>  
MR^(NMQN;Y\_-N';^M2;C66DZCH=A>HIDRSV&/(H.8Q^M2?3? M8VE\_1VS\_P" " X4?V-I?\_0-L\_]  
OPO^%4XMH171O/P6\$@^<\_!% @TRL;IO MGM^\_I^;EPT\_P 2+V-FR(H8U'H-@;^&OI>\_. (HUCC1411A548 'L^<\_OC  
M;O;\_>ZE88%S!%ON NS^<\_B2M\$%N>Z^ K9+3P!H;#\_ RCD\_%QN/ZL;Z^N M7^5I?PIT26-@+ME@;V\*?>? T&NHJEL(\*)I^<\_  
=TUO/9(U; N+J\*O<= MM\_-17HE>??&T>Y^5Q(HSJFGBE/TSM\_1FHEL"W/%\_ GCEO\_IU>7>G>)>/  
M9;V=O\$^;HXE4X^H%/E;W8KEFODJR\_Y%/\_JA=?\_ \$=7UK7R;RQP\_ \$&\*65U M2--5#;I^4?7))\_ \$^@1/KBBB!#  
\$\$\$D\$4M6(^=CG;+ #X|@E50#;/8ONQI2& M=?Y 5ZO)YFG^&>GESEE\$J?@)7\_3%>/\_ &G48HX@R11MN%G;1V|>FIES\_Z'  
M7M/PSLWL/ASHD+C!; R\_@LX\_1JSC|3&B#XK\_1);M9\_P|V+ T;E>8\_3\_D M;M2\_Z|O\_&=;L\_\* P#R3+6?IV+\_  
&I7P'P#8Q;I\*YY-BD?I)S\_P\_;;) MMCZ|KD\_B;=-9\_#C6Y4;I;19IG94/Z-765ROQ)LV00AUK<#)6WWW\$8.2T6  
M|>PD>\_I&T6Y^ (FD\_9K.249I\$E4 | 9Z^D\*^;/@SJ;=A10H(Y6VBI@DMU;M; <<\_!^;W%?2I3#8<\_1V)7\_=-O7\*?W\_D|ZA\_I?+\_ M  
H-) ""4D^D48|\_I\*42>\_I2V;2 @ (ZG|Z|KRCX\_ | (JZE\_P|?W\_LB MUZO3CE)  
IA7S)X|I/ZKX+UH0L\$F.F>;YEM=1\$YA\_A|\_H/IND95=2 MK\_I&"" @BG)7I.OX5X;^;MW;)^<\_I4HX-S;X63?J5/I/T(KU|P\_XHT?Q  
M1.&XTFI2<+H/NA\_P|H3RY5S7B7X2>&M>CDDM;<\_9>\$966V&\$) P|H.F/I M@^I>\$03;M/?&JPX2L)MD@4Y65.XIU8?  
S'0U\*W'^=D|CZTHH\_U#\*PZ\$H;=5B/\_CE;K-X%BG\*C?I>(P; MN 58\$?J/RKF@!\_POI/N;L2?5\$4Y/ MYLM9?  
P|L\$M;BP.QFB@0^I+-;S@V5T/0?B/\_D|US\_KVA\_5XO|\$8H MY/B 6=#9H;1D)'W3E1D?  
@2/OVKVCX\_ |DIUS\_KVA07C7P\_YYZ3\_KOD\_P#0 MDIR^>)60I&T4458@HHHH R/?> (G;Y\_V#Y\_ \$6U?/?  
P<\_Y\*58?I\_ 'W48GN=&TQ!^EC62>I? M0-M" P#H+4Y| MS8^L|X6U\* DE8|S7\$>G)>/9;V=O\$^;HXE4X^H  
M%/E;W8KEFODJR\_Y%/\_JA=?\_ \$=7UK7R59?E'M\_ ^PNO\_HZB?0(GUK1115B/ MDSQ|\_OO\$UH\_8\_P")A(?  
I^OK.OBWOM\_R4760^PA) Z%7UE40ZCD>0\_W\_D| MZA\_I?+\_ /H-3\_7\_D5=2\_Z\_O\_9%J#X^P#(H?T\_ \*^7\_P#0.6^O\_(JZE\_U\_M\_?  
I\_LBT?;#H>KUYH<@#X^B)&<7T9'M|KUZZ77FOOO\_Y\$&A\_Z\_8\_07JL"6 MY@\_L\_?ZCO!\_O6+\_2\*O;\*I7\_&?  
O|HX@\_P|ZW\_E)7IWB|6F|>M2U6; RV\ M;8/3>3M7/MDBE110YNL9%M^N^3^N.@\_ \$BN\$#CHZL MWV70KJ5>QEG6;G|  
&KS.P3X>E|>\_LH=2E6#7\_W-G+LH(SSZDD#/?\_20UA M|A PEIT"PPZ|82I?XKB\$3.??+Y)\_O8-\$>\*\_ \_BO\_P|E7A\_ ^ROI\$^R?  
QEEW\_M|5Y63&@\_I?6NC\_9J\_YF+\_ MV\_P#;M;OCT;2I?P(9K33; WE^UIC?#\_I\_CGC M(%8\_I/O\_#;7\_M |5L;VH^AI97R59?  
I'E'M\_P#L+K\_Z.KZUKY^LO^2CV\_ |MV%U\_14YI|1/K6BBBK\$?)GC4|?B)K0\_Q\_P3^0\_/\_U|9U|F^\_O| DHNM?|A"  
M3\_T^OK^HAU^ (^9OC)<\_A2+V-FR(H8U'H-@;^&O= \_5LEIX T&\_I@\_91R? MBXW^I6->%?&>U>W^ (U\*PP+F""5?  
W\_#I^CU#X>Z)+&P/EVRP\_I@/ MDA\_Z#2C|3I^44445H(I^-=TUO/9(U; N+J\*O<ZO+ MB/3DO^N45/FE\*;  
"2>QSGC|JH^;|HHS\_KB116I-/-%?IG; P""S5P^+QS MZYME=002M);K(BRH&^ZV#C/^I6\_X7\_=?I^I# P"!1+\_B;9+>|B  
M">2)O^T\_UU^G\_2CT(Q\_ =KVC^QM+\_ \_@\_9+I^A2^I^H&TO| Z|MG\_P|^% P| MK2|BNCY>+&D|Q\$T/R@Q;  
I2.XI\_ /Z9KZNM|H;E;R>9;V=O\$^;HXE4X^H% M6;(PPIA1115\_?EOJ1/B|75)4|\_3<A\_- P^XC/\_>H|+\_ NO^A>A+\_ M\_H\_-I-  
>31C1?3I<\*NVSU(APPR"\$DYX|\_\*K1H&E;H9=.LB#R"(Y\_2LH| M|F>\_-I\_ |K\_H7H?\_H\_P#O->>^>?  
%>\_M=75^LEM&\$\*Q%#DWYP3SG\_I?TK MZG\_L;2\_ ^@\_9\_I^% PH\_L;2\_ ^@\_9\_I^% P|G%O|P\_Z;3X)\_L^ |S% V|?^U;|LHAL#W.0^\*A  
R376O^N2\_M?^C%KRCX#\_ | (I7O\_8-D\_P#1D5>K\_%)KK7\_7)A T8M>4?\_?\_D>+W\_L&MR?| HR^D\_B0+8^A|H^%/ETSZ\_I-  
H6^2\_U:0#W9L\_P!\_>I5X|I?1TU?I?W\_M^R20%GW5@?\_>G/8(HF-X^+/@A\_P|%I\_6C1W\_1W=I6G^EBQSTVGM@?A6I\_M\_P  
+\_NO^A>A\_|C\_ /SUTOP;ATH?\_RVEK-;WSD;EXE9N3N&I3NP/G MDQ?+HE12A\_T\_U6^/UJZ3HMXAD4D1/NZ@C\_T  
T\_X|WT;Z%JVG|AYD5RL\_M^/9U"" |LE+I8=#UZBBBM;I7SY>?^1QT\_ |I\_Z\_ ^C^KZ#KY|^/\_ (XZ?-V# MU+\_1CU;IAQW/5A=\_R371?  
^N3\_ ^C&KKZX\_X6\_ ^&FBE3D>6X\_\*1A784UL)G\_M@7Q|NF?Q)H5F6^2\*T;H^H7<@\_P#H KOO@S;+;?#BTE\_-S+??#EA\_V2N\$  
M^/EFR;\_I\_Z1|DMJT0/NC9A\_Z&\*I3X;C'=^4M%;EG<21NOH&\_I\_Z2?R\_ M2OB\*>QZ-39\$26-HY%#(P^LI&00>UJO?  
7D&G6Q>W+A(+>-I9&/95&35DGR5 MH^I3/AL\_P#4L)6VHO@?\$?L\_@\_ PKZ|KY)\_VLNL^/=)BP2TMZDZX|\_V|OT|KZV|H\_M#D?\*Q'\_  
\_2B\_Y\_U|G^0KZFTZ;\_3+2)%2-(45548 P|7RS|\_1\_P^DHFN? M|)?\_D\*^J+A\_X|?\_KFOV|L&3T4458@HHHH ^9/C'\_E\*O+\_KE#\_  
\_BQ\_M7T|X\_Y\$P?\_@VW\_ |I\_U| P#QC\_Y\$5?I\_7\* P|P|BOH#P;\_R(A\_ L&V\_M\_P#Z+6HC|3&I;K;Y-  
^ (7)\_0==\_Z^WKZRKY/^ (BE/B^K@/7I4Q\_/FB>P1/K"B\_MHK69;FTAG1MRR(K@^H(S4M6(^7OBY\_R4\_6/^VA\_Z)CKZ+\_?|BKH\_|  
UY0\_M^@\_"OF\_XKS1S\_1\_UEXI%=0T2DJA\_\$0|RKCB\_WPUUH\$9\_ =H?\_ (BUV%#X> (IAK/POJURC;6ALYI\_?0A"?Z5X?^|O^  
M1QU#\_L^M\_P^C\$KW+7I5|\_P\_..G9H;O;2Q\*/4LA^I;F/PC>YIS\_ "^2I^);B\_MQN\_A96D\_%\$9A^|BOJFOE^X<7T>G?\$/I;B1@J&?  
RB3VWJ4\_|9J^KJ;I(\*\*\*\* M\*L100Q?\_29;S

<>@^Z"O7;#X(>\$!59+AK^!QU2:8 M\*!/\_ \*?UKT^PT^STNS2TL!;.\*VMXOA8XE"@?EIRMI/A+=+8FAACMX(X(4"11J M\$11T4 8  
KR3X^+!(&#T? KY? P!IKUZL Q3X0TKQA90VNJ+-MA?&T3I6!Q@ M^U4U=6\$CAO@+ P BKJ7 \_% ?^R+7JH8?A?  
PHGA'3I++2UE\$9IA:2V.C+&RD" \_!M!(\*C!2=^@?W4KWOQH(6UL9+>XN;N7'\$4<#\*2?JV!7B<\_&H\_\$:OZ!H08FOY  
M!fW)6&/@SD^BKC \_!@M \_@5X8B'BKBSU= M\$ME"SV=SGI3!^!DX&X^S<<^N:245H39(TEC.1%=&&5AD\$>A%)JZ! QX/X  
M#^\_2:+ID&D:l.S300\*\$AN8<%E0=%93C(3(YOV=A= \_#PK!;LINE!P%3Z%>X8T;PU;F'2-/BM@WWV&6= \_  
MJQR3^=;U.;L&SE B/\_ DfUS\_KVA\_5XU#O^!^D\_Z!9/\_ODKZ!U33+;6 M=+N=.O\$+VUPACD"M@X/H:YWPOL;-  
!);D!\_!PN6N&C>Z:7<IOP+Z"AJ MN">AUU%%4(\*\*\*\* \*VHV@U#3+NR8X6XA>(GT# C^M2)NC:A=^#?&%O>20!3  
MHP5EA8X)QE77!O&^NZY3Q+!\_?#GBJY^UWJ!-=VIAH=|C\_/?J!2.U.E M?8:9S4\_OU!)-."2"SU&6<+|(QJN/J=Q\_3->EVTZW5I#  
<("E17/4 C><= MV?P;!\*VUP)9IM!NE!SY4LRA2/0!5!\_45Z4JJB!\$4\*JC \_!M?7ZB=NAIT?%/ MP5<>@O\$4VH6!3'2!V0R1R\*.  
(G)R4!SDCV>AKL!/"7Q0MH!BM!D\$S\_ GQJ!^U M?P\$F;+!P0!IG/M!7L5U:6H!26UW!/\_!C/\_#\*H96N#7G^H\_!PE>RF2\_7MB  
M3GY+>8%<\_1PWZ&Y6G=#OW\*NI \_!+PY;6C-HO>7EP0=B\_@C7/N2!P6 MVN\_\$\_P\_9R2!=|Q<.&ED" \_NI>.<#Z #@=S!DUZ\_9\_  
SPM;RJHQ<;C=8ZQO\*JJ MW\_?@\_K72:1HFF;#9"TTNRAM8!R5C7ECZD!2?HHJQ!5/5=-@UC2;O3KH9@N8FB?U (QD>XZU;T?  
&RYMG)BD\*GR!B\_!9!U(Z^GU%>OZ3!ZQH6E^(!+!+JMC#=#0!A6.5!U(Y4^X<^=\_ SPO/(SP7.16V>B)  
M\*K\*/^/^E)\_6HLUL.Z>Y+>\_!PG;1L;?!=N.BQPI0?Q8BF^!B?<^~?%5SI\_!MF!VMG';-  
C;R!FY\*#3P;\_-=Z4E!#O"ENX";74;KCE99E53\_WRH/ZUW+C>'=\_MV/0&2=/(M\$;!Q1?F;\_>8!G!337-U#0TZ^2K+\_DHJO!\_!A=?\_1U?  
6M<~!)? M!6O+JZQW?G+/!H\$?G\_ (W'NE.XS!T25P!Z=S11!5"/DWOM\_R4760^PA) Z% M7UE?#;G!)O#&JZY-  
JUREWY!TGFR(DV\$9NI/3( \_UW-3%6&W<|A^/O\_(&#T? \_!MZ^7 \_/O:G^O\_Q(JZE\_U\_?^R+7<^??"&E>.+\*&UU19ML+  
!XVB?;P\_!V!WA?P MHGA'3I++2UE\$; \_ D08 \_OV/\_!>O2JR M/\$GAO3O%6DG3=360P%Q(#&^UE89P0?Q--JZ\$CRH!G!\_4>  
(!ZW\_E)7!P(C!H M/\$@!5+AQYT!V!H^NZD\_H\_\$@5%X4!%;1X-AN8!+\$!+D4RM-)N)VYQV\_!4 MUT5!+2P-  
ZGRAX!)2R^! \_!HO9!1E4;\_W4&-KA2!D#/<\$ X!BO<6^\_O@M;4S M"AN&?&?)%L^\_!FY&WVZUI^(\_ASX!47)NKZS;.  
!/#3VH&Z!G!2;US<P! M+W0?7F2?>IS!@\_@B-!4 /!L2!\$ \_!%2V!=-W!;/\_-7!2>MG;2PZ+8CSGC/? M>0!;|X  
!^\_6NK\_9!\_YF+\_ MV P#;M>G'P;H0!\_3^X+!+&?3YUR" "<.>@EN MI/ Y;B!)^"=  
(!&QW2Z6)R;HJ96FDW\$!+7EU=8!OSEG^T"/S\_D#|MW3<&9!Z;(B38!FZD!C!#7"WEM+B M!KK3)FWM&K8>\_  
NA9<|'C(H.1W^FZXO7\_A7X5!0W#W;MFH;XY>%DMO\_B@U&27'\$7DJ#GW.!|ZY'2/B+XD!9\_\$72(C M;S+6P2X#-.VY)!C\_B\_A BX!  
<#VS756\_P)!2!Y;S4YE!R\$;J""/0X3/Y\$5 MW6A^&M&+VQ@TC3XK96^&RC+O\_O>3^!HMD!AH6M5TV#6-JN!NAF"YB-) \_4 M  
C&1HCK7R!<6VN\_#&QFCXV7-LY\_4A4^7<1GC/N!7T^HKZMK.UC0M+!06?V7 M5;&ZAJ^0 M\_!PG;1L;?!=N.BQPI0?  
Q8BHKOX&>%YY&>"YU\*VST!591\_WT!ZT!ZT^!HWA\_M2W<--!J-UORLLRJ!P""5!\_6E!P:"^!|B?<^~?%5SI\_JF!VMG';-C;R!FY\*#  
M.3P;\_-=Z5Z569HWAUW!\_#T!ATG3X+1&^!47YF\_WF!)\_ \$UIU2OU\$PHHHH!> \_?& MP3<6^!XFL83!;7 NPB\_P"!<#&X^Q&?7ZB!/  
\_QGCTO3(-+!0V!|J0\*\$BN MX<\_VT<\_!S@=P?P!U!HZ))&R.H9&!#\*PR"#V<+K^P?!(ZM;TRVLUA(OROL MY-@/\_ 2"H \_"H<7>Z?/  
N!O!&\_P8L887ERY!A\*VS9\_Y!5R^L?N\_,\$T3!V?G M\_67C8S\_P%2?YUJQ\_?PTKDR;AJKKG@2,?G!G^%=1HGPW!^Z!;D!H;27""\*  
MS7#&5@?49X!H!P!1P;\_!5\*=R@X(R;X;O-OCC\_P B#^\_U^Q \_@O7!59'B3PW!  
MWBK23!N!K(8"XD!C?;RL\_X(XF!;NA(!J\_9!\_P'9B \_!O=M>V5S6A3P3!@\_MV.Z72A/FY\*F5H\_O.W\_.P^!Z.B\*L@>YR'Q1\_Y)KK7-  
\_M3Z\_P!&+7E'P\_Y MB!J\_HLG\_HR(X?O>\_8TFUW2;C3+Y&>VN%VN!%;>N!@\_4"L!PK!;!"WTMHH MN6N)8C\$6FEW84D\$@\_#JH!-  
\_W"?0ZRN!<(^A)O% A:2U@VB^@;SK8GC+\_\*Y MJ9!Q!<E==15-7\$?+7@SQG?P!U!YBFM">!SLN!\_3\*;&'0C/!AS!?R(HBM?C  
M3X/GB#RSW=LW!R6W)( \_!YR\*Z/O#X(!/>\_\*#OU33HY)P \_="4D'\_AU^AR\*XV3 MX#^&FD!34-51/0'9\_C46DMAW3\$U/XZ^!;  
(V=97EY+CC>!\$GXDY/ MZ5TGPZ!7W7C30;G4;NUBMVCNFA58LD%0JD=>\_P\_U9NG?CPA8N'E@NKT@YV ME?  
C!D"@UW5G8VNG6J6ME;16!N@PL42!5^X"FK!0=C%|;^&E!6>+>O2P56=@) M^C;HLB!C!^0?8FOFWP\_KNK\_#\_P\_4M;  
(&CN(28;FUFR!>ZGT!\$Z'FOK\_N? \_!M1^!=15\_5+!7G486XC.R0#\_!AU'L^WAKPO(LVGZ>INATN)SYD@^A/\_!@!2M)AH;6D?;?I  
%M/L/MFH!5!GCH!ZUW!HNS!YF57CWO!TF4S;3K"(3%L;VD8#A3GJV.ME?V!@Q;2C!<@R#\_  
\_H;HJZL)\_!^&WO4THPUH!C;O#>O;%>F># \_ (B;XTU&|M=/M;F;9%?S)PHW@G'0\$XK#NO  
M@;X5GEWPS;E;+G.R.92,>@W\*3^M=3X4!\$+X.BF72XY3)/@2S3/N=@\_X'8#J  
M>@%2E)M#<BC!2?">+> \_"SV!L!HOMFZVSON(&"F>V!^N^!&|&^\_2^!^NS!K9  
MFB<^7=VDGR\$E3^C#)\_U!55SGB+P+X=|4MYFIZ>K7\_!<1\$D^!)7!>)-CS)0#\_#UR?;G;/\_  
!H\_O#9D!74=5"=U!R;G!JE=#H'PN^\*^YDN(C%KJY0Y6; M!;S"#Z@<#\*XS2M)AH M\*!KD<;&TOU4\_X"RJ;8!D \$>O!7T-  
5;\_T^SU6RDL!^VCN+;48>1<@P"? M6G)70D!P7B@+XQ6NC+!H&O6!PZ6RB."Y@\_8L!P8\$CIT!;">1\_WQL^V6C M6'A>WN(D)?  
E-W\_&&>R\*!^YZ>G>NBO/(@9X6N)C)!<C;J3 \_\*M)590!&O"TRW-G.O/=K!VYNFWNOTX"@^X-3.6P/H^;==T+4=NH8-4C  
M;5S/"MP8V.64;3C=|9O!^M75\_AK\_D5=\_Z!H?\_T 5B^)\_AQH'BS5!0U(7  
M(N\$C\$>89=H902!D8!/>E=1\_VT5E9P6L^E88(UC0\$Y!P!C\_Y^@!QC9@WN^?#UAXGTB33-25VMW8-^!;P(!! MKA  
\_G@;\_!O!OVDZ6)R!SM\$CS2;B0\_X'0#N;O>N^!#!Y#XH\_P#)=;\_ZY)\_MZ.6NO!CK&DVFNZ3<9?!(SVUPNUPK;3UR\_Z@4WL(!\*^  
W\_(XZA\_V#V !&?)T M'7\*>%?AYH?@^!FNL;%RT!L!E;TTN!Y!P!U\_KJZ459 W<^7\_B9X/N"OB" M;:>&-  
A!MW(9;5!A4)\_2F?O\_YQ7<?%O!OCC;OZ=%;^!<X-S&H7!5;\_!>E)! M!^F!U^O7^G6>JV>W P;!\*W4K26!NH6>>D<4  
MH9!\_WT!ZTN5!Z#NGN9FO2!;3HK9H!H!9Y!D!)6Z4)&OO@'+!3BM+X.ZOKNN MV&KZCK-S<3!+<+Y+R?>S@!@Z?  
=X'%6M\*^#A'39A+++=7!\_Y NI05!^BA0 M?HI200+ 4;&XC7ABAQG&>X(!O!8XKZOKB?;\$P  
M!+^C(V2HFMXK6YE.9)+20)O!00!GWOSWHE%05\_F97\_ NWPY=-6MO;6FH3\_M23RK&=R\*@3) R2F>00?  
G7I=>>Z+!&\_#&C;A#>EKV!FA<2(+B1=@8'(C;49\_M(KT^FK!J.W0^2K+\_DHJO\_V%U+1U?6M<~!)?"6O+JZQW?G+/!H\$?G\_(!  
MW;NF;XS!UW\_\*L\_NYX!H!O!5O?"/O+IT+2O#\_Y=W@R=@R0\_OCH?;8&N4^! MGQ5?PG9C2M3MY+G30Q!)HB/;ARNSO=X  
4FNCUG\_D!ZA\_U!2!J!H!J3)H4N!O(95W!R\*48>H(P;JV@CY;\_M^%M^W;J2M% ZZ/\_BVKZHKB="^Q?  
AKPIK4;V;W9N(23&))LH((Z8&>">M=M2 MBK(;=PKY!\_\*?E)TC\_L\*1+HP5!95PUE!)O#&GZ!%J!"78GBF\$!&?&X.1  
MVSU!3!7!QW-%%4(\*\*\*\* "BBB@ HHHH \*\*\*\* "BBB@ HHHH \*\*\*\* "BBB@ M HHHH \*\*\*\* "BBB@ HHHH \*\*\*\* "BBB@ HHHH  
\*\*\*\* "BBB@ HHHH \*\*\*\* "MBBB@ HHHH \*\*\*\* "BBB@ KPWP!\_R<+!O=W\_P"B)\*!RKPWP!\_R<\_P#!O=W\_M  
\_B)\*B>PXGTU!11619!M\_S\_)+5+!KT\_-&+7OE?\_PE!1;3X>|4.E=; MK>L02VY!96.3O!QP#V%>P?+!1%?1\_O>A\_H!2?  
\_UK!H!Q#W.OHKD/^%H^"O^@!#\_WZD+!B;/^%H^"O^@!#\_WZD+!B;JZ?8Z^BN0\_X6CX\* \_Z#TA\_WZD\_M^H\_X6CX\*\_Z#TA  
WZD\_!HN@L=717(2!+1!%?1H\_Z' \_!H2?\_?T?+1!%?1\_M0>A\_H2?\_?T706.OHKD/^%H^"O^@!#\_H/0\_!^!/\_B;+  
MH+!7T5R'\_!T?17\_0>A\_H2?\_!-!\_!T?17\_0>A\_H2?\_!-%T%CKZ\*Y#\_A;/M@K\_H/0\_!^!/\_ (FC\_A;/@K\_H/0\_!^!/\_ (FBZ"QU!%A\_H2!\_O-  
%T%CKZ\*Y#\_ (6CX\*\_Z#T/\_ZD\_P#B;A MA;/@K\_H/0\_!^!/\_?J3\_ )HN@L=717(2!+1!%?1H\_Z' \_!H2?\_?T?+1!%?1H\_Z' \_M+!2?  
\_!\$T706.OHKD/^%H^"O^@!#\_!^!/\_B;/\_%H^"O^@!#\_!^!/\_B;+H+!7T5R'\_!T?17\_ \$H?^\_4G\_O'\_!T?17\_ \$H?^\_4G\_O-  
%T%CKZ\*Y#\_A;/@K\_M\*#T/\_?J3\_XFC\_A;/@K\_\*#T/\_?J3\_XFBZ"QU!%A\_H2!\_O'\_ M'P5\_T'H?^\_4G\_ \_31  
M=|8Z^BN0\_P""H^"O^@!#\_M\_P!^!A\_XFC\_ (6CX\*\_Z#T/\_ZD\_P#B;+H+!7T5R'\_!T?17\_0>A\_P" 4G\_O\_M'\_!T?17\_0>A\_P" 4G\_O-  
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
%T%CKZ\*Y#\_A;/@K\_M\*#T/\_?J3\_XFC\_A;/@K\_M\*#T/\_?J3\_XFBZ"QU!%A\_H2!\_O'\_ M'P5\_T'H?^\_4G\_ \_31=|8Z^BN0\_P""H^"O^@!#\_M\_P!^!A\_XFC\_ (6CX\*\_Z#T/\_ZD\_P#B;+H+!7T5R'\_!T?17\_0>A\_P" 4G\_O\_M'\_!T?17\_0>A\_P" 4G\_O-  
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
\$H?^\_4G\_O'\_!T?17\_ \$H?^\_4G\_O-%T%CKZ\*Y#\_A;/@K\_\*#T/\_?J3\_XFC\_A;/@K\_\*#T/\_?J3\_XFBZ"QU%Y\_MQXW" 7-OY5XA! ?  
^OKK7\_7""P!->A77O&A;3(NNPEF!@!YA\_P" 4G\_O'\_!T?17\_0>A\_P" M4G\_O%T%CKZ\*Y#\_A;/@K\_H/0\_P#?  
J3\_XFC\_A;/@K\_H/0\_P#?J3\_XFBZ"QU!%A\_H2?\_?T?+1!M%?1\_O>A\_H2?\_?T706.OHKD/^%H^"O^@!#\_H/0\_!^!/\_B;/\_%H^"O^@!#\_H/0\_!^!/\_M\_B;+H+!7T5R'\_!T?17\_0>A\_H2?\_!-!\_!T?17\_0>A\_H2?\_!-%T%CKZ\*Y#\_M\_A;/@K\_H/0\_!^!/\_ (FC\_A;/@K\_H/0\_!^!/\_

```
(FBZ"QUI% A H2? Q-%T%CKZY# (6CX* Z#T/ 'ZD P#B:A MA:/@K H/O | ?J3 )HN@L=217(?+1+%?HIZ' +I2? $T?+1+%? MIZ' +I2? $T706.OHKD/^%H^O^@|# - /I/ B:/^%H^O^@|# - /I/ B: M+H+'7T5R' "T?:7 $H?^ 4G O-' "T?:7 $H? ^ 4G O-%T%CKZY# A:/@K *#T/ ?J3 XFC A:/@K *#T/ ?J3 XFBZ"QUI% A H2? Q- M'P5 T'H?^ 4G M .31=I8Z^BN0 P""H^O^@|# P!^IA XFC (6CX* Z#T/ 'ZD P#B:+H+'M7T5R' "T?:7 0>A P" 4G O-"T?:7 0>A P" 4G O-%T%CKZY# A:/@K M/H/O P#?J3 XFC A:/@K H/O P#?J3 XFBZ"QUI% #/:FV?UW9V=<YI:F5GU& MM?>BN0 X6CX* Z#TA WZD ^)H X6CX* Z#TA WZD ^)JKH5CKZY# A:/M@K H/O I^I/ (FC A:/@K H/O I^I/ (FBZ"QUI% A H2? Q-%T%CKZY# (6CX* Z#T/ 'ZD P#B:A MA:/@K H/O | ?J3 )HN@L=217(?+1+%?HIZ' +I2? $T?+1+%?HIZ' M +I2? $T706.OHKD/^%H^O^@|# - /I/ B:/^%H^O^@|# - /I/ B: +H+'M7T5R' "T?:7 $H?^ 4G O-' "T?:7 $H?^ 4G O-%T%CKZY# A:/@K M *#T/ ?J3 XFC A:/@K *#T/ ?J3 XFBZ"QUI% A H2? Q- M'P5 T'H?^ 4G .31 M=I8Z^BN0 P""H^O^@|# P!^IA XFC (6CX* Z#T/ 'ZD P#B:+H+'7T5 MR' "T?:7 0>A P" 4G O-"T?:7 0>A P" 4G O-%T%CKZY# A:/@K H/O M P#?J3 XFC A:/@K H/O P#?J3 XFBZ"QUI% A H2? $T?+1+%? H/O H2? $T706.OHKD/M^%H^O^ H/O I^I/ B:/^%H^O^ H/O I^I/ B: +H+'7T5R' "T?:7 0>A I MJ2? !- "T?:7 0>A H2? !-%T%CKZY# A:/@K H/O I^I/ (FC A:/M@K H/O I^I/ (FBZ"QUI% A H2? Q-%T%CKZY# (6CX* Z#T/ 'ZD P#B:A MA:/@K H/O | ?J3 )HMN@L=217(?+1+%?HIZ' +I2? $T?+1+%?HIZ' +I2? $T706.OHKD/^%H^O^@|# - /I/ B:/^%H^O^@|# - /I/ B: +H+'7T5R' "T?:7 $H?^ 4 MG O-' "T?:7 $H?^ 4G O-%T%CKZY# A:/@K *#T/ ?J3 XFC A:/@K M *#T/ ?J3 XFBZ"QUI% A H2? Q- M'P5 T'H?^ 4G .31=I8Z^BN/XI^E4DZI@>M>D4A P#9:1/BIX)<9&NOCZPRC^:T706.OHKD/^%H^O^@|# - /I/ B:/^%H^O^@|# - /I/ B: +H+'7T5R' "T?:7 $H?^ 4G O-"T?:7 $H?^ 4 MG O-%T%CKZY# A:/@K *#T/ ?J3 XFC A:/@K M *#T/ ?J3 XFBZ"QUI% A H2? Q- M'P5 T'H?^ 4G .31=I8Z^BN0 P""H^O^@|# P!^IA XFC (6CX* Z#T/ 'ZD P#B:+H+'7T5 MR' "T?:7 0>A P" 4G O-"T?:7 0>A P" 4G O-M-%T%CKZY# A:/@K H/O P#?J3 XFC A:/@K H/O P#? J3 XFBZ"QUI% A H2? $T?+1+%? M0>A H2? $T706.OHKD/^%H^O^ H/O I^I/ B:/^%H^O^ H/O I^I/ B: + MH+'7T5R' "T?:7 0>A H2? !- "T?:7 0>A H2? !-%T%CKZY# A:/M@K H/O I^I/ (FC A:/@K H/O I^I/ (FBZ"QUI% A H2? Q-%T%CKZY# (6CX* Z#T/ 'ZD P#B:A MA:/@K H/O | ?J3 )HN@L=217(?+1+%?HIZ' +I2? $T?+1+%?HIZ' +I2? $T706.OHKD/^%H^O^@|# - /I/ B:/^%H^O^@|# - /I/ B: +H+'7T5R' "T?:7 $H?^ 4 MG O-' "T?:7 $H?^ 4G O-%T%CKZY# A:/@K *#T/ ?J3 XFC A:/@K M *#T/ ?J3 XFBZ"QUI% A H2? Q- M'P5 T'H?^ 4G .31 M=I8Z^BN0 P""H^O^@|# P!^IA XFC (6CX* Z#T/ 'ZD P#B:+H+'7T5 MR' "T?:7 0>A P" 4G O-"T?:7 0>A P" 4G O-%T%CKZY# A:/@K H/O M P#?J3 XFC A:/@K H/O P#?J3 XFBZ"QUI% A H2? $T?+1+%? H/O H2? $T706.OHKD/M^%H^O^ H/O I^I/ B:/^%H^O^ H/O I^I/ B: +H+'7T5R' "T?:7 0>A I MJ2? !- "T?:7 0>A H2? !-%T%CKZY# A:/@K H/O I^I/ (FC A:/M@K H/O I^I/ (FBZ"QUI% A H2? Q-%T%CKZY# (6CX* Z#T/ 'ZD P#B:A MA:/@K H/O | ?J3 )HMN@L=217(?+1+%?HIZ' +I2? $T?+1+%?HIZ' +I2? $T706.OHKD/^%H^O^@|# - /I/ B:/^%H^O^@|# - /I/ B: +H+'7T5R' "T?:7 $H?^ 4 MG O-' "T?:7 $H?^ 4G O-%T%CKZY# A:/@K *#T/ ?J3 XFC A:/@K M *#T/ ?J3 XFBZ"QUI% A H2? Q- M'P5 T'H?^ 4G .31=I8Z^BN0 P""H^O^@|# M P!^IA XFC (6CX* Z#T/ 'ZD P#B:+H+'7T5R' "T?:7 0>A P" 4G O-M-"T?:7 0>A P" 4G O-%T%CKZY# A:/@K H/O P#?J3 XFC A:/@K H/O P#?J3 XFBZ"QUI% A H2? $T?+1+%? H/O $25Z' ,+1+%?HIZ' +I2? $UYIXOK:4 P:I&+HY1+:3W-T<@: M 8&3GFHFU8J)14445F4?(7PL%Z5XS)2:C8:HUPLO:F5/( <*@IC7 MK7 @OW/75/ A? B:X?I 9 | ^IWUG KS; T8M?I4D2SRJ A07@f GKJ MG @00 Q-' "@OW/ #UU3 P(7 XF04:*>D%SRJ A07@f GKJG @00 Q-' "@MOIW #UU3 P(7 XF04:*+(GEW "@OW/75/ A? B:/^%>#O^>NJ? ^!" M $UZC119:<|N P"%!>#O^>NJ?^!" P#Q-' "@OW/75/ A? B:1HHHL@N> M7?|"@OW/75A P(7 )H P"%!>#O^>NJ? ^!" P#Q->HT4607/+O^%!># MO^>NJ? @00 .31 P-*"?I=4 P# A? XF04:*+(GEW "@OW/75/ M (7 P")H X4%X YZZI P"! | Q->HT4607/+O^%!>#O GKJG @00 P 3 M1 PH+P= SUU3 P "% | B:1HHHL@N>7?|*"?I/75/ A? B:/^%>#O GKJG @00 P 37J-%D%SRJ A07@f GKJG @00 Q-' "@OW/ #UU3 P(7 XF04:*+(GEW "@OW/75/ A? B:/^%>#O^>NJ?^!" $UZC119:<|N P"%!>#O^>NJ?^!" P#Q-' "@OW/75/ A? B:1HHHL@N>7?|"@OW/75A MP(7 )H P"%!>#O^>NJ?^!" P#Q->HT4607/+O^%!>#O^>NJ? @00 .31 M P-*"?I=4 P# A? XF04:*+(GEW "@OW/75/ (7 P")H X4%X MYZZI P"! | Q->HT4607/+O^%!>#O GKJG @00 P 31 PH+P= SUU3 P "M% | B:1HHHL@N>7?|*"?I/75/ A? B:/^%>#O GKJG @00 P 37J-% M%D%SRJ A07@f GKJG @00 Q-' "@OW/ #UU3 P(7 XF04:*+(GEW "@OW/75/ A? B:/^%>#O^>NJ?^!" $UZC119:<|N P"%!>#O^>NJ?^!" P#Q-M-"@OW/75/ A? B:1HHHL@N>7?|"@OW/75A P(7 )H P"%!>#O M^>NJ?^!" P#Q->HT4607/+O^%!>#O^>NJ? @00 .31 P-*"?I=4 P# MA? XF04:*+(GEW "@OW/75/ (7 P")H X4%X YZZI P"! | Q->HT4607/+O^%!>#O GKJG @00 P 31 PH+P= SUU3 P "% | B:1HHHL@N>7?|*"?I/75/ A? B:/^%>#O GKJG @00 P 37J-%D%SRJ A07@f GKJG @00 Q-' "@OW/ #UU3 P(7 XF04:*+(GEW "@OW/75/ A? B:/^%>#O^>NJ?^!" $UZC119:<|N P"%!>#O^>NJ?^!" P#Q-"@OW/75/ A M? B:1HHHL@N>7?|"@OW/75A P(7 )H P"%!>#O^>NJ?^!" P#Q->HT4607/+O^%!>#O^>NJ? @00 .31 P-*"?I=4 P# A? XF04:*+(GEW M "@OW/75/ (7 P")H X4%X YZZI P"! | Q->HT4607/+O^%!>#O GKJG @00 P 31 PH+P= SUU3 P "% | B:1HHHL@N>7?|*"?I/75/ A? B:/^%>#O GKJG @00 P 37J-%D%SRJ A07@f GKJG @00 Q-' "@OW/ #UU3 P(7 XF04:*+(GEW "@OW/75/ A? B:/^%>#O^>NJ?^!" $UZC119:<|N P"%!>#O M^>NJ?^!" P#Q-"@OW/75/ A? B:1HHHL@N>7?|"@OW/75A P(7 )H P"%!>#O^>NJ?^!" P#Q->HT4607/+O^%!>#O^>NJ? @00 .31 P-*"?I=4 P# A? XF04:*+(GEW "@OW/75/ (7 P")H X4%X YZZI P"! | Q->HT4607/+O^%!>#O GKJG @00 P 31 PH+P= SUU3 P "% | B:1HHHL@N>7?|*"?I/75/ A? B:/^%>#O GKJG @00 P 37J-%D%SRJ A07@f GKJG @00 Q-' "@OW/ #UU3 P(7 XF04:*+(GEW "@OW/75/ A? B:/^%>#O M^>NJ?^!" $UZC119:<|N P"%!>#O^>NJ?^!" P#Q-"@OW/75/ A? B:1HHHL@N>7?|"@OW/75A P(7 )H P"%!>#O^>NJ?^!" P#Q->HT4607/+O^%!>#O^>NJ? @00 .31 P-*"?I=4 P# A? XF04:*+(GEW "@OW/75/ (7 P")H X4%X YZZI P"! | Q->HT4607/+O^%!>#O GKJG @00 P 31 PH+P= SUU3 P "% | B:1HHHL@N>7?|*"?I/75/ A? B:/^%>#O GKJG @00 P 37J-%D%SRJ A07@f GKJG @00 Q-'
```

```

>HT4607/+O!A07@[-GK MJG @00!|31 PH+P= SUU3 P(7 XF04:*(+GEW H+P= SUU3 ,"% P#B:A A07@[-GKJG @00!|37J-%%D%SR| A07@[-GKJG ($+ P#$T?| "@O! MW /75/ P(7 )KU&BBR"YY= PH+P= SUU3 P "%| B:/^%!>#O^>NJ?| M@00 ,37J-%%D%SR| A07@[- )ZZI X$+| $T?|*!|?|]=4|A? (FO M4:*(+GEW "@O!W #UU3 P(7 XFC A07@[- )ZZI X$+| $UZC119!<|N MX4%X, YZZI X$+|31 PH+P= P|=4|1%" ^)KU&BBR"YY= PH+P= SUU3 P M(7 XFC A07@[-GKJG @00 Q->HT4607/+O!A07@[-GKJG @00!|31 PH+P= SUU3 P(7 XF04:*(+GEW H+P= SUU3 ,"% P#B:A A07@[-GKJG @M00!|37J-%%D%SR| A07@[-GKJG ($+ P#$T?| "@O!W /75/ P(7 )K MU&BBR"YY= PH+P= SUU3 P "%| B:/^%!>#O^>NJ?| @00 ,37J-%%D%SR M| A07@[- )ZZI X$+| $T?|*!|?|]=4|A? (FO4:*(+GEW "@O!W M #UU3 P(7 XFC A07@[- )ZZI X$+| $UZC119!<|N X4%X, YZZI X$+| M31 PH+P= P|=4|1%" ^)KU&BBR"YY= PH+P= SUU3 P(7 XFC A07@[-GKJG @00 Q->HT4607/+O!A07@[-GKJG @00!|31 PH+P= SUU3 P(7 XF04: M*(+GEW H+P= SUU3 ,"% P#B:A A07@[-GKJG @00!|37J-%%D%SR| A07@[-GKJG ($+ P#$T?| "@O!W /75/ P(7 )KU&BBR"YY= PH+P= MSUU3 P "%| B:/^%!>#O^>NJ?| @00 ,37J-%%D%SR| A07@[- )ZZI X$ M+| $T?|*!|?|]=4|A? (FO4:*(+GEW "@O!W #UU3 P(7 XFC A0 M7@[- )ZZI X$+| $UZC119!<|N X4%X, YZZI X$+|31 PH+P= P|=4|1%" ^)KU&BBR"YY= PH+P= SUU3 P(7 XFC A07@[-GKJG @00 Q->HT4607/ M+O!A07@[-GKJG @00!|31 PH+P= SUU3 P(7 XF04:*(+GEW H+P= S MUU3 ,"% P#B:A A07@[-GKJG @00!|37J-%%D%SR| A07@[-GKJG ($+ M P#$T?| "@O!W /75/ P(7 )KU&BBR"YY= PH+P= SUU3 P "%| B:/^ M%!>#O^>NJ?| @00 ,37J-%%D%SR| A07@[- )ZZI X$+| $T?|*!|?|]= M4|A? (FO4:*(+GEW "@O!W #UU3 P(7 XFC A07@[- )ZZI X$+| M$UZC119!<|N X4%X, YZZI X$+|31 PH+P= P|=4|1%" ^)KU&BBR"YY= MPH+P= SUU3 P(7 XFC A07@[-GKJG @00 Q->HT4607/+O!A07@[-GKJG @M00!|31 PH+P= SUU3 P(7 XF04:*(+GEW H+P= SUU3 ,"% P#B:A MA07@[-GKJG @00!|37J-%%D%SR| A07@[-GKJG ($+ P#$T?| "@O!W /7 M5/ P(7 )KU&BBR"YY= PH+P= SUU3 P "%| B:/^%!>#O^>NJ?| @00 M,37J-%%D%SR| A07@[- )ZZI X$+| $T?|*!|?|]=4|A? (FO4:*(+ M(+GEW "@O!W #UU3 P(7 XFC A07@[- )ZZI X$+| $UZC119!<|N MPOX>|&:HUE)H:N:(&))E*YW l6=+MX000 MH0J$<%3S|OKUGXJ?|DOU| K@A T:YKIG /Y)|<|A&3- C16U#H2?| M*!|?|]=4|A? (FC A07@[-GKJG ($+ P#$UZC13|@N>7?|*!|?|]= M4|A? (FC A07@[-GKJG ($+ P#$UZC119!<|N X4%X, P">NJ?^!" M!-" "@O!W /75/ (7 P")KU&BBR"YY= PH+P= P|=4|1%" ^)H X4%X, M P">NJ?^!" !->HT4607/+O^%!>#O^>NJ?^!" $T?|*!|?|/75/ A? M:B:|HHL@N>7?|*!|?|]=4|1%" ^)H X4%X, YZZI X$+|37J-%%D%SR| M (4%X, YZZI X$+| /$T?|*!|?|]=4|1%" ^)KU&BBR"YY= P *!|?|]=4 M P# A?| XFC (4%X, YZZI X$+| /$UZC119!<|N X4%X, YZZI P"!| |MO-' H+P= SUU3 ,"% P#B:|HHL@N>7?|*!|?|]=4|A? (FC A07 M@[-GKJG ($+ P#$UZC119!<|N X4%X, P">NJ?^!" !-" "@O!W /75/ M (7 P")KU&BBR"YY= PH+P= P|=4|1%" ^)H X4%X, P">NJ?^!" !->MHT4607/+O^%!>#O^>NJ?^!" $T?|*!|?|/75/ A? B:|HHL@N>7?|*!|?|]=4|1%" ^)H X4%X, YZZI X$+|37J-%%D%SR| (4%X, YZZI X$+| M /$T?|*!|?|]=4|1%" ^)KU&BBR"YY= P *!|?|]=4 P# A?| XFC (4% MX, YZZI X$+| /$UZC119!<|N X4%X, YZZI P"!| |O-' H+P= SUU3 ,"% P#B:|HHL@N>7?|*!|?|]=4|A? (FC A07@[-GKJG ($+ P#$ MUZC119!<|N X4%X, P">NJ?^!" !-" "@O!W /75/ (7 P")KU&BBR"Y MY= PH+P= P|=4|1%" ^)H X4%X, P">NJ?^!" !->HT4607/+O^%!>#O^ M>NJ?^!" $T?|*!|?|/75/ A? B:|HHL@N>7?|*!|?|]=4|1%" ^)H MX4%X, YZZI X$+|37J-%%D%SR| (4%X, YZZI X$+| /$T?|*!|?|]=4 M"% ^)KU&BBR"YY= P *!|?|]=4 P# A?| XFC (4%X, YZZI X$+| /$U MZC119!<|N X4%X, YZZI P"!| |O-' H+P= SUU3 ,"% P#B:|HHL@N M>7?|*!|?|]=4|A? (FC A07@[-GKJG ($+ P#$UZC119!<|N X4%X, M P">NJ?^!" !-" "@O!W /75/ (7 P")KU&BBR"YY= PH+P= P|=4|1%" ^)H X4%X, P">NJ?^!" !->HT4607/+O^%!>#O^>NJ?^!" $T?|*!|?|/75/ A? B:|HHL@N>7?|*!|?|]=4|1%" ^)H X4%X, YZZI X$+| M37J-%%D%SR| (4%X, YZZI X$+| /$T?|*!|?|]=4|1%" ^)KU&BBR"YY= M P *!|?|]=4 P# A?| XFC (4%X, YZZI X$+| /$UZC119!<|N X4%X, MYZZI P"!| |O-' H+P= SUU3 ,"% P#B:|HHL@N>7?|*!|?|]=4| M A? (FC A07@[-GKJG ($+ P#$UZC119!<|N X4%X, P">NJ?^!" !-" M " "@O!W /75/ (7 P")KU&BBR"YY= PH+P= P|=4|1%" ^)H X4%X, P"> MNJ?^!" !->HT4607/+O^%!>#O^>NJ?^!" $T?|*!|?|/75/ A? B:| M|HHL@N>7?|*!|?|]=4|1%" ^)H X4%X, YZZI X$+|37J-%%D%SR| (4% MX, YZZI X$+| /$T?|*!|?|]=4|1%" ^)KU&BBR"YY= P *!|?|]=4 P# MA?| XFC (4%X, YZZI X$+| /$UZC119!<|N X4%X, YZZI P"!| |O-' H+P= SUU3 ,"% M P#B:|HHL@N>7?|*!|?|]=4|A? (FC A07@[-GKJG ($+ P#$UZC1 M19!<|N X4%X, P">NJ?^!" !-" "@O!W /75/ (7 P")KU&BBR"YY= P MH+P= P|=4|1%" ^)H X4%X, P">NJ?^!" !->HT4607/+O^%!>#O^>NJ? M^!" $T?|*!|?|/75/ A? B:|HHL@N>7?|*!|?|]=4|1%" ^)H X4%X M, YZZI X$+|37J-%%D%SR| (4%X, YZZI X$+| /$T?|*!|?|]=4|1%" ^)KU&BBR"YY= P *!|?|]=4 P# A?| XFC (4%X, YZZI X$+| /$UZC11 M9!<|N X4%X, YZZI P"!| |O-' H+P= SUU3 ,"% P#B:|HHL@N>7?|*!|?|]=4|A? (FC A07@[-GKJG ($+ P#$UZC119!<|N X4%X, P"> MNJ?^!" !-" M " "@O!W /75/ (7 P")KU&BBR"YY= PH+P= P|=4|1%" ^)M H X4%X, P">NJ?^!" !->HT4607/+O^%!>#O^>NJ?^!" $T?|*!|?| M/75/ A? B:|HHL@N>7?|*!|?|]=4|1%" ^)H X4%X, YZZI X$+|37J- M% %D%SR| (4%X, YZZI X$+| /$T?|*!|?|]=4|1%" ^)KU&BBR"YY= P * M^!|?|]=4 P# A?| XFC (4%X, YZZI X$+| /$UZC119!<|N X4%X, YZZI P"!| |O-' H+P= SUU3 ,"% P#B:|HHL@N>7?|*!|?|]=4|A? (FC A07@[-GKJG ($+ P#$UZC119!<|N X4%X, P"> MNJ?^!" !-" M " "@O!W /75/ (7 P")KU&BBR"YY= PH+P= P|=4|1%" ^)M H X4%X, P">NJ?^!" !->HT4607/+O^%!>#O^>NJ?^!" $T?|*!|?| M/75/ A? B:|HHL@N>7?|*!|?|]=4|1%" ^)H X4%X, YZZI X$+|37J- M% %D%SR| (4%X, YZZI X$+| /$T?|*!|?|]=4|1%" ^)KU&BBR"YY= P * M^!|?|]=4 P# A?| XFC (4%X, YZZI X$+| /$UZC119!<|N X4%X, YZZI P"!| |O-' H+P= SUU3 ,"% P#B:|HHL@N>7?|*!|?|]=4|A? (FC A07@[-GKJG ($+ P#$UZC119!<|N X4%X, P"> MNJ?^!" !-" M " "@O!W /75/ (7 P")KU&BBR"YY= PH+P= P|=4|1%" ^)M H X4%X, P">NJ?^!" !->HT4607/+O^%!>#O^>NJ?^!" $T?|*!|?| M/75/ A? B:|HHL@N>7?|*!|?|]=4|1%" ^)H X4%X, YZZI X$+|37J- M% %D%SR| (4%X,
```

=YM&^ZH(=,?3I^>J\_LI:Y.FZGX@E3YKAQ:PDG80+>\$>Q)47:JM M^T-H&4TOO#SG3-  
G.O.W+)\_/^-8J:;#ZGLNA:M#KN@V.JV\_1JIN:90,=)('M^H.L^1^>?>?L\_P#B#LX8O-#E?NGR^9\$#\_SS?)\_1@W\_-'T\*!?  
JD(BNOFXJWLK M62YNXX+>)=TDLKA54>DX%4M)0Z-KOF\_V3JEI>^5CS!!\*\*YZ9 Z=-RK!^M\*G\_)=>ZX#-  
#60FOPAXWO?IEJWIFH/MMH&D4OUZSDF+(SJ-N:C@-S M^W7M+>?XF4D8\_\$YJHP?OPLU:P-#M^>?/?<L/M\$:  
I2C=@RDG&>QR12NPL?655IV^M-M7NKZZ@M;9;YIY B+D MX&2>!R:ID^!CB/UJUN?  
#VISM//9QB6VE\*Z%M(H(LC^67\*G\_!13N!XY?;TK69H.EZG97PB6?S#-W"R!F/&=I M,,X/Y5T\_P5\2Z#I7@  
6VHZWIMG/IKD:RKBZ2-L;@X8@XKR:QI/+OP^I@MU M?0W7VP2%?0KMV;>N?1>K4!%?2\*\*P#&N@?VM;:L6T?  
FM^YF20)XY^YU=N;JWLK:2YNIXX(IEW M22RL%51ZDG@5Y=1/A>>"O\$CZM=K#<#I.T^Q0QD9+\$')/(<5TWQ4\_Y)CKW M\_7?  
^AK5^-020\$VA.Y^16E:097DL:IF2^968#IG\_<?1.M?2?I/? (7W\_8+ MD\_1L5?2E""GOW12A  
Df'B#\_K!>OKZZN!>RMWN+NXBMX&\$7DE<(JCW)X%? M(QC\_P^2D>(/<OQZ5D9\_&\$79)A0;;  
WRAW(MI<>G^T^:/T%)\_9I@WQ2\ M\$+Y)\16F/U\_8K\_WUC^ZUTUAJ-EJEJMUH^W!=6I=)8) ZG\17@U!^SKJ\$5BT  
MEEKJO<70&1#):F-2?3=N/AJ\ P#?#?B37/AQXI?"RQ/#+Y=I9.<+(>01TSZ-M\_3J7IBL?85%5M/OK75-MK^T?S+>YB66-  
O56&165XQ\46O@\_PU8OLA MB\$@RR^I\ P\3J\ TQ&O>7UHUINUQ>W4%M\_O62:0(H\_\$15RTWQ4#P/L?Q%:D\_ M^"NX\_  
BOG3S/^GQ9\4^50>YG;+!"Q6^V3Z=%3W/N:1#M\_VPZ1XJT#7FVZ5K%G=R#K^"\*\_ P#WSU\_2M>ODSQ@=-?^  
M^D5^9A/9IP(IVV)4QM^VW#JH\#DCW^KUOX\_\$>X\3V\NB:O+YFIV;XICUGB& M=WJP)/<V)HN%GUB@<D/9/  
HKYT^\_Q&NH5\CP5RT5A;R\IMXR09\XE M\ NCICN0?FW8#V\_P#B/X.TR8PW7B&R\$BG\6-S)@<^T^M+1O\$VA^D9M(U2  
MUO-O++%(^RCW7J/RKY\(\\_I6/\$>EOZE?W>EV\ZAX4:(RR\IZ,5R>W.W?: MH?\$GPN\4\_#UEUW2\XW,%L=QNK0%)(?  
=EY^7UP2/6E=A8R/B\_P E4US\_XO M\_125\2>?^18TG\_KSA\_1%?"B^7;KQ+KD^KWP075P\$|S8\_E45O7/&7B  
MMRODKXM>SX=^(<=^J^5MIP\_:(3f.26X\_&Y5D)> M?\_.\$F\$Z7f\_-NF>\$)  
M/\_UT7Y6\_C/XTT06.CJEJfL;HEL+G5+^VLX2VT/(\$/H\_135VOF\_X\_Z\_1M;O%=IHL3YBTZ'=(!\_P\_I9,\$Y^BA/S-#8(^<L\_U?  
3=;M367F^5N+XFES\_M@;?I OP+>:IR@ HHHB/G;H MC\_D9fC\_ZIS\_Z&S:I\_#7\_ "2?1A MO\^CY^Q:(Y&?2/^O\_ ^AFO3O@U\_  
MR2?1/^V\_H^2IZCZ?7\_U;V5M)2QKN90E9@<F<YQIUB?%3 DE.O?J\_L\ P#(7W\_&"Y/\_1L M5.X^TI7QW12/^2D>A  
K!>OL2OCOXD?E(A0?1\_7X\\*0(^Q\*BN;FWL\2YN MIXH((QN>65PJ/4D)"G3316\ \$D\TBQO1J7=W.H"))/85\Q?%#XCW/C?5%T?  
M1\_-LF:0+&B\KN3\_Q?7&?NC\>O\_:=@2/H33?%GA\6+O)INMV%U<8)\$4\_P MK.0.I\YK8KRWX4?"X">%  
(5UG5U#;S\*F%CS6RGJ/=CW/H.Y/TF\5M;RW\$| MK^%A=W;HJ@9)/X4\_.DD2&-D)75(U&69C@>I\_  
\$%\$/IDGYOK@4K\@L>M:/XPI\_1M)/+TK6;ZEZ^4L@<P\_ JGG\ M^VZ^6O?PGU:P) FKVEHML\$8;KA%J2\B?  
ER.GC;\_#UI#BO3O@S\O\GO19 MS+JHEU^\*S0",WWIHN\WJP)3WR\_ ^33N%CU>BBBF(^Q\O7X>O-3\_LRVUO  
M3YKD)7R(IA2Y(Z@#)/^L\_V^<-M)UP>&O^JL^IYYM+J5Q^NON/S\_#/IDTF MJ#2/KS5-8TW1+0W6J7UO9P#^..0?"09ZGV%8-  
K\3/=Y<""Q%9;RVT>8QC M\U8\_5X7\A+QA\7\2EU04+L0V>XJMQ.#L4?W(Df@?@/4DTGC;X\_.KX2TE\4 MMKY\_  
3LXN9RL7EO&/(VW)R/H?P\I%=A8^GU974\I#^1D\$'(JEJNLZ9H=KHU2\_M\_M\H^FD^Y/H\3\^OFGX?\_!O\ND7VG7,3WT^fK&-  
FXBEST)Z\#DD@=MQQU)\1O\^C#XLWCZHEJY-JQ^K(K+S"<2.8P3\@<174@A@""#R""^7/P M+//)7)R\_GJ#75?>  
OK=R7TGA6\_G:6\$Q&6R+G)C^>O>Q^(':"6BX6>J;H M&C/(RJB<+OP\_\*=7S\_1\$70\_?C3X@7ND6=O=628^GDF\QVP\126+=&2?  
4\ MNU>@>KWWQ&BZ?T=OXB\Z\1YNA OC-2=100^K2K^9^<+I&L\_%1Y/+ M9CZ\_  
C)KRJO\_9SE:%6U#Q&B2D+^#Y^N7\>?IS4?IVEMJUO?H-MA&O)CY1C>+P)P^1D@CD#>\_2E=AH?45%>?>  
OK>7LEQX8U"=YEBB\ZS=SDJH M(#)GTY^I@^U>XTT^D:EXJ\Z/=K\_:EK5A:7#\_\$137^HV#T)\\_ K3DGAA@>\_ M65\$A5=QD9@%1  
<^E?+GQQ\_Y^==\_J<(?\_ \$5+=ZKXM^+VJL/43Q::1HHA M+EBD\_&-K=R<<#GV^4TKA8\UG^)\_@FWN#\_B^S+@XRA9U\_IZ  
(6NATW5M.U MFT%UIELWD\:/@D#@^T\_AJH(G\_9UU)/\_2#7f:6^Y\$+6\A\OW\$ \_P#C MM>=:K>N?SQ8TB^2WN;:7RJHU8+  
>4;L?8\_B^+A8^R^AN\SVL+62Z0+^B^ MWMXAN>65PJ/4D^F?:>PZEIMK^V\H+Y)9HSZJP\Z^N1+>\_P#R2O7\IR+\_M-&I3  
Z20\$NAZ\))16K6=J&S^NI,KLH2?^1VU^L^X M.CKZHO.9-\_%(P23SR)%&I=Y^8^J\223T?9>F>^O#^LW1M=UJPN\@#=#Y4  
M.ZLV.YP#R^J^/?\ DGWB+L\_3+H\KY^I^W\_)3K3\_KA\_Z\_+@?4%Y>VFG6\_MKW5\=0VUM^C?/(<16\YD%K<)+LR\$QG  
M:3CO7KWCOPP\_C#PC=Z+%/OAQ=^4L&NK^"Z^V M&O+Y2%=NS;US\_O4F"/4/@=XBT+2/\_US;ZEK.G64\7\CB.YNDC8KLC\_&  
(..# MS\5ZUINM:5K(D.EZG97PBQYAM9UEV9Z9VDXS@\_E7S^X^<^H\XT^35+4J>V M1+AH^DB.22 ISQ\_O5f\W\AM<^I\_  
2ENM1BNFNO&JK%&5"A=W))Z>\_2A ST-M7I7-ZC\0^6DRF^106^2+IY\$E\$C#ZAL5O\_9M/^IWC6\LO\$4?AJHG>33IP-Y^N<^3\*  
6X\0",M>N/?N%CZ/HHKR\_XP?\*\$6;PC81:5\3A=6O\$+>@/R(NFX#^13D#Z^VI@=SK^B MG0=P-5U>SM/(CEE  
ZBT+D27MSEVD?OM^5CZDD#WKKM\9UU^&V9\06U\16S6Y MAHLAFI7861J  
1R)+&LD;JZ\_,IRG((10:Q\2\4>^M/DGM+W7=,MKE%PT,UW& MCKD9&5)R\_.\*\?^#G\_ "4>?&JUX6U6^YAM\:/>491&I&0L^)\P?  
PJ\_XT M^"5\X@14:CK5OK-O^%/J#N;J>""\_I MGEE<\*JCU)/\_/?5?\_ F\_A\Z&C1?\_!A%\_1%5\A>^IDU\_7\28I5BDNY1\$ MLC#  
(4GN:16\_X9UU\_ H\67\_?IZE#9H\OS17.\$<1\$J2PR^21&#^RGD\$=\$=0:RM  
M2\6>^M^O/LFHZW86ES@Q37^JP\Z\$@GBI/^FD^O/#>G:29S;..W2\$RXON(&\_MX\^OF7XT\_P#)5-5-W(/\_  
\$4E4V^U9^D\22Q.KQNH974Y#\_1^"W%K%)\\_ MB3H/\_8\_M\_P#T6M;5\_C^U7O/H6AS)#JNKV5G^ZIECGH56(Z9P3G^!YK0MKJWO  
M;..YM9XYXJ5W1RO\_&5AZ@C@BOFSIH#\_DH\_M\_V#H\_0Y^H^H^? ).=1\_ZX^T M\_  
J+C.KNKJWLK62YNXX+>)=TDLKA54>DX%4M)0Z-KOF\_V3JEI>^5CS!!\* M^YZ9 Z=-RK!^M\*G\_)=>ZX#-  
#60FSPCXUNO!^GZT/^6^OXDABF\0@\$EF^ MO^USVP1L+^U^K/COPOX?N^LVIZW:P7\_ZQ9+LOU"@D?C6CH^NZ5X@M#>Z3?  
P\_M7D\_UFB;T^A^4V?\_WAWX^)^.G?YO=O!(H3R> MN\*!<^O@;5? HEJMOJYVSM<3(T:0.6\IYY(ZT)@=GJWB\1=^\_ZKJMG9-  
+MDHLRH6\_ZD\_U=TDLKA54>DX%4M)0Z-M-KOF\_P\DZL7OE8\PO2ARN>F0.G?JP?BI\_R3^7O^N\_1#60FOPAXWO?IEJ  
WIFH/MMH&D4OUZSDF+(SJ-N:C@-S M^W7M+>?XF4D8\_\$YJHP?OPLU:P-#M^>?/?<L/M\$:=@RDG&>QR12N MPL?  
65%>?\_2QQ=ZU:W/Af4YVGLGXO+2N^TD8IGf5\3\_9+!\$! MLTB1OH.LL^L^?J2>E)FS@.24D\I^<=GIOf-R\_  
8(VIZZ7;+EDMX040^F2\$+B/S\$13:2\Z27:(?R8@U/%XQ\+SS)##XDT>25V^HB7T19B> M@\_#(5A5)MD\  
MB7C92^1G=Z8/(O1=A8^FJ^H0444 %%%1110\_4444 P\I\_O/P1XT<516\_ X1KX MB7R6Z>5;W)%Y;f1@-UQClA@P\_  
5\+^"M>7O\_X.T05MP.DT(\$V.TB\_\*\_CP\_M>= M;H\K\6.N\1F2QEJ4@?LWZ\$\_1@! P^LHGGO!NAU/P\^\*#7<^H<M^X\_1  
/XFC9CZ^N=EEC@A>:1(XHU+^LJ\223T%/K\/\_/(<(^P7<\_M^BFIDE62Q\$VA\_Y)\H6KV5Y+&NYD@F5V^YQG/3)/O3M8\1Z\_  
X?C5I6U:UL MPWW1(^S?0=3^>?)7@QOC<="K\_4-OLX5DNYD\K%G^I&S.C.B\_<IX\<5UWA\_M\X4^H^O^Y.NZS?  
M:1W/S/+>?R2RLOf1A?3)^%#X^N-A\2\HVS\K^G(MR<^LC&^N^H S74UK^\_OA#JW@O3\_I2CNHH\T2DEE2/RVBR<  
LN3P2<9\ M=6\^/"WX7-U;V5M)\_\*^A COX@T76/^NEQ:9JA>R)=EG2VN4D^C8>2%)P\*!+\_M7Z^WB?PGJ&C)  
<^W>ZC^K^5W\2&#&#("OFGQY\+fWP)IUK>76HV\TMQ^8@L2\$ M\$&<1\_2A@CO\_(\$^(<=%TCPMJ4.IZOHE^HN5+FY2-  
F&Q1DIB.\*\>L2\$V@:I MO2RQP0O--(L<M2^6=W.H^))Z^LK3?%2A\_6;LVNFZU87=P\_6\J&=68@=2\_#R^A\;P#(@<^C\_  
M^P7<\_P#HJ^=O@=\_R4ZT\_P^N\$W\_H\IW^IZ^3?C+\_P E8UO\_+8?^B(Z^LJ^M3?C+\_P E8UO\_+8?^B(Z4@1L\_<^  
%<^\$M.FGE2\*)^\$L\H\51L^Z)5CR\_\*# MP3#>O\_B.S+YQO^S+ WT 1^M>#)<^?BU=6NCV^"/3\_&^RIY6^("1C^Q M\_  
%<<<@ZUT\O\EMD7A\16\W>/\4ULRIG\_PW\$^\_T7H\8\STS5\UJU^UUE M;WD\ C@D#@^T\_AJNU(^AKXN<+OM;ZU<+/  
ORDJ<-CAE(Y\BBO\_MK3P\_K=MXCT^RU>S)\BZC#@^JHZ3f(@@C\^\*8-E45S^8/I22+=13T89N85\*  
\$<1%FYQSW\//IO2NPLCZLHKQ\_X.?JHUB;\_A&MM;N&GNE0M9W#G+R\_#+(Q\D#D^T\SVKVFF\_5S6I\_\$PEH\07NOV22K\Y\$?S&  
M7V(7\_\*M^<GO&NK>L\_PKHPI(10;Z;X8DC(CH#!!/KG^KG\_D\_1P:UCQ;H M;G<7<=>F6.O\J6DC.DD@\_O\\_\$3%=(U>UNI\_F^  
MPX^KM.#C^<=OCK\_E+F\_Z\8?Y&K7B3X^)?\A?IL:/?&\_2V>>2V5HIXL? MO! M\_P^O^+\_T\$59N\_&7AFQOWL\_O7\\_  
@ND;14ERJE3Z^&\_fWPI\_P2=^O^O^+\_M\_P!1!>?^P1=1>O?1KBWU;3J>PN4P\_3\5VG\1f@15U^4f^2+<  
K04;R^TMU(EGD^+\_DI MDIZATK7^URY^>^U&UO4C.US;RAHH^\*1\_&U\_P R\TOP\_#RQ^N8#^1 MO\_>JUX1^T?\_  
\_RS\_P\O7\_M&D\AHZGX#?DW^\_7Y+\_1+7I@KS3X#?DW^\_7Y+\_1+78>-\_P#D0?>?\_8+N?\_13\_M4+8^32%2A\_6;LVNFZU87=P  
6\J&=68@=2\_#R^Y^\*6/@=\_R4ZT\_ZX3?^@&OJ M>A.&?)OOE\_Y^OK?\_&P\_1\$1UJ0>?^18TG\_KSA\_1%?+\_P\_9?^2L;W\_VP\_1M1\$=?  
3\_AY@OA?2F8@64)\Y\26X;D)98X(7EFD6.1%+IG\_4#J23T^68\CXQ\_M\;E?+96.O:=<7+\$A8HKE69L>F^S^%>?>  
%OXGMXD9\7Z^WIE1OB:5#\_P? M3@H\_L\1/4^E=?I(A4VB>3XCUV(C42N;U;\_E@/^O\_-MD^IV^O1W^Q\2\_MP52S\$9)/E)\_I\_  
\_J2/Q%<^fJ>+?;0\DE\_LKS?(AA@R^NVSC+>H)Z^M^ MITT^V\_IUO0B1X-TV8PB^B^R\Q3@B)S+<+M;1XW\;L(=URS6f;H  
M7E;Z^Y^":1CTA\_9Y>3XYM;UAK>Z<9-O;1AA^fB>3HCW-<JXX^&I^M^M.M5M.OOHLX1NF(CN2)>?WL9.X>XYICFE=AH?  
3E%>+\_4^<(UWK,C>&M9G: M>YCC+VEQ(Y Y\I^<E>T4P^BBBF(Q\_P#A^\_#PU;^ROf\_T\_P^W^9Y7 MV?I0N\_?TVXSH/&.M7\

%&RTNT:ZU"l@M;=>LLT@11^)(KY)UG45T?XP:AJ; MQF1;7Y+@H#@L\$N"V,^^\*Z"UTGOE!:=.EU":40Z?SY59)"1!/H/+\_ \$V,9\_#  
M)Z5-QV/+/@JWAW19=3LM1CU-(\$WSQK"8W50.E@-QW?@?:LSX;\_ \$^Z)#\_ .K6Y26f MTV2-FCMPV-  
Dw8@6H#T/Y1N2<+U/H.V&D6C7>HWDpLl,KUDFD"Z<L.N=M.B=X\*N:D01^(f.,3C.A\*+WTP\_60#-.lA  
C+XS:M)JEY(\$l.W<126%\$X&+SJSYS.H&l+P! MXl<=>?HVFG6.3S"J%\$7F7Q7TIQ.MOXh:KH.DVUXVDK-C  
)E(&)SN9VZ\$CI@GMP.>:NF\_LZ73P\*^I^(H92.8f:W.M.@\_ (LOJ+@>J6/Q0l&ZC\*(f?Q%8fV.)7K)lM^\*Z@\$.000>017S5XT^  
M""X:T>;5=.U%=1MK=2ll;1>7(BCJPY(8#J>F/>M+X\$^~KR/6?l A%;V=Y;2 M>-FM YSY3J-O4?  
D4\$XlHfE<+T)65JOB:0l#FCAU75l\*SED7l:M?\_2lOG\_ (6/\_8+<C+llM-@CZ/2X@DMEN8YHWMV02+\*K J5(SN!Z8Q  
MSFN9N\_B9X+LK@P3>(<K/S<'RR9\_#l5!%> OX@l4\_ \$2WTCPCHD.J6=G9PP/#& MV%8\_P!2+=C'GTWYS\_Xf2N%CW+2=MN\_  
K\_DlO\_ M""8B18>+O#FJ7PLK#7=.N;lH8HKA69L=<'G!\$U;FY@Ll:2YNHX((E+2 M2RL%5.D)/%?)?PE\_Y\*CH7\_%U?  
\_P!%M7U!XLT-0\$OA74="2<0=1.%D\*!@\_ MIR"\_.C)28VCR?Xf>(M&U?PHUOIFL?>R+?lWCMKE)&V\_..D\*3@<\_K5?X#;J  
MHVCZ+JZ:GJUA8R27""%N:E(BP"l1N(R\*XGOW+l+WP)l=M?7.16lTLWDA8D8  
M\$\_.36GZ5'X#^&5YXlL;NZM=1@M5MH!&5E0DMD9SQ4l1#ZBTf7l&UB1Xl;U: MPO6C&76VN4E\*CU(46%:->7\_#/X57?  
@77+O4KK5(KGS:8VZQO1D#EE8DD\_P"Z M/S-4?C.GC#4Hl2l\$V07SV=S&QF^S A7:(&?2H%l2!S5".^U3Q\$X6T:5HK\_M  
%ZQBE7\_2\_2AG'U5H(ZT^OEfX.>-KS02%=KHTTfOI>H2"\$PLY6W+#+(C48W.1l9\_l3f&O"?G@?Q^l2lN;TW)l7\_TB\_NV+  
M98lX'=CCMVXZ9%#86/HFw^l\_@FZFfJ/Q9Jv<9E)C'YL\_ZfZ">^Y@2>WE26)  
MQE9(V#\*P!01UKP2l\_9SO\$@+<67B2"\_:7lPDUH8U^l^H9OY57^%HXKl&?SZWl-Z MA'<0V=TDK2Q'YHF"HS!T/3J  
\_CUP:5V%CW.\_l2Z#l5SIFU'6l-LY!lO\*N+I( MVP>APQ!O7R5#\_HD:l%lYf\_.Hf<>E#&CZl\_X3?P MG\_T-&B\_#^"+\_  
\_\*K8M;JWOK:YM+B\*XMY!E)8G#JP!01P:l\_P"&==6\_Z#UE\_M\_Pl^GKV?P7X=;PGX0T\_1'N;l<RJO7IG!;  
<<'GVKlMfH"lMXlBVfCG@D4.DL3!E8"N"l""^\_/Cf\_ M\_E\$C\_Zl(O!T)ZlP^&/\_)-\_Zl\_ T7\_ZRLW50\$;C\_%Y?IK:l:6lESY8GF  
M5"V.N>M:5?/7l17\_(?T\_KU?\_T\*A@CWVQO!f4\_.lL+J&ZMl.4EA<.K=C@C MWJ666."%YH\$CBC4lLNp"JHY")05Y\_l\$O!  
DEVG\_P#76;\_T8U=+XW\_Y\$Q'\_M\_P!@N\_l\_%0!9TKO\_H6N3R0:5JE>2OKN9OE=@N<9P#TR15lU7UOOXl;3  
M""5M8MK:8C/E%MS@>l5""%lW@NlU\* M8HW/8;6l'HCLZ' MN'Z'PUl\*?%CJW?7+FY2VBN6+K<7C.SSD\_Q=<>YQl9l7"Ql  
(Z)XDT:Q^lV MCZE;WB)C>(V^9.lJ>1^ (J35==TG0HHY-5U\*ULDD)"&XE";B.N.l;l^\$ \_Pl MUCP-J&L-J@KS3X#?DW  
M'\_7Y+\_l+78>-\_P#D0?S?\_8+N?\_134\_6=\*3:3%KDlD&E:O97DL;fE2"978+G& M<l.D<^l.UCO'HWA^\_7U;4l6S#?=\$T@#\_  
\_HU/X5lE>"O&-QX\*O!\_4-0LX5DN MYfDK:%G^l&S;C;B.^ lXl<5UWAIX4^\*O'Y.NZS?M:1W/S+/@R2RCL0F1A?3  
M)l\_%X6/<;#XD>#M3G6"U0VlD8X59&>3Z#G\_-l1 MW4>HZ>I"RRfY;19\_67Y)l\_@GFNS^!CBfN;f7PMJ;  
f31K\$9)G:2FWfT> M>XPT^61=M)2?G\_4 M>Z70Q\*!&?8lL \$5B7P!P!YEP?l @\_-36WQ\_lW4 M>^/Q-l2C IKM)&?R8@UYlH?  
l/+SZ2"K6LM;W+KEK>WB#"/V+!\$GUP/Q-<7l M0 A=??^l%BNUNl?;\_WEB<@lL9'O6##G><^lM2NPLCZ2?QKX49@J^l)%)P  
M+^+G\_P>K=ZUl> OA9'XlTF2lMl>CMI8)?+GMVMBs)W!lW#((^G(f7U%:P M"VM(<\_SB\*4W-U:l)HH&2T444Q!1110  
5l>>O^3IG\_P"ORl\_l\$25l"U!M>O^3IG\_.ORl\_l\_1\$E3G/>BBBf\*/F3IG\_/Y?26?^O-O\_\$8M?1-?Wf/M\_P#R.^l\_l>?\_  
^C%KZ)JEL2PHHHJA!1110\_4444\_%%%%!1110\_4444\_%%%% M!1110\_4444\_%%%%!1110\_4444\_%%%%!1110\_4444\_%%%%!1110\_4444\_%%%%  
4444\_%M%&%!1110\_4444\_%%%%!1110\_4444\_%%%%!1110\_4444\_%%%%!1110\_4444\_%%%%!1110\_4444\_%%%%!1110\_4444\_%%%%  
%%%%!1110\_4444\_%%%%!1110\_4444\_%%%%!1110\_4444\_%%%%!1110\_4444\_%%%%!1110\_4444\_%%%%!1110\_4444\_%%%%  
%%%%!1110\_4444\_%%%%!1110\_4444\_07W\_'A<\_l7\_B)<6L!+PZ>l9Q\*O\_7l^?CUW\$C\_@  
M(KZ3l3ZW'X<l;\_CJfE.6L#\_H/1GZ\*/Q8@?C7Ql:W=1534+QS"X#l\_YW MALlB""#SZC%2RD?8W@\_0E!>=\$;T@\_l>  
\_3">0\_Y\_lZ)l#QWH'\_3">M4T MM4W320EX/^NB\_OZ@#l:^=^%L?S\$K\_H\*S\_l@OA\_^T?l8^>7\_05G\_l%l/\_M  
\_HNA6\*GPEl0'Pl0HlFV6lX?L\_ (VY^Cl3^=26M?#5W)=/>R7%P&2X MD)O!VF:MN!EFA FOVD7Y7\_l@:\_\$-F=15A  
MDF:O?l12ZG!U=+6+XP\_Y\$G70^P=" M'\_l^QX<\_PlRX\_G?76?\_ DEF\_X\_Z\_M)?\_V6N3\_..X^/#G^Y\_ZX#\_-#6F(l\_9l\_1^OO!  
l%R?>C8l^E^>\_Y=M\_P#PD?Kl\_+fP#&U\_M?>7"CN3W8GN2>2\_2\_B1\_R4CQ!\_U^/7V)0@85lV\_M\_Zl'9^,+4HP!HOML2#'  
M5T\_..P#?l4?A7TE7@7l1LJ&lVOC&lYVfT)0#\_T\$TWL".W^"&H??#2UC=B MQM)Y8  
3Z9W#l'KA\_VB=6=MlT;1E>\_M!OLOCRR\$--\_X2CQlHEG>\_9!>W8>X)Y+C.Y\_S/YUJ9^+\$.3P;KB) MlYM/G  
^OEM7R\_P#"298/BEH;MCIDD3GU\_PYT\_\$27\_P!2\_JNl5@&4C! M&0l2T51l)>\_ \$02K/l?B)K%AR(AM8Y%9(QT7lHF2C\_D"3^  
H>XUL M?7MS7/fVC'\_JX;IGKP\_YM\_J?B&5/E@46L Ml(C\_B;#\_?JfM'\_C0lQ(fYDDMf"R>2lD@MK>\_LS'A411R?8\_"N1\_X6SX%l\_Y&  
2KM+JU9BHD(Y'4\$ M'D5Yl\_PSG:2l#)/\_@\_P#BH+l#^\$&(!fAX:3!>= S\_TKJ%R3@<#MP!0 MK@>-2M\$?2CfT\_7F?  
\_0S7IWP:\_Y)/HG\_&W\_/lE>8\_M\$?lCfT\_7F?\_0S7 MIWP:\_P"23Z)\_VW\_l'R4NH="W5/^28Zl\_P!\_Ll\_lCl??)@N3\_P!&  
MO5D)l5^28Zl\_P!\_Ll\_lCl??)@N3\_P!&Q4/<\_Al\*5)=\_ \$C\_DfB#\_M\_Kl>0L2OCOXD?E(l0?l?CT2!l:??OXGOXBN7l.Z%\*3l/MFFC/\_  
l\_#T^ MP#^9YZ8KO/A5l\*H\_#\$.>lZS&lFLR+lE\_lBUH#U?U;lH.Y/GGQD^7\_..D=  
M=TN^E7\_08U^O\*O>WlH>AR/2NY^#O&\_MNR7PYfTV=2MD\_T:1SS&\_WNRC\_MQSV\_74?  
0l>KSfXTZl^E\_#6l6)BKWBD6H(9CEA^\*JP\_&00:Al\_!C9\_Al: MLN<lZC&S?  
3RYl\_BFO(l^lUH&DZYJ6l:UJG:2l0K%&YD\_PEB=Q7/LH\_ M+WKW/\_ (6%X\_Z&72\_E?l^>/\_A?l/K+QD)J<=U?SVCV@C9/\*O-  
O#;LYS MZ;1^=>B?l\_ZZ3\_T'KW\_0TE)7&SL?\$/C'P7l\_AO4M/Dl0Z5\*+BVDC"&X7DE3C MOUSB0\_?A#>/9?  
%#1Bl^65GA8>H9&\_l"l\*\_P"&==)\_Z#Uf\_P!^DK9l+?l/  
M2/#B\*UU@:G=W4EL2T<\_JlKNQ@\$Xl\_T:AH>GT4451(5l8Z=80:l0K33lD;\_  
M>ZU500lP=K2A3@lN#7V=7QWX=-Y\*Kl/\_8\_A\_P#1XJ6^Ul:6EO86D-l\_Pl#\_M;PH\$CC08"J\_@%\_U"SCU#3;JRF4-  
^<00\$X8<#\_#G4ZlT50XlL(;=:OXQT?\_M3K02UM\_Z\_XO!\_T(5D)5lLS>LXl0V;E9Rf&2>UDC/(3E2\*^5/A1;\_XH:\$Zl3\_R M?  
@R.O!\_&M+l\_ (l+G\_KDWlC7R+l;\_?2EZl\_U#^lH8T8%\_%%?2?O\_^^\*K:AK MESH/AZYEM;\*OP!><27#@X&\_(7.0\_.OXX#;\$?  
05UJ5C99^UWMM!@9/FRJO\_MlS7)^\_O%/A>lL&Zl9#QH\$DTEA.BQ+>QEB^Pl0!NR3G&\*lGT7Xl^<5@%WK;  
MlPZ?)>AO+93/+S>Y!\_ \$UH:O!\_?2= O!l/B\*69l2VDGVBt"ARBEL??.Xl M78'(l1ROQ3TP#HTB/^\$WU\$9Y.FM\_Z.CKZl1+8&  
<lXl\_Y M)lXB\_P"P=^l^&O6GX?lE.MA KA\_-Z: ^AO^O\_)O\$7\_8.G\_l-?l/P\_ MY\*=2l  
<O\_0#0lP6Ql3UX9^T= O!^/l^X\_E'7N=>&?M?l^OX<\_Pl^X\_E' M3>P(WOV?\_P#DGUS\_-A&3\_T".O5\_lJ\_9\_P#^2?  
7l\_8lD\_P#0(ZlH0^\_@N+V MUM#)O=LFK;K?K9lW"B1N=TLs@l'1G@>\$lSf47"QfYXO!\*\_#/XC MT8!AAD>^B&0?^!5J>  
YlKXc;lL\_l:~\*@H+@5ZO^SE:A?WGB>5fFl5@l\_ MZ&l;fM#l+l(N@+G.W4X!\_P"l128T?95?  
(7Q2U1l5^).MRNQ\*PW!MD!Wl'lG M'X@Gl\_^O: ^\_?%X\_7Q\_UWS.JZl<\$G\_MJU#\$CZZl\_Z1%H/AO3M\*A4\*MM\_D9P.K  
M8^8\_4G)\_&M2DlU=\_%=2"K#((fBEIB"HY\_>/>3+\_M+0'\_0);\_L'l\_l HT?"O\_DF.@\_l7\_ ^AM26XWl\_Q4\_Y)CKW\_7?^AK7  
M@P>l\_V?B?QW"#?C?V<#7C1\$9\$15E4\*?+\_ GUOC07O\_.5/^28Zl\_UP'\_H; MUXW^SW\_R/Ul\_V"Y/\_1L5#W&MCZ4Z4445l)W?M\$?  
lCfT\_7F?\_0S7IWP:\_Y) M/HG\_&W\_/lE>8\_M\$?lCfT\_7F?\_0S7IWP:\_P"23Z)\_VW\_l'R5/4?0M\_%3\_M))CKW\_7?\_H:UX9l#M&L=9l?  
DWl\_F6SM&NHE;fO!fT4\$COC<3l<5fG!5^l M28Zl\_P!\_Ll\_lCl??)@N3\_P!&Q4/<\_Al\*5S7QlL8M1^NOP2H&\_l9  
M95l\_Ol=3^\_BNEK%8?B3KW\_8\_M/1\_4O^SElHfB^l)UHBG6B?9&^FW=\_" MOH45E?3+Ml^T+A;?WMlQ^M?  
+WP2\_Y\*Cl\_7\*\_P!%M7U0fT&TCL%102S\_M,<=S20V?)PFEMX/BCH;76  
GFNHRO(GB+O\_J9YX(X%);\_lLZ@<@\$@D#MD"NJL\_CKXRTNV^Q7=08W;T0V^9=0.),\_P"U MM8  
\_E0G8;lZ#^Tf%;lX%lX)"OGR7Z-N>?E!HQ^@Rl\_P(5G\_+JRC0l=@?M)\_S&\$l\_P4lOT\*UYK)#XV^+>NQSM!<?\_  
(lFPl;6Zl^>@\_4G>O!P7X5MO!O\_MAFVTBW;S?&7+52XQYLA^lVR\_l@%lJO=#H\*\*\*\*H0444\_%%%%!1110\_4444  
MfT444Q!1110\_4455U^fP<^TNfU"Y;..lP\_O\_-M?l\_94\$G^5\_5E!>O\$H?\_H=)B?\_fL;6\_YZOAF\_38P>T>#+0A/\_  
M&EVCIMGEC^T3^Nl\_PP?<#\_"OD^<O!O6;\_N=1D4R75S.Tl+NY)STf!/\_A: M\_P2?^@f\_X+lXlXW47^L?23B/lXO\$^AS4-  
)EQMNX&C!A\_"Q'RM^!P?PKY\_M.l\$S+X/^(%A=W.8A!<&"Z4\_PH?D?/TSGZBMK\_A;O\*\_Z"l\_@OA\_P#C=<lJ MM5?  
7^l3W^HAC=7+f6lS\$(Hl\$G\_7T%#8)W#UKl;\_f@^<^P7<\_<BfK  
M\_<%WB#\_A\_C\_A IMRHKB/lLYSSO3C)IRNT\_C6GXW\_P"l1l\_l@NY\_P#1350C MYG^\$NBV&N\_\$OM-  
l@<lNJO\_8F^Z05UDC/(NlKY8^\$LS0?^0V0X)E=#l#&PAZ^ MLKl\_ (l+G\_KDWlC7R3\*\_P#DIV@\_l=S\_.@\_0QH^O\_l;\_  
(\_Y%C2/^OP\_P#H MlKV20&\_VBA\_D6-(P"OP\_l\_HlH082)A>^/10U3\_K\_/\_l;UH7C\_l'\_ (H\_M;l\_U\_P#\_+3608%lL#\_QO!  
lB#XC\_l=S\_Z\*OG;X?lE\_M/^N\$W\_HlKZ!\_M;\_l@<^P#l%W/\_\*\*OG;X?l)3K3\_KA\_P"l@DlP6Ql3Uf&7\_DK&M\_Ml/\_  
\$1'7UE7R;9?^2L\_W\_VP\_l1\$=\$@l'l^!=\$L\_""lZ9;? (TD@2:0\_Q\_M2.R@LS'N?Z8^NCK-l\_ BQl/\_7G#\_Z\*TJ8CP!HG2(XfWlM80



M72" Q/X8\OZHMO\%:Q12)N6=7+%A@8\_KBC4#W60#VCO^/?PY OW\HZI MSKR XR>"  
:A96NDG1HHI7M&EIQ'E"\$AMEF.9X A/>FIA(B\_9\_P"2?7/-&9 M/ 0(ZI5KA-A-X5U/PAX/DT\_5DB2YDNWGV100VJ54  
\$CCRG17=T(&?)& CV.6 M#XB^(\F/\*X/AH4=8\_Q:9%>0 MHH^(\O,OV D^"M\*.IU"4-P/D6JL/F;V8>IZ#\A7 MRSX&?;  
\$7P-V;M2@/ )\$%>F>?>9J\IZ>@NH< \YE7(9)=JO-FDIF?D ?0 MD\_3K3X1^(-\XJPZI:V5K#HL.IBYC99E-6\$/N"A>N<<8Q1H  
IY7RSI\#TN MC>/HT(1.ZFHN(VOQNP X^N1G\_@0KZFKA7>=\$=,9Z(\FZBA'.Z&9/OPO->' M11WTM"1R\_P  
)\_UCXD)-6>FW%RB:Q9QB&2%V:55& Z^N1C/H<^U>@7=W;6% MK)P+./RI786/=\$^\*VD>(-\Z5#)/#Y3MM  
M)VJS+SA5(R1C//THUWK\_14C((P+Z^/PHM/!\$S:C11MCB41 M0HZD^Y\_(5Z-30'OCX/-N+LE4L;L/HJOAOTS7V2MS  
HLMRLT9MV0 M)0PVE2.YSTOIHUXK10@K=ZMK-QK7AN2(R73F2>TE;9IYZLC=.3R0<(&)-DT+POI>E32K++6R1.ZYP  
M21@XSVKA<^"K#QOH?V"IP8S1MOMIE5R8G^G<N/Z(4WJ)\_.IOQA9ZIX.L1 M\*>=J6G1^2U).&:-  
>\$8#N.8\IQHBN21^\*M(4)Z8IHUVB2<@RX(09)3Z(O< M\_H\_<^<1^"OCC3;D\_9K&\*IC4Y6:VN\$?CAB&S^%&@\_  
WO1K%L\_B2<6\$&? MWA:833./!(U)XJ#2NOG">-%FWXT123:O=1K\$I B@B7\_EG&"2%SW/)/J\_ M^G/A7\_R3'0?^N!\_1#;N  
^ (WPBOKN'1K;PE80?9+.%XW1H51RQ.=Q+8W\$^O1 M2O3\_ /HHUX?%:5I5H^TVT.V0(V0#DGK^-"W\$S/^\*G\_)=>\_ZX#\_T\_+;\_M  
&>\_1^00^P7)\_Z-BKW3QQHUUX@1%:KI5EL^TW\_V/>V 3D^K^%>\_+X<^ (M\_ "7BBIU+6;>&&IHV% "S\*%BZ-  
VSOA30IPZ'M%/%%4(=OVB/^1GTC\_KS^M Z&:1.#7) )\$ \_P#H^2N;\_7P^10>+17TZT:"&9(8#% (K3!&W\$YYP<  
MUW^PZT&|\_1^IC41P+&NW\$AD\$;@\_TC;\_HPJ>H^A^7^G\_)=>\_ZX#\_+6 MO&\_V>+D?K1\_1%R?^C8JHT<=>=/(6JZ59;/M-  
S#MCWM@SYIZ\_A7F\_P\_ M ASXCU>\*+04M9M88^L^F+4L\_KL6+HW;/&%\_#W#H>T5B^/1U)U^L?\_ HM MFVJSM  
L9=3!\_I80%1=6DL\_98X&YD(&?)IB/F:X)?EIT\_KE\_ P"BVKZ0 M17VEU? @S6K2Q1:ZFLHXE7JS%".#Z1^B^&PM4>&O-  
OJNJ6T\$-K DBD MK.KEBRE1@#Z151#XFU^U+^+W6;L%HK9-P0! =B<\*H^I(%);#9IO?#/OE\_ M^1/%;UH%G++#+  
UM)Y8^F1\_IR<9Y7D@ZJ?Q=1>W5Q.8;6-SYUW+#+&%6\_@\_ '=CT&>>L<5ZM\_PSWX3\_P"@CK7\_ M^B\_P#C="N-  
V.AL BYX\$NML<>NO1^& LL\$D8^XE0/UKL;2\ M=0M4NKH.XBN+  
M>0926%PZL/8CBO%=8\_9XMA92/HVLSFZ5B\_<5CZTHHHJA1110 4444 %%% M!1110:Q\_Q4\_Y)CKW\_7?^AK7-?L\_P#)/KG\_  
+";G\_H\$=+=+5A\_DF:0?JHT44Q1H110 5Y5!>?5^F>?"X1\*B M?;\$^IRI2>?3#-^NP?B:15KQ/XL\_#  
IQ=XPI60W66G1\$UA%;K%F=4VG)+\$@+M1GMV L\_+HGG0/N14\02IQ\$HM(">FXX\_Q\_0"?H&O?YGP!X8;PCX-L=)E M\*-3?^SP-  
VCX/M17B3\_VFS?0/^63X4\_^ M;/UKUFJ6L:9#K6C7NF7\_Y7(Z=ZIH2:2\_JWA?51.MRHGN!";N<#-HM4U6V@AM8HI\$RLZN6+#+  
P\_M!\_7%>ZTT#(+L CPN?^N3R-2)/PK\_P"2G:#+-S\_P"=@7US<1F;VEB4@%T^ M@GW%?A\_X#^&GBS00>FZE?  
VULEI:REWDD55LC:1P1SWI@4F"/H2O(?VA;=W M1^<";K%?A61MR\_A7KU9B?P19^\*O#UUHHN\$4ZC#KIY&!RK#Z\$?TIL#R/  
MIG?519;51>55N6D2XCC)Y=<6Q1;#U/%>WM<0LD#31K\_(-4C+;\_P7\_IU M1PZK1\$&@F7C\_?1+=  
M1+99/E>X\$LDG;C+\_"2;3;R:2!GK^C?1 Y\$^O' V"IG\_T4U?;WP\_Y\*=?1<) MO\_0#7TIXDT^;50^"KZ=;E1=V4T\$9-HM4U6V@  
MAM8HI\$RLZN6+#+P!\_7%#W\_IUKY\_<O\_R5C6\_P#MA\_Z(CKZRKP;XA?^"KQ1XB-M^ (UYJ^GP6165RT)\$CSA=NV-%.1UZJ>F:&\_-  
CX5?%FRU#31?0=>GBM;Z1!%; MY"1SJ!@\_GH'>\_UXKUZ6:\*%HI4CB0;F=V 4#U)->/?\$#X(OZ5>2ZKX;DAM  
M;J4HK23Y8G/54WL1C^T^2%&H17O&-O MXN\7 V\$IDTZQC\F%TC9RSCV)P/<^\*#7N\_P)\_#TOAOX?6-O<(8JY+74R\$8\*  
ME^@/N%)"YJZOP#^#A1=1JGB>2^XEB@\_\*RB^9 W8N3H^H/<1^JH2!GEGO\_MV1.ZQX-BU^VC+S:7\*9&  
&3Y3#%G1%"/TIKSOX\*";K3PSJMU16JW @L+XJR2 MN^%)%\*\_.3V1^&851^NB21M(JNC AE89^H\$5X;XR^C3W/81/6AKJ"/\$-  
N8HH&UB;\_ ML0(V74D8#L\_P'7GKC%>^)\_?B99;=>#3IN\_/VYB&\_C'^?7A1#1;U="^WB;4 MKH2ZY/HF);F9!  
\_WT"DK^);#1=A8R/@X9G1>+6/=&:STUQ=3R^O!R M@SZEAGZ\_U15UC^&?#&E^\$M^CTS2H+/B7EW:EY61LOIG\_"\_.\*V\*:5@9!  
<>\_J& MN/"GCS4;1=T7E7)GMG^IPG+1A8Z!1?VDR&?81^(&DWA^QV M^G8\_U;BTNT4^Z996  
^H%+8>Y1\$^\* &>B^#M\_:ZU2Z428S%;(0993Z^OHH!7 MR;XL137GBIQ%JI^?0JHTC0<^N>^1WKT;PI!"?\$.I7RW^B>Z6R@W9D59  
M1\_-T(RH^N3!>V\_BA(M1OY1(B)V)VN+&TM?;9E",&W%BQW=<@?M\$Y4GZKQ\_P K@=>19W&M>\_"^#@2;L:8)-!^MH\_  
(\_P^OE^O!^MDTB;\_F\_P W\$?M^IRS\_V1^M&O=ZIL^M.O.@;6<&6C/HL44K69F\$B/\$/SL\$9X\_@/>DIAHE^W\_"3-  
HM4U6V@AM8HI\$RLZN6+#+P!\_7%>ZT(&?)OOE\_Y^OK?;\_# P!\$ M1U1-Z+;PW?@\_3K;XB66"6PB22-QD\_IC((KOKXD\_"KQ3XB1?  
7^K:9;VMI=> M5M9IU4KMC1#D^W41\_UAI-K)8Z-8VDI4R06<313D950#C1J2!GRO1O!%UX M!3^JHTHT^9\_-  
L;@\$IDC=I/IY3CGN;&O=OA;10C\_&NA^3=JZQ91%N4Z>8\_ M@D1#W1#1172>^O#\_CXN\W&DWZ\_)6OR?\_  
\$X^ZXIQ^HR\_1>%^A7100^O MBJVU#34M\_P28H12!^(G<\_/O8(I0Y4;#W=?%>B#Q^X4U/2\_@=0;B\$1\_52 M?^1 5L^!?  
\$4\_+&QW%=7D4D<^;\_WT17Y@A&XJ00#C\_&^OZT^?PAL/& M;L:G83+8;L1E1@:KK^(#;?T1?^Q1#6GB1P^ZU\_81GJHKK4T  
4444Q\_QWXB-M\_P"2JZW\_V&YO\_1YK1\$KYWUGX0>+;SXA71N0VJUE<DITLON\_(TA;D=O-B1  
(OXONO1^7T>\_&VU3;MF27(2<#H21T;\_& M<=<1=;5YC1- BGHA-OIL51#%\$Y\_?L>1^B-ZYPX\_6C8>YIOXY1=;1X;TF22IE6  
M21D0BWM\$;YY#\_1^4G13Q7S11;? DI>@?1?0\_D;1(1^\_O4+S41J7C;W L^ M:U24R22GT>3L/H23ZBDV/\_"?O^I7Q3BU;  
D:Q:11?;CLN!^D10%^(X&\_4 M:@15^U\_M"1C18\_1@N/\_P1&RU1^5XO18/AQXC16^1)34M&MX9X4LUMV5E1  
M@P=V1XPPIL2.X^%? )=;\_ZX^T\_J1^N?1 VCW7A\_P5I6E7VS13;019\_C\_ M@#DGK^=10!X#^T9\_P?A\_\*Y3\_P  
TKN/@=\_R3T^Z\_V1\$^AFLWXR>\_1=18 MS:3\_HL\_ WV99QD1Y0A^8J01GCL:ZCX8^0+>172136;19)98WW1FR!  
MFEU#H;@OZ>VJ^4TY?O7=1+ /R%?ZUD>1J>\_X1^QSI^H^L=L=O^81A2#D  
M(P\*MOZ@\$G^J^R^\*8^ (WP5DUO4Y11\_2PQ7\_Y+W^1\*=-JNYZLK=B>X/&^Y^E>H?#\_"EOX?NXM51 M02Q7M\_&=T-  
O&PQ^L22/F8?0>\_!HU1C^\$W\_)4=" ZZO\_Z+;OKFO ? OPG1\_M4Z#101+5+Z^V2RMI7=15G#;@58#\_/'<=<5H0@9X\_P#M#\_1  
(H:7\_P1?\_P#1 M3;11\_O\_"\_Z^D\_10:Z7XO1\_A#50&^ANSM="2^2>"Z\$K1)(\$RNUAP3QU\_M(J+X/>#=#1^+J\$;L1Q12W;ZNB)(('7)  
7)^%4.AZ17R1178IHOBCK?G\_Y=T M92>ZF-?\_SOX96\_CJVBN;..UU;W7;\_Z\_+(O1\_<  
M;\_0(Z+P7J5CJO\_W2;G3G1K<6L<=>U3\_JV50^HP1B1\$WBK2?^6E?ZM5OHCN?T"?%?7PO1\_B;X?E8Z7%<1HB\_9+4%CW>F?  
F4\_16YHPI12\_M;Y^WOC^4@B&Z>?S1AP\_VD4#WR212NPL>91?\_J^EU^R+^UZGY^S.= MN^7=C/2&^T;^?  
M9^#6MK10EN=%L;6+1\$GA>(^>1L10N<@\_3D^USFOH&A\_S MYM^/OA^6R170\_VB\$V^H0JK/C@2H-  
N#\_P;CZ^TKNO@QX1L=31\_VWAZIN4BU.MR^E1+(V//C\_AVYZD#C^H^IZ%XD1;=XJT2?2M3BWP21AAPT;#HRGL1\_GBOG  
MW7O@\_XHT^Y8Z-T&J6Y/R8D6^0#\_#D#B;-E\_&E9HHK;%YIY4BB0;G=V^JH1\_M23TK@K;XMZ1)7C1Q1-  
\_4C7JW#\_LEZC8C4A2P^C^S=9X^FO0%H^A+11-2^0W M%Y)1^#@\_ED5LVFK\_Y ZG;\*3Q^5?95>/?\$IX/3^)-4DUW098  
MD09L?;+415D(C-RMV\_@1@N:48(I;M+VVOI&^IM9X;9(DJ-E641T^& M>\*YA6:"5)8F^ZZ;^!^A^3>?&  
P@^ (6YK;8R0DY8FBI1L);+^+1+O^Q^YTCU^R9\_\*M8X;L11(I2^2>@%=-IXM1^?XQ MT^72M01^L=14J>B<=&^YD81@F0GC5\_@?  
XRTVZ86-M#J\_5F@F5#CME7((MTS1:6S&?2.N^(-+1Z;1\_JUY;0^\*C(^NR+HN;GFF\$TA7\_952?U(KKO^W  
MP@GD;Z+IOA&SC=;Y6G;LJK)\*SA/F).31OX<8H=V1TWP2\_Y)=1\_P#UUF\_1 M&-72^\_1H1\_P#8+N?\_\$4U9\_PTV7-  
(71#66E;DL;W<;2\_ZQMN\_W2!GZ M&MOQ)HVK>%17TZW^B>1LIH(RYP-SH5&?;1H1^S71#O^2G6G\_7";\_T\_U13U\_MX51+?A?XG1>+  
HM4U6V@AM8HI\$RLZN6+#+P!\_7%>ZT(&%)>\$2M^IRS\_V1^1 MM&O=ZIL^O.@;6\_&6C/HL44K69F\$B/\$/SL\$9X\_@/>A1\_B7X#?  
1DW'\_%^2 M\_P#LM=AXW\_Y\$^Q' \_@NY\_135C\_"OPSJ4/P6FG;JD:71G>4K&^X^\*C)\_ M&=>Z/Q)HVK>%17TZW^B>1LIH(RYP-  
SH5&?)HZ?\_2P\_Y\*=?1<)O\_ \$U M13UX51+?A?XG1>+HM4U6V@AM8HI\$RLZN6+#+  
P!\_7%>ZT(&07W\_1A<\_1<^"DP11WJ\$4T^FW4\_NVV=X76-L1&((1\_0DCP+XC^@+Q\_MLE\_J-A+)Y D@GAQMDC)X\_>X1#  
1U1;M1JEMHND7>IWC;=>UB:60CK@#;1HGH M/>OEJ\_+5?C%11F^1P6IF&YV2;8@>7NV;7;D#)ZDCH.@P1^QQM1^78^VB6Y3 M R!-  
%L2?EFM^S^+W@\*<+^"K:0^BR61B?B5Q^M<^N/>O^F1G4=)1D31#\_VG M6=JH\_VG-/ \_&9KEU!^HN45U1)1#M  
(^O/THU#01AT\_4K5;1;031N^ZMW\_MZ20N^71QWJU7R1X9U\_5OAOXU<\_Q0V1YM1ZWSE9%#88?7C/(1^\*OP01D;?1 HQ: ^B: ^=OV?  
D=19\_Z1V\_14+7T M35+8EA1115""BBB@\_HHHH \*\*\*\*\*BBB@\_HHHH \*\*\*\*\*BBB@\_HHHH \*\*\*\*\*BBB@  
KY@^1/\_"4@\_P#7G%1-7T\_7S1A>1 DH\_ZIXO M\_9IE1#1SWBKP1\_9\_AKPQK<\*8AU&S^R\$#\_EJC\$2JNWC7T1\$G\_D/@^S6  
M11UU8?Z)-G10H&P\_B1^X@URI/>1^\$D\_9RL88TW7-K;&1@1=R.Q(O^U7)?L/AZTT" M"3\$U^\_F3\_1\$AX!^K8\_1Y>1W?AO^SOA39ZY-  
'B?4=3VQ\$CD1(CG16W?D^G1 M7:C;1HJNVWM;E(8Q MI+\$P^XU10^LZ?1@C7?1 KO%\_Z^U>UUX1^SI\_R"-  
= P"N17\_H+5175+83^HY) MX8<+;^B9Z;F\_S7S5K?CGQ1XIUZZTW05O(K5)&1>P10A\_H6GGG^DDKA^Z@CM  
M33^QV5%?)TOB^;3/C+/?WE\_(Y)+>97\_7N0#GCU\_1:5PL?7%?>\_WPD^\*6IO\_U: ^M< MNY+JRNW\$5O-  
\_Q9X91^T;CR5)\_P>F1VX1JHW\_\*1A\_;"NKBW1+6L\$1L2R7A\_M#A^\*H<^9Q1U/V?+JXN/^VJ+>1\$QO  
\$#N3MR@SC/2B^H6/7Z\*1V^\_5S?\_? M^EV@FDB+W42\_48120/QVXH\_DHKPO1\_9VNI^=\$4UO+)&@MRJNY(4GS;D  
M1.@\_\*NL^+\_AWO1XATS3( \_#(E=H9G;>..Y6\$D\$#:B6;2C1V1\_6O1=+1^@+XC;CI-K>;9;7;6;T8> KJ\$;J>F%.(C\_\*IOJ\_1^L M^\*XGX6:-

#####0L?B(OIL-RJCS"4HA P"1">O>O"/WO 19:QXROO#'A MP7,\$=M\*80EBA,FI18L.O,^F:CK57%8^@D8X5#2R(O)OEF  
I4=9\$#HP93T\*MG(-,4?P4)>I\_15XMO',XR?M=WN<\_4C=\_.L+6/#'C+X;W,-U\*,BR#M^JNK2 M8E"WJTD=^#P>H17"QI>45YOI  
(B%-XTTJXM-3\*VK9;=J1\_AZ/CL01@XXY M'K@>D4P"FNZOH7=^JCGJ6.\*1M^\*Q3:PEC1M&\*J/B:D6 86RGIOI+J>@MY?  
I=OYI,\*,\*VHN%OZT1TD0&RLIZ M%3D&G51H7?P1^C@M6U\*VNHECY:23IC<5 YR0IW8\_#%>Q\_1OQWJ7C+2;^WU M;)=Z>T8-  
PJA3\*KL9 XR-AY M1<+?0\$?\_DFFO\_7J?YB0\$ V?P#DH-S\_M-@Z3 T.LSQ)X%^(FGVNHW^J1W+Z?  
&6>:4WZK+GKMWY(JBN81+Z)KVO:H MHX=CE?16GR(YUB.P\$ 1E@.F&:F^HSI2HKYCL0AO1%+^W9HKR\$(I,C: MG&0G/7  
D)XIA7TY5(0451A'5-0/Q2/PWUSO\_+8ON1ULXV1&:OIQ7UI0G<+!  
M117R+1M3OT^).N.EIV1\$6/D321-1057V,5W#RW.#CMF@#UBF/-%&ZH8B\*S?=4L 3I^\*8M1/^\*M-  
UX8^&;Z78W#R:Q<7DA660EOLT.U:1GN3G Z=3I<./X?>.M?M3K/1D7UTLPW M^=,  
(/D^KAFW'ZXI7"QI>5D/X4/2ZE\_4FAZ%\_M\$W=S\_AZ.&XECC87#J.0"1Y>"<=>I\_A@ M>Z4R2:.\$ RR(@/  
+1,757^17=0TSP!H\_A 1'DDU7RW6XNY 79,R M1>K8(Y MYOP1STS?^%5?\$/7XFU21LY9)H N'VVZ43A 4,NM1')  
<6TEN^V>PG)M04%>G/JX<1Y1KZM1.J>)> #MEK-H"(KJ/=MR4  
M8<,I^A'1X4T1@T:M%17%Q#;6TMS<2+'#^ADD=CPJ@9)/X51Q>\*OB3XF1>Z1\_  
M9>@M=P64K^7.6EJ2LDPI7(Z^N.@TS0W8+T^9HEE\$1D02'HH89/X4^OF0?  
M3QE)&=YM.\$FY,+7#%| 7:M 6N'U)O\$7A^ETN N+^SN(#M:\$S\_-O<8P<\$>X MXI7"QHT5X)1-  
17CJR15Z5K%W=LVDE3(1\_Q\*LD;(<8 8YSYD?SKWNF@'BBB MF(\*\*\*\*"BBB@ HHHH \*\*\*\*"BBB@ HHHH  
\*\*\*\*"BBB@ M HHHH \*\*\*\*(1+ CPN?^N3?R>=>?LZ?A?7?1\_H351W7?1>?%S\_P1Z;13<?1/3A0?JV M3\_P"O;J1F1)M8/B  
012JB+^UM0.2J\_1AGG)1 MC3210RIAFAQ:0\$C1^>6(HBV1\_P"O\_R\_#FA6WAKPI9;./:M\$M;?QI OQ?"YSEF M/N22?  
QK4H01113\$%%%% 1110 4444 %%% 1110 4444 %%% 1110 4 4444 %%% 1110 4444 %%% 1110 4444 %%%  
1110 4444 %%% 111 M10 4444 %%% 1110 4444 %%% 1110 4444 %%% 1110 4444 %%% M 1110 4444 %%%  
1110 4444 %%% 17G\_P-:NM1^&M1+56=K>2.=U4 MD.^7 @YXJTW?J M JQ:TOUC!N%0MY;)NQ MD#G1W1GM7T1^<\_  
"EU&'A1:205W8-Y&K>X)R/OKC\_!|&#?^M7#W-DT^ ME3N<^QKPCX<1?>?B';7#(S0PW/O;R;'R@!MV M#1L>  
/KZ5Z9IOI.VEP31M2UYZT1SL@A67L22U>JZ'X?TKPWIRW&D64=K;C MDA:DL25B>6/N;+7 TZ\*\*\*H0444 %%% 1110 4444  
7F444Q1110 4444 %%% 1110 4444 %%% 1110 4444 %%% M% 1110 4444 %%% 1110 4444 %%% 1110 4444 %%%  
11101Y31 M>/\$GIE^#XM'A2%QJ1VJ1U+Q\*#GRPJ+2 D?Q'# M.2J1M\_ C777\$/X37/CGQ#J:ZZ+6..181 10OVX))((8=#\_#5  
MMHUM^9A%N9YBNTR.0R21V1/H1411#==HHHJA1110 4444 %%% 1110 44 M44 %%% 1110 4444 %%% 1110 4444 %%%  
%% 1110 4444 %%% 1111 M0 4444 %%% 1110 4444 %%% 1110 4444 %%% 1110 4444 %%% M1110 4444  
%% 1110 4444 %%% 1110 4444 %%% 1110 4444 %%% 1110 4444 <  
ME13M.NM5^&MVEDK1.80ZJHR6".KD#U)"D51^??"OI9>"%\_EOJ20IBNH?(D MD1=QB.X\$-  
@#Q)I9WC(5H\$;\_OEB"(RK)U\_XK^\$-^LD5U>WOYPO1N"R MD\$1<1AN7('U)KSN;1G\*4/^X13H5\_V1(@C1GYH8?LZ6\$%  
M=&1\*6'V31I)+=P9'ZO(25F)\_1VK9H PHHHB"BBB@ KYZ1-?1G3/-?E MW\_Z(DKZ%KYZ1-?1)TS\_7Y=-1 HB2ID-  
TO1114E'S)^S\_1(HZS\_P1>M;?1 HQ:~B:~^=OV?\_/D=19\_Z1V\_1&+7T35+8EA1115""BBB@ HHHH \*\*\*\*"MBBB@ HHHH  
"BBB@ HHHH \*\*\*\*"BBB@ HHHH \*\*\*\*"BBB@ KY@^/\_ M^4@\_P#7G%1-7T\_7S11>?1 DI1\_Z1XO\_9JE1#11?1+1#1-"1YV<^A-7S  
MAXUTB?P11;1\*TS\$+>X6ZLV192=Z8^G3ZK7T1?1\_282#\_UP1\_H5PG10?AS MS1,T\_P 10IE19OLUP/OX&Y4GV#9'\_Z'L'/6?  
#^L0^&(1A1JACRIN9;P2 M1ROX(^N9+^/B7\_1(KP#>O\$^V1OA 1G=061W1%#ZXKCOV?2\$GVG2;\_M  
..S/^M6^T6X)\_Y9L<\_1H1L\_@=<=1=?\$OIK^DTFHUM1;#@1&5L%OR&T M?4&B^@6U+P1-;?&-  
WX@F3.5@GE0DCK\*XY(^BY\_P"1A75\_M# 1BAI?\_7\_M.TVKM/AMX;\_.\$61"Z=8.FVYD311<1<^8\_1)^@PO\_1XO1:'Y%#2\_@O1  
M\_P#::4=ZE3IG3\_D\$1\_-=XQ\_06KVNO%/V=/\_01KO1 UWB\_11:O:F941G=@ MJ1.DDX%\_;  
R\*WM+T5UMK>.\*%78NPB0\*&812<=3IU-7SYXT^\_6IW>12:=X1" MPVZOY:W9C#RS'\_D4Y\_H<\$GCITK.@1\_1%17XARC9  
Z+=O(22P\_X(OU=^=SI\_R1)=\_ZX1? M^A1U1T/H\*OC'O\_>GX@ZQ &VF759TSZ9E(K1.KXWUO\_)\*JA\_V&9?\_1QH  
M8(^K'GA73?1B1.91T0 S+0\_1SV8\_P"=BMME#\*58 @C11TM;D^%\_1MM@/#?CS5+2R)C6S0&\_1HSN71ABOLB'3SK>.7&-  
Z1L>F17R-15/^2G:1 P1=MQ\_Z M?6UC\_OX6W\_7?Y"DAL1B:(P"18TC\_\*#\_P"@&CIG?\_D6-7\_Z1\_Z M^VBA\_D6-(P"OP\_1  
H11V=B/^\$;U@9Y%O1\_Z\*H=#V6O.?CS\_R3<1 M?D7\_+7IU>8'\_G\_))N?^OR+V.FP1R?1/\_OXC\_W+?^15X+^SC\_P?M'B/\_1+?  
14+8&2\_QY Y\*0?^O+1\_FKW;X;P#)-#\_1UY17A/QY Y M\*0?^O+1\_FKW;X;P#)-#\_1UY126X/8ZF8K2V@FEFAMXHY9B#\*Z(  
SD=MV(Z\_C4U>(?\$XV3Z9J4^C>^!\$9(&\_<1H1STXO>+^EO6O-5BAD^93/>^W4Y1A.CCW MQW1+60A?X1TW0KW4=0U2-  
16""1V9H\_MLC\$J1DC&\_E<+^="X\_B'+^=LMC(MK#UPR^E?3+NL4.2.P5%19B>P%?7P&\_Y\*0^O\_7\_P1EKZ0UPL\_U(H16LN  
MWZ130M@91B#Y\_7Q4ARNPDUE"ECU16;\_1Y7^5285C8VVFV\$%C9PK#;0(X MXU""J1@51D?"XJ/B9H\_1H\_7:1 N#^5>3?M#21  
(DZ=P1A%?1 T7)7K'\_M 11Q\_P"X/Y5Y\_1T\_P B3IW\_&\$5\_P#1\*E1/>B9H;<.N1"!EA M'/7L/K7 MN%>8\_+\_  
)N/^OR7\_V6O3J\$#1\_VB=(A5M&UE% F?2?2G^11AE\_++?G6\_1ML^W16WE18:A/JM/ M19\$Q9\*Y81B/PX\_&O?/\$-  
G87\_A54;751'8RV1K/3C8F.6SVQU\_1OD/PUXF MO1OB5=4TF1921+1D.1"S1GLPZC\_?8@>E#W&C1/KY1\_&BH+=-;T2=HN)+  
M>191'R5#;G1VK911>G?9 S>1K13W03KL\_1ZOG1100KKO%16O&H>.V#W\_M@\$1Q@^7;Q 1SV  
R22>1N10V""1 P1#J>6X^%ND&4DE/123U42MC1NGX5W ME9?AS1(?#GAVPT>W:=1OB;1C>U>K^>))XUJ4Q1113\$%%  
1110 4444 M %%% 1110 4444 %%% 1110 4444 %%% 1110 4444 %%% 1110 4444 %%% \$1Q1 OX M7A>UR\_1K1P31G3\_)"^N17+\_  
":O>11 CPN?^N3?R>=>?LZ?A?7?1 MKA%\_Z\$U)1CZ'T%1113\$%% 1110 4444 %%% 1110 4444 %%% 1110 4444 %%%  
%% 1110 4444 %%% 1110 4444 %%% 1110 4444 %%% M1110 4444 %%% 1110 4444 %%% 1110 4444 %%%  
1110 4444 %%% 1110 4444 %%% 1110 4444 %%% 1110 4444 %



[illegible]

MX=Z):WEO+;W\$<'SQ2J59?FYIY'6NJH AMK6WLK=;>UMXH(4X6.)JCZ <5- M113\$(RAE\*L  
5(P0>AJG::/EA.TUGIUL2OPSPPC'ZD'KM% !1110 560M. ML=3@|B L|>|A P"><|2R+^1%6:\* .?P)X124R#PSI&X^ME&1^  
Q@5N0P0VT M\*PP1) %\$HPJHJ4?0!1\*0!1113 0@, "" 0>="#6%/X)!\*W4WG3^!)>3=N+&S MCR0!^.?QK>HI  
5:3;#2X2)T^TRMK2+^Y.Q+&OY "K5%0%. JG?Z5IVJQB/A=/ MM.Q!T6X460?DP-7\*\* .?3P)X1CD9U,Z1N)SS91D#Z  
CC(\*VK:UMI.\$0VL\$4 M\$0Z)\$@51^J.BD 5/!#\$.S.)CX9TC> . V M\*/Y8QFMBTLK2PA|FSM8;>+.=D.80?D\*GHI  
%1SP0W.313Q1ROMU210P/X&I M\*\*8& ? WA.S"8^&=(WCO|BCQ^6.9K8M+\*TL(?)LI6&WBSG9#&\$Y"IZ\*0!11 M13 KWEA9ZA  
8+VT@N8CUCFC#K^1K& X0(PB)3) PC&CICV^Q1X +&\*Z&BD!6 MLM.LM-A|JQL|>UB N01\*@( ("K-  
%|. |KHDB.DBJR. %6&016^X(!\*7\$WFR^&M)>3.2OLX^3|< C61I2 JV6F6&FH4L+&VM5/58(E0^A5JBBF 4444 %%%M  
!1110 4444 %%% !1110 4444 %%% !1110 4444 %%% !1110 4444 %%% !1110 4444 %%% !1110 4444 %%% !1110 4444 %%% !1110  
4444 %?7AK DZ9 ^ MOR| /!\$E20M3/7AK DZ9 |K|N 1\$E3C/H>BBBI\*CX7>>.XO VO7VHR6 M#W@N83\$S64)M^8-  
G.#Z5Z3 PT9:?!W/ P"i8 |B.Y3X+Z?97 BI58KRTM| MF-.4E5FC#@"S%Y (KW# (1K0?H"-. P" B?X4<8MHELZ P"&C+3 .%N  
M? P+^ Q-^ #1EI T+< (C%P")KT7 (1K0?H"-. P" B?X4?(UHA MT!-- P# 1A "JY6\*Z/O^&C+3 H6Y +^ P 31 PT9:?!W/  
!8 P#B M:1% X1K0?^@HO|X") A1 PC6@\_133? 1A\*5A='G7 #1EI T+< @6/ M B:/^&C+3 H6Y |P+^ \_37HO|  
PC6@\_P#0\$TW \_!\$ P\*/^\$T' H"-. M. B?X4=? #1EI P!"WA M^!8 ^)H X;M/^A.G |L? !->B |"-.# P! 33? \$3 "C (1K0?  
MH"-; P" B?X4=?&6G 0MS P#@6A MFC (G.MA H6Y L? \$UZ+ PC6@\_133? 1A\*/^\$T' H"-. X") A1  
A1RL+H|Z X;M/^A.G P# ML? Q- T9:?!OMS /@6/ B:1% X1K0?^@HO |M O\_@ (G^% "-.# T!-- !\$ PHY6%T>=?&6G 0MS |@6/  
(FC AHRT Z% MN?|!^Q |37HO "-.# T!-- !\$ PH X1K0?^@HO \_@ (G^%\*PNC SK AHRT MZ%N? P "Q |\$T?|&6G 0MS P#@6A  
XFO1?^\$T' H"-. B?X4?(UH M/ 0\$TW P\$3 "CE871YU PT9:?!W/ X% C XFC AHRT Z%N? "Q P#\$UZ+ M (UHA T!-- P# 1A  
"C A&M! Z FF P#@ (G^%\*PNC SK G.MA H6Y M L? \$T?|&6G 0MS |@6/ (FO1?A&M! P"@)HO (") A1 PC6@\_P#0 M\$TW  
\_!\$ P\*5A='G7 T9:?!OMS /@6/ B:/^&C+3 H6Y +^ P 3 M7HO C6@\_10\$TW P!\$ PH P"\$T' \*FF |  
@ (G^%\*PNC SK AHRT Z% MN?|!^Q |31 PT9:?!W/ X% C XFO1?^\$T' H"-. X") A1 P (UH/ \$!- |1A\*5A='G7 #1EI T+< |  
X% C -)H P"&C+3 %N? P+^ Q>B |M (UH/ 0\$TW P\$3 "C A&M! Z FF ^ B?X4=?&6G 0MS ^!8 ^)H X;M/^A.G P# L? Q-  
>B P#"-.# - 33? P\$3 H X1K0 M?^@HO|X") A1RL+H|Z P"&C+3 %N? P+^ Q-^ #1EI T+< (C%P") MKT7 (1K0?H"-. P"  
B?X4?(UHA T!-- P# 1A "CE871YU P-&6G M \$+< P#X% C XFC AHRT Z%N? P "Q |\$UZ+ P (UH/ \$!- |1A\*  
MA&M! P"@)HO (") A1RL+H|Z X;M/^A.G /L? \$T?|&6G 0MS ^!8 ^ MDKT7 A&M! Z FF ^ B?X4?| "-.# P! 33?  
\$3 "CE871YU PT9:?!W/ M !8 P#B:A AHRT P"A.G |Q |37HO "-.# T!-- !\$ PH X1K0?^@HO M\_@ (G^%\*PNC SK AHRT Z%N?  
"Q P#\$T?| #1EI P!"WA ^!8 ^)KT7 A&M! Z FF ^ B?X4?(UH/ 0\$TW P\$3 "CE871YU PT9:?!W/ P"i8 |B:/^  
M&C+3 H6Y P#P+^ Q>B |M (UH/ 0\$TW P\$3 "C A&M! Z FF ^ B?X4=? #1EI P!"WA ^!8 ^)H X;M/^A.G |M L? !->B |"-.# P!  
33? \$3 "C (1K0?H"-. P" B?X4=?&6G 0MS P#@6A XFC (G.MA H6Y L? M \$UZ+ PC6@\_133?  
1A\*/^\$T' H"-. X") A1RL+H|Z X;M/^A.G P# ML? Q- T9:?!OMS /@6/ B:1% X1K0?^@HO \_@ (G^% "-.# T!-- |  
M!\$ PHY6%T>=?&6G 0MS |@6/ (FC AHRT Z%N?|!^Q |37HO "-.# T!-- !\$ PH X1K0?  
^@HO \_@ (G^%\*PNC SK AHRT Z%N? P "Q |\$T?|&6G M 0MS P#@6A XFO1?^\$T' H"-. B?X4?(UH/ 0\$TW P\$3 "CE871YU  
MPT9:?!W/ X% C XFC AHRT Z%N? "Q P#\$UZ+ (UHA T!-- P# 1A M^C A&M! Z FF P#@ (G^%\*PNC SK G.MA H6Y L? \$T?  
|&6G 0MS |M@6/ (FO1?A&M! P"@)HO (") A1 PC6@\_P#0\$TW \_!\$ P\*5A='G7 M T9:?!OMS /@6/ B:/^&C+3 H6Y +^ P  
37HO C6@\_10\$TW P! M\$ PH P"\$T' \*FF |@ (G^%\*PNC SK AHRT Z%N?|!^Q |31 PT9:?!W M/ X% C XFO1?  
^\$T' H"-. X") A1 P (UH/ \$!- |1A\*5A='G7 #1EI T+< |X% C -)H P"&C+3 %N? P+^ Q>B |M (UH/ 0\$TW P\$3 "C A&M  
M! Z FF ^ B?X4=?&6G 0MS ^!8 ^)H X;M/^A.G M P# L? Q>B P#"-.# - 33? P\$3 H X1K0?^@HO|X") A1RL+H|Z  
M P"&C+3 %N? P+^ Q-^ #1EI T+< (C%P")KT7 (1K0?H"-. P" MB?X4?(UHA T!-- P# 1A "CE871YU P-&6G \$+  
< P#X% C XFC AHRT MZ%N? P "Q |\$UZ+ P (UH/ \$!- |1A\*5A='G7 #1EI T+< |X% C -)H P"&C+3 %N? P+^ Q>B |M (UH/ 0\$TW P\$3 "C A&M!  
&6G 0MS ^!8 ^)KT7 A&M! Z FF ^ B?X4?| "-.# P! 33? \$3 "CE871YU PT9:?!W/ !8 P#B:A AHRT P"A.M.G |Q |37HO "-  
.# T!-- !\$ PH X1K0?^@HO \_@ (G^%\*PNC SK AHRT Z M%N? "Q P#\$T?| #1EI P!"WA ^!8 ^)KT7 A&M! Z FF ^ B?X4?(UH/  
M 0\$TW P\$3 "CE871YU PT9:?!W/ P"i8 |B:/^&C+3 H6Y P#P+^ Q>B M (UH/ 0\$TW P\$3 "C A&M! Z FF ^ B?X4=?  
#1EI P!"WA ^!8 ^)H X;M/^A.G |L? !->B |"-.# P! M33? \$3 "C (1K0?H"-. P" B?X4=?&6G 0MS P#@6A XFC (G.MA  
H6Y L? \$UZ+ PC6@\_133? 1A\*/^\$T' H"-. X") A1RL+H|Z X;M/^A.G P# L? Q- T9:?!OMS /@6/ B:1% X1K0?  
^@HO \_@ (G^% "-.# T!-- !\$ PHY6%T>=?&6G 0MS |@6/ (FC AHRT Z%N?|!^Q |37HO "-.# T!-- !\$ PH X1K0?^@H  
MO \_@ (G^%\*PNC SK AHRT Z%N? P "Q |\$T?|&6G 0MS P#@6A XFO1?^\$T' H"-. B?X4?  
(UH/ 0\$TW P\$3 "CE871YU PT9:?!W/ X% C XFC AH MRT Z%N? "Q P#\$UZ+ (UHA T!-- P# 1A "C A&M! Z FF P#@ (G^%  
M\*PNC SK G.MA H6Y L? \$T?|&6G 0MS |@6/ (FO1?A&M! P"@)HO (") A1 PC6@\_P#0\$TW \_!\$ P\*5A='G7 T9:?!OMS /@6/ B:/^&C+3  
(Y-Z%< :Q MOD?IM>??#7X@1> :R GETYP74:(LH3:@D^ASUKZ\$N #>A+93D+IP(C8@B MU3T^E>? W3K^4-  
3UA:VSMIE4ACB?)7" >F1AN+N.^ATW T9:?!OMS M /@6/ B:/^&C+3 H6Y +^ P 37HO C6@\_10\$TW P!\$ PH P"\$T' M\*  
FF |@ (G^%5RLT?>=?&6G 0MS ^!8 ^)H X;M/^A.G P# L? Q>B M P#"-.# - 33? P\$3 H X1K0?^@HO|  
X") A1RL+H|Z P"&C+3 %N M? P+^ Q-^ #1EI T+< (C%P")KT7 (1K0?H"-. P" B?X4?(UHA MT!-- P# 1A "CE871YU P-  
&6G \$+< P#X% C XFC AHRT Z%N? P "Q |M\$UZ+ P (UH/ \$!- |1A\*5A='G7 #1EI T+< |X% C -)H P"&C+3 %N? P+^ Q>B |M (UH/ 0\$TW P\$3 "C A&M!  
&6G 0MS ^!8 ^)KT7 A&M! Z FF ^ B?X4?| "-.# P! M33? \$3 "CE871YU PT9:?!W/ !8 P#B:A AHRT P"A.G |Q |37HO M "-  
.# T!-- !\$ PH X1K0?^@HO \_@ (G^%\*PNC SK AHRT Z M%N? "Q P#\$T?| #1EI P!"WA ^!8 ^)KT7 A&M! Z FF ^ B?X4?  
(UH/ 0\$TW P\$3 "C ME871YU PT9:?!W/ P"i8 |B:/^&C+3 H6Y P#P+^ Q>B |M (UH/ 0\$TW P\$3 "C A&M! Z FF ^ B?X4=?  
#1EI P!"WA ^!8 ^)H X;M/^A.G |L? !->B |"-.# P! 33? \$3 "C M (1K0?H"-. P" B?X4=?&6G 0MS M P#@6A XFC (G.MA  
H6Y L? \$UZ+ PC6@\_133? 1A\*/^\$T' H"-. M. X") A1RL+H|Z X;M/^A.G P# L? Q- T9:?!OMS /@6/ B:1% X1K0?  
^@HO \_@ (G^% "-.# T!-- !\$ PHY6%T>=?&6G 0MS |@6/ (FC M AHRT Z%N?|!^Q |37HO "-.# T!-- !\$ PH X1K0?  
^@HO \_@ (G^%\*PNC MSK AHRT Z%N? P "Q |\$T?|&6G 0MS P#@6A XFO1?^\$T' H"-. B M?X4?  
(UH/ 0\$TW P\$3 "CE871YU PT9:?!W/ X% C XFC AHRT Z%N? "Q M P#\$UZ+ (UHA T!-- P# 1A "C A&M! Z  
FF P#@ (G^%\*PNC SK G.MA H6Y L? \$T?|&6G 0MS |@6/ (FO1?A&M! P"@)HO (") A1 MPC6@\_P#0\$TW \_!\$ P  
\*5A='G7 T9:?!OMS /@6/ B:/^&C+3 H6Y M +^ P 37HO C6@\_10\$TW P!\$ PH P"\$T' \*FF |@ (G^%\*PNC SK  
M AHRT Z%N?|!^Q |31 PT9:?!W/ X% C XFO1?^\$T' H"-. X") A1 P (MUH/ \$!- |1A\*5A='G7 #1EI T+< |X% C -)H P"&C+3  
%N? P+^ M^ Q>B |M (UH/ 0\$TW P\$3 "C A&M! Z FF ^ B?X4=?&6G 0MS ^!8 ^)H X;M/^A.G P# L? Q>B P#"-.# - 33? P\$3  
P\$3 M H X1K0?^@HO|X") A1RL+H|Z P"&C+3 %N? P+^ Q-^ #1EI T+< M (C%P")KT7 (1K0?H"-. P" B?X4?(UHA T!--  
P# 1A "CE871YU M P-&6G \$+< P#X% C XFC AHRT Z%N? P "Q |\$UZ+ P (UH/ \$!- |M 1A\*5A='G7 #1EI T+< |X% C -)H P"&C+3  
(") A1RL+H|Z X;M/^A.G /L? \$T?|&6G 0MS ^!8 ^)KT7 A&M! Z FF ^ B?X4?| "-.# P! 33? \$3 "CE871YU PT M9:?!W/  
!8 P#B:A AHRT P"A.G |Q |37HO "-.# T!-- !\$ PH X1 MK0?^@HO \_@ (G^%\*PNC SK AHRT Z%N? "Q P#\$T?| #1EI P!"WA  
^!8 M^)KT7 A&M! Z FF ^ B?X4?(UH/ 0\$TW P\$3 "CE871YU PT9:?!W/ P"i8 |B:/^&C+3 H6Y P#P+^ Q>B |  
(UH/ 0\$TW P\$3 "C A&M! Z FF ^ B? MX4=? #1EI P!"WA ^!8 ^)H X;M M/^A.G |L? !->B |"-.# P! 33? \$3 "C (1K0?  
H"-. P" B?X4 M=?&6G 0MS P#@6A XFC (G.MA MH6Y L? \$UZ+ PC6@\_133? 1A\*/^\$T' H"-. X") A1RL+H|Z X;M/  
M^A.G P# L? Q- T9:?!OMS /@6/ B:1% X1K0?^@HO \_@ (G^% "-.# T!-- !\$ PHY6%T>=?&6G 0MS |@6/  
(FC AHRT Z%N?|!^Q |37HO M "-.# T!-- !\$ PH X1K0?^@HO \_@ (G^%\*PNC SK AHRT Z%N? P "Q |M\$T?|&6G 0MS P#@6A  
XFO1?^\$T' H"-. B?X4?(UH/ 0\$TW P\$3 "MCE871YU PT9:?!W/ X% C XFC AHRT Z%N? "Q P#\$UZ+ (UHA T!-- M P# 1A  
"C A&M! Z FF P#@ (G^%\*PNC SK G.MA H6Y L? \$T?|&6G 0MS |@6/ (FO1?A&M! P"@)HO (") A1 PC6@\_P#0\$TW  
\_!\$ P\*M.5A='G7 T9:?!OMS /@6/ B:/^&C+3 H6Y +^ P 37HO C6@\_10\$TW P!\$ PH P"\$T' \*FF |  
@ (G^%\*PNC SK AHRT Z%N?|!^Q |31 MPT9:?!W/ X% C XFO1?^\$T' H"-. X") A1 P (UH/ \$!- |1A\*5A M='G7 #1EI T+< |  
X% C -)H P"&C+3 %N? P+^ Q>B |M (UH/ 0\$TW P\$3 M3 "C A&M! Z FF ^ B?X4=?&6G 0MS ^!8 ^)H X M;M/^A.G P# L? Q-  
>B P#"-.# - 33? P\$3 H X1K0?^@HO|X") A1RL+H|Z P"&C+3 %N? P+^ Q-^ #1EI T+< (C%P")KT7 (1K0?H"-. P"  
B?X4?(UHA T!-- P# 1A "CE871YU P-&6G \$+< P#X% C X MFC AHRT Z%N? P "Q |\$UZ+ P (UH/ \$!- |1A\*5A='G7 #1EI T+< |  
M (") A1RL+H|Z X;M/^A.G /L? \$T?|&6G 0MS ^!8 ^)KT7 A&M! Z MFF ^ B?X4?| "-.# P! 33? \$3 "CE871YU PT9:?!W/

!8 P#B:A MAHRT P"A;G !"Q !37HO "-:# T!-- !\\$ PH X1K0?^@)HO @(G^%\*PNCS MK AHRT Z%N?,"Q P#\$T? !1EI P!"WA  
^!8 ^)KT7 A&M! Z FF ^ B? MX4?!(UH/ 0\$TW P\$3 "CE871YU PT9:2!W/ P" !8 |B:/^&C+3 H6Y P#P M+! Q->B |  
(UH/ 0\$TW P\$3 "C A&M! Z FF ^ B?X4=? !1EI P!"WA ^!8 ^)H X;M/^A;G |L? !->B | "-:# P! 33? \$3 "C (1K0? H"; P"  
B?X4=? !&6G 0MS P#@6A XFC (C;MA H6Y L? \$UZ+ PC6@ !M 33? 1A\*/^\$;T' H"; X") A1RL+H MZ X;M/^A;G P# L? Q-  
T9:2! 0MS /@6/ B:1% X1K0?^@)HO @(G^% "-:# T!-- !\\$ PHY6%T>=? M!&6G 0MS |@6/ (FC AHRT Z%N? !"Q !37HO "-  
:# T!-- !\\$ PH X M1K0?^@)HO @(G^%\*PNCSK AHRT Z%N? P "Q |\$T? !&6G 0MS P#@6A MXFO1?^\$;T' H"; . B?X4?  
(UH/ 0\$TW P\$3 "CE871YU PT9:2!W/ X% MC XFC AHRT Z%N? "Q P#\$UZ+ (UHA T!-- P# 1A "C A&M! Z FF  
M P#@ (G^%\*PNCSK (C;MA H6Y L? \$T? !&6G 0MS |@6/ (FO1? !A&M! P"@)HO (") A1 PC6@ P#0\$TW !\$ P \*5A='G7  
T9:2! 0MS M /@6/ B:/^&C+3 H6Y +! P 37HO C6@ |0\$TW P !\$ PH P"\$;T' \*FF |@ (G^%\*PNCSK AHRT Z%N? !  
!"Q !31 PT9:2!W/ X% C XFO1?^\$;T' H"; X") A1 P (UH/ \$!-- !1A\*5A='G7 #1EI T+< |X% C )H P"&C+3 \*%N? P+! Q-  
>B |(UH/ 0\$TW P\$3 "C A&M! Z FF ^ B?X M4Y: ?S%G" 951C&T W?UKTKXBZ#HJK\A 6)H?2;&&5(05DCMT5E.X="!6  
M#1%="TR !\$W\$MYUI= ? !1EI P!"WA ^!8 M^ )H X;M/^A;G |L? !->B | "-:# P! 33? \$3 "C (1K0? H"; M P" B?X4=? !  
&6G 0MS P#@6A XFC M (C;MA H6Y L? \$UZ+ PC6@ !33? 1A\*/^\$;T' H"; X") A1RL+H MZ X;M/^A;G P# L? Q-  
T9:2! 0MS /@6/ B:1% X1K0?^@)HO @(MG^% "-:# T!-- !\\$ PHY6%T>=? !&6G 0MS |@6/ (FC AHRT Z%N? M!"Q !37HO "-:# T!--  
!\$ PH X1K0?^@)HO @(G^%\*PNCSK AHRT Z%N? M P "Q |\$T? !&6G 0MS P#@6A XFO1?^\$;T' H"; . B?X4?!(UH/ 0\$  
MTW P\$3 "CE871YU PT9:2!W/ X% C XFC AHRT Z%N? "Q P#\$UZ+ (UMHA T!-- P# 1A "C A&M! Z  
FF P#@ (G^%\*PNCSK (C;MA H6Y L? M \$T? !&6G 0MS |@6/ (FO1? !A&M! P"@)HO (") A1 PC6@ P#0\$TW M !\$ P  
\*5A='G7 T9:2! 0MS /@6/ B:/^&C+3 H6Y +! P 37HO M C6@ |0\$TW P !\$ PH P"\$;T' \*FF |@ (G^%\*PNCSK AHRT Z%N? !  
M!"Q !31 PT9:2!W/ X% C XFO1?^\$;T' H"; X") A1 P (UH/ \$!-- !M 1A\*5A='G7 #1EI T+< |X% C )H P"&C+3 \*%N? P+! Q-  
>B |(UH/ M 0\$TW P\$3 "C A&M! Z FF ^ B?X4=? !&6G 0MS ^ M!8 ^)H X;M/^A;G P# L? Q->B P# "-:# - 33? P\$3 H X1K0?  
^@) MIO\ X") A1RL+H Z P"&C+3 \*%N? P+! Q- #1EI T+< (%C P)KT7 (1K0? H"; P" B?X4?!(UHA T!-- P# 1A  
"CE871YU P-&6G \$+< M P#X% C XFC AHRT Z%N? P "Q |\$UZ+ P (UH/ \$!-- !1A\*! A&M! M P"@)HO  
(") A1RL+H Z X;M/^A;G /L? \$T? !&6G 0MS ^!8 ^)KT7 M A&M! Z FF ^ B?X4? "-:# P! 33? \$3 "CE871YU PT9:2!W/ !8  
M P#B:A AHRT P"A;G !"Q !37HO "-:# T!-- !\\$ PH X1K0?^@)HO @(G M^%\*PNCSK AHRT Z%N? "Q P#\$T? !1EI P!"WA  
^!8 ^)KT7 A&M! Z M FF ^ B?X4?!(UH/ 0\$TW P\$3 "CE871YU PT9:2!W/ P" !8 |B:/^&C+3 M H6Y P#P+! Q->B |  
(UH/ 0\$TW P\$3 "C A&M! Z FF ^ B?X4=? !1EI P!"WA ^!8 ^)H X;M/^A;G |L? M !->B | "-:# P! 33? \$3 "C (1K0? H"; P"  
B?X4=? !&6G 0MS P#@6A XFC (C;MA H6Y L? \$UZ+ PC6@ !33? 1A\*/^\$;T' H"; X") A1RL+H Z X;M/^A;G P# L? Q-  
T9:2! 0MS /@6/ B:1% X1K0?^@)HO @(G^% "-:# T!-- !\\$ P MHY6%T>=? !&6G 0MS |@6/ (FC AHRT Z%N? !"Q !37HO "-  
:# T!-- M!\$ PH X1K0?^@)HO @(G^%\*PNCSK AHRT Z%N? P "Q |\$T? !&6G 0MS M P#@6A XFO1?^\$;T' H"; . B?X4?  
(UH/ 0\$TW P\$3 "CE871YU PT9: M? !W/ X% C XFC AHRT Z%N? "Q P#\$UZ+ (UHA T!-- P# 1A "C A M&M! Z  
FF P#@ (G^%\*PNCSK (C;MA H6Y L? \$T? !&6G 0MS |@6/ M (FO1? !A&M! P"@)HO (") A1 PC6@ P#0\$TW !\$ P \*5A='G7  
T9:2! 0MS /@6/ B:/^&C+3 H6Y +! P 37HO C6@ |0\$TW P !\$ PH M P"\$;T' \*FF |@ (G^%\*PNCSK AHRT Z%N? !  
!"Q !31 PT9:2!W/ X% MC XFO1?^\$;T' H"; X") A1 P (UH/ \$!-- !1A\*5A='G7 #1EI T+< |X% C )H P"&C+3 \*%N? P+! Q-  
>B |(UH/ 0\$TW P\$3 "C A&M! Z MFF ^ B?X4=? !&6G 0MS ^!8 ^)H X;M/^A;G P# M L? Q->B P# "-:# - 33? P\$3 H X1K0?  
^@)HO\ X") A1RL+H Z P"& MC+3 \*%N? P+! Q- #1EI T+< (%C P)KT7 (1K0? H"; P" B?X4 M?!(UHA T!-- P# 1A  
"CE871YU P-&6G \$+< P#X% C XFC AHRT Z%N? M P "Q |\$UZ+ P (UH/ \$!-- !1A\*! A&M! P"@)HO (") A1RL+H  
MZ X;M/^A;G /L? \$T? !&6G 0MS ^!8 ^)KT7 A&M! Z FF ^ B?X4? M "-:# P! 33? \$3 "CE871YU PT9:2!W/ !8 P#B:A  
AHRT P"A;G !M"Q !37HO "-:# T!-- !\\$ PH X1K0?^@)HO @(G^%\*PNCSK AHRT Z%N? M "Q P#\$T? !1EI P!"WA  
^!8 ^)KT7 A&M! Z FF ^ B?X4?!(UH/ 0\$TW P\$3 "CE871YU PT9:2!W/ P" !8 |B:/^&C+3 H6Y P#P+! Q->B |(UH  
M/ 0\$TW P\$3 "C A&M! Z FF ^ B?X4 M=? !1EI P!"WA ^!8 ^)H X;M/^A;G |L? !->B | "-:# P! 33? M \$3 "C (1K0? H"; P"  
B?X4=? !M-&6G 0MS P#@6A XFC (C;MA H6Y L? \$UZ+ PC6@ !33? 1A\*/^ M\$;T' H"; X") A1RL+H Z X;M/^A;G P# L? Q-  
T9:2! 0MS /@6 M/ B:1% X1K0?^@)HO @(G^% "-:# T!-- !\\$ PHY6%T>=? !&6G 0MS |M@6/ (FC AHRT Z%N? !"Q !37HO "-  
:# T!-- !\\$ PH X1K0?^@)HO @(MG^%\*PNCSK AHRT Z%N? P "Q |\$T? !&6G 0MS P#@6A XFO1?^\$;T' H M"; . B?X4?  
(UH/ 0\$TW P\$3 "CE871YU PT9:2!W/ X% C XFC AHRT Z M%N? "Q P#\$UZ+ (UHA T!-- P# 1A "C A&M! Z  
FF P#@ (G^%\*PN MCSK (C;MA H6Y L? \$T? !&6G 0MS |@6/ (FO1? !A&M! P"@)HO M (") A1 PC6@ P#0\$TW !\$ P  
\*5A='G7 T9:2! 0MS /@6/ B:/^&C M+3 H6Y +! P 37HO C6@ |0\$TW P !\$ PH P"\$;T' \*FF |@ (G^  
M%\*PNCSK AHRT Z%N? !"Q !31 PT9:2!W/ X% C XFO1?^\$;T' H"; X") M) A1 P (UH/ \$!-- !1A\*5A='G7 #1EI T+< |X% C  
)H P"&C+3 M \*%N? P+! Q->B |(UH/ 0\$TW P\$3 "C A&M! Z FF ^ B?X4! S )+5 |KT; -&+7OE.0V(EN%%%%4(\*\*\*\* "BBB@  
HH MHH \*\*\*\* "BBB@ HHHH \*\*\*\* "BBB@ HHHH \*\*\*\* "BBB@ HHHH \*\*\*\* "BBB M@ HHHH \*\*\*\* "BBB@ HHHH \*\*\*\* "BBB@  
HHHH \*\*\*\* "BBB@ HHHH \*\*\*\* "BBB@ HHHH \*\*\*\* "BBB@ HHHH \*\*\*\* "BBB@ HHHH \*\*\*\* "BBB@ HHHH \*M\*\*\*\* "BBB@  
HHHH \*\*\*\* "BBB@ HHHH \*\*\*\* "BBB@ HHHH \*\*\*\* "BBB@ HH MHH \*\*\*\* "BBB@ HHHH \*\*\*\* "BBB@ HHHH \*\*\*\* "BBB@  
HHHH \*\*\*\* "BBB M@ " " P"/&X ZYM \*O\$/@# R%=: ZX1 ^A&O;S CON/^N;?RKQ#X | (5UK  
M KA' P"A&I>Z&MCW:BBB!\$%%%% !1110 4444 %%% !1110 4444 %%% ! M1110 4444 %%% !1110 4444 %%%9&H>\*=  
TJY-M?ZS86TXZQ23J&?D9R\*T M+ ^M-1MEN;ZAN8&SMEAD#?H100!/1110 45%<7.% |!S-#"@RTDC!54> MY/K) X3+PO-  
#)H |X'1? %4;=%0!7BSPY,VV+Q!4C>B7D9!ZU8I8Y MHQ)%(LB-R&0Y!&@H%%9>I>)=#T;=8-2U:SM)F7<(VIE5L>N.N\*  
-2BH&L:Z MM!VV2YM6XIX!)E)8G\*#P!B.#4M !1110 45C6 BWP! =WRV5OKFCRW+MM6)+A M6+T&#R:V:  
"BBJ&LW6CH&U+46T!Z>?J\$ 0\$T 7Z?Y3 A9?@T2"/^WI M7)FVON+|^@M8 <&2>0(N?3)XK-  
L\_% AN N%M!77=,EFE^)/@Z\*01MX@M'2<94EA^8&\*+@=3 M16=I>O:1K;%M,U\*UN!#+"&4,5^HZC!T: "BBB@ HJ"  
!O:6P@ !Y#HW" X@LRHK3H \*\*\*\* "BBO)OBS!1-2!ZA::3H=RL%R4!ZXD!M7\*|^N&!8D A2; ML"5SUFBL#P5<M>>#1-  
N!E\$M !%YKL\$?2\*QRN0.#.W:M^F 445FZEXAT;1 MV"ZEJMG:>BS3\*K"!-@P\BBX\$E%%4+  
%O2=?95U'5+\*S9QE1<7"1EALB\*+!%8G "9>% M^ADT? P.B |BJLP>(M#NB!ZSRL/ANZIL D;+@:5% .1D=\*\* "BBB@ HH  
MK'OO?A 3+LVEIK5A;W'XW1R3J&U>\* -BBFOR+&LD;J;@,K'A!H U M !1152 U2PTJ#SM00;>TB\_O3RA?SH  
MT5RI+@)X2^6=M-WJ-Q'YXO706& MIV&JV GZ?>VJW?TWP2!P!BBX%JBBB@ HJ->XAM86FN)HXHEY9Y&J/J37-W  
M'O&V'VK;9/\$%FQSC!TOD'VJ#1<#J\*\*R=\*13Z%K;L-U:SN!/^><L'D!#.%0'&5T!O44 @C(.0\*8!165<^/\*#JE ML5D7!R+\*8?4  
M+F@#H\*\*YZP|=^%=3E6\*UUVR:1ONH!FPD^@#8R:Z&@ HHKR XN^)/\$ A?^S;O M1KT6!E-NCE\_<(!P&^%A DY\_+>  
!O T1)7N5>&^%/^3G P#M!N \$!43V'\$^FJ\*\*R M+!EOX&?CEJ 7HW HO:HKP/X&?CEJ P#UZ- Z,6O?\*VAL1+<\*\*\*\*H0444  
M4 %%% !1110 4444 %%% !1110 4444 %%% !1110 4444 %%% !1110 M 4444 %%% !1110 4444 %%% !1110 4444  
%% !1110 4444 %%% ! M1110 4444 %%% !1110 4444 %%% !1110 4444 %%% !1110 4444 %%% M% !1110 4444  
%% !1110 4444 %%% !1110 4444 %%% !1110 444 M4 %%% !1110 4444 %%% !1110 4444 %%% !1110 4444 %%%  
!1110 M 4444 %%% \$%Y QXW' %S;^5>(?' )NM? !7/ "->WWG 'C!44450@HHHH \*\*\*\* "BBB@ HHHH \*\*\*\* M "BBB@  
HHHH \*\*\*\* "BBB@ HHHH \*\*\*\* "H+VIAT^PN+RX;#;OM+(WHJC) ME4!>;&K7OI+!XWQ/J4@BP#SY; ,Y P#01 P\*DW9  
GP+4;F!0ZMJ J-& MTDDC/=BEOY#(>%K?;7ML^HZ!\* #@74C!X +;P-+!% "D.H>!"?UO-/E7L+LPW' =  
M^A!9T4BLKJ&4@!1D\$="\*6MB#S/XYNR^ XOK\$!K^!;W&US, "O'O!>@2 P#& M!WJV5U:0&T"% /W<[MV,8! NFO8/CI R(EO-  
A/!T'2N= 9^ U B# ;? M^WXCM7G^QZT,K<9KL; \*ZFUFN,LGY M@M^OK(^!5W+%XUNK92?\*GLV+VRK\*0?  
U/YUP^X T/A?2!6\*ING\$?FP^N!M!F UQC!;?Q1\*96% -G7/M7A!T:1LR64OF1@G EF 821@?^>H9KY=^%.N? MV)X^L2H8+S-  
I+ P/&W ,>"U!14X.Z!A7+ \$36 P"P/ NIW:MMF>/R(?7> M P N1! 2?PKJ^V/6MHJC3-"C:A  
J89!G^I^F !Q3DH(2W.9^#>AG5O^45 MTZY@T^,W#>F!HJC!SG @-?2U>; !/0O!+&O!B8FU\*4N"!SY;Y5?UW"!Z; MQ!KY!  
>#-0U"-MMQLJ CP&X! #.2PHIT0WJSS )?Q7GT^!ET/PI+LGB) M2YO =HHGN.Y! =O6O/O#OP^!3^F; C7;!  
(V60!V0@2'N!U9OKT!ZA^!OAD M>+O&,%G<[FM8P;BZ.3ED!"&?" "&-8XHU"HB# 4#@ "I2MY6 M-ZA?  
"-@=1!O/INV09^IY+8OI<- TKC?G@#Q)X\*9+RXCW0\*3PV7EHY^HW)X M^GZ@5!4U%Z;S^\*O);OGGRVY7GU'3ZB  
MOIGP9K!0^#!U1S!F6;\$4^KJ2K!P:(OHP:ZF!H17"2%3QA P (OX8&VDV MZC?9B@P>47^ ) P  
<#W(!^INPCRSXI>)I\_&'C'+1+=W36UK)GA1#GSIB<.W MY\_\*/H3WKBMB&B:#Q7H+XW1WT:G'3(<"O4?@CX/

.GD\47L>4C)BLPPZMT9 MP^Z\5C\5&. MG^Z,5TS?&^%MN77I%O#MKI=LJYC7,K@LGO\^\*,7(9DOIPNZ\_P\I  
M%>=OX(N^S^\*VJMI/P\U)HVVRW(6V4\_IYPW\_(HNSX^B#:8MOXCU+46&?LEN M(UIFD/7\D8?C42U:0UM<H50JA5\_P.U+17#?  
%CQ&\_A\P3+=REW?\_JFB9\_M3@J^,L?^01H2^INPC@\_B+6HJ2IFT\PW<&^(E)KU#\TAJA#V^T.3VXZ\H MX<^&B?  
Q7^+Y8TMK:7YA<7C\$>9I@8+L^ZXP?6I\A1XB4>\*3)>QB33I^1+,A M^#L3A5/L3D\_12^\*F@\_H X %0ES:LINVQX\,?AEJR.RW%BS-  
G\Z^?8X^5OYCVKZHKJ&G66JV.V>H6L5S:OIZ.50 MP\I?W\BZ^YAND7QU\I,^\_9 ANK>.8J/X=R@X\_6OFIXPLS?S04@22%2\$#V  
M^EJ?ZFOJ\*\*.""(8D5(XU^HJC 4#@\_5R?%\_DINJ?H\H^\*)H^O^%W\#O%>O&SPRZ==8SA(HF5C\_WTH^ZU MH=X(C\_P^1\$T#^+H^H  
K>HY\$,SY3@U7QA\|=3%N9:RPD7G\H\T3CV\RI^MN\SKW3X?2\$:T:6I6TR+,:K^FZ6\$Y7?3C2Z=J\$ M0(0BE^)^>S^?I.^>E?  
+:/@KQ?E6V7VFW\|VG::<\$?HK#\P:6L1HGU\5\_M74M3M(L9+|4+F.VMHOED@#\_#\$^U&FW\J:7:~A:Y\FYA29\|<,1G\ZPO^M?  
A23QCX>&EOW:VH)3(RA@9I&CU\_2K1^3RSQA19+\_%5M\+1RV+G9I\_MIVYFESQA\^\_#  
#^>6:C9WMAJ\$MMJ\4D5VHE27P\&IGWYKZC?)#I00^\$8 M>S@Z\I(PHW\_7/KCLHIA^..H\^\*)\_2M: ZZ) Z+6LY)VNRDSZ4\^?I  
(JZ/M\_P\>4A Z^\*U^R\_#7\_(JZ\I>4/H\_K4K5\$G,?S^7:SPWX)O\3L\_OVF/8J\_MRY^;G^H=19\_/%>"Z5X(19>/9SJ4BR.DO\_+I?  
R%5;Z=21H\BOIV>"&YA:&XB\_MCEB\IR2\*4I^0.D &\_+5+C<:=CY\G^VOI^;X=2TZ68\_DQDNH\L#M\_6BN% M@N>+|^#(CL\_UA\^  
EV^0I^..N^..C^1^<KZ\KPOX\_6<\$>HZ+>HJB>..6.0@&\_/5HE^..N)8P?N2^AA^?3V(K:9MJ.V.X<5 MY=|S(?)=|N^R#4^V\_|?N/  
>15:=T2SYC6Q\^\_#74WNMLDMN^UY&V6\LO\_M\H@3ZUT?P\OC:EI=>MEGI(MNS+\_-I9\\_2O1=1W/  
MDKQ\X3UGP1JL45\A8E\>Y@<I7P>JG\^...HKW^X2>+GQ3HDIKJ,GF:A8%5\_M:4I94:UC\H^V6H\QWAC\_A#+(N\YWVY?+/?  
&Q\AT\_2N7+44C\H\H\H^M\_M+94;ZELC\_P\I^):2L/=^O5%%%>:S^H17FNH^&G0I+UFY\TZZTW4U>WF^\*1MB=0  
M<\$XW=/Z4FT@/2J^AM+J^M(C\_NVD66^9I)&Z\&4C(-2DA022^R2:8^T5YL/C\_M3H\$NMKIMH8ZC=%YQ\^+SB\$2\$G  
\*C=D@H\H\DI@%%%, "KJ6HVND;,<A>RB\_M^VMT+R.>P\SV\FOFWQE\2\_-197K65F9K;37;9%9P\_?E\^6) N\KUKK?  
MCMX(C)X0Z8)>E6?@AX0A%G)XG0@(\SN8K\Y.5\_^M0VVI(C:T5SEI(^?B;4\_=9\MI73U8\_B.9BTF/<\*^I\^+=>2S\_MN@?  
W>XX#&G\O?I^KZ.JE=Z1IU\>6UW=64\$US:MN@E=6C/L:NU25A-W/C:V\_MM)=6UZ&R60\^|NEB#OT#.V.G\37I+?\_77H\VZHA:~  
3(A\_V6N#1^?CQH\_M\_82A\_P#1HKZK;4IRF\53J7P\8;~&988;|V\G\I^P^<8^3^%5^WQ&|\_M4>+>W\^/-  
<01MB6ROW1#;J=M^JZK91F174\_M-::!G\J\#^VE7&XGY&\_IOT\KZ=I(P^T)JQX\2;\_P5>|\_5WX6TE+M\_M2TM@@^SP?  
\*K;D5BTAZ8R<2^L\_0K3O9\I^C\^N4\^HR^M^ZCX>.:O\_6C\ZA.TUK,I^R.YR8G\_SM\ND|=B\CK7K?C/R#X(US\O\_8OL\_MV?  
KL./QSBOFSXZ\^N8^<(6B+K\_@?4\3\_M;NF2(SP^N\H\F&K@C\Z>@C(P>E;\$GSU\#M>:Q\4SZ\(^=(0B)13\_P14Y^\_M  
(H\_N\_(5I^U\FWFP=|H^@4:=D9\ZH^R\^\* SKZQ1E=%>2^K#((BH@I+^#\_MD+1115B^BBB@\_HHHH \*\*\*\* "BBB@\_HHHH \*\*\*\*  
\_3^G)\_-Z\_X#\_T(5SWP\_M+\_Y\$2X\_I^M^G\_!^70\_\$\$D6&M\_I^5X\^#/\^1RU?\_KT\_P\&+7OE:0V(EN0%%0%4(\*\*\*\* "BBB@\_HHHH  
M\*\*\*\* "BBB@\_HHHH \*\*\*\* "BBB@\_HHHH \*\*\*\* "BBB@\_HHHH \*\*\*\* "BBB@\_H\_MHHH \*\*\*\* "BBB@\_HHHH \*\*\*\* "BBB@\_HHHH \*\*\*\*  
"BBB@\_HHHH \*\*\*\* "BB MB@\_HHHH \*\*\*\* "BBB@\_HHHH \*\*\*\* "BBB@\_HHHH \*\*\*\* "BBB@\_HHHH \*\*\*\* "BBB@\_HHHH \*\*\*\* M "BBB@\_HHHH \*\*\*\*  
"BBB@\_HHHH \*\*\*\* "BBB@\_HHHH \*\*\*\* "BBB@\_HHHH M\*\*\*\* "BBB@\_HHHH \*\*\*\* "BBB@\_HHHH \*\*\*\* "BBB@\_HHHH \*\*\*\*  
"BBB@\_"" M\X\C\_KFW\H0^/\_ (5UK\_KA^Z\$;100A^CON/^N:R^KQ#X\_1A760^N\$?\_M\_H1J7NAK8IVHHHJA\1110\_4444\_%%%%  
+1110\_4444\_%%%%+1110\_4444\_%%%%M%%%%+1110\_4444\_%%?-7QAUPZSX\IDLX6+PZ>HMD^Y?J\_XY.W\_@-?FOZM^H6  
M@>7VJ38VVL+2\_^(@<#|3?C7S=|J^E\4C\$;UDN<|3GGZ5^XU\_M^PX\SZ\(^Z\#OA/3+=P\\_|W^>0\_~P#X\37A0QLT+^S?  
&2ZC&F(=1B#Y^M\>8N^Y\|&O\_HV\O\4C\$H7K>!9;J\_I=^N>O?\_MV\X^LF=IUQ9\_Z+&SSE?NG\5^\_K7:5\^  
S70L7B6ZT:5\1W\6Z^\_GHF3^H^MOR%?05\$7=">YFE|=/^1\$M\_|L(I\_@<25SO\W^O\0?HMO\_2NB^G\_(B6+MV\$(-0)\*2I-  
ZWXCT9KD^IKE,RA?\_1B\$29QG;G(..H6I2^6Q\=5Y%0#ID\T^N^X\O%?Q+U\#;K<:R^H\I^;6\_-5\JY MX>^\$B;7KP7&KJV66S-  
NDDN#F9\_7^|<\_J\VOHC\_Q#\_CZ\I\_WU7NM9^BZ+8^J^@TS3H?^MX5P\W8\I\|DI\ZT^N^LB6\ MGRAX^T5O#7CO4+;\$&\_S?  
M^N5XPK?..?0Y^X5\^&-93Q\X8T\55(S<0JS@= MG^#&|&1%>8^G0O\_L\I-UZ)/FB8VLO\ITY9\P\W?H^I\_@/KGVC\H0T25\O\_R-M">  
(^X\_|^C#/\_JA\_2L4\>O5\H^>R;QK\I;EK4\5>78M\TV9^)(R/YU\_M\H?^\$36\_|^ZG=JVV9X\_(A)=|+D?0\$G\^<^<6A?  
VCXODU^18^M571Q\_4Y:M(2IGT^IUC#HFFVMA;KB&VB6\H^#\_#5>7^N^Z;PWI=H#A9;L\_MNPI=H#A9?^?S5ZU7COQ\_0G3-\$DI^:4?  
FJ\_X4Y;MRK\+1\$?\_)B4XZ#YB?\_M\_9;ILKOKX\_2J;#78L\_..LL+Z\$;Z5\+1^8^N%%0%4(^?OCU;I^FG7\_&\_L@\_MA\RK\_M\_|  
%5V\_P.N&F\ R1DY\$-J)&8;4;\_V8UR^QJE4ZYH\(/S+;\_Q^A^\_J\_M\=-;|^(C^X#G8@\_O+^1A\_P\I  
(Z5FOB^\*Z1%Q%\_VTMO\Q<L<2%Y^8X^T\DD\_M\_A7S+J\_S2\_?3XD+;\_HEAE?RX0>1#\_O)8\_AD\_4XK0OC;XP^RV4?AFSD\_?7\_\$E  
MV5/W8\_X5\_C\I\A\UJ?IOP^I\_V\H\UFICQ?\_BH^CF^JH\_X#J\OGTIO5V\$M\_M%<|^TW3\2=-MM/LX+M\>\_1OK\#U\Z^3;+  
\_BW^I^2\_+HVOKROD\_R\_Y^MBW^I^2\_<C:4^<XGUY1116A)S7B\Q\X+|+7L=CJMT5PZ>8(TB9R%)(!.OT\_M^BKXH-W#92,K\$1  
MH<R::=-BOX\2>Y.<#M7T+X1-6/APY::5 PD9.O+&C^2JWH\I\_5^Z\X\_M\6?#^" AFBOY8X)&=7\_K(?+0\54L?PKX)\-  
WUM\_PG&GZE\DPDPC@6\ M6YGD8\$@8;<>R>17U=J@8Z1>A>&\_#X^NTU\C>=')77?66GZ6TQA6ZF6(R<|  
M<|43Z\^IDUCX\6\$C1Z\I\_M\T\I\_P\KB3RUSZA0^2\KBL^X^ZH),R:)9M^G\H\_MRL#CZ\ RKT?1A;X2T:%5\_LN.JE^:6\I-E+?  
H\RC\H5\4A\_P^#J3@:~\*O\_M%-RXWP1^A\I^N\*=I=O:&3X\_>B^+;A;(H\A\#?=@F8\$22\K=SI\$ UW52)^B  
MO0KCP\_XON^..9P>026\P\_M^\*GYD:(C^8KZ@+ZJ^M^>M+U^3^FW^%LCR8Z\ M^>N:<7?1@T:1%0%4(I^?U\ZT>CZ-8@\_+^?)\_?  
JB@^\_T8^F\_EJ>&M4O\XI\_M^P1Z(@/\_LYK^&H\DW^AQEBF8B5\_PKJ?@<@7P#(0>6O9^?>^<4^?C\8^AZ\_M57A?  
Q<0^4M%LL\_(D\_BN\4L0\_9?YUHF^Q^O\G(4:9)SAK+;P=O:<|<CN\_M=^I^):8?IUY=X\_>7%XPQ^"JKG\2U>I5YO\I  
!^59/A^4&QWDBG\EA\_6O2^M<=A/<\*\*\*\*8\7S#17\_P#DINJ^H\^\_\*\*2OIZOF^XO\_P#)3=4\_W8?\_ \$4E\8<M=SZ\5?  
|B)H^\_8/@\_P#0\6\6#X(Y\$30/^P?I\_Z^\*WJ\^""OF\XVV26GQ\;R\_MC\N\2.9OJ-R?R05\I\U\I^?699/^\_M&ISY5@BL/OEW\A(BIGL..YZE\I  
(HMO MX::9O;N#^#D/E?#\_P?&/\_DF?\_?C(I7>52V\$IPKY7^\*/\_M\_)2M: ZZ) Z+6O\BOE^XH\^2M: P^NB?I  
HM:F>PX\GTFX:\_Y%71\_0^\* M\_-%E9?AK\_D5=^\_O^\*T\_5J5:\$%0%%0%17S\19?54>M>.OL=NX;#34,&X=M#)G+\_EP/^UZ?I42B  
GA;2VTZPE\UBZ3^X\^""^\_I^?GS?X3>?11:LNM\_MZC\$3IEK)N4/\_MY1SCW\_ZG\O6HD\Z\FU?7/AEH\_GA\I\_P+8VUPA2YGS  
<=1UKF+KXU>\_M\$((BT\_UWM^<(B\IK:Y&FSM;P\I);QY98\I6= MN@)XR3@<"O:OA\X+3P7X^?  
M(Z2WUPWF7\_B#C..1\I#G\57BWB7P)XF^174K\_M/4)^M\_P7\7:T:(>V\<19^I^>A?^\_XGS^<(KE=#UK;\_&AL)@N%&/P\_D;\_  
MS8YXX.#T\I\$?7<VT/5:\*\*\*\*T^O&/C9X\_I^R-2%-C%Z\_1WJ\H.Z+)^""G\VO\_MU\45S;0WEK+;7\$;R03(4D1APRD8(-  
J)Z\;QXW\O&6Y6\+7LG^YDLBQZCJR\_M?S8?^K^9^GC/^Q=%&AV4F+Z\_0^:5\@WWP\_|>7;R:@  
MBD^Q97^I\4WT7RKF.Q5AU\H\PY4^CZ^O:Z@L\I.WT^R@L\I6)8K>|!&B\I\_M%4#  
%3UHE9\$MW^BBBF\H\_>Z\>I^<(VLNQSLF\$2CT^%0\_I7T=X\_LET\_P5HMLH\_MQMLXB>/XBH8\_J37S-X^C;?C\_?Y3G)O9&YISG^M?  
42AZ59\_#E3+&C:JG^PQ\H^SCNRGL5%0%%>:SA1110\A^<O^D>^\_P^PE#\_Z\_?%?7E?Q?AK\_D>^\_..PE\_M#\_Z-?  
7E9TOR"@C(P>E%:~/CS68^HWPBK4+>W.PV5\I(D9^8Y\_E7U\_~RBXM\_MHIATD0\_/O&^1?%LPN?&>MS(=RR7\Y4CN\;\_%?  
6HE#1GL>#\_GG\$J?D\_5G#I\_M5(@UC6+^#0=+FU+4IQ\;PXWOM+=3@\_W\$A^\*VS\Y@^N^MH\3>^K7Q3H-Q\I^X\<\_O4\XB  
RE2^\_9X\5YW+I^9:0:S?(WJZ(P\_(-53OT\_M\$K=3E?^Q\_N\_&T0T^0+&Z2T=@7\_7=+<8Z#;N<+GG^>^\*ZW\X3\_#BZT^8Z\K;8  
MCO?C^6\N>6A\ZLWHO^&P)SUXY3O\H^&T^V74^&U\$7XA^=D1#M\_/\_H\I^I\_MP^04G@^XMZCI=  
I^#INOW^WFG^%Q^\*V9(C\RO^<OKGD=O2I6\_O#Z:T)10^D9\_M^2MB^3YD^\_HMK\2+YU&|^I%+CWV^I5KW\I?>\_  
J^@G1;ESEW\XPQ\2%)\_M5XA^N?^VOR?^#716\4INOY2/Z5\$2B8WL=A1115B^M BBB@\_HHHH \*\*\*\* "BBB@\_HHHH \*\*\*\*  
\_3^G)\_-Z\_X#\_T(5SWP+\_Y\$2X\_I^M^G\_!^70\_\$\$D6&M\_I^5X\^#/\^1RU?\_KT\_P\&+7OE:0V(EN0%%0%4(\*\*\*\* "BBB@\_HHHH  
\*\*\*\* "BB MB@\_HHHH \*\*\*\* "BBB@\_HHHH \*\*\*\* "BBB@\_HHHH \*\*\*\* "BBB@\_HHHH \*\*\*\* M "BBB@\_HHHH \*\*\*\* "BBB@\_HHHH \*\*\*\*  
"BBB@\_HHHH \*\*\*\* "BBB@\_HHHH M\*\*\*\* "BBB@\_HHHH \*\*\*\* "BBB@\_HHHH \*\*\*\* "BBB@\_HHHH \*\*\*\* "BBB@\_H\_MHHH \*\*\*\*  
"BBB@\_HHHH \*\*\*\* "BBB@\_HHHH \*\*\*\* "BBB@\_HHHH \*\*\*\* "BB MB@\_HHHH \*\*\*\* "BBB@\_HHHH \*\*\*\* "BBB@\_HHHH \*\*\*\*  
"BBB@\_"" X\C\_KFW\H0^/\_ (5UK\_KA^Z\$;100A^CON/^N:R^KQ#X\_1A760^N\$?\_M\_H1J7NAK8IVHHHJA\1110\_4444\_%%%%  
+1110\_4444\_%%%%+1110\_4444\_%%%%+1110\_M0\_4444\_>2\_?7LNA66B1A\_O+R3S90#\_P\_LTZ\_5B#\_~JKR00?AYXE\2Z8\_M-  
0TRR22V+E\I\$F2.N\_34\_Q+UM0\$7CZ^DB8O#\_PM(^-?^@=#\_X%1\_XT?^\*<|\_I\_M\_Z^\_~H\_P#&OINBGR(7.SX\_MWO\_  
C\KX>6.QWNFW0+QY\J>1GN#^H-775G\_M=PW\IE>6L^X9XUEC;U5AD^C7S\_|<="^P>\*K?5HTQ^J\$7SD#\_EHF^?I\_QTK^  
MM=|H|= \_M7P4+^1SZ:(8B#U\I\_A\_|0A\_P&E^1V&15WT445H(\*\*\*\*\_7Q=HB^<(O^FI:60^H\I)O\O?2\_G\_CP^?2\_PRUH^~I^J  
M@|I^13N;28^C\_?@9^C;3^>24U?+?Q0T0Z\X\_OA\$^D-RPNX2..ISDX^C\A^%1\_M/N;8\3X\I\_WON\_T^N\$^NIAGNBL25Y\I:=\*?4?  
3W\$;GL9TG^NWE3\_Z\$#^>B5#^>LKM\_M\_93V=S&)OXVCD\_0^PP1^HFKH2/GKX(ZY^IOC^73YQ^OZC#L3/\_I3E?TW  
M^#ZD5\I^UG^>O^NI^<O\$7EDRK\$>6DM>\_XIR^..C#C\H^VQ7^F\A3XX6;MK^;M>2\H\+E0%-W^FY\I4<@\_0\$23I4I=M&4U?  
4\@HKBV^+/@A8O\_..ML\$H\2Y\_M+;7GOC;XTG4;\*73O#D.T\$RP/OM\4^UB8=PF=Q^FXM^>?\_?#1WT+P+I5C^NV;RO-

E'<Y+\$'W&@>"%OO!O&&F6UY+?36DDP\$ZRVH5=GAV^@BDW?H<-I3YD%F6-IG;WO@'7(  
MfE%94LY)ESV=%+\*1^(-%)/?266/XF:2L1/ISS5<9KZY3\$RS^%=-12/BQ:-1MIDFB:\$LOV6;'VBYP7:74'.U1U-/&2<>F\*N?-P  
)3K=3>)KN(I%Y9AMP^3MJOYQ#^OD^E0I9;(<IMD02Q^&V=K\*5./>OD;1)#H'CFP:X.WI#J"46L%D  
M;-1KZIKYJ^/AF31&E;U"119:B?1P.1)&OUSW\_J<^XHGTK17E/@7XO:M/<:-V/B"Z-I?P(M-(I\*3#-;(SAL=  
<1^GI6QKWQ=|+Z38/97BZC=D?NX(M<\$\_f38P!^OM5Q?#"2+X;.\*LF=QB M9AGT+L1^A%?EA8ZM1O&KX!;YO93+/(  
=L\*=Sf\_#\_X'JOHQLX.L+>RMEV M06!2Q1KZ\*HP/T%3'5MC>UB>BBBK\$>)\_M\_P-H\$P'&)T)\_P"94:V\_@1-O!M!-  
Y\$3S'J#|>Q1/ZYJ3XY:2!;2!-VH<:TNT8GT5@5ZE;Y\_X WV)-TIFY(MBG09I- RM\_-:C18^AL:7D/QZTAYI&TS5HTR+65H9".RN  
03I97"-J|>JAK>D M6NO;+=Z7>J3!-?C7XH+S4-!F<\*UOBXMP3IY@\_M\_/KC!\_X"-ITKY(UK1=;!^!)5CE;D\$S\_F6URG-D/#\*?Z?  
@:1!-1/3H9(M?5M+;7(&#/?F^-?53I#-1&5M&4UW/7;\*X.XPQ^!H8?349IVQGRXI60-1M/F'ZUYUXJ^  
FIZJCF6@0/IT+!G8AIFMCA?PR?>JVM(HI-L M;CWH\*HP?PH<\_#P!#6A2\_N!^D(7RQ%-25A69Z/+ +!^!TSK'%&I9W8X"  
M@GL/QS76?"CX9W%M=1>(M=MS\$R/9VSCY@?^>C#MCL.O?L\*F  
MOF=D4M#U;PUI(T+PUINE\K;W1\*J"^-/F/XG)K4HK/UK6MA/:7+J6IS^3:Q MX#-M+);\_!R:T)-OE?  
XH\!E\*UK\_KHG\_HM;JL X7\*X\*P"@C-X'R?X5X-X MJU:SUSQKJ>I6\$ADM9W4QL5\*D@(<HZ'GJ#6'2%.C^\*K26YTBZ,Z1/LD  
M!1D\*GKT(0%6FB;&S7\$\$\_X@VW@S3\_"H=D^K3K^YA)X0?WWI00=-SQ>|>+5!M&^&7U%8A+<:7!50  
6C;\_#1^GBY@MH5VHBVQ\_\HDISWJY\_P+MJI\_//:1^!F5R?ASXC>?%1^3!N)CAN+M4;XSE2\_P#=#79)40:3PF4;J"%"9HI  
WY%WGC M;-O-TVD8-2G@V66'QMHP3PDB3!>ISURX!X@XKU7QW19-/N-(N-1F6:6X M0QO=LA144!;#X#@DXID#%#%#)  
(f=%4#)-35XC\;/&FIOX6L)!E7\$ ME\RGJ>JO\_P B?PIZ3=D"5SB-8U#4OB?X\_1+96-G<0VT;=(8ASD\_AEC^/M533  
M;W5/ASXYW2(1<64HCGBSQ+&>H^A&^#1#7K?P7!^?V5H|>(+R%W?+B\_,4AZ MY\_X%P?  
HIZU#|;-!WJH;-OB2RCSVX#-P^OR@\_C7JOPAU^+6?MUM;EP;K3OI^E7/(7^\_3"35SX>#|XO|\_F\*\_\*1M29+5B<GNAIC@?B!7  
MSWH&OZSX#|1-^COW\$1.5S;S@\_..ZL/Y&LWILKE;H^MJ^!UTGXV^@|VW4ZA|MIT^?C>KQ&1<^Q7)(^H%3;E!;O"-G"S6DUS?  
R?P!^PE#\_P"C17UY7QYHHY%I\_BFP09R1#;WL/H^\*^@/^%U>#\_1MGM>?^YJ(-J1Z'6)XMA0P>%#5YJDS^&C0B%3\_-(1V\_G^@-  
<1J/QUV/6\;M?8+^\*NY^\_Y12?T%-R M7021#X\$T:7Q'XYTZV(+IYXGN"?IBG&=/LY#IDLFI7>.(B1LB\_!3;!O|\_UXKHNDZK!0  
MO&14EGENIC-=S@<1(3IS>V.@T%1-WT121|+>#I99\_!6ARSDF1!"L2>OR#F MMNH|>".UMHK>%0D42!\$4=F  
P!4E;\$GS;1YA)!0Y\$!SY5K\$AINI\_K7M/PWA|MCX=-&A&V^\_+Z)/!^>OB%#MJOQ&UEX\_G)NO(4#OLP@Q\_WS7U'I=DNFZ19  
M6"8VVT'0C'HJ>?TJ(HMC>Q;HHHJO!1110 4444 %%%%1110 4444 %%%%M')\_S\_D&M\_J&^%/3G\_P#MfN\_  
\$1)7N5>&^%/3G\_/MfN\_|T1)43V'\$^FJ\* M\*\*R+/EOX&?I(Y;O\_P!>C?H;O|HKP/X&?CEJ\_7HW\_HQ;HK&Q\$MPHHH MJA!1110  
4444 %%%%1110 4444 %%%%1110 4444 %%%%1110 4444 %%%%1110 4444 %%%%1110 4444 %%%%1110 4444 %%%%1110 4444  
%%%%1110 M4444 %%%%1110 4444 %%%%1110 4444 %%%%1110 4444 %%%%11 M110 4444 %%%%1110 4444  
%%%%1110 4444 %%%%1110 4444 %%% M%1110 4444 %%%%1110 4444 %%%%1110 4444 %%%%1110 4444 M  
%%%%1110 4444 07G\_C?I^C^-&7 M3H9X&CE\$LR \$JV"-AZ@/@!67X\$^'\$/(>ZNfB+5)KLW\*!^C1A%&#G/4Y/^M-  
=O12LKW"YSOC3PE|XST/9)=26P699DDC4-A@\_0>H^8UO!?"#ZV|#+>F&^MENY+O8&+H\$A=V\_  
9-O'078T465fA<\*\*\*8!1110 5QWCKX>V7G<6CS74EI< M6VY5E1\_VY3C@@\_3CGN:f&BAJX'GG@WX3:?  
X2UH;J=0EO;A\$98@T814R.\$!3D\_MXR/Q->AT44DK %%%%, "GJ>DV&M6+V6I6D5U;OU21L44FDIPN>))@S|\_F?  
XD79V(LN3\_X\_Q^M=+H?P M5!-7\*D|ZT^I2J|<f9B%BS\_NCK|2\*|H|@\_MZ4^BBJ\_\*\*\*\*"O+(O@E!7B%=3&L7)1\_@7 A|I<|  
NONS\_2O4Z\*3287"H+VR MM=1LY;|@CGMY5VO^N585/I3|NU?X&>'KVH-.NKO3VA")8QI?F\_|M'TPO^&2I/  
Q\_PDB>7>^Q^Y;\_ZUI=14J^GFN@\_!3PYI4R3W|DVI2JQ|Z@^XJ13|=U+X!64LK/fMS6Z\$Y\$=O")\_?!"17^5,L/@#;I\*K;  
MAKTTL?"/VXC/\_T6;^5>RT5/\*AW9D>'\_SfA@\_R^RZ3P C8+OU>0^K M;\_3\_)Q6O115"\*\*\*BBB@#|3Z:NO!AC4=+8  
FX@94SV?JH\_!@#7SK|\*M4;1B5M+8!2B7);TEIX;6^ZA\_OL+7U!75!6#S^&3&YU'TfBMfX\_!H67C9#X\_-M+?#1%1N/  
=CZ5HK(!+;W'XC|;?JR8S<1N!"XX8?@P-;I6(SM9T+2\_\$ M%D;/5;\*\*\*ZA/O\_5/JI^C(N\*UU^X".3-(6T\_5fNU4\_P2OK;H/NG%>MT4FDP  
MN>,P?L\_VZOFX|12R+GI!:#^9&?#fJW%K9FXNU^|<71|QU/f|@\_M'W\_S7744\*\*0785P'BfX3Z5XMUIM5DO;FUN)\$59!&%96VC  
\_#T\_#KVKOZ^&K M@>0\_|\*TO\_H-WG\_?L;LV\_P\_!O#Z;IGU/4I<=0K(H/\_CIKU6BERH+LYK0?'A MGPYOM/TN,7  
Z3S\$R\_#Z@MG\_&^\*Z6BBJ\_\*O/%GAFV|6Z!+!U-)"CNKB2/&5 M\*G/O!\_VZ^/(!?^%1:7\_T&fS\_  
+!+1\_PH+2^@W>?|J^EKUZBIY4V>0\_|\*TO M\_H-WG\_?L;f7P3X'L\_!%G=06MU-0\_8P\_#ZG|ZZFBFHI!>G.^,O"% MIXTT9-  
/NY83!)DDBP2&\_YI\_Z2P&#N#\_%.1:7\_T&fS\_+!+7KU%#BF%SR'\_M(4%I?T&S\_  
fS\_OTM'\_@M+Z#>Y\_WZ6O7J\*7\*%NS@/!\_PIfIPCK@U6+4+FYE M6-HT6154#4|>W|ZfR6\*;)XI462-U\*LCC(8J".XH%  
\_\*P'FVM?!3PSJ4C2\_MV37&FR^&%M|>?|=G|B\*YI\_P!GZ3S!Y?B12F>2UER/\_^?TKVZBERH+L|L MT;X%Z%92K+J=f3&?J\_2?-JH-  
M;2WL;6\_UM(X(XOM2-0HJ8" MJ\*26P7"BBBF\_5Y0OP.L)=9\_?ZW=WBO.99(VB\_0DY(9L|^\_Y5ZO12;3W M'XU\$6-  
%1%"HHPJ@8\_!1+>DT3Q2HKONI5E89#\_!0=13\_!E?X\$V".GJfLM#D8;/\_UQ7K\*@(H!)8@8R>|+1222V"X4444P"N<|3>|M|6)G  
M4L?;+;W|P M'DM)\$5|29X\$ML)|\_!H0R\_P\_JEL?@\_M%IL);X7@;>DV\$<+;/\_?FD?ZL>\_M<>W2MNBBJ>47OP(T6XO9IH-  
4O(Y^+;+KJ|@?2H|!M\*SSK=YC\_KFM>O4 M5/\*@NSS&?I^ABWE^M%SJ-T|\_TJH^NUO?UKN-\$LZ+X MN(N?V?  
U+\$VOB(A<|+;9/YA\_Z5f512<4PNSOJ3\_@%812\*VHZY<7"<\$H!"(OP MR2WJH-T+PH/ANO^QZ39QVT1Y8CEG/JS'DGZUJ44)!  
<\*HZSJ\*1HEHJ4F\_MEK|Q|H03C|>E7J|J^7B|f#X&O|/T"?79X|3WYV19'(B4\_U;M/Y"O5:4%9#>X44450@HHHH \*\*\*\*"BBB@  
HHHH \*\*\*\*"BBB@#D\_B9\_R3C6\_M^N\_J"%%<H" ^1\$N/^PA)\_Z!70\_\$S\_DG&M\_JFT4450@HHHH \*\*\*\*"BBB@ HHHH \*\*\*\*"BBB@  
HHHH \*\*\*\*"BBB M@ HHHH \*\*\*\*"BBB@ HHHH \*\*\*\*"BBB@ HHHH \*\*\*\*"BBB@ HHHH \*\*\*\*"BBB@ HHHH \*\*\*\*"BBB@ HHHH  
HHHH \*\*\*\*"BBB@ HHHH \*\*\*\*"BBB@ HHHH \*\*\*\*"BBB@ HHHH \*\*\*\*"BBB@ HHHH \*\*\*\*"BBB@ HHHH \*\*\*\*"BBB@ HH  
HHH \*\*\*\*"BBB@ HHHH \*\*\*\*"BBB@ HHHH \*\*\*\*"BBB@ HHHH \*\*\*\*"BBB M@ HHHH \*\*\*\*"BBB@ HHHH \*\*\*\*"BBB@ HHHH  
\*\*\*\*"BBB@ HHHH \*|\_\*M?AG/P#;W=^B)\*JRKPWPI\_R<|\_!O=W\_P"B)\*B>PXGTU11619\_M\_S\_D^5M#8B6X44450@HHHH  
\*\*\*\*"BBB@ HHHH \*\*M\*\*"BBB@ HHHH \*\*\*\*"BBB@ HHHH \*\*\*\*"BBB@ HHHH \*\*\*\*"BBB@ HHH MH \*\*\*\*"BBB@ HHHH \*\*\*\*  
"BBB@ HHHH \*\*\*\*"BBB@ HHHH \*\*\*\*"BBB@ M HHHH \*\*\*\*"BBB@ HHHH \*\*\*\*"BBB@ HHHH \*\*\*\*"BBB@ HHHH \*\*\*\*"  
M BBB@ HHHH \*\*\*\*"BBB@ HHHH \*\*\*\*"BBB@ HHHH \*\*\*\*"BBB@ HHHH \*\*\*\*"BBB@ HHHH \*\*\*\*"BBB@ HHHH \*\*\*\*  
"BBB@ HHHH \*\*\*\*(+S\_CQN/^MN;?RKQ#X\_|5UK\_KA'P^A&O;fS\_CQNA\_KFW|J0^/A R%=;\_P"N\$?|\_MZ\$;E!H-V|=J\*\*\*H04444  
%%%%1110 4444 %%%%1110 4444 %%%%1110 4444 %%%%1110 4444 %%%%1110 4444 %%%%1110 4444 %%%%1110 4444  
M%1110 4444 %%%%1110 4444 %%%%1110 4444 %%%%1110 4444 M %%%%1110 4444 %%%%1110 4444 %%%%1110 4444  
!117#^@OBMX>|\_V^DW4=|\_M/<1?;-M&K^A(!P26";\_F:3=@.XHI%<@;|&1G!TP"BBB@ HHHH \*\*\*\* M "BBB@ HHHH \*\*\*\*  
"BBB@ HHHH \*\*\*\*"BBB@ HHHH \*\*\*\*"BBB@ HHHH M\*\*\*\*"BBB@ HHHH \*\*\*\*"BBB@ HHHH \*\*\*\*"BBB@ HHHH \*\*\*\*"BBB@  
HHKG/%WC33O!>L;W\_M!07fO\_M\_\$25fE7AOA3\_DY\_MfN\_P#T1)43V'\$^fJ\*\*\*R+/EOX&?ACEJ\_|UZ\_-Z\_6O M?#|^!G\_-".6K\_|  
7HW\_\*6O?^VAL1+>\*\*\*\*\*H04444 %%%%1110 4444 M %%%%1110 4444 %%%%1110 4444 %%%%1110 4444 %%%%1110 4444  
4 M444 %%%%1110 4444 %%%%1110 4444 %%%%1110 4444 %%%%1110 4444 %%%%11 M10 4444 %%%%1110 4444 %%%%1110 4444  
%%%%1110 4444 %%%%1110 4444 %%%%1110 4444 %%%%1110 4444 %%%%1110 4444 M %%%%1110 4444  
%%%%1110 4444 %%%%1110 4444 %%%%1110 4444 %%%%1110 4444 %%%%1110 4444 M %%%%1110 4444  
%%%%1110 4444 %%%%1110 4444 %%%%1110 4444 %%%%1110 4444 %%%%1110 4444 %%%%1110 4444 %%%%1110 4444  
M>;\_KPEX>\_LV98M1NY=D3E0VQ&68\_Y!T\*P MM8U^G;G5OOR=O\_-F3LALC="^+GBFTUFTDU'5&N;'S5\$Q\$|\*|/Q=J=F  
MIU^E!VMP|\_(MO^&OIODEE)R<5D^XH?\$(#U);\_KJAA^<(K|!\_!CWK\_/V\$M\_|T\_U!O\_ZBA\_W1\_\*LU=O\_6M\_P  
0>%M13V+VVIv<7;Z=;Z\$U=8T^PU)5VBZMTFV\_W2R@D?A7S%1=#+AWQW!M&f2&23HfCC^OS\_MQ!#D?  
A3DWNA(^K\*\*P\_!^MCQ%X2TW4fV9)H0)?^NB\_\*\_-(#6Y5B'O/BY|O M=7T+7+72=\$O?LS)#YMPRHK\$ECV\_|\_#C

[illegible]

<8'7L\*^JO^\$T' H'"; X") A7C(\$ MOP9IMYX&OI-/TRT@NK0"Y1H(%1B%^\,@?W2W"J!3<7;<\$T!?:7?I5%?8)'  
MS/HLABY/EMR' T(? :!KJY^#>?V1XXCM)'Q!J\*W9/3?U0\_7(Q\_P\_"MKZ5JHNZ\$!SY&L;|CWK\_/V\$)|T.UH!%\_!H1(OAO.D  
G\_2#7A?C?\_D>I M?\_!\$^Z&^MH?H!\_NC^53%)MC9R6F\_"FP=IDHECT>.:0=&N7:4?\_?+"MZ5UZHJ(\$10HJ\_8  
%+16EK\$A1110H02%?\_0\_P"P\_ML3;!>XNXO^!2>\_)  
M'@WZ5!\_X\*UY=>|%:=JDD@|PPI9V)Z.GRL3Z<@G!\_XOXZ:%|L!6NL1KF2QEV M2\$#\_)90@?HP7\57G?  
A7Q!=\$^'OB31C(1/4UW;20"3&=I92N?P MS7AO\_"A->\_Z"NF\_/\_|Q\_?0%4XHB3L?/\_/PH770^@KIOYO!\_\$UZM/\_ M K<>#\_#  
(TRZN8IB4S'6C!VC;!@9^GZUU5%)12!NX45G6VO:3>:G<::Z&: MR7UN<2VX<:U/T!\_A6C5\_%?\_GQIT^"Q!2M)\_H7!7!><2?  
WLL!X!0?QKZ\_OV+ MVUT^TDNKRXB!>\_9>25@J!J/\_6"/\_B\_?2%WC.YOK56:W^6"V&WYF5><?Y). M/\_HGL)HK\B2?  
X::YA!)M!8U!(V+P/PKN:Y\_P.\$(AWP9HFF2C\$T46\_MZ4>CL25#!\_Q'X5<10^A\_Z/!>I2!H(4X51Z1NRJ\_Y\_4M\$+J1^?)\$NG>%=  
M'DU'49=J+Q^OWY6!^HJ?Y5J33>/(BOXR 51ZD\_#^1U\_M'Q!5!/%<4<9+;2L\$)|NVCSR2?YMW\_(5H!>#?|VG^#='6SM0)+A!<  
<7)&E M;^@'8=OKDU'Q>A6Q9!>+&:'PGH<\_F6\*Y"-+\*1A17/5C\_G@8%:5%:%\$A115+ M5!3M!T>|U\*Z.(;)H&|H#H<|/QH  
!3^\_GB3!5JMKX>@?\_=H!/<\_K(P^4'\_MZ\*<\_|"KJ?@EX;\_LWPQ+K\$Z8N\_1;Y.GD1+P/S.3!C%>+6\_0?>\_&L<3L3=;E= M%t&|  
(RQ^BKG!7UG:6L\_C906EN@2""\_8XU'90\_5G'5W\*>BL34445H2%:%M%\_RQ!4XO^\*)6M\*>|B\_<^G^M?  
2/A:7S\_"BR\_WI"!OSC4UX!>|!\$VGQ!>XQ\_MQ=VTT?#6!%\_P##K1)<\_W\_MY7<+;|YBOKM4G'Z5!GV.L6MUXO76?\$.37<33F>XCB  
Z>H7DX'YP;+G?6US\_M;Q?>K\_3IOAF0QNI\_B4C!Y5P!\_W@XDG+L>PN#523>P)V\_O\_A76@\_J K4Q  
MRC^\*K%6\_&+1'\$A74)M!OHY:F.(KR!\_H.0><\_!5UW\_"E2!\_#QO/\_@MU@^\_  
/A7X8T/P=J>IV45R+FWB#1EYR1G\*+7PAXG\_M2|@FF MB!AX!D\_-V3CU(!\*|H&\_\$?2\_&MY?#3P MY!\_BCO:-.U\_9&M\_LIR8C?;!--"  
(S3S:5!(LLZA>20N=HYP/ M3FE"XY6.DHHHK0D^0\_"\_M')Z/\_KOC\_|0GKU!X7?DUT7\_KD\_P#Z;\_H7Q;\_V.OHHHJQ'R-  
X4\_P"1\_P!#\_M\_P"PH\_Z-6OKFOD;P!\_R/^A\_I A2#\_P!&K7US40V"(1E#\*58\_@CH!UR\_%SP\_MH;^'O&K"QA\$-  
M>0K<+&HPJ;20P'H.KG^O7TM<7\_%!O<7\_T<\_8R!DC!54>I M)Z5!P\_%#Q3;^\*O%FW%D2UG;1BWB?M(  
22PIB2<>P\$!@B>U\_"75Y!7^!UFUR MY>TV<=>I"=)2!^@97QT\_Y?2W\_P"PA'\_Z!)6L;=&ET/P#IUO<+MGE4W# MKC!&Y  
/OMQ6#)=/^1\$M\_P#L(1\_@24W!(=3\_9!\_P"9B\_J=>O:\_M>V5XG^!T\_P\$S%\_VI?  
^U;\_JLHAL#W.CO+X>LO\$VAW.FWL2;)\$/EN1S&^\_&H\$&OEKPMJES MX?|\_%NGWL3.DD-PJR+ZJ3AE/U! (KZ:8^+|A(Z--  
=7,R&Z\*!|;\_AOE;H;# MTSU\_2\_0@?2)\_.\$C?3+106!N%FF8!X13N8G!VCZD5;|T.)!4445H2%(S!5+\_M0%  
R23P!2UY3!9O&G!E:4/#UC+B!O4S<\_IYCAZ8^K=/\_IGU%)NR!\_D7CG4'\_7\_M&V!7FD6^VVDD)78!80F?^N0374\_!+6=/\_TWQ9-  
\_7<2+<7T8BM!@\_PL#DI\_MP+C!5!UO\_!P8ICE!37!((8-#9JXSQT= \_YJ/^!5P\_Q%!\*2^\_!%I-IOCLIV^MT6!7Y'U'17)\_#SQ>GB\_P  
\_Q7+LHOX;17;#^\_CAL>C# MGIOYKK^U3N0%#%EE2&!)Y97!1H!9F8X Y)\_#Z#HZ5K.FZY;\_:=+OH+N'H6 MB?\_T^A'4'V-7J\_&R!H-  
\$!%&F^%-(EOK^%#8\*2)AW?/\_W95!>U?..@Z9=>\_3&5O?D%I+V MY;D|^#^2=SM^6:SGV\*B?6EM(TUI#\*PPSHK\$>Y%2T@'\_  
'2EK0DX\_XO\_P#)\_M\_M4\_WH?\_\$E>\_/\_D<=0\_!H?^C\$KTKXO\_/\_M4\_WH?|\_T.E>\_/\_D<=M0\_!H?|\_HQ^S?Q(V/H.JFJ7HTW2+V\_?  
|A:0;5!>JDX\_2K=17\_0%=\_VLUM.F M^&9#&ZG^!)2,\$?E6@CY!>8M;KQ>NL^ (TFNXFG;|Q'\$!FO!00)P%\$S@8!\_!ID\_  
MX7UH/\_0^U+!H\_P#XJM0\_+P<23Y%V/87!H\_X4KX/\_P">\_Y\_X\$<I(GZ;16\_M\_&+1\_\$'A74)\_M!OHY:F.(KR!\_H.0><\_!5P?  
P^!46OA^Q^A\_VI>033!>0!>R M^R!Q)QZD>E>F>\_/\_A7X8T/P=J>IV45R+FWB#1EYR1GX\*UCW7\_P!1!+;WES:65M=6!T\$8D(G"X9G-  
=6BOU)9XQ!2Y\_W^A!7W\_M8H\_K\_A75?^+R\_#M\_STO9&\_11\_2N!\_M!Y\_C2UM5/RVUFN1\_M,\$S\_!MKU  
M3X4V!L/AQI2L;\_KSG\_@3\$C\_:=O4KXA08!\_BBBK\$%\$%\$%\_!1110\_4444\_%%\$%\_!\_SS\_)QK?|\_UP'\_\*%YIX%\_P#(B7'  
&\$)/\_0(ZZ'XF?|\_)-\_P"N\_M\_|0A7/?\_O\_)\_2X!\_!\$G\_H\$=3!H?0!\_HHHJA!1110\_4444\_%%\$%\_!1110\_M4444\_%%\$%\_!1110\_4444  
%%\$%\_!1110\_4444\_%%\$%\_!1110\_4444\_%%\$%\_!1\_M110\_4444\_%%\$%\_!1110\_4444\_%%\$%\_!1110\_4444\_%%\$%\_!1110\_4444\_%%\$%  
M%\_!1110\_4444\_%%\$%\_!16)\_PE\_AW^U\_!\*\_MBT^W^9Y7D>8\_V\_-OUSOCUK;H\_M\_\*\*\*\*\_""BBB@\_HHHH\_\*\*\*\*\_""BBB@\_HHHH\_\*\*\*\*  
""BBB@\_HHHH\_\*\*\*\*\_""BBB@\_HHHH\_\*\*\*\*\_""BBB@\_HHHH\_\*\*\*\*\_""BBB@\_HHHH\_\*\*\*\*\_""B\_MBB@\_HHHH\_\*\*\*\*  
""BBL6H!7^M/U'\_\$S;6+2&|\_3R\_\$!@\_'TZCKZT;5%\$%\_M\_!1110\_4444\_%%\$%\_!1110\_4444\_%%\$%\_!17AOA3\_)??  
\_P"WNI\_!\$25!E7AO\_MA3\_DY\_|>|>|O\_P!\$25\$!AO/HBBBLBSY;^!G\_(Y:O\_UZ\_-Z\_60?^!#^!G\_(Y\_M:O!>C?  
^C%KWRMH;\$2W"BBJH!>V^FZ?<7UU((!>WC:61CV4#)JA%;6M=TSP\_M!H7VJW<=M\_.6ZL?10.2?85Y+K'Q!Q\*4T71PR\_!2W;\_  
\_A\_N+T\_0!/\$WB+\_M5?B!X!4!LC^9Y5E\*>\$!\_/3)XR?Z"O80"2P\_T32K2;\_6XA!^\_0&97)U\_^M@4?>^IZ^@J+M!#LEN<1!>?  
\$@DS+INE;GHJ2?SWG^5=EX<^\_VBZLEOJH!\_MF2L0!^7!R+/N<K^6/>NPE!>\$YH?;PH@7&L\_K?F#7GGBI'X^VD3W?A  
M>5HIAS!BG?\*\_!QY!\_WL\_446D@T!8D=9\$5T8,C#\*LIR"/44ZL7PAH!WI7A#2\_M;"^&+JWMD21=P;:0.F1P<=/\_2MJK\$%\$%\$%  
\_!1110\_4444\_%%\$%\_!1110\_4444\_M\_%%\$%\_!1110\_4444\_%%\$%\_!1110\_C4#2\_M;"^&+JWMD21=P;:0.F1P<=/\_2MJK\$%\$%\$%  
M&Q^5<|!1CCX>\_YC\_)HC\_5X!|"C\_P\_5W<\_!@^3\_#CJ6!P6T/HFBBB!\*\_M\*\*\*\_/\_?B#|4Y!VM1:7...!\_  
(N|S1+&>XEA)>22%2S'<>IK;L!5\_M!8Y6V^!X8"ZV/QL.YBN2OZ%37H?A+XBZ%XP)@LY7@00,FUN\_Y'JT'##Z<^  
MH%0ZG!\*\_!^!6!Q\_V2EJYSMEMF\*\_H0\_A^A!%?/OB?0+\_#>\*WLOM#^6\$K+\_M7;?REF\_A8>AX(^H\_#2.#+(F!8J@=|TR  
M=PZ^E=%X(!1?)3X2L=48!9V4L.H!2\*^\_!Z\_0U;\_P\_S!B>S2UU>S6XC1MR  
M?\_RLA!05(6!5H2<3!)0'6K>+A!5M!JWE22VH1TFC3;D\_D\$%#CL;?C7IE8\_A\_MPKHOA:WDAT>R6W64@R-N9FYXZ?|\_D3M/\_P"P  
M\_@O\_Z!>JOP"Y>L?H?>^@U'VA!#U+5;TZ;HH!Z!\_M;R3!/VU2\*+KQ18PWCVTMI\_MH\_-YM  
LH!STR9H!0NDWRRH<^\*+IP>S\_0?H\_745YQ!\_?AQ\_XSG>|O!)\_M+?286VM(OWI6!JN>G'4\_Y\$.309#2ZLV;CX!^TA\_  
MI>FHG@2B1SCZAE\_E5O\_M3?C!+>(|FBVB!JUK(R\$>^&W9^F17HCV/!\_.GPK'%X?L9\_/XKB(3;?Q?\_4\_M-  
\_!^%A+6(&5=-60F\_AEL\_P!V!\_P!H\_\*BTNX7!K>^&6B^+K5IM+N=TB#|Y!\_M<LD?U'HC(K?KR/P)!>9!^/Y+J26;?  
2\_LSHMPC!2^2\_R9R#QGN..M>N5\_M2O;43"BBBF\_4444\_%%\$%\_!1110\_4444\_%%\$%\_!17S!9V)^\_UR"20((@\_IOEK  
MZ6KYH^\_W)\_!HK\_KA\_\$43V"!<Z!%;6"Z"6!);GPOUS\_M(>|\$^\_M+)\_!%@(9!5V/^TC.Q7<98G\_Z/2N@H26H;\*\*\*\*8!7R=|0G8  
M\_\$7&+^<+ML/(QTKZOKY^!<7\_)0==\_Z^WPI^M?B25!1S^A7;.\*23(2!41!MH\_E3ZL04444\_%%\$%\_!P52S!0.DD!  
5#;WMK=EA;7\_07KY<@;'Y5SWQ&/\_MAYKF/^?8\_P\_Q7CWP^A\_Q7=S\_P!@^3\_T\_L!L!;0^B\_\*\*\*H\_HHHH\_\*\*\*\*\_""MBBB@\_HHHH  
\*\*\*\*\_+S\_CQN/^N;?RKQ#X\_|\_5UK\_KA'\_P"A&O;S\_CQN!MKFW!J0^\_A\_R%=\_P"N\$?|\_Z\$;E!H:V=j\*\*\*H04444\_%%\$%\_!1110  
4444\_M\_%%\$%\_!1110\_4444\_%%\$%\_!379EC9E70)=7?F7YQ;\_0!T<8^9HV/\_UP0\_/!>=J6>J;9\_S9\_"O\$+?P)XZM-WV;2-2AW?  
>|MMN?K@U!44\_-!HIV/E!\_A\$?B+\_SXZO\_MW!/\_\_52IX1^!V!>=MGK;/\_HX^X!H^H\*7(@YB\_2+!&LK!H\_H\$=SCFLKQ  
M+X7TOQ7L6;PI;EZORKP!>JGM\_!ZV;\*\_L!Z>@(|XBTV9WTHQ;G;=5VL(Y\_M/\_=6.#^!/\_TK#2R^!<ND1>3#XFM85XVP^>J#-  
+YXKZGHJ\_1#YCY8A3Q\_P"CM952YTW6KAL^&+J?7\_A\_KNO!\_P4OK74!74M=O(8Q;RK^MKAY8J<@\_W0#(I  
M9^HKVVBAB007?!?PQJWA\_3=4GU6UDM6NY(Q%\*-A\_V2!VSN!^E^-.GZ\_K&GZ98;3I\_MUS=VWF+\_.8%W88  
!00.>A:O4Z\*.72P7UN>?;!SPC>^!\_O;S5+5K;|O)\_%C?\_M&Y8U^&?3))X!A7I=%%"5E8\_IKHL;1NH9&!#>A!H4ZBF!OZGV?  
%6B>|A\_M!FDWLL=O<H6XB3<"H\_\*D=^E?35K)+9PR3Q>5;\_!L!><|&(Y^X&H^E!#\_M=SYH7>|!%\_YXWU>6VT.  
|EBN+R62\*1!RC\*\$S@|N@X!\_!E8U\_Q(OIZ@\_&G44U&MP-W"BBBF\_4444\_4;\_TN+6!#OM,FQ!NH6BS=)!\_X/X5!NR\_#SQ=#<-?  
#!M!S^WY3J!&^\*^L\_\$E%N\_.OR?PX!\_R>\_%!E!97;82!D)GN5R^AV!<44A1^M%=9115+004444\_%%\$%\_!A^CSX4^!\_!\$MIK6C".  
|BN9C,(TD?20L>3UP#\*SZ/\_MM7\_BY^\*^&E#R\_#^E15^4;DE>?H"01^523M!6R#N?+K>&B?XJ!E!+RSUFY^G^F\_M\_9D1<IOYA  
'X5Z?X!^\$7A^!CU76Y8KJ\_C\_Z&&F.( \_WB2/F8?D/?@CU.BFH\_M!<^J^\_AK7/\$\$6CG2;\_6!C@\_OFI&1D%MNTX\_|\_P">|T4VKJPD?  
^UOX#\_!M16KQH(TN9-V7R>0\_G"7!^!7HJ!\_@\_MN%>\_&\_WU!4?#H!>C;=Y;!=Q\_7!52!S@DY\_X"#!HIM70CR#X.>|\_M+\_1KN!UK6;)  
!6;\_H/\_QKU^BBA\*RI'NX4444P"BBB@#Q\$X!Z\_MTGZ7K;8R(7\_WE^CZ!6BBBK\$%<|X!T^ZU7P.  
JUE90F\_YEAPD;!6(!\_!^5=%10!X!|\_M(O">OZ3XS!\_J.DW5K;K;2(9)DVC)(P!GK7N!%)^\*P-W;?Q5!4OA74X!+C4  
M&MV\$!C;\_V!8!CZ>I?O\_"/?\$\_|YY!\_P"!+!\_O5?35%)QN"=CY7N\_OCN\_M\_F!ZTC4KB7&W?\_V!>F2;LV\_A7XD6D"P6UIK4;\_  
<+!\_RJOT\_0!BER(2\_M>5?2"3&C-J.HGO?%IO6T;)2+6!E+/\_GJH!\_Y\_"O5;\*\*\*P?F?+EW!\_O&=AJ  
MLGD;1=T4H;\_>|@0<!(92#QV/J\*\_L\_P#"/?\$\_\_GEKW\_@2\_P#|57TU14B'S'S\_M)\_PKSXAZRZBZLKR0^\*|NEP/^!FS^E>@>^"O@O#I-  
Y%|B">|!GB8^\_Q\_F(\$M="Q(!;Z8\_!M>MT4U!|<^X;XK^!M!12>#1\_Z7!Y!S#!F|ZZD\_#-!>?PK!F374T4U%(&|A1115"  
(+V;6WL+B>\_!KB;)G\_M2%3@R;|D\*/J>^\*^<\_?P+XO!8^\_3VKG;C:(TS\_MZ'H?KGM73T4H\_?P!P!?  
QGX4!8P;=!OA;3L(+L\_F\$V\$>ST^7K^8!U!#444D\_MK\_W<\*K\_A;+J&FW5DS%5N(7B+\_9P&!&?UJS13^\_K\_P"%\_C?  
PU>+&XTV;6<)|V\_MXT^8A!73(8'Z\_U7\_+1^\*\_.BW)!3\_MT^0S;C!^!FO!VBYH.P^8^8K/X=>\_0%M\_Z)!VUND9!K64Y"!  
HV7Y5LX\$^<VG^\*^K!F!OM.HS^!+)\_Z!U!2!HFT@;T\_2M\_NW+?P\_#\_ST!KVRBDXZW"^@4444P"BBB@#G?FGW6J^  
M!M6LK\*\$S7;L\_\$C7JQ!|P!RKRKX!>|?TGQF;W4)=NK6W6VD0R3)M&21@#/6O\_M=Z\*35W<+A116^XPUU?#7A34-4)'F11\$1

!Y#PH\_C)TP/G#OM=R>) B3!V M8;VGNQ:P =&VXC7UQG!^H=L8!TNTL(O!7:0!^OT50! \*OG?X^WUGQJ  
MNHR@M;Z:~)X\_"/AFXU5XA-(H6.&(MC>|@9^F3!7E M%E)|>|2^VOB|TBS^REP^HF#JN>2.D@G%QXU|S|3L-"B?Y+=#<3?  
WVX4W" M@\_@5<XE!)7?A!1!OY=V-3M3\*P(^ZV!0W/C\_K\_6N!T^P3X7N!/FES3:|HRR6 MD3N!0\*2Q\* DFJ^L\_"/PGJMT<%@-  
/N,2);1M,N!"/U!Q!2M+N&K&H%&B M>.(;&3)V\$!8S);3#.(@!<=Q!@D5074DL5!-)##%YLFHLR1YQO8#@9!Z^2;J5 M?  
WBV2%)C#J&GS?+(AX8=0?=6!|Z@|U!4^!7CU!P\_8;K&-JW4\*R%?IK8Y^MX('G&5P;L>2:~)<Z!U^TL!2TRTBM)YEB>2-  
F#1HC)R2#C/>VU!J\_\$K0 MO^\$?1=ZA;HNV"=OM,/M?G ^C;A^%?17@C6\_&\$A!&Z9J);=\*(28\_P#31?E; MH03^\*+=  
L&CH\*\*\*\*L1P7Q)^(4G@B\*RBM+6&YN|K+OB9H/A)VM!9 M&O-0^6U@07\_!ST7Z=2;JWQ3!;MX2T!8;J!N!WV4@;KY;C&Y\_KR  
/<^U>\*^ M!O!%|X|UB5D)GCLXCONK!OF8D!X>>K^GZ=3Z\$E+6R!+|SJ+WX|ZW)(WV^2;" M".!L7E8?B"H\_2H+;X|^)(V7!18:9.@/  
(W5C^XCI^J3P^=E!8R/L!S!0S\_ M^H6ZA6!KZ!#|H!U!O&O&LV!6!GAS4)6DFMH\_M9'.28Q@%#1;C^M!%\*)WLP:  
MZH|=HHHJQ^\$A5+0\_23VKQ+7/GM<0;K!>|IMK+1N42=F)E\_B\_&JZ M^XR>./!\$T  
+:28OM14AR#S^#T)\_X%|W\_OJO!GPF!A|H/\$=T!6:|OTAMU/ M&(MDA+?B0,>R^!1\*3V0TNY|E|\_?|QXXAU\_75C%;2V?EY:~)R5?2  
N^!C9ZGK M7=UXG^S|\_P S%\_ V!^?^U;|L!Q=T)!A!116%XP!2P>\$\_#5UJDVU!%&R",6\_ %DA M^Z/ZGV!J@..!2\_ %G\_A%=8\_L63;.&  
!N40-!KD+&3R%P;IQ@!>XJEX&^+M\_XG M!46NC7NF6T8N=^V6%V&W;C-R#G/W<=1UKS3PYX>NO%B>(?!U!G>&RL|BYDE/  
M62>+/"DFEV;L4<|31N\*%Q^X!YS@|Z!U;LDX;7?CS:PR M!%H>EM< <"XN6V\*?H@Y(^!TKFO^%|>\*/-W?8!^V?W!)DQ^>\_<  
>@>|/QX=S T M%67U16U2!Q!OD)6)3\_LJ/ZD\_A7!W7P^!)7=L8^V^~01NAA\$;#/\_TN#46DQ MW1R/A/XU;=K-  
W^8ZQ;C3Y#M2F/NA8^AY7H!B04Z^5B%X/X\_ X0SQ(;\*\*H M^\_9!+;N^~VWH0<=P0?TKW^X5-W-  
KG@&RDN6+SVQ;V=SU;|T\_7:5HBW>S!KJ M=H115B^L/Q?KZ>&/"U!JK\$;XH0J?XI#PH\_ \_EFMRO%/CWK?&EZ%&WK=S#|  
MU3\_V>E)V0(Y|X:~)KOC>35KK;D=@#;|SNF;(7/O!YQJ M^1E>=\_!2/!L!  
M!~N)+^9YCGKM^RK\_P"@D\_C7HE\*\*LAO<|V^(<Q!D!&ZQ#IEKHJ74SPB9Y)" MJH^2-O&X\_P#X7J|G\_0\$!\_P#OZU9?QQ\_YZ/  
\*!8\_P#T)Z!\$^!7A#PYJ\_M|@/2;N!T2QN+B2-B!LD(9F^=AR?PJ;MNR!8Y>V^/!P&^VKP\_\$XIF\*Y\*\_H5-M>A^\$OB/H/B|\_LH(O!0?9-  
K<|B;Y4CAOPIYJCU+X6>#|2MWC\_LB.V=LXEMF M;\_?74=OP((KY|!5^)/P\_X!R!T/OCV\$6U\$&A92?E88Z\$\$\$44-RCN&C/K2  
MH+VJMM;L!KR!G2^VA4O)(Y P%#8/@Q&\_BCP=9;C;1HP8K Q^Q^!)@\_C!7 MG^QZUR='TS0HW^PNANI@/X^=J?  
EAOT!\*MNRN3;4F!0\_>\*&9H?#VG"=5X^T7 M>55OH@P.V\_A%|M^U!1O!UBV2 M;DK);PR#..A>"Q^1B3D8/%>JS^\$O#EQ  
(9=|TQHP\_?94&WZ<MQ MZ(XOP?|&30\$6H0:9?V;Y%|P2)@V^~V/09XO|<ZUZ97F!\_!S1K?Q-IV!  
M;3<2V2VMS^!H09\$;P\_"DG^\*CWKTB|J5^HG;H M5#2;515QDGGC;H;XG3\_C!^!%U^0XQ\_3AG@F.Y1Z@\$<\_F^C^/\_/Q\_:%\_U  
/MSF\_FE>|K^7XE;#>2VDQ!^"5D/\_\*%<0J)2=|DE8^L!6YAO;2&ZMW\$ M\$D\$R+)&XZ;I&0?RJ6O-  
@|X@\_M3P@VF2OFXTU|@R>3\$V2!\_E/;=T2PH MHKD/B7XB\_PW\$<|\$7L!;|JX^V;#UW;#DCZ+N/X^F!\_.\*!0\_';6.KW%|H.EQ7  
M;\$+E|M\$|L!D(X)\_Z9Z^=|\_OB4\_C|N!^YT!6X@C\$JMK&Y967;#U^!&1Z  
MYKPO20#YNO!VOZ!^TNS\$;4)!9^D7/Y+G\_OH5VOP\$\_Y&K40^O+\_V=;S4G^+!2-8|\_+;-8F+/W0 M!AL?7A\_2N@^\_VO?9M%L=#B?  
#W470A\*XL\_6F^!6W M;+NYDB\*XX50/DXE9/TK;3=|DCZGTG4H-8TBSU^V/|FZA65!W&1G!HQTJY7 MEGP-UW!^X7N-  
(D;NGRY0^GF^2/R8-^8KU.K3NB6%#%#; HHHH \*\*\*\*"BB MB@ HHHH \*X+Q9!6-!;3;L;M!OD)#PP\_L9!&?H#|!#)|<5F\_%  
!QW+X>T^1 MM.F;H>HWB;GE4X;6<9^H200#V\_/M7F?P!^!5QXTNGN|J!X^A;\_\*OWY6Z!5 MS!>3VS4.3O9#2ZLV!6X!\_!TA-  
K!6FG)6<2B!SCZAE;E5O3?CY?K|HFBVTJ^ MJUKT9^OAMV7S>G6^PH(Z="L<6@64@!50&)FXOFJ6L "KPEK\$#(-2QE  
M/W9;/V5\_#H\_!\$46EW^Z-3POXTT7Q?;~)H=R3\*^S);RC;(GU^<>XR^TM9U/\_M!M\$OM3E0NE!|Q0^!;..?|(@Z!\_P!>\_O^Z^;..M|H!F  
X\_~D7)30!0+G@&9B0/KBA/CJ M08;1#M^O<^9@?SQ7)?^O3K/5?^UE;7!K%C>)/&>@^  
M^HMVEWR^!EK= \_EE7ZJ>H!QD5SFM?|OPH<+\_8|>33;@CY9(^+##J|Q(O!#% M>^<(^?VM\_#\_O%&DDKQ2H?M;N  
D!P\_X/8^H\_H>7>2W^9\_<L!^XKX;>-QXRT\$ MFXPN!6F\$N5\_P&ST<#T;#^<(^M7;U;=O^G\_B!XMXZ!X8NI+&~!H0XSM>~)@H!G  
MT9>?78 ^<^!|NOCOXCD<\_9M/TV!VY^=A^X#!ZW2O@I9-K%WJ^B|^!XLL! MR!V!)\*\*06)&|N!\_PQ!37?V\_A/P!P&^#0M-2.C##  
LAW?7Y\_&HM)CT(^C^\*M^>|H;HUC2;6\$G!T+!P^KAB0?S>R2%KNG>(!^BU+3)O;R<=..K#JKK!11 M7D7Q>^VEZ9!0(!;~)  
ES!&.(0W\_9!T7G\_P;\_SSO@1JLL^B;^TLL?(N M;8R!>P="|F/Z4)M.S!H6NCZ\_KP;X!>^OLVK66OPIB.Z7R)R!\_RT4?^3!E> M/^  
5!S7(?\$|2/!8^~VJ!^NZ6!/M;?L4^8\_|CNX?C3DKH2W#X;^)/^\$F!%VD  
MK|KNW^V>XR>2R@8;1@\_4FNOKY\_!6M\_9/\$EY!\$C8C08=|8/\_!L>|^EOR MKZ HB|H^N%#%#4\_4444 %%%#!1110\_4444  
%%%%!7AOA3\_~)?\_P^WN!\_!M\$25!E7AOA3\_DY\_|!>|O\_P!\$25\$!AO/HBBBLBSY;^!G\_(Y;O\_UZ-Z;6O?\*M!#^!G\_(Y;O!|>C?  
^C%KWRM\$;2W^!O\_OCAJIV^@R&PB^ M\_2DW6@Q=E2=OS^\*^E\$M@6Y1^!AQWFO7VL3\*&%C&(XLC|HYR1!%!"\_M^O?J|J^  
L2CPA!O&YK|J27\_C0\_P!37JM\$=^@X44450@KYR^!C7Q+8>/\_M M4MK!6KN^""4+^%&^U5&T!T!XU!U!J?  
\$S\_DH^M\_|=Q\_Z^M!8<3ZCL9^FT^ MVEZ\_ZX1? M^@U!SX(^Y\$30/^P?|\_Z^B;|&|C/^)VIWND>\_!O=/N^M!E#\$\$E3!R@R^#C!  
M^!R!\$\_%&|TCPUK=YK=\_J\_RCO)903299F8/GGKM&3\_(FO0OB\_P DRU3\_M^H?\_1J5X3X^!)(2^?<  
\$D=EEDLXAYMU;|H#T^N3P/S!4H\_V@UL6+GQ^X!5 M3S7T\_!L3!H3E;%9!%#83@=>\_!O7LGP=U35M4!^73;OM^KW!)<\*\$0  
MX)!Y)ZUW5AHH=C#96\_"06T^!4C08\_!>|6;H!MPL\_!<^BK7M^!7VUH MNJW-  
L\_8TDV00M!8NX)..0046BWXMWMOH>FZ7HUR#J#V<+WMZ "5ECSIM5!>Z4R;C=>((  
3D2SF78WUW<\$>QKZJ);\_E00\$#~.K\$! M8;T?WA^!43T^00GR!|^!O\_CQ^4E83=S@\_B)!6\_!N^Y=&T)8Y;^Y9!AQ  
MN2%O|JC^)!AWSP;G!..#M;^X!^+(!J%O\_JTL\$GS^QNO;HWNJEE<^<JOPM;O M>\*O&ZG4!YUO;(UW;LGS>:00\_#ZY9@36J^!G  
JA5\_!|5^3EJQO0^9G!1 M?;\$3P+>1?VAEW2^5FC(1B;F\_X6^N^7SC!+=5DTCXAZ;ABJ7+ MFUE7U#|  
?H;3^%&L6&Z!20G8>\_!M\_B!\_UKMO^H>K~%)&|F(EA\$H!^3 M&VOHFOD3O'  
IUX|U;WCQOEU;9%STR92!3FQ!0/Q;UO7M2.E^\$8YH82Q!) M(HH!\_N!CY!L??M7\*:@\_P\_1\_!^\_N!\$%LAQF;2>7;  
HCG^X&O?2!/@2?| MFE+##JRW!TBC|3=\$?Y!Z^P\_K727 M!>6TEMX7/ M(AE!5;O5-2AT+Q\_ZR33?+7>\_I9O!KXXY!UXYS7LE?  
(>LVC^?&EU;VIG= MHX3?^O!%#^GZXO?UO&XDC61>C^\$?C!H!S>(^0^)#VM\_#|T>M#3R6\$\_F M6S^+;G^!MOCL\_YOPW<>  
(+;4G?PVMZ;TQ\$-ICC+OLR\_|C\_/TKZ7^<(\_3O\_M7A\_KV!Q7COP\*\_Y^NY\_|!G\_H<=2UJ\_/099Z!66O8!Y6O!R+K;1PG7^!E  
M<8^M?1M%#);6);"BBBF!W\_&|\_DH\_Z!O!\_V;O9/AG\_~DXT3\_K@?T!UX MW!;O^2@G\_KTB\_P#9H\_P!0?"ND^~!L;f6(H;F&  
(K)&8W)4|B>PK\_/W!F4!C MU&OG\_P^!L3>\*~B7\_6199<^Q=L?R/YUWVM?&7PKIUHSV\_P^!7/DABC9\_3! MLP  
^F3!5X7<2ZS!00&#R)\$9K^!DPJ+!V-1P!^H!TYO2R\$D>W?!"X\_A^6; M;)+R!E^F%|P;|&36!3T/PL3;7>2VDLMXL;O\$<\_5V;  
<9!<@5V/AS1^!#G MAVQTBL;MR6T84OC&YCRS?B23!>?\_!Y\_Y\$!3\_P#L(+\_Z+>F!AU)\_@OKN;Y MHFI;JE!^M#<^L;3-  
N(!7!<)>M>ER\$K\$!#J!>1\_+D!ZQ\_U!Z#7KWISKH(MS;)(4)!^V4#;&UG<H=|\_%;X9#GUP!3=X MZ@M3ZYK^!1>  
(;#POHLVJ;BY6&A57E!&15^J^!Z!6=(OUU3!K^4% NK>\_ M8=MR@\_UKP;XXZ!>^H=^1\_W%A\$&90>LC@D\$-|  
=OYGUJL.RN2EIX5R;|= M^%\_ABW!>#;.01K!LOHUN+B3^S^<JOT (&7)HVE)1ON.YX^X+^;N!6=|^ M8^W^TVC-L^T!|  
)83ZMCIPI>\_P!>E>HZNBNCE!E89#\_Y!%?|\_P<HMM;U^Q MU6V0!=(0!Q;JC  
+IM^;ZD;/RKTGX1.M)JOP!LQ^Q;2T=K4D^B!J/P4J/PHBW> MS!JS\$^/\_/ (G;2\_V\$%+1;U5^7\_~!8\_Z^4\_|0;M?^G\_D3M/\_  
\_P@O\_HM MZ!\_+D!ZQ\_U!Z#1H!LAZY(2L3L;H4D5^X^!&B;4^NE07>M7@\_!OHV;\_42?H\_E7RG!A DHFA\_P#7R/Y&B6Z!^U?  
7A0QC!5;1 MH\_B^VM~\_U6YM+!2^DFR^H+!W!)OUZ^OPZ8;C!K!XFW<)U;\_ M(2.Q?W^TJX^7(48P!H;5Z)!C?  
%E;5;>);Y4N+VX&^V!&5@7IG\_>|KVI= MZ!;I6;W^!CYP!^?%|6M&OHH;N9=1TYB%\*10Z;IR&!&017SA!9!M!^!9KO M??#?  
2^D)+QH!/HCLJ\_H!1%N!F^!G8UXGX!^!L\_Y-IGA@H!&2DE!RALL;HC M!XQ!G.>WK7>\$9 MP1^  
J&#QOX!|Z#ZFMQJDIV^!F;VU!\_@=29CSCZ&O!>N^<^N@VYN>!M!J#S! M%KJ^3^S^4&X@?4\_C!\_&VP7^PAXLL?&&AH-  
F#&P.R;|CEHG!><A|\_~50 MUZ\_~5!+|QD!^X^3?6! KZNGS\_EN\_OHJG^WOFK!1145S\*8+2;4=41F\_(!  
M9J@/DWQGJDOB#QMJ=V&\_@DN6CA\_W%;U/P\_KZC!;~X#>+V.E0@;..;X^! M3=6;13D\_C7REX6B\$ \_B\_18FQM>\_@4YZ&  
MY=4-W\_P^!8HHMV SG..GL\_FNB|CJVCZ^KME!CU\_U2YM!XZ!RWSC(^BA@?L\_M^~B\_XTG673&0%CIYCTV(H!25QS^;5%  
<~!4M/B>|D.NJ\$^9G2!9V^J<^Q?\_M25M;V!E);!6L\$<\$8PD<2A54>P%2U^+YCN?/?@XPZMIVH0VGB&017S)!7L@TSXA7?V=  
B74;7!4=-S9#^2 M^?QKW!P3Z!X\_U^!T^X>WN4;06\_M5/O^#(H/P)KS+PA4Y!T#6;G7!^XU&X5XA9V!DF7%R>WU>A?%  
M\_P#Y)EJG^!#\_~C4KQ3X;^#(O&7B)H;J7996!B6=5.&D^V>Y!^4F^0;  
MV+|\_BCXB>\_KB633C!ME;^EZ<&CC3\_9+^#K\_P(F!R^Q=XX!);D(!F\_P!2AF3# M&VORSJP\_W7!^U^YU!0V=G;~2;16EG!^!Q+M2-  
<^\*HKA^C#H\_OJO@>XOC&OV MO3R)HY;<|<@\_N?3!S!0!%VO<+FSX\$!9V\_C30?MBQB&A;R!F\$;\_UL9R/!D! MOQ^;NHKY!^  
!Z!7BR\_LLGRV!N!ZLCK!&OH^!B!H!HEK4X^C\_#6+P9;1VM! M&D^XSKN2-  
\_NOKTWMZ!H!WP;+7BUSX@>+J1K2!UB!(<^!MHS)&OU^845G>(K^ MY!7^~KJ;

(F22IN\_)MU\_ AW;4Y8KZBT#0I/PYHMMH=C&J10J 2:RI=V/N34Z MR96Q^V7C+QIX%OXAJOVIX&/-OJ(9E<#CY6/C  
XIC6+I0/\$5IXI4 JUFKI M+!&I0RC!<\$> />OJ+5M(L-QH:-1I0 M&/@04TM=2\N;<I0:WX82X\_O\*!<-GD5Q\_BW4K?  
6/%FIZC%W;WYDCW#I P?4 M5I3>)/?#F^\*M?3I2A#JM=?# J(P#=#JH:MH&DZZ+  
<:I80W8MWQ?49"GZ=H>\*T>VA)I^KXB^GC M-FEL)=3:/I15,,:^VY<9 \$FHYI P 3/#INU <2:YI"G+R+=LX4?I6UCQI>  
M^\*FD1(HUCC1411A548 'H:3B,C:Z5)YCN>(2#GXMWISJUOHOB\*19TN&\$<%W MM 97/ 5L<\$5I9ZYZY>WUFE>.  
K"/0\_>JVMH/\*CAN2I07^<# #Z9KZPM9?/ MM(9C\_P M\$50S&(-L&?-/B#4/B0IK?Q:M^K0TIEA/YELPBVY\_O;<8\_&N;+  
MW'B"VU)W-K>FL1#?8XRHL C/!XSCJ^E\_BA\DIUS\_KV/AQ7COP\* P"1 M\N?^P?)\_Z"4M:C3T&6>J2%EKV  
>5K\_B\_ZVT<)U\_B)7&/K7T:15;4;V3=, MNIZ\_56T+S/I%!)\_E6B5B6IG"?\$7XGP^\$&\_LZPC2YU9E#\$/IR!3T+8ZDIA^/  
MIGRZTE^WCA70+\*XU..#)&Z<\*6T10V\*J(H8U'I&BX50:\_/ '2H5Y'/'S3=WOO)I\$. MEQ>W6JVI9;\_#/:  
Y1I/IR6606OAS+280&4-V-I&EQJ?R;J201W'X\_ M3N+@QMM3L)I/B66WGOHC#(I-2\*MA+X-^<(R)\_'2I\_UH6;'WD#E&-<-G1  
M!+<#<^LJ1^(<?O:OX=5GT7PTZQ+^QBENPH9G<<=<4SP #OGJ3TOWIM.<"7M7R M5X5N?I?1\_>GW.LJ1%;W>;C>;E&!(W'Z'G!\*=  
+I7Z;H?B#I7)!="SI"4OD);#&#IP3O7 M\_'3P2I+%(H9'1@58'H01UI7BCD\*&2-6\*N4L;I3ZCT-/E\PN/HHHJA\$%Y\_QX MW' 7-OY5XA|  
?^0KK7 7"/A I">WWG\_IXW' 7-OY5XA| ?^0KK7 7"/ T (MU+W0UL>I44450@HHHH \*\*\*\*\* "BBB@ HHHH \*\*\*\*\* "BBB@ HHHH  
\*\*\*\*\* "BBB-M@ HHHH \*\*\*\*\* "BBB@ HHHH \*\*\*\*\* "BBB@ HHHH \*\*\*\*\* "BBB@ HHHH \*\*\*\*\* "BBB@ HHHH \*\*\*\*\*  
"BBB@ HHHH \*\*\*\*\* "BBB@ HHHH \*\*\*\*\* "BBB@ HHHH \*\*\*\*\* "BBB@ HHHH \*\*\*\*\* "BBB@ HHHH \*\*\*\*\* "BBB@ HHHH \*\*\*\*\*  
M3;C1\$E)C+\*0>Y&?K7K%)G)I+B(&"\*8,P) QD\_2EHHH%%%% 11110 444 M4 %%% 11110 4444 %%% 11110 4444 %%% 11110 4444 %%%  
11110 4444 %%% 11110 M 4444 %%% 11110 4444 %%% 11110 4444 %%% 17&\_ \$7P=?>--M; &U  
MU&.TCBF\_LBR(6#G&R#VR?SJI\*BAJX';>I?I?/O0/L "S"XN)I)#+I/%VIFZ M<I #ISWKIZ\*\*@ "BBB@ HHHH \*\*\*\*\* "BBB@ HHHH  
Y/XF?DXUO) ZX#\_ M\_ "%<I" P#DI+C\_ +"\$G\_H\$==#3A DG&M\_P#7?I H0KGO@7\_ B)7/?(C \$4 MFI>(I^<I0?B<"P8KJ%  
IDCNL(C1?TKV\_P"\_.@+JWP\_N3&^&\_T\_%\$%15&& M'TVD6\I7"?\_?0\_.U/4--U\*LI3Z M'@BIBKH;>I^? I7?L'BJ?29Q)QJ\$7R  
G\_EHF2/\_IW=^E?0U?')\_I<^?4 ML<1/G;9>:HR?XE!RI/U7YI?V-Y#I.GVU\ MNAN(EEG/JK#( G1I^D6^&5 M\_BC\_  
\_E\*UK\_KHG\_HM;^J^&5 BC\_R4K60^NB?^BUHGL\$=SZ4?I (JZ/I?> M4J\_Z\_\*UX#00B5X/M#VVFU^MQ)%;Q1NIC?Y6"\_\$?  
=I:I^<(OC3X=FVT8:0 MS:G=D8551DC4^K\_0\_0?I3NK"LSS/XS2Q2?;\$Z6/IT<\$2R?I VWAB\*IG^%<3 MP\_#315?3'(W/H9&  
(\_0B0G02I\_UCXA>+G5UD.\$Q'IQN M5)^C#'\_ JJ? 77-T6IZ#(W^D7<(ICA7\_/9/S->J)=>3Q;X:U#26Q\_I+(I M/I7ZJ?P8  
\_A7S+X\$U=\_'#CS3IB;,+I-GN W96^5L\_3?PH>DK@M4?5I9?B3 M5TTPWJ;I I HT#\_H=L84?BQ\_&M2O)OCMK?  
V70+1HVPIY+YL@I\_@3H#I6 M(A/P&K;LB4>9\_#31G!&\_&\$R&X,D<+F\N"W\_0IR\_5BH\_&OJ6O(\_@3H7V;0I  
MI6Y4PIW)Y;I4O?I'U8D?IKURE!60Y;GS)7I5?40B>1;IT-D6B8I;#+? M^/?RKVIX;+HG@2XU11+R2-  
I#TIZM5X;+0&'G3Q^&I\_ M3\*1D2WA4I6JZG6=3ID>E6W9\$IF7.5TRUO0BK2'EN=RP2/YLY:XA@7@\*?&^ MISZUZ1<8(K;X?  
Z=I&L<46H1(B\*15\$4@\_%?PM'I\_ (KX722YCVZE?8EN, MCE!\_ "GX^Y-8\_OX\_P"1^LO^PE'\_ .BY:BUHCOJ8GI/O\_Q?INW\_  
+5KVRO\$ M\_P!GW\_F8O^W\_ P;JUI950VIA7SC\3\_ \$EQXS190Z+I>Z\_VMI?L"(?I 6S\$X  
M9OSX'L;IZI2^\*OC#\_A&/##6IK)MU&\_!BAP>47^> P!P%/A%JVE0X9TFRX;0?IM)#\$VYO\_MZ#V\_KQ7X1\_I  
I3I\_P"VW\_HF2OH;OE\_R(C\_B#\_L&W'\_HMJ^>?>A\_R4\_1^VW\_M\*)DI2W0UL?4-%%%:SA115/5=4M-M^TNXU&^E\$5M;H7=C\_(>I)X  
I30I?X>I MJ\_- \$6E6JD\$K5G;4;FX\_P#0;IKX+6C6WPLAD9XR#I+9;I2G24\_  
MB1XI9HD/GW\V%'40Q#@9IE4<^OXU\I75IMOH^DVFFVJX@MHEB3U^ZGW/6LX  
MZNXXWM8N4445H(^\*6\_BMJ'IH\_ \$;5"&RD#+;K;5/\_ CVZOJ2OD6\_/IH>;HGY MOM&IMUHH3\_C43V'\$^J?#IC\_  
&9X%-\_M&>RN7U&XQID;\_?>F\_YGVKPR\_O-9^<(C RK#YU MI=N\$CAC^I&HZ#V\_4GW\_-;5K"2/I?@;\$I?@9FSB2^D9?IM0?  
S!KEOCWI\$XU\_M+2I95"-=H3:NP"LL+\_'ZAF\_IY>N^%I"BI->&K'2(B&^SOX=Q\_\$Y.6/XDFK M&M;-9;-I-  
OIFH!>9;KAAG!I?@I/B#S3Y?>L6I3R#X;\_/K"RLA\_A4F2V(I MD9I6>1L(VXY\*ICG)'KG'IGVJK7S1XP^\$^N>?9;BRB?4=-  
I8)ES(<\_VU/ MXC^G2L PQI2\_LGA?RX8;LW5D6?V6YRR>>BGJOX"M4I5M&-J^O13T5QW@SX  
MCZ/XQ00QDVFH@9;TE89/NA\_B'Z^U=C6B=R3PWX\_ /IH7\_7\_.;5;+."OB\_M3X^H>T&66YE;\$GM(IH5\_4?0FJGO\_/\_/H0O\_KG\_-  
\*ZCX"?I#B)\_ U^R? M^@I6?VBNAY7!M>;P;XIMHYB4@O#IDF#<8)/RG|&\_ FOIZOF#XJZ"WA\_P>  
M73PI4@O\_7<)7C;8\_ /P8!""^@/I>O#Q+XIT\_4RP.TD86?\_1>&\_49^A%&F M@GW\_  
^OGCXV^<(OJ24Q\_1^"8\_-3#@'@RM@GIAM'US7N^NZO#H.A7NJ7^KM8F MDQ\_>?9?O\_!^?>P^TF:OE1HHISJZIRM?7;\$<-  
ALX\_KB!I")I)@?I!U\_P\_M\_P(U^S\_ "6+IMN&\$UOZ^8TJ?>3A?PKGO@)\_ R-6I?I>7\_LZUZA7\_ ^29:I M\_OO\_<C4KSCX"?  
I(C5I7\_7E\_I\_) M\_AI?Z\_HHK&\_&NCPYX\_U+40VY9(BD/\_71 MOE7B<-A6A)I^<(M2F8?>FXBM#Y@I;U&U>#@I>/8L2?QKW?  
Q#X2AO/AQ/X M/K^\*%\$&\*\_ M2075N5XPKI?I1LCI^\*D/"FM+XB|+:=JH(+3P@R8I\_- "70\_\$P2IFS1115B\_M(I-B-YK:6\*.5HG="JR\*  
2A(ZC/I7S5=>?&W@\_P\_6R6VH:M=W\$EI-B2&:0M', MF<I#V8=#U&^F;I^N^\_O@S^V-&&O646;ZP3I%';D/4\_BO)^F?;IDG;0;0I'  
MU:UUS2+74I)HO?GOH'HH MY\_ (=Z)^#?C>IIV70M2N%CL;C.D\$DC86\*0#D9H@/S'07.^+I=O?B-XX2\*P  
M1WB9Q;6;3Y<>\_IGJ3V'TL6@6U\_R\$UIXM3>)OKS6KZ33+0\$S+ (^5D=@\_M<(>?CI@>M>XUC>?>  
#EKX5I6VE6N'Y8S+<C;DD/WF/I^>@\_K9JHJR\$PHHIL MK^47\$[XSM4G%;#YI=;M)KOC5;O<74W#10\_I BG;N/P&?  
QKZ=I\_);%X=I\_>6&E\_M1\_#I\$^I3GEC^+<\$FOE/P(I@N?%;E)(I82IA#\$1\_7&\_&PZSAW^D% %%%;#A7/  
M>>//^1UI\_KOE\_P#0370USWCS\_D0=>\_ZI9?I T\$TGLIX+I^I^2E6' 7\*'\_ P!% MFOINOEF3X.?)2K#\_KE\_ P"BS7FW4PV+  
<\$XOXI^XMI>I"WS;\_FR0W4+XY& MT98?BN1I<>E=I5;44633+M'^ZI+@YI-IJGJ(^/A#JH;7I0;.(N1#>JUM(7 M(RO\_(!^=?3E?  
(G@QV3QOH+)RWIHO#KF1I7UW4PV'(\*\*XJ?)M=I;Z18S\_M;F'FF^22^3YFT 9 P>.>?RKR^I^\* CETJ34S;D?PVT;LIH=N?  
RIN20)7/3 M/C;XCM;+PM\_80<=>7S(Q0?P1JP;=WKGFI7O.XWHK&Y3)8DGA>&0;D=2K#U!X/HK0D-M^3/I^I^OB'IS2-M-M?K#  
(?0;MC?H37UCG7R3XYC^S^/M=" \*12L=LL3\_60 MK^\*43V4HZ.;@/QFHAU0Y\$E% %6(\*\*\*\*\* "BBB@ HHHH \*\*\*\*\* "BBB@ KPWPI  
M\_P G/\_I;W=-^B)\*IRKPWPLR<\_ -O=W\_Z(DP)I#B?35% %9%GRW#I^1RU M?\_KT\_T8M>^X5X#B^I^RU2I  
ZI&\_I&+7OE;0V(EN%>+?^T?<(K3I\_? M<I"/Y-7M-I^E@/^+X#A517LH8V@Y+4FHHJAJ^M;H-@UJEW'\_6  
MZI;G/4^<4GV%6(OUIJ?S\$ \_DH^M\_I=Q\_Z'M?3^E:I\_ZUI5OJ5DY>VN\$WOL5( M;H: ^?BS;M;\_ \$K5LC"R&.13Z@QK\_7-  
1/8<=SZ8TS\_D%6?I UP3\_ -I%6IQ? M"&I0ZMX0TFI@8,KVR\_XL;I M8?@0160--;PO--(L<4;EG=S@\*IU)/858CYK^M.W)1HK\_\*X1?  
^@UISX(P"1\$T#\_ +I^\_H\_KYO(VOV?B7OK>:A8;C;86)' M88W1ICA\_I&I7G\_M\_P O^0YK'\_7LG\_H5>@?%+Y)EJG^I#\_P"C4KS\_  
7\_(I\_L'O M\_P#HO?#C\_)WH?I UI#^?9J( \_Q008ZBO/OC.S+I;D+T:>(<I-V?Y@5Z#\_M7?\*\$K2WU?  
X2;M\_1^6E2(3(HURC^<@I(GI);GSSX;L?%E)=W2^\$W66=I4GIF MX6(I<I9+;IUVAPC\_QE\_YIE\_X\_XO\_  
(Y67I&M<@TCQRL%PVV4(3;\*O/M?(\*Y^N^/J17TI415T4W8^?I\_A'\_ (R\_I M2\_P#IG%\_I OH>BJY\*\$X5IFZG\_P.E.O/^PR\_.\*\_-M?  
65?)NI\_I.E.O/^PR\_P#Z\_-\*8I/K\*BBBK?\*\$GO\_Y\*/K?\_7\_ K\_D>IG\_L'R?^AQU^I15+?#S7\_I D\_96/Y8->+\_'=8?B\_48@  
M&:SD1<I SE6\_DIHEI2I;T?1115B"BBB@#YO^W\_)03\_UZ1?^S5?I\_?2 A(O\_M#EEJ\_P#;P;IG^U)O^KI'OV'D=^XSTI'H?&I\_)"?<  
^O2+V\_O9/AG\_R3C1/^MN;\_I^9I)R=RFI(XNR^\_GOR\_WVNW\_P=UA@6(GI26KT;PIX3T7PM;&2;)(2 MXQ)\*3ND?ZL>?  
PZ5M45:21 PKROX\_I#(G;I?>\_A?I?\_1\_UZ17E?QY\_P"1.T\_ M+""P\_P#HMZ4M@6Y5^7\_ "I8\_Z^4+I0;I F\_U\$G^Z?Y5Y)I^O^0'K'\_7RG  
M\_H>MS?ZB3=AJ(I#>YI#\_#C\_DHEA\_I?<C^KZ^O^/FK02%JTFW5+A>&V  
MG#NJ==O0XKZVT\_4+35+&^L9TGMIEW1R(<@C\_/E#8)%FOF?XRAI+2+PJ>3#\_M\$6^NP?TQ7TNS\*BEF(50;DDX  
%)GC750^\$FVPIQ9YQ'\_%YWIH""1I0 M?QHGL\$3Z0I\_ O^%?Z%NZ\_8X\_RQO7SOI\_ \$IF;XC;V7Z^?C)\_H\_2OIW1/\_LG  
M0=/TIC\_1;\_;\$XIE5\_A^\*OG?XRZ6^G\_&\$XN2I85I\$DR\_MD%;155^-\$I@CN;\_M5KH/Q?>TA;VFU#R'BF/I40&W'&I OI^E\_P"\$?  
^O\_/\_4O\_I G%\_I^I7^>N M0;IX^TR>)OWD\$\*VTRY5T I\_/\_@\_0BNIH44\$SYPUP3I^4-6)=4M;I6(DH)I  
M^%MN>N\_OI^O5\_A5X9U+PMX2DLI5C6^YFNGGL\_V\_JH I^<C(ASP)=I=O1344G M<SROX|\_B=I\_P#V\$%\_I%O57X!?  
I@/6I^OE/I\_0;M2'\_I\$3\_I L(+\_BW\_MJK\_I O^0'K'\_7RG\_H+I0=#UN;\_42I\_H\_E7RG;I^2B;\_PI?<I\_D^<K)OI)\_ MNG^5?2\*PX\_Y)H?<  
%I^<1HGN@1I7UIZ\_7\_')NV\_IH?I\_Z')7T57SK|=? M^I MO^P?\_Z')1/8(I GL7PX\_Y)WH?\_7L/YFNHKE\_AQ\_R3O0\_ ^O8?S=-15+81  
MX3I?O^0KH0I\_UPD\_I"%=UI^<2;V'\_72;\_T8U<+I?OI\_D^Z+\_PI<)>A T(5W\_M7P<\_Y)K8I?)O\_1C5^\*(<?0Y\_X^;PI;2H^X;MB?  
J\$;YFO\_?IFF^;ZSN6I)\_MR72P+(<I\_Y\_VD7S8XR&89XKV#XU26^H>\_S<I J6\_QN\$E;IT@I?\_0@?PKC/@/K MP%KJYH;\_  
\_VUIQOE@I)/5DSN7ZD/\_ \$TFO>&MB#\_ (I\_XR\_I M2\_I&<7\_P<\_MIDWAKXPW\$D.SZ@I4BE^I M2B(8\$8(SUI^T57(\*YX7I-  
OAOXHT3O09ZHE/M MK;VRR\$19XW+^%D90\_%8\_WL^I^>Z444TK^N;D021LAZ;\_#3J^8^Q58R/HGB2\_MVEF7#V\_VK;I='&?  
Y5I BJP90RD%2;@@I\$5R\_#OPX^A>\_KFY2\_BTU\$FYC;MN\_M^J?I;\_OO\_ZHL^CW4ARKJEE&(PKF;\_#I^/4@<Z9IUG^IV\*>NIZ/  
M1116A(5FZIKVG^&I(FU/I0+MX^!E8I)%4=R?I/%5HO%VAW^B/^P(+I)M1\_M^LS1Q@L%VI06^&?\_VKRKX\_7DWVKI;+)\$





[illegible]

```

11110 4444 %%% % !1110 4444 %%% % M% !1110 4444 %%% % 'SS[<==^W^*H-)C;6GQ?/^FCX] |=V K7I?PBT3^ MQ_-
K*Zl9HC= /D=CPG_ (Z ?QK9U P'X7U;4GU^ ^T> ".ZD(+R$ L-O"(P: MZ"...&)(HD5(T4*j* ;0.@
!E1U.N.^EAU%%%%4(X+XOZ%_ /@:_YFC3=H"/Z M37:~.~|=)/_ $5Y9!%M= LOOKl@D:$&Hf+VlO?F0 ^A#_ (%7T=+%- $l
M4j!_!J59&0P/4$5SMCV_ "NF:C?V>BP17.3:T<%CM/J 3BI<=:H>:EB[XK M P"1.US _+l_ P#Z+:OG^X4?E-
T_>E P#13U13007$5$D$T:R12*4=&NOR MD8((!PM+!#>=&%U!_ 3M"@NESMD!8E<@<XR3C@D<4-7=P3.@HHHJA!1110
M 5Y!|=l^TZ8ZW$OSVdGDR2?W'Z$ _1AC @5>N57OKU+U:RELfVWCN+:48>* M095AUf.
75@1!FXN:F"WLRlRlO?)CZX+$9Ql2!7UOX4T5?#WA;3M*:"$ " M3'=SRy -J)JC9?#OPEHY%=VVAVZSQ.&1F+-M(Y!)
($73U,8V&W<****L1Y MA5?Al-KTAUf18PU^J 7%N!S: fT9?H#C'< =QSY7X9!/^ (? MU+VY(BW_O MK*Z0f0WJfM
(?!#2!AHf!H474N#_ Xl6Mf?@+PKHSB2RT.T60='D4RL/H7)(HM+N%T M>(?# P"%VH>)+R* U:&6UTA2?<%7N/9lUP>f?Ef?H
<:00)%$B!&BA55l@* M!T-%.HJE&PFfB.H92K.$58/(>OEKQOXlU#P-XE.L D2S:7S;&Z3/.0N>S+_ M $S7U-4-W9VU_:/7EO%
<0.._*@96^H-4;@68?7T?Xl_#8l%K&D-)/l-T^V.GV;@VR /Ndf^H3C@>PZ^O:O6;6X
M2~"KF7S#H EDG$4lB@_ ANP!PK3TGP-X7T*83;7HMM;IRLCYE=3f.Y)X4K M2VN.Z:/A!+/JfO$!2ZQ
T)53lC@D&&R1@NPl<=/KGTkVfBBJ2L)NYy %C MP%FV$^2.O _l_.f!_ =fYSWQCuoZUIWPU^Z7.LUOH M<#2+T:=FFYf
<.:2*Zl5^J4 *!@ #@"CE=fL+!A: ^?/&B:O?X,^(>l30W=RE MK/+YD,<^7@D3 O@'CClO@!5l!U#=#K?6f6JY;0W$+?
>Cf0.l^H/%4U<29XO M8?YQ&BZCH^L P#%);W&T'Z*PA Z%4.J_ 'NZEMY(l*T9+>0C"S3S>9CWV@#
MG!37H=W!*_!=Xf.^B!Ol<:/LD8*X*PZ4MEf/+!=BXDCT2*lOWGD>4_ (C'O M(-2fM+N.Z/?"WA+6_B%KfW.S3&W>7?
>7l@X<@NWHfTXZ'OJ'SM(+ "R@Lf M.:lP0lK^&_ A4#_ Y"GPP06!0P1%>@PJ(H55^H.E/QC83=PHHHJ@*M6 M-U30f_3R?
M?O)*S_ M*1_6OFX#S=WWJG_ !%TfB6;^?D>0X&X<_ BU?5E?+ MOQ0T>3P_lOKUX@8XfH.fO?;ODPW%R%"^82P)
Z9P1G!V+2TMf!"TBM+6%(;>%0D<: # 4#H!4 Ml6=QMZ$U>:;.BNW@_ O-*ATE;HB)9'D>;9RV>_ 'MWlZl+K%U;PEH&NW2W6
MlZ5:74ZH$5$DBf!fV_4TW?H)B^N?&RXUO0Kf2VT.*);N%H3(+@DKD8SC.S7# M>$?;$C^$ _$<&Kl+)"B3Ql<0V.B9B+@Q6-
f&2&2fG?8Uf!_."$;! MAX?Yl2l>3C (ULZ?H^F.3&4fH3l6T4fH!^J9^N!S1RMfHl+Hl^ ^%/PfG!_lR:
MOJRA=2N$M(00?0D$YfXx^T-U>G44525A/RXX!^CS7C^GS?^AfO1O^M%_ W7_000 P#@4?l XF05=2l%^&l7O&O+_1;2>Y?
f!K)Af^f7l;J?Xl_ l M_ 9_HG_ fJ>5K8=T>5WOQfU>6)ELf!R.fY)&DOf@<5QVfZ+Xf^@<OR7 M66YEE<>?>2#$<8Z-
E:28U_4fO>8DZ_P!>PjSGM7H?8>M^#_#_ (BN8fG5 MM.BNfHTV*f%@0N2<<#=#R?5f!fM
lXM)&?lWlKZfVO7D>;.P8>2&$Dw4?Hl M?Jl7OUf9V^H64fG=1++;SH8Y$;HRD8(fG?;9:18QV6GVt=M;1YVQOC &>35
MJA*RI NfG>(-U#X?^~3# #R2Vl@GM)_fZ9RK?T(f017fMX2l26WBOPY;K; MX56&V;_5R#
fR_U^l14FM^%M$!1^4=7TZ&Z.60C-D.H;((^FT;0=+V6C M6NDV4=K"S;V5.G+=.DGDf^2C9C;N:
%%%4(BNK;&fM9K6Yc66"9#'(C=&4C! M!KYE)=?#C4 _fZlS;f+A_0?3l(RAE*L 5(P0lP12<
M!@G8^= #00MUW2;9+;4K;/58D&%=W_ ;2D=9+S(-M4_0)S^E>B:C!?"&j2^9W4-0 EER.43^l/R.3fG^N_HHf
Ml6$>4_&OPC_6C)X@M(AW5B-LX Y>$GK P f)Sl"?
2N4^"OB_P#LS6^V7$Ff!/^!#CZ@>M>_ RQlS1/%*BO&ZE6lAD.#U!%"_ #FO7HO-3TF&XN0H7S"6l('3._C4R5T"=B#X?2
lD^T+KT2NEf&TM+> MPM(K2UA2&WA4)&@P% Z 5-5(#{YS^+^*YT36H:l8&?2fMS(Yl+>+>0GD^Tl M)R#
fXl(?HfO/fL5fW0HSR O<+>_%.P MELf!L/H$@*M^>N/6M.^&O@_2YEFMf#@:1>C3lTW/KARl75*H50f@!0_<4 MNfHW_C
M@:J;lA(f+VTG6B3A>CKN-U?~4?Yf!> Z Uf9UX)&_ $-QK=K4B?Nf6+R M8B100?KcW"C_>KWNl@M!R"BBBk$%%% % !1110
4444 %%% % !1110 4444 M &^%A Df!_>lO_Tl Ml43V$^fJf**R+EOX&2CEf_P#UZ_-Z.60?^*^lG (Y:O_>C?^C%KWRM
MfH;$2W"BBBf$%% % !1110 4444 %%% % !1110 4444 %%% % !1110 4444 %%% % !1110 4444 %%% % !1110 4444 %%% %
!1110 4444 %%% % !1110 44 M44 %%% % !1110 4444 %%% % !1110 4444 %%% % !1110 4444 %%% % !111 M0 4444 %%% %
!1110 4444 %%% % !1110 4444 %%% % !1110 4444 %%% % M!1110 4444 %%% % !1110 4444 %%% % !1110 4444 %%% % !1110
4444 %%% % !1110 4444 %%% % !1110!>?A>-Q US;^5>(? ' D*ZU UPC_l0C7M MfY QXW_ %S;^5>(? ' )NM?l 7"/_-"2fT-
^NUO%%%4(**** "BBB@ MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B MBB@ HHHH **** "BBB@
HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KSGXP^%)/$Af.^LH^FO
Ml/5_! "fU!="OM0K2YB2UE$D#ROLH(? M.5&?0C/_ *05***$K(&%% %0%, HHHH **** "BBB@ HHHH **** "BBB@ HH MHH ****
"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
*)^~4FKZQXfL)fL)O)K M>UBW*8X6822fUQ@^!/? (B7' 80D_l M0(ZGf0^AZ;115""BBB@ HHHH **** "BBB@ HHHH ****
"BBB@ HHHH * M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
"BBB@ HHHH **** "BBB@ KPW MPI_R<+_lO=W_P"B)*lRKpWPl_R<_P#lO=W_.B)*B>PXGTU111619fM_S_M')'+5+_KT_-
&+7OE>!_S D^!/? (B7-M' 80D+_l0(ZZ^XFAD^XUO_K@/_0A7/?O_Dl+C l(2?^@fU/VAl#TVBBBf$% M%% % !1110 4444 %%% %
!1110 4444 %%% % !1110 4444 %%% % !1110 44 M44 %%% % !1110 4444 %%% % !1110 4444 %%% % !1110 4444 %%% % !111
M0 4444 %%% % !1110 4444 %%% % !1110 4444 %%% % !1110 4444 %%% % M!1110 4444 %%% % !1110 4444 %%% % !1110
4444 %%% % !1110 4444 %%% % !1110 4444 %%% % !1110 4444 %%% % !1110 4444 %%% % !1110 44 M44 %%% % !1110 4444
%% % !1110 4444 %%% % !7AOA3_DY_l>fO_P!$ M25fE7AOA3_DY_P#fO_-$25fAOQfBBBfLBSY;^!G_ "6K_l7HW_ *6 MO?
*!#^!G (Y:O_UZ_-Z.60?*VALl+<****H04444 %%% % !1110 4444 %%% % M% !1110 4444 %%% % !1110 4444 %%% % !1110 4444
%% % !1110 4444 M %%% % !1110 4444 %%% % !1110 4444 %%% % !1110 4444 %%% % !1110 M4444 %%% % !1110 4444
%% % !1110 4444 %%% % !1110 4444 %%% % !1 M110 4444 %%%
```

MT:,%\*G @1'X^M<:|=2F@|5WNG:SY%\$S:F0KGC>C#| (M78 & 7K>S!)HPD MS=7TBL4':#DD+|@  
/O!\*\$Y/X#::7+|XBU5%'TFWMO!|QP7=@?Y\*?S2- B' MT/3 (F-%: ( #U"%\$W3VZ :8>.=R-OY0-7< /!5L\$  
@C/4/400Q7IVD1,9M:GS:9AV4D.A \$?B M\*)Z.X+L?6M%9^AZI%K>A6.IPXV74\*R8")C'X' ("M" M"3QCXI:WLMJ,T\*  
MN7)NI@#V&531= Y'M/X&: #1B? 7.L2)B6 EVH3 SS3C 1'+?D\*UJ|=E+XL+ M(MX;7IYON!6RCN%.P8^IR?  
OKZ:T73(M%T2RTR# \_% =K'L0/K@0)\*S/ ( # -? 'A+O:GOMXOALYH&+IVGNY MRYO<\*IX -A^58OP LE:ZUN\_91O1(H M4/?%#BW\_  
\*"M\*6LK#6B/9M.TZTFG3X:&Q@2"VA7:D: #@#^H^|6J\*\*T)\*>JZ M59:UHL^GZA LHM,NUD8?J0CL>U?\*"B'2:OP?  
XMN:%972:RF#03\*<\$CAD8>^ M:'ZUI=U|\_>U6+QC8W"JYUDH8CN5=N?R(D)K2XXGMWA?6510^&-U5<W;  
M(9P:<=<,/P8\$5K5YO(\$IKCX?)CD6IW+ \$OL#M?^&Q01ZLZ\$PHHK/US5H-! MT:U2Y\_U5K\$9"/O!+I2<#1:8'B'OQ12?:MLK#@?  
@O\_H1K MN @WX< L7P.M\_FVZU,B8YZB,<(RRW\_\*O\$- TZ|<^H:8AF>2IN#,:)\$Y:G5IB\_13W@>M-  
IF<06IDF7)SEG9I\$|B09Z\*H.FYX|:M.LM!\$:39Z?:Q6UO'> \_+ \$N/MDF:1?>H @! QXZ| UUA DI7OCU\_R\*NF\_1?W\_LC51^  
'\_CKO\_%UA\_DH1LKH M>RT445H2>4^+OA:J/B\_QD|J|:Z48HU!+2<#E57H:|>?B#KW\_7C+\_Z".FRW"YX+|/|  
M^2E6' 7\*: T6: ^FZ^9/@Y\_R4JP\_ZY3?^BS7TW2AL.6X44458@KD0B7J|+X MU2>\_L32QBWC^KG:2/H"3^%=;7D?Q|OYBT#2K  
<^XN6E/\_%Q\_P"STL.R|:G+ M? K2UNO%MWJ+C(LK;\_"SN<# \_=# G7T+7D7P"LPF@Z0>XYFNEA IX7/ M2O M7:4-AO3\_K-D>  
IG\_L'R?|H<=>L?>\_DF6L |L M7\_HU\*|G^|7 (HW/ &#Y/ 0XZ3^ ) MCZ\*KB0B6X?MM<| #7LD8^TV\$374.F. M5VC+ #Z%0?T|\*  
|6N)^\*NO6^X^|Z)Y:7% ^AM845MPPQ^@/7YCUJGL)C'PAU M\*:P^ (EA\$CD17?O!\*N>&^TD?>/  
5L:US\_102Y;\_A6AMPJGRK\*2:0XXY4H!^ M;#C7TQ4PV+<^10&| R/>O\_P#80G\_1#\_?6TA|C(H?RKY)|\_P#(I2\_M-A"?  
\_T.U|:0\_P"HC\_W1\_\*E# =A(??\_\$?X=VGBK3)KVR@2/6H5+1R( //Q\_ MWKGL>Q|JZBK:N(^5?  
AIXIE| )^+>9Y62RG80W:'H4)QN(I5)S^?K7U57R=| M0L32OB:K5K&H5/M'FJHZ. ^A  
QZOIGPG?|7A#1R0YDFLXF<^K:1G|9?^3\_D1+?|I"\$?\_H\$E\*6P+ M?L\_ZZ\_Q|\_NV+\_2O:Z4-AO<\*\*\*\*H1XQHGP3EN-M=7N+\_P  
3W@>\_IF<06IDF7)SEG9I\$|B09Z\*H.FYX|:M.LM!\$:39Z?:Q6UO'> \_+ \$N/MDF:1?>H @! QXZ| UUA DI7OCU\_R\*NF\_1?W\_LC51^  
<^XN6E/\_%Q\_P"STL.R|:G+ M? K2UNO%MWJ+C(LK;\_"SN<# \_=# G7T+7D7P"LPF@Z0>XYFNEA IX7/ M2O M7:4-AO3\_K-D>  
IG\_L'R?|H<=>L?>\_DF6L |L M7\_HU\*|G^|7 (HW/ &#Y/ 0XZ3^ ) MCZ\*KB0B6X?MM<| #7LD8^TV\$374.F. M5VC+ #Z%0?T|\*  
45|+1%MK4&%%%,#P+XX>\*O\_:AV6|H^S6:B2=0>&E89\_/4C\_OHUT/ MP9|6|K|>)KZ\$/=W&?L@89V|AN  
\_O'GGT^HKQWQ+=R:QXP2X/+W%Y)M|/ M0:B%#X# KZUT^SCTI3:6RA \$=O\$L2@#LH\_ |JSCHE/1^FBBBM"3#3PAH\*\_|D3M<  
M\_P"P?^A^BVI?\_/PH\_Y\*:HW^|+\_ .BGKZEKY: ^%)3=& WI?| T4|24M3# M8^=K|JLWB31H^AB# 7D\$8PJY.  
ZGMS@#\$0U|H:ISJAK MFG)J^@W^G2\*\*MS:O%SEZ2 ?P:4U="3L>\_ IQ5+?J\$WAJYE+0S\*9K13SL<< MLHJB\_G|\_#ZUIK7R-  
X\*OGTFQOHHXARQMO(U; =9MK?H37US4P>@Y|7S?30SD\_C M3QG%Q^H^EYFMK:7|/HA\_U|&: ^!  
|#/>O4\_BOXP\_X1CPPUM:R;=10P8H2#RB M?Q/^1P/<^U<:|\$/|^23Q1>1\_\*N8K(,IZ\_ LH\_X%1+5V|\_:E#XG^&K?PIX M%|\_  
Z7#AG261HY!\_RTD\*KN;^@|@\*Z/X|\_BYJO\_7V/ 0!4/Q^\_P"05HQ\_%WD\_M\_P#014WP#\_Y%\$5?^OL?^@ "EHH?  
0|:KYA^+6MOK^CZIC\$A:"QQ:QCL"OW\_P =MV|A7T|7R#\*WH^ -7=QN^U:B20>^Z3\_ZL8HGTYX^/Q>&O"-A8)&%FL27!  
M|M\*PRV?IT^@%=%115B/\_CH\$5CKUEK\$%:HM|R3;1UD3'SW(C |FYKM@EJ M|ZAX(>SER,  
R\_J6^X56^/?N)/UC<8^\_\*5<^@9'S^H#80I/AQW M; >F(^ CX|?SYD5T|: ^5\_UF\_AOXEZB:4|"ERMW"1V+8D/H3C|\*^J^\*  
M>\_CO9B\_QA972|+BS\_A\_O\*S#^1%>PH|GO\_EWR:H%G|8PEU\_DRCT\*## 6K M=<7|\*+XWWPXTLM|^\$//?^  
N0/TQ7:52V\$%%%, HHHH \*\*\*\* "BBB@ HHHH M\*\*\*\*.3^G ).-: \_N\_P#0A7/? O|Y\$2X\_P"PA)\_Z!70\_\$S\_)OK?| MUP'\_  
\*\$\*Y|X%\_P#(B7' \_\$&)/\_0(ZG|0^AZ:1115""BBB@ HHHH \*\*\*\* "BB MB@ HHHH \*\*\*\* "BBB@ HHHH \*\*\*\* "BBB@ HHHH \*\*\*\*  
"BBB@ HHHH \*\*\*\* M "BBB@ HHHH \*\*\*\* "BBB@ HHHH \*\*\*\* "BBB@ HHHH \*\*\*\* "BBB@ HHHH M\*\*\*\* "BBB@ HHHH \*\*\*\*  
"BBB@ HHHH \*\*\*\* "BBB@ HHHH \*\*\*\* "BBB@ H MHHH \*\*\*\* "BBB@ HHHH \*\*\*\* "BBB@ HHHH \*\*\*\* "BBB@ HHHH \*\*\*\* "BB  
MB@ HHHH \*\*\*\* "BBB@ HHHH \*\*\*\* "BBB@ HHHH \*\*\*\* "BBB@ HHHH \*\*\*\* M "BBB@ HHHH \*\*\*\* "BBB@ HHHH \*\*\*\* "BBB@ KPWPI\_P G/\_|  
\_W=^B)\*IRKPWPI\_R< \_O= MW\_Z(D)|#B?35%%9%GRW|\_#/^1RU?\_KT\_T8M>^5X|\_#/^1RU?|Z|&-1&+7  
MOE;0V(EN%%%)4(\*\*\*\* "BBB@ HHHH \*\*\*\* "BBB@ HHHH \*\*\*\* "BBB@ HHH MH \*\*\*\* "BBB@ HHHH \*\*\*\* "BBB@ HHHH \*\*\*\*  
"BBB@ HHHH \*\*\*\* "BBB@ M HHHH \*\*\*\* "BBB@ HHHH \*\*\*\* "BBB@ HHHH \*\*\*\* "BBB@ HHHH \*\*\*\* "M BBB@ HHHH \*\*\*\*  
"BBB@ HHHH \*\*\*\* "BBB@ HHHH \*\*\*\* "BBB@ HHHH \*\* M\*\*\*\* "BBB@ HHHH \*\*\*\* "BBB@ HHHH \*\*\*\* "BBB@ HHHH \*\*\*\*  
"BBB@ HHH MH \*\*\*\* "BBB@ HHHH \*\*\*\* "BBB@ ""|\_X|C\_KFW|J0^/\_ "%=: ZX1\_|MH1KV^|\_X|C\_\*YM\_\*O\$/@#\_A76O|KA'\_  
\_A&I>Z&MCW:BBB|\$%%%,11 M110 4444 %%%%,1110 4444 %%%%,1110 4444 %%%%,1535-0ATG2.O4;  
M@XAMH6E:W"C\_/K5NO+OCAKOV#PHL;XEU&7Y@/^>:8) P# "MOZTF|(\$>4^# M+\_,OE|2;9KL>8)KEKRZ)Z%0=Y|IB<+^?<  
4|?)^A|2O%CHVH>;:50IS\$UQ8| MUST)7=\$PPP\_.'4CL<9%#>MPMI M8^OZIR^\_G (B6\_|V\$(\_0)\*!AECGACFB: '3\_D1+?\_L(  
M1\_|H\$E:2V)6YXSX3|ZKX\_:L2UMF-T\$GGH6^IG&,\$?WC70W'QL|7S0LB/\_M8P>DD=OEA\_WT2/TK=^UG:W2)0T?1%\_  
KZK|LGBN665AYM>9">@>V?O>P7|\*^B?^W-MAFR|)Z%#I=B"57YD6'S2N>K' #L\_\*VJ\*H|L)NX5XC|>M"VRZ:KT2<,#:S\$>  
MHRR?^S\_D|NKG?>A?|\_1">|2T|5W3+&S(^7S% ^91^>\_?C3DKH2W.-^|>N? M;/\_#\_UI\$C9DL)MT8\_Z9OD\_P#H0|O7>\_>  
M;\_X1P;|J\_HJV5(2D)\_Z-|J|\_M\_PPKP#X2ZY\_8OCZT21ML%#:2,25ON\_P#CP4?B:|?X|:WLM|T\_N7)NI@#V&5  
M3|=Y"H4O=\*U:2^#>A\_VMXYCNY\$W0:=&9V)Z:\_B#ZY)/\_ ^E\*|V^"FA?V9 MX\_H2)B?4I3)G^/EK|JCH|Q\_X%7I-5%60GN>\_?|2=,  
T-NPFE!)?|\*(@ X. MG:XG|0FB)^A#?X5L?^#36O/\_|=VBDM972.O'9&|4\_J5KB|/5|)=GXHO=,D8+ M|N@:/3/=XR3C\_+Y9C^%3H?<  
0^@|J\*\*T)"O!\_CZZG6M&0?>%NY/T+#!^C7O%? M.GQ?UF/5\_ |RD+AXK&:\_4\$@EF\_JIX\$N6A>H2/\_^^(MQ\_2O3JY'X9:4^C\_#  
|2H)4VRQOFX<^K|Y+#!\_ \$@?A7754=A/<\*|8^\_WB39|\_M9^(^\_3\_2;G^H.\$7|G|7L5U^/\_M&TDT:DW&HW(2%#\_I.U1|\_?<  
E45>EAQ|5O@>5X<@SZ=>>(9TPIR?L|N2/X%.6 M(^K #\_@>PU2T?2X-%T:STRV&(^6)UJ3@>O\_M15TW\_K^\_JD:J/P  
\_X|= =P"NL^|Z0?^K\_D5= \_Z O\_&1HJ\_#\_COUW\_KK M%#)ZS^Y5T9.\*\*T)"N>|>B#KW\_7C+\_P" ^FNAK^O'G\_ (CZ| UXR\_|  
H|H/\_M8#P7X.?E\*L/^N4W\_HLUI\_UR?|S\_DI5A\_URF\_|19KZ;J8:#EN%%%)6(\*\_M;\_E)O="B|+^,WYE!\_208?F7?X&ND|OZ@X\_  
I&?:1/QV\$|SC?BO|\_DRUG\_ =B\_M\_P#1J5|Z^% \_%H>=\$4?=-6\$SO\$82)D+#+2#T!/\_RBOHKXK\_)M9\_W8O|  
MT:E>1\_\*V@NO&IQ^<0QS(+^0|9\$##.L<^HE|12V\$D^\_BYXV5HZ\$CAE@.1 M^\_5\$C0Z3XS^ (NJ+\_+@ "(P^-"4H\_-OS&?  
ZURZC/<+>?&O:\_QDSZE>'RD/QY)\_:O"41G|U|\_O)VK\_#V&5IO| PHPG\_STU+\_O^O|  
M33|X6AU/A3QGI7C&VN)|+X%NX219D9D90>)>\_#^5WT0V|HA1115""O\*/\_MCU\_R\*NF\_1?W\_+  
(U>KUY|>O^15TW\_K^\_P#9&J9: MRC|/\_?7^NL&AGV M6O&O@! QXZ|\_-=8?Y/7LM\$=AO<\*\*\*\*H05C^\*/#UKXH/76E70  
\$JYCDQDQN M/NL/H?TR:1%5M1U"VTK3KB\_O)1%;6|9DD<|@/Z^U'\_ROH^J:A.O&C2/\$1< M6DC0W\$!\_!^G<9|P#0?  
H:N^&="U#XE>.WDO79DDD-O>RCHB9^Z/3/"@=OPJKJ\_M4^K?SQM 3|\_>Y/O6E|+O%\_|PB7BCR+P|+^|AN-  
MW'EL"=KGZ\$D^V|)^Q6\_D6?3\$\$\$5K;O6|\$:\_QPO(\$1%&\_J@8\_%24\_Y&1THK8@\*M\*\*\*\_CF\$^3XCC.O.R|&\_/?  
#|U|C5|E>\_M;\_1\_'L64A|HN6DC^PYW+^A%23 MGA/6H\_A;3M3C8\_9H5|SG\_'##|P:SAU14C9HHHK0D^R/^? (G\_Y\_V#Y\_|  
MT6U:|9^BO\_D3M<|!|\_\*+A@?/PH\_Y\*:HW^|+\_P"BGKZEKY: ^%)3=& WI?| T4|24M3# M8^=K|JLWB31H^AB# 7D\$8PJY.  
#R&X|4Z5&\_#>P|\_>P|\_>LN^\*OKFYAL|66YN)C@A0R2.W15\_R2\_M;^8 A/H|O|\_&P\_P9NALR:J0^FWIO\_Q6O7?  
C5=7%M/VG2|F59|J\_\*4K\_2WDU\_|5?B2\$BW)#\_ ^R//D6Z|S|XR?G6|A:1B\_M.WMXO^&H| "OE/PIXSU^P=+<3:9|9M-<^%0:2>\_LP4>F\_|  
?AO\_(E&26X^-6?^D%:\_+ \_=Y/\_014WP#\_P"1#K.>UTQ+4QSR>8\_G MIECG&\_,\$4%U+4(8 MHY\_>|2E5<#&-"2?  
7^X5|WZ|\$VC>\_>=0C"D&UOY-HZ<^Y(^3%?1A\$^O^\_C@\_MFCN:>\*> (HHY4#J?4\$9%25H2>?)MO@\*\$?WKZ;^\_N:Y?X(3?  
ZX\_!%"/S+ M?X5J?^R\_5\_%TG3MWSRW#3E29%VY\_|?H^5BT^BZO?E<+<^)\$H=BDG\_T.L\_M MCZ^K|>&\_M  
1XO="D|M^OY^A:IRKPKX\_2YU718L\_=@D;\_U\_153V|;G6?^M4R>\_?\_7\_GG>R+\_P"J?ZUZ37G/P2B|OX?^V|I9=RM\_C?  
TKF:G83W"BBBF\_44 M44 %%%%,1110 4444 %%%%,1) \$S\_DG&M^>U^/\_^3G\_P#M|N\_-\$|7N5>&^&/M^3G\_/M|N\_|  
T1)43V\$^\_FJ\*\*R+/\_EOX&?|\_Y(O\_P|>C?|\_HO:\_|KP/X&?|\_MCEJ\_7HW\_HO:\_|K:&O\$MPHHHJA!1110 4444 %%%%,1110 4444  
%%%,11 M110 4444 %%%%,1110 4444 %%%%,1110 4444 %%%%,1110 4444 %%%%,1110 4444 %%%%,1110 4444 %%%%,1110 4444  
%%%,1110 4444 %%%%,1110 4444 M %%%%,1110 4444 %%%%,1110 4444 %%%%,1110 4444 %%%%,1110 4444 %%%%,1110 4444  
%%%,1110 4444 %%%%,1110 4444 %%%%,1110 4444 %%%%,1110 4444 %%%%,1110 4444 %%%%,1110 4444  
07G\_C'J\_C#QE?O'\_+\_Z+#!|7TXX8QL\$:\_O|PO<^&O%="^&H0>G;  
M>IU35;2>VCG\$TBHK^|<^\_#G&|^34R3>B&CTSP/HG\_"/>#\_-TYEVRI" F?S M&^9OR)Q^%=115""OG#XU:%\_9GC07|:X@U^\*  
(2^WF+K#\_P|!/\_J^CZY#XA^M"O|\_A-M\$AM8IX|>|MY?\_BDD4D8(P5..@/\_|\_5.E=#3LRC|(==\_MGP):PR/FX



[illegible]

[illegible]

I^/-5M(8Z/345KH>EV5V;NVL88ISGYU7IGK@=!GV MI7'9F,LGIB7Y96@ND)OK\CWN';'T8;QI[%3I\*S\_%EQIKUB2&.&ZEDTZV\$  
ML!@MWD"W)8,NXJ#CA!U!::ZDZ'I9U 7--BA^TIM^-'17H'3/OU)H=1M|N  
MXDLK/3PDSAV=YG#.=H&3A3V&\*+B:=K%&INX|^H+7D)S'/'<&1?H8'-5f.\_CT MN'Q1>6Z@VT-QF%5'#2^6NY117./J36N-  
\$LK63+>TQ;"WV0G+?;H"RD;@;Y^0|>M9=G=36FG7^EH["35fE;LWITF9XYWNH8-0@02VPFY60I"&4CJ1@GDX-4DUK6-/  
M\_=ZMHLTX' N=.'FJWN4SN7I:Z\*BG<5NQS+PEMLPQ#IFL3/WI;:P0?0D@? MG44D.N^(!Y5S'\_8^G-H%D#W\$H,CA?Q-  
=+11<5KID-I.06-I%:VL2Q01+M M1%Z 5-112\*"BBB@ HHHH \*\*\*\* "BBB@ HHHH \*\*\*\* "BBB@ HHHH \*\*\*\* "B MBB@ HHHH  
\*\*\*\* "BBB@ HHHH \*\*\*\* "BBB@ HHHH \*\*\*\* "BBB@ HHHH \_\_9 end "